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This thesis examines and reviews multiple aspects of dysbetalipoproteinaemia. 
Dysbetalipoproteinaemia is a severe, highly atherogenic mixed hyperlipidaernia 
characterized by the accwnulation of remnants of triglyceride-rich lipoproteins. 
Genetic susceptibility is conferred by mutations in apolipoproteinE, but manifest 
hyperlipidaemia often only occurs in the presence of metabolic abnormalities that 
influence lipoprotein production or clearance. 
Nor:m.al lipid metabolism is briefly reviewed to enable a better understanding of the 
pathophysiology of dysbetalipoproteinaernia. Hepatic remnant clearance is reviewed 
in detail with particular emphasis on the roles of all hepatic lipoprotein receptors. The 
importance of differential hepatic lipoprotein receptor binding affinities according to 
apoE mutation is emphasized. 
Clinical and laboratory records of all patients diagnosed with dysbetalipoproteinaernia 
at the lipid clinic of Groote Schuur Hospital, Cape Town (South Africa) were 
retrieved and reviewed. The diagnosis of dysbetalipoproteinaemia was made if 
cholesterol-enriched VLDL and/or mutations in apoE known to be associated with 
dysbetalipoproteinaernia were identified in patients with mixed hyperlipidaemia. 
Dysbetalipoproteinaemia was diagnosed in 136 patients. Seventy patients were apoE2 














4 homozygotes) and there were 2 apoE (KI46Q) heterozygotes. No mutation was 
found in 37 patients despite sequencing of the apoE ligand binding domain. 
The mean total cholesterol and triglyceride at presentation were 11.79 mmol/L and 
8.28 mmollL respectively. Men presented a mean of 6.25 years earlier than women. 
Characteristic palmar crease xanthomata were found in 25% of patients. 
Atherosclerotic complications were frequent and peripheral vascular disease was 
highly prevalent. 
The majority of patients had identifiable precipitating disorders or metabolic stressors. 
The BMI was more than 25 kg/m2 in almost 80% of patients. At first presentation 
27% of patients were diabetic. Other identified precipitants included renal disease, 
hypothyroidism, alcohol abuse and antiretroviral therapy. 
Agarose gel electrophoresis was found to be a poor diagnostic test for 
dysbetalipoproteinaemia, while non-denaturing polyacrylamide gradient gel 
electrophoresis is a useful screening test. A ratio of apoB/total cholesterol of less than 
0.15 g!mmol predicts dysbetalipoproteinaemia in patients with mixed 
hyperlipidaemia. The diagnostic utility of VLDL-compositional analysis was 
evaluated at various diagnostic thresholds. 
The effects of lipid lowering therapy in dysbetalipoproteinaemia were evaluated both 
in an observational fashion and in a double-blind randomized clinical trial. The mean 
observed reductions in triglycerides and total cholesterol at the clinic were 62% and 











total cholesterol to the same extent, but fenofibrate reduced triglycerides more 
effectively. The major effect of lipid lowering therapy was to reduce lipid masses in 
the VLDLl and VLDL2 fractions. VLDLl core composition was altered significantly 
with a decrease in cholesterylester content and a relative increase in triglyceride 
content. 
Chylomicron remnant metabolism was studied in a subset of trial participants. The 
fatty acid of the cholesterylester in an artificial chylomicron remnant-like emulsion 
was labelled with l3c. The emulsion was injected intravenously and the fractional 
catabolic rate was determined by measurement of 13C02 in the breath and 
compartmental modelling. Treatment with fenofibrate was associated with a 
























































Scandinavian Simvastatin Survival Study 
acylCoA: cholesterol acyltransferase 
American Diabetes Association 
alkaline phosphatase 
alanine aminotransferase 
analysis of variance 
apolipoprotein B 
apolipoprotein E 
amplification refractory mutation system 
antiretroviral therapy 
aspartate aminotransferase 
area under the curve 
body mass index 
coronary artery bypass grafting 
cholesterol ester 
cholesteryl ester transfer protein 
coronary heart disease 
chinese hamster ovary 
creatinine kinase 
cholesterol in VLDL 
cardiovascular disease 
cerebrovascular disease 
cholesterol in VLDL 
free cholesterol 
familial combined hyperlipidaemia 
fractional catabolic rate 
free fatty acids 
familial hypercholesterolaemia 
FH heterozygotes 




Groote Schuur Hospital 
glycated haemoglobin 
high density lipoprotein cholesterol 
human immunodeficiency virus 
hepatic lipase 
3-hydroxy-3-methylglutaryl coenzyme A 
heparan sulfate proteoglycan 
Honnone replacement therapy 
intennediate density lipoproteins 
isoelectric focusing 



























































low density lipoproteins 
low density lipoprotein-cholesterol 
lipoprotein lipase 
lipoprotein X 
LDL-receptor related protein 
Monitoring of Trends and Determinants 
in Cardiovascular Disease 
Medical Research Laboratories 
messenger RNA 
non-alcoholic fatty liver disease 
National Cholesterol Education Program 
nanometers 
Online Mendelian Inheritance in Man 
percutaneous coronary intervention 
polycystic ovarian syndrome 
polymerase chain reaction 






peripheral vascular disease 
receptor associated protein 
retardation factor 
remnant-like particles cholesterol 
receiver-operator characteristic curve 
revolutions per minute 
serious adverse events 
SREBP-cleavage activating protein 
single nucleotide polymorphism 





triglycerides in VLDL 
transient ischaemic attack 
Treat to New Targets Study 
triglycerides in plasma 
triglycerides in VLDL 
University of Cape Town 
upper limit of normal 












Table of Contents 
Chapter One: Introduction to dysbetalipoproteinaemia ......................................... 1 
1.1 Introduction .................................................................................................... 1 
1.2 Terminology .................................................................................................... 1 
1.3 Historical aspects ........................................................................................... 4 
1.3.1 Overview of the history of atherosclerosis ........................................... .4 
1.3.2 The history of dysbetalipoproteinaemia ................................................. 6 
1.4 Lipids and lipoproteins .................................................................................. 8 
1.4.1 Lipids ..................................................................................................... 8 
1.4.2 Apolipoproteins .................................................................................... 12 
1.4.2.1 Apolipoprotein B ............................................................................. 15 
1.4.2.2 Apolipoprotein E .............................................................................. 16 
1.4.2.2.1 ApolipoproteinE cell biology ..................................................... 17 
1.4.2.2.2 ApolipoproteinE structure .......................................................... 18 
1.4.2.2.3 ApolipoproteinE polymorphism ................................................ 19 
1.4.2.2.4 ApolipoproteinE population genetics ........................................ 20 
1.4.2.2.5 Apolipoprotein E polymorphisms and cardiovascular disease .. 23 
1.4.3 Lipoproteins ......................................................................................... 24 
1.4.4 Lipoprotein metabolism ....................................................................... 27 
1.4.4.1 Remnant metabolism ....................................................................... 32 
1.5 Pathophysiology of dysbetalipoproteinaemia .............................................. 36 
] .5.1 Precipitating factors ............................................................................. 36 
] .5.2 Defective receptor binding ................................................................... 39 
1.5.3 ApoE and lipolysis .............................................................................. .40 
1.5.4 ApoE distribution in lipoproteins ........................................................ ,41 
1.5.5 ApoE and VLDL production .............................................................. .41 
1.5.6 Pathophysiology of apoE deficiency ................................................... 42 
1.5.7 ApoE variants associated with dysbetalipoproteinaemia ..................... 42 
] .5.8 ApoE and lipoprotein glomerulopatby ................................................ ,46 
1.6 The dysbetalipoproteinaemic phenotype .................................................... ,48 
1.6.1 Clinical features ................................................................................... 48 
1.6.2 Diagnosis of dysbetalipoproteinaemia ................................................. 49 
1.6.2.1 A alysis oflipoprotein phenotype .................................................. .49 
1.6.2.2 Analysis of apoE .............................................................................. 50 
1.6.3 Treatment of dysbetalipoproteinaemia ................................................ 51 
2 Chapter Two: Methods ........................................................................................ 52 
2.1 Clinical methods .......................................................................................... 52 
2.1.1 Clinical documentation ........................................................................ 53 
2.1.2 Collection of clinical data .................................................................... 53 
2.1.3 Consent for DNA extraction and storage ............................................. 60 
2.2 Special investigations ................................................................................... 62 
2.2.1 Routine biochemical investigations ..................................................... 62 
2.2.2 Electrophoresis ..................................................................................... 63 
2.2.2.1 Agarose gel electrophoresis ............................................................. 63 
2.2.2.2 Polyacrylamide gradient gel electrophoresis (PGGE) ..................... 64 
2.2.2.2.1 PGGE analysis ........................................................................... 65 











2.2.3 VLDL compositional analysis ............................................................. 69 
2.2.4 Genotyping ........................................................................................... 70 
2.2.4.1 DNA extraction and storage ............................................................. 70 
2.2.4.2 Determination of common apoE isoforms ....................................... 70 
2.2.4.3 Determination of apoE (Arg 145---*Cys) mutation ............................ 73 
2.2.4.3.1 Method 1 .................................................................................... 73 
2.2.4.3.2 Method 2 .................................................................................... 75 
2.2.4.4 Determination of apoE (Lys 146---*G ly) mutation ............................ 76 
2.2.4.5 ApoE sequencing ............................................................................. 77 
2.3 Statistical Methods ....................................................................................... 78 
2.3.1 Data Management ................................................................................ 78 
2.3.2 Data Analysis ....................................................................................... 79 
2.3.3 Statistical analysis ................................................................................ 79 
2.4 Reviewing the Cape Town experience of dysbetalipoproteinaemia ............ 80 
2.4.1 Dysbetalipoproteinaemia: definition for this study .............................. 80 
2.4.2 Case finding ......................................................................................... 82 
3 Chapter Three: Clinical and laboratory findings ................................................. 84 
3.1 Demographics .............................................................................................. 84 
3.1.1 Comparison with previously published case series ............................. 86 
3.2 ApoE genotypes ........................................................................................... 86 
3.2.1 ApoE (R145C) mutation ...................................................................... 87 
3.2.1.1 ApoE (R145C) population distribution ............................................ 89 
3.2.1.2 ApoE (R145C) and the common apoE isofonns ............................. 90 
3.2.1.3 Haplotype analysis of the apoE (R145C) gene ................................ 91 
3.2.2 ApoE sequences in patients with no identified apoE mutations .......... 94 
3.3 Total clinical experience .............................................................................. 96 
3.3.1 Follow-up ............................................................................................. 96 
3.3.2 Final outcomes ..................................................................................... 97 
3.4 Age at presentation ...................................................................................... 98 
3.4.1 Factors influencing age at presentation ................................................ 99 
3.4.1.1 Gender ............................................................................................ 100 
3.4.1.2 ApoE Genotype .............................................................................. 101 
3.4.1.3 Ethnicity ......................................................................................... 102 
3.4 .1.4 Physical signs of a lipid disorder ................................................... 102 
3.4.1.5 Metabolic precipitants of dysbetalipoproteinaemia ....................... 1 04 
3.4.1.6 Comparison with previous case series ........................................... 106 
3.5 Lipid investigations .................................................................................... 107 
3.5.1 Triglycerides ...................................................................................... 108 
3.5.1.1 Comparison with previously published case series ....................... 112 
3.5.2 Total cholesterol. ................................................................................ 112 
3.5.2.1 Comparison with previously published case series ....................... 115 
3.5.3 Ratio of total cholesterol to triglyceride ............................................ 115 
3.5.4 HDL Cholesterol ................................................................................ 116 
3.5.4.1 Comparison with previously reported case series .......................... 119 
3.5.5 Apolipoproteins .................................................................................. 119 
3.5.5.1 Apolipoprotein B ........................................................................... 119 
3.5.5.2 ApolipoproteinAl ........................................................................... 122 
3.5.5.3 Comparison with previously published case series ....................... 123 
3.5.6 VLDL compositional analysis ........................................................... 123 











3.5.6.2 Ratio of cholesterol vLDdtriglyceride Plasma (CV/TP) ..................... 125 
3.5.6.3 Comparison with previously published case series ....................... 127 
3.5.7 Agarose gel electrophoresis ............................................................... 127 
3.5.8 Polyacrylamide gradient gel electrophoresis ..................................... 131 
3.5.8.1 PGGE patterns ............................................................................... 134 
3.5.8.1.1 LDL particle sizes by PGGE .................................................... 142 
3.6 Physical stigmata of dyslipidaemia ............................................................ l46 
3.6.1 Palmar crease xanthomata .................................................................. 146 
3.6.1.1 Comparison with previously published case series ....................... 151 
3.6.2 Eruptive and tuboeruptive xanthomata .............................................. 152 
3.6.2.1 Comparison with previously published case series ....................... 156 
3.6.3 Tendinous xanthomata ....................................................................... 156 
3.6.3.1 Comparison with previously published case series ....................... 158 
3.6.4 Xanthelasmata .................................................................................... 159 
3.6.4.1 Comparison with previously published case series ....................... 161 
3.6.5 Arcus cornealis ................................................................................... 161 
3.6.5.1 Comparison with previously published case series ....................... 163 
3.6.6 Clustering of physical signs of dyslipidaemia ................................... 164 
3.7 Atherosclerotic complications ................................................................... 166 
3.7.1 lschaemic Heart Disease .................................................................... 167 
3.7.1.1 Comparison with previously published case series ....................... 169 
3.7.2 Peripheral vascular disease ................................................................ 171 
3.7.2.1 Comparison with previously published case series ....................... 173 
3.7.3 Cerebrovascular disease ..................................................................... 173 
3.7.3.1 Comparison with previously published case series ....................... 174 
3.8 Pancreatitis ................................................................................................. 174 
3.9 Disorders precipitating dysbetalipoproteinaemia ...................................... 176 
3.9.1 Diabetes .............................................................................................. 176 
3.9.1.1 Comparison with previously published case series ....................... 179 
3.9.2 Hypothyroidism ................................................................................. 180 
3.9.2.1 Comparison with previous case series ........................................... 181 
3.9.3 Renal disease ...................................................................................... 181 
3.9.3.1 Comparison with previously published case series ....................... 182 
3.9.4 Obesity ............................................................................................... 182 
3.9.4.1 Comparison with previously published case series ....................... 184 
3.9.5 Alcohol abuse ..................................................................................... 184 
3.9.5.1 Comparison with previously published case series ....................... 184 
3.9.6 Human immunodeficiency virus (HIV) infection and antiretroviral 
therapy (ART) .................................................................................................... 185 
3.9.6.1 Comparison with previously published case series ....................... 187 
3.10 Treatment experience ................................................................................. 187 
3.10.1 Lipid responses to therapy ................................................................. 191 
3.10.1.1 Triglycerides .............................................................................. 192 
3.10.1.2 Total cholesteroL ....................................................................... 194 
3.10.1.3 High density lipoprotein cholesterol.. ........................................ 199 
3.10.1.4 Apolipoproteins and PGGE ....................................................... 201 
4 Chapter Four: A clinical trial evaluating lipid-lowering therapy for 
dysbetalipoproteinaemia ............................................................................................ 203 
4.1 Study BayerW6228110176 ........................................................................ 203 











4.1.2 Laboratory evaluation ........................................................................ 206 
4.2 Study results ............................................................................................... 208 
4.2.1 Bayer Study ........................................................................................ 208 
4.2.1.1 Study course ................................................................................... 208 
4.2.1.2 Patient characteristics ..................................................................... 210 
4.2.1.3 Lipid results ................................................................................... 211 
4.2.1.3.1 Total cholesteroL .................................................................... 211 
4.2.1.3.2 Triglycerides ............................................................................ 214 
4.2.1.3.3 lIDLC ....................................................................................... 217 
4.2.1.3.4 Previously published data on treating dysbetalipoproteinaemia 
(plasma lipids) ............................................................................................ 222 
4.2.1.3.4.1 Historical overview ........................................................... 222 
4.2.1.3.4.2 Overview of drug trials in dysbetalipoproteinaemic patients 
224 
4.2.1.3.4.3 Bayer study versus historical data ..................................... 235 
4.2.1.4 VLDL compositional analysis ....................................................... 236 
4.2.1.4.1 Ratio CV/TV ............................................................................ 236 
4.2.1.4.2 Ratio CV/TP ............................................................................. 239 
4.2.1.4.3 Previously published data on changes in the VLDL 
compositional analysis with dysbetalipoproteinaemia treatment .............. 242 
4.2.1.5 Lipoprotein fractions: absolute masses .......................................... 245 
4.2.1.5.1 Method ..................................................................................... 245 
4.2.1.5 .1.1 Sequential ultracentrifugation ........................................... 245 
4.2.1.5.1.2 Lipoprotein fraction analysis ............................................ 248 
4.2.1.5.2 Plasma lipids ............................................................................ 249 
4.2.1.5.2.1 Plasma free cholesterol (FC) ............................................. 249 
4.2.1.5 .2.2 Plasma cholesterol ester (CE) ........................................... 251 
4.2.1.5.2.3 Plasma phospholipid (PL) ................................................. 253 
4.2.1.5.3 VLDL1 ..................................................................................... 254 
4.2.1.5.3.1 VLDLl protein .................................................................. 254 
4.2.1.5.3.2 VLDLI triglycerides ......................................................... 256 
4.2.1.5.3.3 VLDLI total cholesterol ................................................... 257 
4.2.1.5.3.4 VLDLl free cholesterol .................................................... 259 
4.2.1.5.3.5 VLDLl cholesterol ester ................................................... 260 
4.2.1.5.3.6 VLDLI phospholipid ........................................................ 262 
4.2.1.5.4 VLDL2 ..................................................................................... 263 
4.2.1.5.4.1 VLDL2 protein .................................................................. 263 
4.2.1.5.4.2 VLDL2 triglycerides ......................................................... 265 
4.2.1.5.4.3 VLDL2 total cholesterol ................................................... 266 
4.2.1.5.4.4 VLDL2 free cholesterol .................................................... 268 
4.2.1.5.4.5 VLDL2 cholesterol ester ................................................... 269 
4.2.1.5.4.6 VLDL2 phospholipid ........................................................ 271 
4.2.1.5.5 IDL ........................................................................................... 272 
4.2.1.5.5.1 IDL protein ........................................................................ 272 
4.2.1.5.5.2 IDL triglycerides ............................................................... 274 
4.2.1.5.5.3 IDL total cholesterol ......................................................... 276 
4.2.1.5.5.4 IDL free cholesterol .......................................................... 277 
4.2.1.5.5.5 IDL cholesterol ester ......................................................... 279 
4.2.1.5.5.6 IDL phospholipid .............................................................. 281 











4.2.1.5.6.1 LDL protein ...................................................................... 282 
4.2.1.5.6.2 LDL trig1ycerides .............................................................. 284 
4.2.1.5.6.3 LDL total cholesterol ........................................................ 285 
4.2.1.5.6.4 LDL free cholesterol ......................................................... 287 
4.2.1.5.6.5 LDL CE ............................................................................. 288 
4.2.1.5.6.6 LDL phospholipid ............................................................. 290 
4.2.1.5.7 HDL fraction ............................................................................ 291 
4.2.1.5.7.1 HDL protein ...................................................................... 291 
4.2.1.5.7.2 HDL triglycerides ............................................................. 291 
4.2.1.5.7.3 HDL total cholesteroL. ..................................................... 293 
4.2.1.5.7.4 HDL free cholesterol... ...................................................... 295 
4.2.1.5.7.5 HDL cholesterol ester ....................................................... 297 
4.2.1.5.7.6 HDL phospholipid ............................................................ 298 
4.2.1.6 Lipoproteins fractions: compositional changes ............................. 300 
4.2.1.6.1 VLDLl fractional composition ................................................ 300 
4.2.1.6.2 VLDL2 fractional composition ................................................ 302 
4.2.1.6.3 IDL fractional composition ...................................................... 303 
4.2.1.6.4 LDL fractional composition ..................................................... 305 
4.2.1.6.5 HDL fractional composition .................................................... 306 
4.2.1. 7 Lipoprotein fractions: Summary statistics ..................................... 307 
4.2.1.7.1 Triglycerides ............................................................................ 307 
4.2.1.7.1.1 Changes in triglyceride according to apoE genotype ....... 309 
4.2.1.7.2 Total cholesterol... .................................................................... 310 
4.2.1.7.2.1 Changes in total cholesterol according to apoE genotype 312 
4.2.1. 7.3 Free cholesterol and cholesterol ester ...................................... 314 
4.2.1.7.3.1 Changes in free cholesterol and cholesterol ester according 
to apoE genotype .................................................................................... 315 
4.2.1.7.4 Phospholipid ............................................................................ 317 
4.2.1. 7.4.1 Changes in phospholipid according to apoE genotype ..... 318 
4.2.1.8 Lipoprotein fractions: Graphical representation ............................ 320 
4.2.1.8.1 Lipoprotein fractions: absolute masses .................................... 320 
4.2.1.8.2 Lipoprotein fractions: relative masses ..................................... 323 
4.2.1.9 Previously published data on changes in lipoprotein fractions with 
lipid-lowering therapy in dysbetalipoproteinaemic patients .......................... 327 
4.2.1.9.1 VLDL ....................................................................................... 327 
4.2.1.9.2 IDL ........................................................................................... 333 
4.2.1.9.3 LDL .......................................................................................... 336 
4.2.1.9.4 HDLC ....................................................................................... 342 
4.2.1.9.5 Studies that report changes in compositional analysis of 
lipoprotein fractions ................................................................................... 344 
4.2.1.9.5.1 VLDL composition ........................................................... 344 
4.2.1.9.5.2 IDL .................................................................................... 346 
4.2.1.9.5.3 LDL ................................................................................... 346 
4.2.1.9.5.4 HDL .................................................................................. 347 
4.2.1.10 Agarose gel electrophoresis ....................................................... 347 
4.2.1.10.1 Agarose gel electrophoresis of plasma .................................. 360 
4.2.1.1 0.2 Agarose gel electrophoresis of lipoprotein fractions ............. 361 
4.2.1.11 Polyacrylamide gradient gel electrophoresis ............................. 364 
4.2.1.11.1 PGGE and apoE genotype ..................................................... 368 











4.2.1.11.3 TGRL size and lipid lowering treatment ............................... 370 
4.2.1.12 Safety Results ............................................................................. 371 
4.2.1.12.1 Serious adverse events (SAEs) .............................................. 371 
4.2.1.12.2 Adverse events leading to discontinuation of study medication 
373 
4.2.1.12.3 Other clinical adverse events ................................................. 374 
4.2.1.12.4 Laboratory monitoring ........................................................... 375 
4.2.1.12.4.1 Creatine kinase ................................................................ 375 
4.2.1.12.4.2 Liver function tests ......................................................... 376 
4.2.1.12.4.2.1 Transaminases .......................................................... 376 
4.2.1.12.4.2.2 Alkaline phosphatase (ALP) .................................... 380 
4.2.1.12.4.2.3 Other measures of hepatic function ......................... 380 
4.2.1.12.4.3 Amylase .......................................................................... 380 
4.2.1.12.4.4 Renal function tests ......................................................... 381 
4.2.1.12.4.4.1 Urea .......................................................................... 381 
4.2.1.12.4.4.2 Creatinine ................................................................. 382· 
4.2.1.12.4.4.3 Electrolytes .............................................................. 383 
4.2.1.12.4.5 Urate ................................................................................ 383 
4.2.] .]2.4.6 Glucose ........................................................................... 385 
4.2.1.] 2.4.7 Haematological parameters ............................................. 385 
5 Chapter Five: Breath test to study chylomicron remnant metabolism ............... 387 
5.1 Material and methods ................................................................................. 387 
5.1.1 Introduction ........................................................................................ 387 
5.1.2 Preparation of emulsions ..................................................................... 389 
5.1.3 Clinical protocol. ................................................................................ 391 
5.1.4 Breath sample analysis ....................................................................... 393 
5.1.5 Kinetic analysis of 13C-enrichment of CO2 ........................................ 393 
5.1.6 Illustrative Results ............................................................................. 397 
5.1.7 Limitations of breath test .................................................................. .400 
5.2 Results ........................................................................................................ 402 
5.2.1 13C02 profiles at baseline (prior to fitting data to compartmental 
model) 403 
5.2.2 13C0 2 profiles with lipid-lowering therapy (data not fitted to 
compartmental model) ....................................................................................... 405 
5.2.3 Breath test data fitted to compartmental model ................................ .408 
5.2.3. ] Individual patient example ............................................................ .408 
5.2.3.2 Study cohort ................................................................................... 411 
5.2.4 Kinetic variables ................................................................................ 414 
5.3 Discussion .................................................................................................. 416 
5.3. ] Kinetic studies in dysbeta]ipoproteinaemia ...................................... .416 
5.3.2 Lipoprotein kinetics in dysbetalipoproteinaemia ............................... 421 
5.3.2.1 Chylomicron metabolism ............................................................... 421 
5.3.2.2 VLDL, lDL and LDL metabolism ................................................. 422 
5.3.2.3 Changes in lipoprotein kinetics with lipid-lowering therapy ........ .422 
5.3.2.3.1 F ibrate therapy ......................................................................... 423 
5.3.2.3.2 Statin therapy ........................................................................... 423 
5.3.2.3.3 Comparison of breath test results with previously published 
literature 424 
6 Chapter Six: Diagnostic issues in dysbetalipoproteinaemia ............................. .427 











6.1.1 VLDL-compositional analysis cohort ............................................... .427 
6.1.1.1 ApoE genotyping .......................................................................... .428 
6.1.2 VLDL-cholesterol enrichment ratios ................................................ .430 
6.1.2.1 Ratio CV lTV .................................................................................. 430 
6.1.2.2 Ratio CV/TP ................................................................................... 431 
6.1.2.3 Relationship between ratios ofVLDL cholesterol-enrichment .... .432 
6.1.3 Diagnostic performance ofVLDL-compositional analysis .............. .433 
6.1.3.1 Ratio CV/TV .................................................................................. 433 
6.1.3.2 Ratio CV/TP ................................................................................... 435 
6.1.3.3 Concordance of ratios ................................................................... .436 
6.1.3.4 Concordance ofVLDL-compositional analysis for individual 
patients 437 
6.1.3.5 Receiver-operator characteristic curve (ROC) analysis ............... ..439 
6.1.3.5.1 Ratio CVITV ............................................................................ 439 
6.1.3.5.2 Ratio CVITP ............................................................................. 442 
6.1.3.5.3 Defining a diagnostic threshold .............................................. .445 
6.1.3.6 Other ratios ..................................................................................... 447 
6.1.3.7 VLDL-compositional analysis in the context of previously published 
experience ...................................................................................................... 448 
6.2 ApoB as a diagnostic test.. ........................................................................ .452 
6.2.1 Definition of patient groups studied ................................................ ..453 
6.2.2 Results ................................................................................................ 454 
6.2.2.1 Lipids ............................................................................................. 454 
6.2.2.2 Ratio apoB/TC ............................................................................... 457 
6.2.2.3 Ratio apoB/TG ............................................................................... 459 
6.2.3 Discussion of utility of apoB as a diagnostic test ............................. .460 
6.3 Suggested diagnostic strategy for dysbetalipoproteinaemia ..................... .462 
7 Chapter Seven: Conclusions ............................................................................. .464 
7.1 Clinical aspects of dysbetalipoproteinaemia ............................................. .464 
7.2 Special investigations in dysbetalipoproteinaemia .................................. ..467 
7.2.1 Lipids and apolipoproteins ................................................................. 467 
7.2.2 Electrophoresis in dysbetalipoproteinaemia ..................................... .468 
7.3 Treatment of dysbetalipoproteinaemia ..................................................... .470 
7.4 Diagnosis of dysbetalipoproteinaemia ....................................................... 472 
7.5 Changes in lipoprotein fractions associated with lipid-lowering medication 
473 
7.6 Patients without identified apoE mutations ............................................. ..474 
7.6.1 Similarities between genonegative and genopositive patients .......... .474 
7.6.2 Differences between genonegative and genopositive patients .......... .475 
7.6.3 Conclusions ........................................................................................ 475 
7.7 Limitations of this study ........................................................................... .477 
7.7.1 Dysbetalipoproteinaemia cohort ........................................................ 477 
7.7.2 Clinical trial ....................................................................................... 479 
7.8 The role of a lipid clinic in the diagnosis and management of 
dysbetalipoproteinaemia ........................................................................................ 480 
7.9 Future work on dysbetalipoproteinaemia in Cape Town .......................... .481 











Table of Contents: Tables 
Table I-I Characteristics of Selected Apolipoproteins in Nonnolipidaemic Fasting 
Humans 14 
Table 1-2 Amino acid differences between the three common apoE isofonns .... 20 
Table 1-3 Frequencies of common alleles at the apoE gene locus and resultant apoE 
phenotypes 22 
Table 1-4 Physico-chemical characteristics of the major lipoprotein classes .......... 26 
Table 1-5 ApoE variants associated with dysbetalipoproteinaemia ............................ 43 
Table 1-6 ApoE mutations associated with lipoprotein glomerulopathy .................... .47 
Table 2-1 Categories of dysbetalipoproteinaemic patients .......................................... 82 
Table 3-1 Ethnic and sex distribution of dysbetalipoproteinaemic patients ................ 84 
Table 3-2 Ethnic and sex distribution of all other patients seen at the GSH lipid clinic 
up to February 2004 ..................................................................................................... 85 
Table 3-3 ApoE genotypes in the dysbetalipoproteinaemia cohort ............................. 87 
Table 3-4 ApoE (RI45C) mutation in Zimbabwean patients ...................................... 90 
Table 3-5 Common isofonns of apoE in apoE (R145C) mutation carriers ................. 90 
Table 3-6 Microsatellite markers in two African patients homozygous for the apoE 
(RI45C) mutation ........................................................................................................ 93 
Table 3-7 Ages at presentation .................................................................................... 99 
Table 3-8 Gender differences in age at presentation ................................................. 101 
Table 3-9 Ages at presentation by metabolic precipitants ......................................... 105 
Table 3-10 Age at presentation and obesity ............................................................... 106 
Table 3-11 Untreated lipid values at presentation ..................................................... 108 
Table 3-12 Triglycerides by apoE mutation .............................................................. 110 
Table 3-13 Total cholesterol by apoE mutation ......................................................... 114 
Table 3-14 HDLC by apoE mutation ......................................................................... 117 
Table 3-15 ApoB (giL) levels by apoE genotype ...................................................... 120 
Table 3-16 CV/TV ratio by apoE genotype in untreated patients ............................. 124 
Table 3-17 Patients meeting phenotypic diagnostic criteria (CV /TV) in the untreated 
state ............................................................................................................................ 125 
Table 3-18 CV/TP ratio by apoE genotype in untreated patients .............................. 126 
Table 3-19 Patients meeting phenotypic (CV ITP) diagnostic criteria in the untreated 
state ............................................................................................................................ 126 
Table 3-20 Fredrickson classification of agarose gel electrophoresis ....................... 128 
Table 3-21 Final Fredrickson classification of agarose gels suggestive of 
dysbetalipoproteinaemia ............................................................................................ 129 
Table 3-22 ApoE genotypes in patients with Fredrickson Type III pattern who were 
not diagnosed with dysbetalipoproteinaemia ............................................................. 130 
Table 3-23 PGGE reports in dysbetalipoproteinaemia .............................................. 134 
Table 3-24 PGGE patterns by apoE genotype ........................................................... 135 
Table 3-25 Origin of specimens with PGGE reports suggesting 
dysbetalipoproteinaemia ............................................................................................ 138 
Table 3-26 Genotypic and phenotypic results in patients with PGGE patterns 
suggestive of dysbetalipoproteinaemia ...................................................................... 139 
Table 3-27 LDL size by apoE genotype .................................................................... 144 
Table 3-28 Palmar crease xanthoma by apoE genotype ............................................ 150 











Table 3-30 Eruptive/tuboeruptive xanthomata by genotype ...................................... 154 
Table 3-31 Eruptive/tuboeruptive xanthomata and lipid values ................................ 155 
Table 3-32 Tendinous xanthomata by genotype ........................................................ 15 7 
Table 3-33 Tendinous xanthomata and lipid values .................................................. 158 
Table 3-34 Xanthelasmata by genotype ..................................................................... 160 
Table 3-35 Xanthelasmata and lipid values ............................................................... 160 
Table 3-36 Arcus comealis by genotype ................................................................... 162 
Table 3-37 Arcus comealis and lipid values .............................................................. 163 
Table 3-38 IHD and other cardiovascular risk factors ............................................... 168 
Table 3-39 Age at diagnosis of IHD in the presence of other cardiovascular risk 
factors ......................................................................................................................... 169 
Table 3-40 PVD and other cardiovascular risk factors .............................................. 171 
Table 3-41 Age of diagnosis ofPVD in the presence of other cardiovascular risk 
factors ......................................................................................................................... 172 
Table 3-42 Diabetes at initial presentation by apoE genotype .................................. 178 
Table 3-43 Diabetes at initial presentation and measures of obesity ......................... 179 
Table 3-44 TC response to therapy by apoE genotype .............................................. 197 
Table 3-45 TC response to therapy by glycaemic status ........................................... 198 
Table 4-1 Study arms completed and reasons for early discontinuation ................... 209 
Table 4-2 Medication arms completed ...................................................................... 209 
Table 4-3 Clinical characteristics of the patients that completed at least one treatment 
arm ............................................................................................................................. 210 
Table 4-4 ApoE genotypes in patients that completed at least one treatment arm .... 211 
Table 4-5 TC during lipid-lowering therapy .............................................................. 212 
Table 4-6 TG during lipid-lowering therapy ............................................................. 215 
Table 4-7 HDLC during lipid-lowering therapy ........................................................ 218 
Table 4-8 First attempts at treating dysbetalipoproteinaemia .................................... 224 
Table 4-9 Fibrates for dysbetalipoproteinaemia ........................................................ 227 
Table 4-10 Statins for dysbetalipoproteinaemia ........................................................ 230 
Table 4-11 Trials comparing statins and fibrates ....................................................... 233 
Table 4-12 Ratio CV!TV with lipid-lowering therapy .............................................. 238 
Table 4-13 Ratio CV/TP with lipid-lowering therapy ............................................... 241 
Table 4-14 Changes in VLDL compositional analysis with lipid-lowering therapy .243 
Table 4-15 Sequential ultracentrifugation schedule .................................................. 248 
Table 4-16 Plasma free cholesterol concentration and lipid-lowering therapy ......... 250 
Table 4-17 Plasma cholesterol ester concentration and lipid-lowering therapy ........ 252 
Table 4-18 Plasma PL concentration and lipid-lowering therapy ............................. 253 
Table 4-19 VLDLl protein and lipid-lowering therapy ............................................ 255 
Table 4-20 VLDLl TG concentration and lipid-lowering therapy ............................ 256 
Table 4-21 VLDLl TC concentration and lipid-lowering therapy ............................ 258 
Table 4-22 VLDLl FC response to lipid-lowering therapy ....................................... 259 
Table 4-23 VLDLl CE and lipid-lowering therapy ................................................... 261 
Table 4-24 VLDLl phospholipid concentration and lipid-lowering therapy ............ 262 
Table 4-25 VLDL2 protein concentration and lipid-lowering therapy ...................... 264 
Table 4-26 VLDL2 TG concentration and lipid-lowering therapy ............................ 265 
Table 4-27 VLDL2 TC concentration and lipid-lowering therapy ............................ 267 
Table 4-28 VLDL2 FC and lipid-lowering therapy ................................................... 268 
Table 4-29 VLDL2 CE concentration and lipid-lowering therapy ............................ 270 
Table 4-30 VLDL2 PL concentration and lipid-lowering therapy ............................ 271 











Table 4-32lDL TG concentration and lipid-lowering therapy .................................. 275 
Table 4-33lDL TC concentration and lipid-lowering therapy .................................. 276 
Table 4-34 lDL FC concentration and lipid-lowering therapy .................................. 278 
Table 4-35lDL CE concentration and lipid-lowering therapy .................................. 280 
Table 4-36lDL PL concentration and lipid-lowering therapy .................................. 281 
Table 4-37 LDL protein concentration and lipid lowering therapy ........................... 283 
Table 4-38 LDL TG concentration and lipid-lowering therapy ................................. 284 
Table 4-39 LDL TC concentration and lipid-lowering therapy ................................. 286 
Table 4-40 LDL FC concentration and lipid-lowering treatment.. ............................ 287 
Table 4-41 LDL CE concentration and lipid-lowering therapy ................................. 289 
Table 4-42 LDL PL concentration and lipid-lowering therapy ................................. 290 
Table 4-43 HDL TG and lipid-lowering therapy ....................................................... 292 
Table 4-44 HDL TC and lipid lowering therapy ....................................................... 294 
Table 4-45 HDL FC concentration and lipid-lowering therapy ................................. 296 
Table 4-46 HDL CE concentration and lipid-lowering therapy ................................ 297 
Table 4-47 HDL PL concentration and lipid-lowering therapy ................................. 299 
Table 4-48 VLDLl fractional composition ............................................................... 300 
Table 4-49 VLDL2 fractional composition ............................................................... 302 
Table 4-50 lDL fractional composition ..................................................................... 303 
Table 4-51 LDL fractional composition .................................................................... 305 
Table 4-52 HDL fractional composition .................................................................... 306 
Table 4-53 Absolute mean reduction in TG (in mmol/L) from baseline ................... 308 
Table 4-54 Mean percentage reduction in TG from baseline within lipoprotein 
fractions ...................................................................................................................... 308 
Table 4-55 Percentage of reduction in total TG accounted for by each lipoprotein 
fraction ....................................................................................................................... 309 
Table 4-56 Absolute mean reduction in TG (in mmol/L) from baseline by apoE 
genotype ..................................................................................................................... 309 
Table 4-57 Mean percentage reduction in TG from baseline within lipoprotein 
fractions by apoE genotype ........................................................................................ 310 
Table 4-58 Percentage of reduction in total TG accounted for by each lipoprotein 
fraction by apoE genotype ......................................................................................... 31 0 
Table 4-59 Absolute mean reduction in TC (in mmol/L) from baseline ................... 311 
Table 4-60 Mean percentage reduction in TC from baseline within lipoprotein 
fractions ...................................................................................................................... 311 
Table 4-61 Percentage of reduction in total TC accounted for by each lipoprotein 
fraction ....................................................................................................................... 312 
Table 4-62 Absolute mean reduction in TC (in mmoVL) from baseline by apoE 
genotype ..................................................................................................................... 313 
Table 4-63 Mean percentage reduction in TC from baseline within lipoprotein 
fractions by apoE genotype ........................................................................................ 313 
Table 4-64 Percentage of reduction in TC accounted for by each lipoprotein fraction 
by apoE genotype ....................................................................................................... 314 
Table 4-65 Absolute mean reduction in FC and CE (in mmol/L) from baseline within 
lipoprotein fractions ................................................................................................... 315 
Table 4-66 Mean percentage reduction in FC and CE from baseline within lipoprotein 
fractions ...................................................................................................................... 315 
Table 4-67 Percentage of reduction in FC and CE accounted for by each lipoprotein 











Table 4-68 Absolute mean reduction in FC and CE (in mmol/L) from baseline within 
lipoprotein fractions by apoE genotype ..................................................................... 316 
Table 4-69 Mean percentage reduction in FC and CE from baseline within lipoprotein 
fractions by apoE genotype ........................................................................................ 316 
Table 4-70 Percentage of reduction in FC and CE accounted for by each lipoprotein 
fraction by apoE genotype ......................................................................................... 317 
Table 4-71 Absolute mean reduction in PL (in mmoUL) from baseline .................... 317 
Table 4-72 Mean percentage reduction in PL from baseline within lipoprotein 
fractions ...................................................................................................................... 318 
Table 4-73 Percentage of reduction in PL accounted for by each lipoprotein fraction 
.................................................................................................................................... 318 
Table 4-74 Absolute mean reduction in PL (in mmol/L) from baseline by apoE 
genotype ..................................................................................................................... 319 
Table 4-75 Mean percentage reduction in TC from baseline within lipoprotein 
fractions by apoE genotype ........................................................................................ 319 
Table 4-76 Percentage of reduction in PL accounted for by each lipoprotein fraction 
by apoE genotype ....................................................................................................... 320 
Table 4-77 VLDL response to lipid-lowering therapy in previously published studies 
.................................................................................................................................... 328 
Table 4-78 lDL response to lipid-lowering therapy in previous studies of 
dysbetalipoproteinaemia ............................................................................................ 334 
Table 4-79 LDL response to lipid-lowering therapy in previously published studies of 
dysbetalipoproteinaemia ............................................................................................ 337 
Table 4-80 VLDL composition as found by Lussier-Cacan et al .............................. 345 
Table 4-81 Agarose gel electrophoresis ofplasma .................................................... 361 
Table 4-82 VLDLl patterns on agarose gel electrophoresis ..................................... 362 
Table 4-83 VLDLl patterns according to apoE mutation status ............................... 363 
Table 4-84 PGGE patterns at baseline and with lipid-lowering therapy ................... 365 
Table 4-85 PGGE patterns and apoE genotype ......................................................... 369 
Table 5-1 Number of patients studied with breath test during Bayer study ............. .402 
Table 5-2 Model rate constants and FCR at baseline and with lipid-lowering therapy 
.................................................................................................................................... 414 
Table 5-3 Model rate constants and FCR: ANOVA ................................................. .415 
Table 5-4 Kinetic studies in dysbetalipoproteinaemia .............................................. .417 
Table 6-1 Number ofVLDL compositional analyses per individual patient ............ .428 
Table 6-2 Lipid concentrations at time ofVLDL-compositional analysis ............... .428 
Table 6-3 ApoE isoforms in patients who underwent VLDL-compositional analysis 
.................................................................................................................................... 429 
Table 6-4 ApoE (R145C) mutational screening ....................................................... .429 
Table 6-5 Concordance ofVLDL-compositional analysis in individual patients .... .438 
Table 6-6 ROC analysis of ratio CV/TV with plasma lipid criteria ......................... .441 
Table 6-7 ROC analysis of ratio CVlTP with plasma lipid criteria .......................... .444 
Table 6-8 Proposed diagnostic cutoffs for VLDL-compositional analysis ............... 448 
Table 6-9 Details of previous studies on VLDL-compositional analysis ................. .450 
Table 6-10 Clinical characteristics and lipid values in patients with 











Table of Contents: Figures 
Figure 1-1 Illustration of remnant metabolism ............................................................ 30 
Figure 2-1 Page 1 of initial visit data sheet... ............................................................... 55 
Figure 2-2 Page 2 of initial visit data sheet... ................................................................ 56 
Figure 2-3 Page 3 of initial visit data sheet... ............................................................... 57 
Figure 2-4 Page 1 of follow-up visit data sheet ........................................................... 58 
Figure 2-5 Page 2 of follow-up visit data sheet ........................................................... 59 
Figure 2-6 DNA consent form ..................................................................................... 61 
Figure 2-7 Calibration ofPGGE .................................................................................. 66 
Figure 2-8 Naming convention for PGGE ................................................................... 68 
Figure 2-9 LDL species size on PGGE ........................................................................ 69 
Figure 2-10 Hhal cleavage sites ................................................................................... 72 
Figure 2-11 Band patterns after Hhal cleavage ........................................................... 72 
Figure 2-12 Example of gel used to determine apoE isoforms .................................... 73 
Figure 2-13 Bbvl digest for ApoE (RI45C) ................................................................ 74 
Figure 2-14 ARMS assay for apoE (RI45C) ............................................................... 76 
Figure 2-15 ARMS assay for ApoE (KI46Q) ............................................................. 77 
Figure 2-16 Illustrative box and whiskers plot ............................................................ 79 
Figure 3-1 Relative proportions of dysbetalipoproteinaemia within ethnic groupings85 
Figure 3-2 Haplotypes in a kindred with the apoE (RI45C) mutation ........................ 92 
Figure 3-3 ApoE sequence in a genonegative patient (E3/E3) .................................... 94 
Figure 3-4 Heterozygous apoE (R145C) mutation carrier. .......................................... 96 
Figure 3-5 Duration of follow-up ................................................................................ 97 
Figure 3-6 Eruptive/tuboeruptive vs. quartiles of age at presentation ....................... 103 
Figure 3-7 Arcus cornealis by quartiles of age at presentation .................................. 1 04 
Figure 3-8 Triglycerides vs. age at presentation quartiles ......................................... 109 
Figure 3-9 Triglycerides by apoE mutation ............................................................... 11 0 
Figure 3-10 Severe hypertriglyceridaemia and gender. ............................................. II2 
Figure 3-] 1 Correlation oftriglycerides and total cholesterol... ................................ I13 
Figure 3-12 Total cholesterol vs. age at presentation quartiles ................................. 114 
Figure 3-13 Total cholesterol by apoE mutation ....................................................... 115 
Figure 3-14 HDLC vs. age at presentation quartiles .................................................. 117 
Figure 3-15 HDLC by apoE mutation ....................................................................... 118 
Figure 3-16 HDLC by triglyceride quartiles .............................................................. II9 
Figure 3-17 ApoB (giL) by apoE mutation ............................................ : ................... 121 
Figure 3-18 ApoB/TC ratio in dysbetalipoproteinaemia and FH .............................. 122 
Figure 3-19 Ratio CV/TV by apoE genotype in untreated patients ........................... 124 
Figure 3-20 Densitometric scans of PGGE patterns .................................................. 132 
Figure 3-21 PGGE patterns ........................................................................................ 133 
Figure 3-22 PGGE with no visible LDL by apoE genotypic status ........................... 135 
Figure 3-23 PGGE patterns by apoE mutation .......................................................... 136 
Figure 3-24 PGGE patterns by TG quartiles in patients with the apoE (RI45C) 
mutation ..................................................................................................................... 137 











Figure 3-26 LDL species in dysbetalipoproteinaemic patients with LDL-sized 
lipoproteins (proportional representation) ................................................................. 144 
Figure 3-27 LDL species size in genopositive patients by quartiles ofTG values .... 145 
Figure 3-28 Hand with palmar crease xanthomata .................................................... 147 
Figure 3-29 Palmar crease infiltration ....................................................................... 147 
Figure 3-30 Digital crease infiltration ........................................................................ 148 
Figure 3-31 Infiltration of toe crease ......................................................................... 148 
Figure 3-32 Palmar crease infiltration with LpX ....................................................... 149 
Figure 3-33 Close-up of palmar crease with LpX ..................................................... 149 
Figure 3-34 Eruptive xanthomata on the trunk and buttocks ..................................... 153 
Figure 3-35 Tuboeruptive xanthomata at the elbow .................................................. 153 
Figure 3-36 Tuboeruptive xanthomata in an African patient ..................................... 154 
Figure 3-37 Achilles tendon xanthomata in a patient with FH .................................. 156 
Figure 3-38 Xanthelasmata ........................................................................................ 159 
Figure 3-39 Arcus cornealis in a patient with dysbetalipoproteinaemia .................... 162 
Figure 3-40 Clustering of physical signs in complete cohort .................................... 165 
Figure 3-41 Clustering of physical signs in apoE2 homozygotes .............................. 166 
Figure 3-42 BMI in dysbetalipoproteinaemic patients .............................................. 183 
Figure 3-43 Waist circumference in dysbetalipoproteinaemic patients ..................... 183 
Figure 3-44 Drug classes used to treat dysbetalipoproteinaemia at the lipid clinic ... 188 
Figure 3-45 Relative proportion of drug classes prescribed to patients by apoE 
genotype ..................................................................................................................... 189 
Figure 3-46 Treatment of dysbetalipoproteinaemia according to duration of follow-up 
.................................................................................................................................... 190 
Figure 3-47 Treatment of dysbetalipoproteinaemia after five years of follow-up ..... 190 
Figure 3-48 Response to lipid lowering therapy and duration of follow-up .............. 192 
Figure 3-49 Baseline TG values and lipid-lowering therapy ..................................... 193 
Figure 3-50 Best TC achieved for monotherapy vs. combination therapy ................ 196 
Figure 3-51 Quartiles of WHR and response to therapy for TC ................................ 199 
Figure 3-52 HDLC and response to therapy by quartiles ofWHR ............................ 201 
Figure 4-1 Bayer W622811 0176 trial design ............................................................. 206 
Figure 4-2 TC during lipid-lowering therapy ............................................................ 213 
Figure 4-3 TC reduction from baseline ...................................................................... 214 
Figure 4-4 TG during lipid-lowering therapy ............................................................ 216 
Figure 4-5 TG reduction from baseline (%) .............................................................. 217 
Figure 4-6 HDLC levels during lipid-lowering treatment ......................................... 218 
Figure 4-7 Change in HDLC from baseline (%) ........................................................ 219 
Figure 4-8 Relationship between TG and HDLC at baseline .................................... 220 
Figure 4-9 Relationship between TG and HDLC on cerivastatin .............................. 220 
Figure 4-10 Relationship between TG and HDLC on fenofibrate ............................. 221 
Figure 4-11 Relationship between TG and HDLC on combination therapy ............. 221 
Figure 4-12 Ratio CV/TV in genopositive vs. genonegative patients at baseline ..... 237 
Figure 4-13 Ratio CV/TV during lipid-lowering treatment... .................................... 238 
Figure 4-14 Ratio CV/TV with lipid-lowering therapy in genopositive and 
genonegative patients ................................................................................................. 239 
Figure 4-15 Ratio CV ITP in genopositive vs. genonegative patients at baseline ...... 240 
Figure 4-16 Ratio CV ITP during lipid-lowering therapy .......................................... 241 
Figure 4-17 Ratio CV ITP with lipid-lowering therapy in genopositive and 
genonegative patients ................................................................................................. 242 











Figure 4-19 Plasma free cholesterol concentration and lipid-lowering therapy ........ 251 
Figure 4-20 Plasma CE concentration and lipid-lowering therapy ............................ 252 
Figure 4-21 Plasma PL concentration and lipid-lowering therapy ............................ 254 
Figure 4-22 VLDLl protein and lipid-lowering therapy ........................................... 255 
Figure 4-23 VLDLl TG and lipid-lowering therapy ................................................. 257 
Figure 4-24 VLDLl TC and lipid-lowering therapy ................................................. 258 
Figure 4-25 VLDLl FC and lipid-lowering therapy .................................................. 260 
Figure 4-26 VLDLl CE and lipid-lowering therapy ................................................. 261 
Figure 4-27 VLDLl PL and lipid-lowering therapy .................................................. 263 
Figure 4-28 VLDL2 protein and lipid-lowering therapy ........................................... 264 
Figure 4-29 VLDL2 TG and lipid-lowering therapy ................................................. 266 
Figure 4-30 VLDL2 TC and lipid-lowering therapy ................................................. 267 
Figure 4-31 VLDL2 FC and lipid-lowering therapy .................................................. 269 
Figure 4-32 VLDL2 CE and lipid-lowering therapy ................................................. 270 
Figure 4-33 VLDL2 PL and lipid-lowering therapy .................................................. 272 
Figure 4-34 IDL protein and lipid-lowering therapy ................................................. 274 
Figure 4-35 IDL TG and lipid-lowering therapy ....................................................... 275 
Figure 4-36 IDL TC and lipid-lowering therapy ....................................................... 277 
Figure 4-37 IDL FC and lipid-lowering therapy ........................................................ 278 
Figure 4-38 IDL CE and lipid-lowering therapy ....................................................... 280 
Figure 4-39 IDL PL and lipid-lowering therapy ........................................................ 282 
Figure 4-40 LDL protein and lipid-lowering therapy ................................................ 283 
Figure 4-41 LDL TG and lipid-lowering therapy ...................................................... 285 
Figure 4-42 LDL TC and lipid-lowering therapy ...................................................... 286 
Figure 4-43 LDL FC and lipid-lowering therapy ...................................................... 288 
Figure 4-44 LDL CE and lipid-lowering therapy ...................................................... 289 
Figure 4-45 LDL PL and lipid-lowering therapy ....................................................... 291 
Figure 4-46 HDL TG and lipid-lowering therapy ...................................................... 293 
Figure 4-47 HDL TC and lipid-lowering therapy ...................................................... 295 
Figure 4-48 HDL FC and lipid-lowering therapy ...................................................... 296 
Figure 4-49 HDL CE and lipid-lowering therapy ...................................................... 298 
Figure 4-50 HDL PL and lipid-lowering therapy ...................................................... 299 
Figure 4-51 VLDLllipids ......................................................................................... 321 
Figure 4-52 VLDL2 lipids ......................................................................................... 321 
Figure 4-53 IDL lipids ............................................................................................... 322 
Figure 4-54 LDL lipids .............................................................................................. 322 
Figure 4-55 All apoB-containing lipoproteins ........................................................... 323 
Figure 4-56 VLDL1 relative masses .......................................................................... 324 
Figure 4-57 VLDL2 relative mass ............................................................................. 324 
Figure 4-58 IDL relative mass ................................................................................... 325 
Figure 4-59 LDL relative mass .................................................................................. 325 
Figure 4-60 All apoB containing lipoproteins- relative masses ................................. 326 
Figure 4-61 Agarose gel (plasma) .............................................................................. 348 
Figure 4-62 Agarose gel of plasma and lipoprotein fractions (Patient JJV) ............. .349 
Figure 4-63 Densitometric scans of plasma and lipoprotein fractions (Pat JJV) ....... 349 
Figure 4-64 VLDL mlgration relative to plasma (Pat IN) ....................................... 352 
Figure 4-65 IDL and LDL mlgration relative to plasma (Pat JJV) ............................ 352 
Figure 4-66 VLDL mlgration relative to LDL (Pat JJV) ........................................... 353 












Figure 4-68 Densitometric scans of plasma and lipoprotein fractions (Pat FCC) ..... 354 
Figure 4-69 VLDL migration relative to plasma (Pat FCC) ...................................... 356 
Figure 4-70 IDL and LDL migration relative to plasma (Pat FCC) .......................... 357 
Figure 4-71 VLDL migration relative to LDL (Pat FCC) ......................................... 357 
Figure 4-72 VLDLl migration: Patients FCC and JJV ............................................. 358 
Figure 4-73 Categorization ofVLDLl migration patterns ........................................ 359 
Figure 4-74 VLDL2 migration: Patients FCC and JJV ............................................. 360 
Figure 4-75 Changes in individual VLDL2 migration from baseline relative to LDL 
migration .................................................................................................................... 364 
Figure 4-76 PGGE pattern showing only minor variations with therapy (pat JCJ) ... 366 
Figure 4-77 PGGE pattern showing increasing amounts of LDL-sized particles (Pat 
MHR) ......................................................................................................................... 367 
Figure 4-78 PGGE pattern showing reduction in TGRL and change in LDL-species 
size (Pat KLL) ............................................................................................................ 367 
Figure 4-79 LDL-species size with lipid-lowering therapy ....................................... 369 
Figure 4-80 Determination ofTGRL size in patients with A pattern ........................ 370 
Figure 4-81 Change in Rf ofTGRL with lipid-lowering therapy in patients 
maintaining an A pattern throughout study period .................................................... 371 
Figure 4-82 CK (x ULN) during the study ................................................................ 376 
Figure 4-83 ALT during lipid lowering therapy ........................................................ 377 
Figure 4-84 AST during lipid lowering therapy ........................................................ 378 
Figure 4-85 Creatinine during lipid-lowering therapy ............................................... 382 
Figure 4-86 Urate during lipid-lowering therapy ....................................................... 384 
Figure 5-1 Breath test of chylomicron remnant metabolism ..................................... 389 
Figure 5-2 Chylomicron remnant-like emulsion prior to injection ............................ 391 
Figure 5-3 Equipment used to collect end-tidal breath samples ................................ 392 
Figure 5-4 Compartmental model used to fit breath test enrichment data ................. 394 
Figure 5-5 Data plot prior to fitting data to compartmental modeL. ......................... 395 
Figure 5-6 Compartmental model fitted to data points .............................................. 396 
Figure 5-7 Kinetic variables obtained after fitting data to compartmental modeL ... 3 97 
Figure 5-8 Breath enrichment with 13C02 in normolipidaemic subjects ................... 397 
Figure 5-9 Breath enrichment with 13COZ in subjects with Type I hyperlipidaemia.399 
Figure 5-10 Breath enrichment with 13COZ in subjects with dysbetalipoproteinaemia 
.................................................................................................................................... 399 
Figure 5-11 13C0 2 profile at baseline in all patients ................................................. .403 
Figure 5-12 l3COz at baseline in genopositive and genonegative patients ............... .404 
Figure 5-13 13C02 at baseline in genopositive and genonegative patients (absolute 
changes) ..................................................................................................................... 404 
Figure 5-14 13C02 at baseline in patients who had breath tests while taking lipid-
lowering medication ................................................................................................... 405 
Figure 5-15 13C02 in patients taking cerivastatin (absolute change) ......................... 406 
Figure 5-16 13C02 in patients taking fenofibrate (absolute change) .......................... 406 
Figure 5-17 13C02 in patients taking cerivastatin and fenofibrate (absolute change)407 
Figure 5-18 13C02 at baseline and with lipid-lowering therapy (overlay of graphs).408 
Figure 5-19 Patient MHH: Compartmental modeling at baseline ............................. 409 
Figure 5-20 Patient MHH: Compartmental modeling on cerivastatin ....................... 409 
Figure 5-21 Patient MHH: Compartmental modeling on fenofibrate ........................ 410 
Figure 5-22 Patient MHH: Overlay of fitted data ..................................................... .410 











Figure 5-24 Compartmental modeling of averaged data at baseline (patients that 
completed more than one breath test) ....................................................................... .412 
Figure 5-25 Compartmental modeling of averaged data on cerivastatin .................. .412 
Figure 5-26 Compartmental modeling of averaged data on fenofibrate .................... 413 
Figure 5-27 Compartmental modeling of averaged data on cerivastatin and fenofibrate 
.................................................................................................................................... 413 
Figure 5-28 Overlay of compartmental models fitted to averaged data .................. ..414 
Figure 5-29 Changes in FCR and k(3,l) ................................................................... .415 
Figure 6-1 Frequency distribution histogram of ratio CVlTV .................................. .431 
Figure 6-2 Frequency distribution histogram of ratio CV/TP .................................. .432 
Figure 6-3 Correlation of ratio CVlTV with ratio CV/TP ........................................ .433 
Figure 6-4 Relative frequency distribution of ratio CV/TV in genopositive and 
genonegative patients ................................................................................................. 434 
Figure 6-5 Relative frequency distribution of ratio CV/TP in genopositive and 
genonegative patients ................................................................................................. 435 
Figure 6-6 Concordance of ratio CV/TV and CV/TP when using "high" threshold.436 
Figure 6-7 Concordance of ratio CV lTV and CV ITP when using "low" threshold .. 437 
Figure 6-8 ROC curve forratio CVITV (all plasma lipid values) ............................. 440 
Figure 6-9 ROC curve for ratio CV lTV (TC >7.5 and TG range 2.5-10.0) ............ ..442 
Figure 6-10 ROC curve for ratio CVITP (all lipid values) ....................................... .443 
Figure 6-]] ROC curve for ratio CVITP (TC >7.5 and TG range 2.5-10.0) ............ .445 
Figure 6-12 Relative frequency distribution of ratio CVITC in genopositive and 
genonegative patients ................................................................................................. 447 
Figure 6-13 ApoB levels ............................................................................................ 456 
Figure 6-14 ApoBITC ratio ........................................................................................ 457 
Figure 6-15 ROC curve for apoBITC ratio for dysbetalipoproteinaemia and mixed 
hyperlipidaemia .......................................................................................................... 459 











1 Chapter One: Introduction to 
dysbetalipoproteinaemia 
1.1 Introduction 
Dysbetalipoproteinaemia IS an uncommon (approximate incidence in a Western 
European population of 0.2-1 per 1000 (l» genetic disorder of lipoprotein 
metabolism. The molecular defect in dysbetalipoproteinaemia is in apolipoproteinE 
(apoE) (2), but isolated cases of complete hepatic lipase (HL) deficiency (3;4) with a 
lipoprotein phenotype similar to that seen in dysbetalipoproteinaemia have been 
described. The dysbetalipoproteinaemic phenotype is characterized by excessive 
accumulation of remnants of triglyceride-rich lipoproteins (TGRL), resulting in a 
variable but often severe mixed hyperlipidaemia in which the mass ratio of plasma 
triglycerides (TG) to plasma total cholesterol (TC) often approaches unity (5). Lipid 
infiltration of the skin and/or tendons may occur; palmar crease infiltration leads to 
the characteristic physical sign of palmar crease xanthomata (or xanthomata striata 
palmaris) seen in a minority of patients. Atherosclerotic complications, with a 
particular emphasis on peripheral vascular disease (PVD), are frequent and premature 
and often occur after relatively short periods ofhyperlipidaemia (6-10). 
1.2 Terminology 
Over the years many terms have been used to describe the disorder that I shall refer to 
as dysbetalipoproteinaemia in this thesis. In 1952 Gofman et al (11) described a lipid 
disorder characterized clinically by tuberous xanthomata over extensor surfaces and 
planar xanthomata of the palms. Analytical ultracentrifugation revealed increased 











lipoproteins (VLDL) and intennediate density lipoproteins (IDL) (SF 12-20). 
Gofman named this disorder xanthoma tuberosum. In 1967 Fredrickson published his 
classification of hyperlipidemias based on paper electrophoretic patterns (12). He 
identified a lipoprotein pattern with broad intense staining starting in the I) zone, 
where low density lipoproteins (LDL) stain, and extending into the pre- I) zone to 
which VLDL usually migrates (13). This broad I)-band pattern was designated as 
Type III hyperlipidaemia. Fredrickson numbered lipoprotein patterns beginning at the 
origin, or cathodal end, of the paper electrophoretic strip and allocated numbers as 
successive bands were unduly prominent (12). Thus Type I hyperlipidaemia describes 
increased chylomicrons that remain at the origin during paper electrophoresis. Type II 
hyperlipidaemia is characterized by a prominent I)-band, which is the first 
electrophoretic band in the absence of chylomicronaemia. Type IV hyperlipidaemia 
refers to an increase in the pre- ~ zone and as the broad I) -band straddles the ~ and 
pre- ~ zone it was allocated the number three. Fredrickson speculated that the patients 
with xanthoma tuberosum described by Gofman might in fact have had Type III 
hyperlipidaemia, as the lipoprotein patterns on analytical ultracentrifugation were 
remarkably similar and both cohorts included patients with unusual xanthomata of the 
hands. Fredrickson also described the unusual migratory behaviour of the 
ultracentrifugally isolated lipoprotein fraction with density < 1.006 glml in patients 
with dysbetalipoproteinaemia. This VLDL fraction migrated to the I)-position instead 
of the pre- ~ position and was referred to as ~-VLDL (14). 
Two of the other tenns used to name this disorder also refer to its unusual 
electrophoretic pattern. Broad- ~ disease describes the abnonnal electrophoretic band 











not manifest this characteristic band as subsequent studies have shown (8;15), and 
using the term broad-~ disease may result in clinicians who have little experience with 
the disorder falsely dismissing the diagnosis if a broad-~ band is not seen on 
electrophoresis. Lipoprotein electrophoresis, which is nowadays generally performed 
in agarose instead of on paper, is often no longer available in routine chemical 
pathology laboratories and many clinicians are not familiar with electrophoretic 
terminology anymore. The term dysbetalipoproteinaemia is not entirely unambiguous 
either, as it refers to the unusual physic,il and chemical properties ofVLDL (~-VLDL) 
in this disorder, causing it to migrate to the ~-position during electrophoresis. The 
main lipoprotein disturbance in this disorder is of course not found in the LDL or ~­
fraction but in larger and less dense lipoproteins such as VLDL and IDL. 
Nevertheless, the term dysbetalipoproteinaemia is commonly used in the literature. 
Searching PubMed at www.ncbi.nlm.nih.gov/entrez/quelyjcgi?db=PubMed (accessed 
on the 13th January 2006) with the search term "type III hyperlipidaemia" retrieved 
471 references while the term "dysbetalipoproteinaemia " retrieved 522 references. 
PubMed does cross reference search terms but the term "dysbetalipoproteinaemia" 
still retrieved more references, indicating more common usage. The designation 
familial dysbetalipoproteinaemia is also commonly used in the literature to indicate 
the genetic nature of the disorder (16-18). 
Most apoE variants associated with dysbetalipoproteinaemia are incompletely 
penetrant and many patients with abnormal apoE will either be normolipidaemic or 
even hypolipidaemic. These individuals may have detectable ~-VLDL and it has been 
suggested that they be labelled as dysbetalipoproteinaennc while patients that develop 











suggestion has not found general acceptance in the literature and the terms 
dysbetalipoproteinaemia and type III hyperlipidaemia are often used interchangeably. 
Dysbetalipoproteinaemia has also been referred to as remnant removal disease (19). 
Although this descriptive term describes the main pathophysiological abnormality in 
dysbetalipoproteinaemia well, it has not been generally adopted and is infrequently 
found in the literature. 
In this thesis I shall only use the term dysbetalipoproteinaemia for the sake of 
uniformity. Unless specifically stated otherwise, the diagnosis of 
dysbetalipoproteinaemia in this thesis defines a group of patients with a lipid 
phenotype characterized by elevation of both plasma triglycerides and total 
cholesterol secondary to accumulation of cholesterol-rich remnant lipoproteins. 
Patients were included in this study based on phenotypic criteria and apoE mutations 
have not been identified in all patients. 
1.3 Historical aspects 
1.3.1 Overview of the history of atherosclerosis 
Evidence of atherosclerosis has been found in some Egyptian mummies (5;20), 
indicating that this disease is certainly not new to mankind. Galen, the most influential 
physician of ancient Greece whose teachings dominated the European medical 
tradition until the Renaissance, described vascular aneurysms but did not describe 
other forms of atherosclerotic cardiovascular disease. During the Renaissance the 











advancing age and Leonardo da Vinci was one of the first to make this observation. 
As aneurysms are much more visible than atherosclerosis and often cause dramatic 
clinical presentations, vascular disease research focussed on them for many centuries. 
The term arteriosclerosis was first used in the early 19th century to describe the gruel-
like atheroma and hardening (sclerosis) of vessels associated with atherosclerosis. 
Virchow and Rokitansky, two of the leading pathologists of the 19th century, provided 
detailed pathological descriptions of atherosclerotic lesions and speculated about the 
causation of the lesion they studied under the microscope. Our modem understanding 
of atherosclerosis still incorporates elements of their theories. 
Experimental research on atherosclerosis first started in Russia in the early 20th 
century. Ignatowski, a young Russian pathologist, showed that feeding rabbits a 
protein-rich diet consisting of eggs, meat and milk was associated with the 
development of atherosclerosis in later life (21). This finding was initially interpreted 
as confirmation of an earlier hypothesis proposed by Metschnikow that high protein 
diets accelerate the ageing process. At that time atherosclerosis was seen as a disease 
of ageing, a chronic process that developed slow ly over many years and was an 
inevitable consequence of senescence. In 1910 Windaus published a paper showing 
that atherosclerotic aortas had a much higher cholesterol content than unaffected 
aortas (22). Inspired by Ignatowski's earlier work Anitschkow, an experimental 
pathologist in St. Petersburg, fed rabbits cholesterol dissolved in sunflower oil and 
rapidly induced lesions resembling human atherosclerosis. Rabbits fed only sunflower 
oil did not develop atherosclerotic lesions (23;24). Although Anitschkow published in 
widely read and well-respected German journals, his work was not taken seriously for 











were unable to do so as they used rats and dogs as experimental animals; species in 
which cholesterol feeding does not provoke atherosclerosis. The plasma cholesterol in 
Anitschkow's rabbits was also very high (around 12-25 mmollL) and as human levels 
are seldom as high as this, the experiments were thought not to be relevant to humans. 
Possibly the most significant reason for Anitschkow's findings being ignored for so 
long was that they simply did not fit in with the prevailing view of atherosclerosis as a 
slowly progressive degenerative disorder (25). 
Anitschkow first published his lipid hypothesis of atherogenesis in 1913, but the role 
of lipids and potential benefits of lipid-lowering therapy in human atherosclerotic 
disease remained controversial for many years (26;27). Epidemiological and early 
intervention studies (28;29) provided strong support for the lipid hypothesis but the 
opposition remained vociferous (30). Only following the discovery of 3-hydroxy-3-
methylglutaryl coenzyme A (HMGCoA) reductase inhibitors, which are now 
generally known as statins, by Endo was it possible to substantially lower cholesterol 
levels without major side effects. The Scandinavian Simvastatin Survival Study (4S) 
(31) was published in 1994 and conclusively showed that lowering cholesterol with 
simvastatin reduced death and cardiovascular events in a high-risk group of patients 
with hypercholesterolaemia and established ischaemic heart disease. The 4S 
persuaded some of the most strident critics of the lipid hypothesis to become 
enthusiastic proponents of statin therapy (32). Steinberg has recently reviewed the 
history of the "cholesterol controversy" in considerable detail (25;33-35). 











Artists depicted tendon xanthomata, which are most commonly associated with 
familial hypercholesterolaemia (FH), well before their clinical significance was 
known (36). I am, however, unaware of any artistic depiction of palmar crease 
xanthomata, the characteristic physical sign of dysbetalipoproteinaemia. This is 
perhaps not surprising as dysbetalipoproteinaemia is less prevalent than FH and 
palmar crease xanthomata may be quite subtle and go unnoticed by patients and many 
physicians. 
The history of dysbetalipoproteinaemia starts with Gofman and the first successful 
characterization of human lipoproteins (37). In 1952 Gofman described 23 patients 
with cutaneous xanthomata (xanthoma tuberosum) and a unique lipoprotein pattern 
(11). Gofman's work was based on analytical ultracentrifugation, a very costly and 
labour intensive method restricted to a few laboratories only. Using paper 
electrophoresis and preparative ultracentrifugation, techniques with greater 
availability and the capacity to process large amounts of specimens, Fredrickson 
further described the lipoprotein phenotype of dysbetalipoproteinaemia (14). 
Cholesterol enriched ~-migrating VLDL was the characteristic and main diagnostic 
feature of dysbetalipoproteinaemia for many years. 
Further studies of the lipoprotein phenotype in dysbetalipoproteinaemia demonstrated 
the presence of lipoprotein particles larger than VLDL and enriched in cholesteryl 
esters in the post-absorptive state (38;39). Chylomicrons studied during active fat 
absorption were of normal composition. This finding led to the suggestion that these 











remnants. Beta-VLDL would simiiarly contain partially degraded normal VLDL or 
VLDL-remnants. 
The fIrst step to understanding dysbetalipoproteinaemia on a molecular basis was 
taken when Havel et af found that the VLDL fraction of patients with 
dysbetalipoproteinaernia contained unusually large amounts of a protein called the 
arginine-rich protein (40). This protein was, of course, apoE. Utermann and his co-
workers analyzed apoE in more detail using isoelectric focusing (IEF) and found that 
a specifIc isoform of apoE was invariably absent in patients with 
dysbetalipoproteinaernia (41). Much work was subsequently done to understand the 
genetics of the apoE system and arrive at a uniform system of classifIcation (42-46). 
Mabley and co-workers determined the amino-acid sequence of apoE and the 
molecular differences between the various isoforms of apoE (47-49). Once the 
causative molecular defect in the vast number of dysbetalipoproteinaemic patients had 
been found, the pathophysiology of this disorder was soon unravelled. The process by 
which the pathophysiology of dysbetalipoproteinaernia came to be understood will not 
be described here, but will be addressed when the pathophysiology of the disorder is 
reviewed. The topic has also recently been reviewed in detail (50). 
1.4 Lipids and lipoproteins 
1.4.1 Lipids 
Lipids are organic compounds containing aliphatic hydrocarbons. They are generally 











or ether. Life as we currently know it would not be possible without lipids as they 
fulfill essential roles in maintaining the structural integrity and biological functioning 
of all cells. Biological systems contain a multitude of lipids and only those lipids 
critical to the understanding of lipoprotein metabolism will be briefly introduced here. 
Cholesterol is a 27-carbon sterol molecule (C27lLt60) that is absolutely essential to 
human life. Its evolutionary importance can be gauged by the fact that more than 100 
genes are involved in the regulation of cholesterol synthesis, concentration, transport 
and metabolism. Cholesterol, its precursors and metabolites are involved in processes 
as diverse as membrane physiology, nutrient absorption, reproduction, stress 
responses, calcium metabolism and regulation of salt and water homeostasis (51). It is 
therefore understandable that there was strong evolutionary pressure to ensure an 
adequate supply of cholesterol to all cells. All human cells are able to synthesize 
cholesterol and low levels of intracellular cholesterol activate a feedback system: 
SREBP-SCAP [sterol regulatory element binding protein (SREBP); SREBP-cleavage 
activating protein (SCAP)] complexes translocate to the Golgi apparatus where two 
proteolytic cleavages generate a protein capable of activating multiple genes involved 
in lipid synthesis and uptake (52). 
Cholesterol is also transported in lipoproteins and may be made available to cells with 
a high demand in this way. Cholesterol may be found either as free cholesterol (FC) 
or cholesteryl esters (CE). Esterification occurs at the alcohol moiety at position 3 of 
the cyclopentane phenanthrene. When cholesterol is esterified a long-chain fatty acid 
is linked to its hydroxyl group. The resulting molecule is less polar than cholesterol 











cholesterol acyltransferase (LCAT) catalyses the transfer of fatty acids from 
phosphatidylcholine to cholesterol while acylCoA: cholesterol acyltransferase 
(ACAT) is responsible for the synthesis of CE in other tissues. Cholesterol is 
therefore clearly essential for human survival and metabolic errors in cholesterol 
synthesis result in severe malformation syndromes (53). Yet excess cholesterol is 
clearly a major factor in the pathogenesis of atherosclerosis, the major cause of 
mortality in the industrialized world. From an evolutionary perspective, man has 
evolved elaborate mechanisms to guard against cholesterol deprivation, but deals with 
cholesterol excess brought about by a diet rich in animal products much less 
efficiently. Guarding against cholesterol excess might not have been subject to 
evolutionary pressure as life expectancy was generally shorter than the time needed 
for atherosclerosis to become overt. Plants have evolved cell membranes that differ 
from those found in the animal kingdom in several critical properties. It is therefore 
not surprising that the sterol molecules that have such profound influences on 
membrane properties differ. Plants do not synthesize cholesterol but a group of 
closely related sterols known collectively as phytosterols (e.g. sitosterol and 
campesterol). 
Triglycerides (or triacylglycerols) (TG) are esters of glycerol in which all three 
hydroxyl groups are esterified with fatty acids. The three fatty acids found in 
triglycerides may be identical or can differ. In biological systems unsaturated fatty 
acids usually occur at the sn2 position. Triglycerides are non-polar and are transported 
in the core of lipoproteins. T riglycerides are energy dense and provide about double 
the amount of energy (44 kilojoules/gram) found in carbohydrates or proteins. 











excess energy in the body. Most triglycerides in the body are stored in adipocytes. 
The ability to store energy and survive limited periods of famine was of great 
evolutionary importance, yet an excess of triglycerides (or their fatty acid 
constituents) in cells not designed for fat storage may have multiple deleterious 
consequences, collectively termed lipotoxicity (54). Adipocyte disorders may be 
associated with profound metabolic consequences (55). 
PhosphoJipids (PL) are chemically much more diverse and complex than the two 
other lipid classes discussed above. Phospholipids are formed from four components: 
fatty acids, a phosphate group with a negative charge, an alcohol and a backbone. The 
backbone may be glycerol in glycerophospholipids or sphingosine in sphingomyelin. 
Diacylglycerol 3-phosphate (or phosphatidate) is the simplest glycerophospholipid. 
Two hydroxyl groups of glycerol are esterified to fatty acids while the sn3 carbon is 
esterified to phosphoric acid. The major glycerophospholipids derive from 
diacylglycerol 3-phosphate. The phosphate group of diacylglycerol 3-phosphate 
becomes esterified to the hydroxy I group of one of several alcohols. Common alcohol 
moieties are serine, ethanolamine, choline, glycerol and inositol. In animal cells 
glycolipids are derived from sphingosine. The amino group of the sphingosine 
backbone is acylated by a fatty acid while the primary hydroxyl group is connected to 
a sugar. The sugar may be simple as in cerebroside or more complex and branched in 
gangliosides. Biologically the most important property of phospholipids is their 
amphipathic nature with both hydrophilic and hydrophobic domains. Phospholipids 
readily self-assemble in lipid bilayers and are the main constituents of cell 
membranes. The amphipathic nature of phospholipids means that they are found 











prone to free radical or enzymatic oxidation and may then exert significant pro-
atherogenic influences (56). Catabolism of many phospholipids requires specific 
lysosomal enzymes and catalytically deficient mutations of these enzymes may give 
rise to a lysosomal storage disorder (57). 
1.4.2 Apolipoproteins 
Human plasma contains a considerable amount of lipid which, according to its 
biochemical definition, should not be soluble in the aqueous milieu of plasma. Plasma 
lipids therefore need to be solubilized by associating with proteins. Additionally, such 
proteins allow for binding to lipoprotein receptors and enzymatic actions. Research on 
plasma lipoproteins started in the early 20th century with studies on horse lipoproteins 
(58). During World War II extensive efforts were made to isolate human serum 
proteins for therapeutic purposes and two major fractions with a1- and p-mobility 
respectively were recognized (59). Studies of the major protein components of these 
fractions successively led to the identification and characterization of many 
apolipoproteins. 
The best-known role of apolipoproteins is probably that of "structural backbone" in 
lipoproteins. Many apolipoproteins have amphipathic regions that aid in the formation 
and physical organization of lipoproteins. However, not all apolipoproteins have 
structural roles and many apolipoproteins have multiple biological functions. Thus 
apolipoproteins also bind to cellular lipoprotein-receptors, regulate enzymes involved 












A full description of all apolipoproteins is beyond the scope of this thesis and only 
apolipoprotein B (apoB) and apoE will be discussed in detaiL Table 1.1 summarizes 











Table 1-1 Characteristics of Selected Apolipoproteins in Normolipidaemic Fasting Humans 
Name Plasma concentration Molecular mass, Da Major tissue source Distribution in lipoproteins Functional role 
(gIL) 
HDL LDL IDL VLDL 
ApoAI 1.3 28016 Liver and intestine 100% Structural component of HDL, activates LCA T 
ApoATI 0.4 17414 Liver and intestine 100% Activate hepatic lipase . 
ApoAIV 46465 Liver and intestine Unknown, may facilitate transfer ofapolipoproteins between HDL and chylomicrons, 
endogenous antioxidant 
ApoAV 0.00015 40000 Liver + - ? + Enhance binding of lipoproteins to endothelium, activates LPL 
ApoCI 0.06 6630 Liver 97% 1% 2% Unknown, may inhibit lipoprotein lipase 
ApoClT 0.Q3 8900 Liver 60% 10% 30% Activates lipoprotein lipase 
ApoClTT 0.12 8800 Liver 60% 10% 10% 20% Inhibits lipoprotein lipase 
ApoD 0.1 29000 Sp leen, brain, testes, adrenals 100% ? Role in regulation of arachidonic acid signaling in brain 
ApoM Very low 26000 Liver, kidney +++ + + + Fonnation ofprejl HDL 











1.4.2.1 Apolipoprotein B 
ApoB plays a central role in human lipoprotein metabolism. The gene for apoB is 
located on chromosome 2 and gives rise to two forms of apoB: a truncated protein 
known as apoB48 and the full-length protein known as apoBlOO. 
ApoB48 is 48% of the amino-terminal portion of apoBlOO. ApoB48 is synthesized in 
the intestines while apoB I 00 is synthesized in the liver. In the intestine apoB 
messenger RNA (mRNA) undergoes organ-specific editing - a stop-codon is 
introduced at nucleotide 6666 by a mRNA editase (68)- resulting in the synthesis of a 
truncated protein. ApoB is a very large protein with a molecular mass of around 550 
kDa for apoBlOO and 265 kDa for apoB48. It is an amphipathic glycoprotein that 
tends to form insoluble aggregates in aqueous solutions. In plasma apoB is only found 
in associations with lipoproteins. ApoB cannot exchange between lipoprotein particles 
and remains with each lipoprotein particle for its entire "lifespan". Each lipoprotein 
particle only contains one apoB molecule. ApoB concentrations directly reflect the 
number of circulating apoB-containing lipoproteins. ApoB-containing lipoproteins are 
atherogenic and apoBlOO can be measured to predict atherosclerotic risk (69;70). 
Chylomicrons are synthesized in the intestines with apoB48 serving as the structural 
template. VLDL is synthesized in the liver with apoBIOO serving as the essential 
structural protein. A critical step in lipoprotein synthesis is the assimilation of 
adequate lipid so that apoB escapes ubiquitinylation and subsequent degradation. 
ApoBlOO remains with VLDL during its metabolism to IDL and LDL. Apart from its 
structural role apoB 100 also has a receptor-binding domain in its carboxyl-terminal 











VLDL, IDL and LDL. LDL uptake is almost entirely dependant on apoB mediated 
LDL-receptor binding, while alternative mechanisms exist for the uptake ofTGRL. 
ApoB 1 00 mutations may result in hypolipidaemic or hyperlipidaemic phenotypes 
depending on the change in the apoB 100 molecule. Truncating mutations cause 
hypocholesterolaemia while mutations in the LDL-receptor binding domain cause 
hypercholesterolaemia (71). 
1.4.2.2 Apolipoprotein E 
ApoE is a critical factor in remnant lipoprotein metabolism, exerting its influence 
through multiple mechanisms. ApoE binds to the LDL-receptor, the LDL-receptor 
related protein (LRP) and heparan sulfate proteoglycans (HSPG) (72) facilitating 
hepatic uptake of remnant lipoproteins. Increased levels of apoE stimulate VLDL 
synthesis and inhibit triglyceride hydrolysis (73). All these properties of apoE are 
important in understanding the pathophysiology of dysbetalipoproteinaemia and will 
be discussed in detail later. 
Shore et al first identified ApoE in 1973 (74) as a protein constituent ofVLDL. Initial 
research on apoE focussed on understanding the polymorphic nature of apoE and the 
role of apoE in lipoprotein metabolism. Clues indicating that apoE may playa role in 
neurological diseases subsequently began emerging and the role that apoE plays in 
neurobiology has been researched intensively since. ApoE is one of the primary 
apolipoproteins in the brain and has roles in neurite growth, neuronal repair and 
remodelling. The apoE4 isoform is a major susceptibility factor for Alzheimer's 











intracerebral haemorrhage and ischaemic stroke. The role of apoE in the central 
nervous system and neurological disorders will not be discussed in further detail but 
more information can be found in references (75-78). 
1.4.2.2.1 ApolipoproteinE cell biology 
The apoE gene is located on the long arm of chromosome 19 (19q 13.2 MIM 107741) 
in close association with apoCI, an apoCI pseudogene, apoClI and apoCIV. The gene 
of 3.7 kilobases (kb) contains four exons separated by three intr ns. ApoE mRNA is 
translated to a 317 amino acid nascent polypeptide. This polypeptide is directed to the 
endoplasmic reticulum by the 18 amino-terminal amino acids that act as a signal 
sequence (79). In the Golgi apparatus the protein undergoes O-linked glycosylation 
with the addition of carbohydrate moieties, with variable sialization at threonine 
residue 194 (80) prior to the protein being secreted (81). A significant amount of 
newly synthesized apoE is degraded prior to secretion (82;83).Secreted apoE may be 
tightly bound to cell surface proteoglycans (84). Surface-bound apoE may be released 
and circulate freely or be internalized by the cell, where it can either be degraded or 
recycled to the cell surface (85-87). 
ApoE mRNA is found in many tissues, with the highest level of expression in the 
liver followed by the brain. ApoE mRNA is found in tissues as diverse as 
macrophages, spleen, kidney, adrenals and muscles (88). In the brain apoE is secreted 
by astrocytes (89). In plasma the majority of apoE is of hepatic origin but extrahepatic 
secretion of apoE, mainly by macrophages, makes up 20-40% of circulating apoE in 











1.4.2.2.2 Apo/ipoproteinE structure 
The mature secreted apoE protein consists of 299 amino acids and has a relative 
molecular mass of 34 kDa. The apoE molecule has two distinct structural domains, 
the amino-terminal two thirds of the molecule and the carboxy-terminal one third. A 
hinge region connects these two domains. 
The amino-terminal domain of apoE consists of four amphipathic a-helix bundles 
(residues 24-42, 54-81, 87-122, 130-164) arranged in an anti-parallel fashion. The 
hydrophobic faces are orientated towards the interior of the bundle (91). The heparin 
and receptor-binding sites of apoE are found within the amino-terminal domain. The 
basic amino acids at positions 136,140,142,143,154,146,147 and 150 are essential for 
heparin binding (92). This arginine- and lysine-rich region of helix 4 (specifically 
residues 136-150) also binds to the acidic residues found in the binding regions of the 
LDL-receptor and LRP. (93). Residues 171-183 contains elements essential for the 
stabilization and proper alignment of the receptor-binding region (94). For apoE to 
bind to the LDL-receptor with high affinity it needs to be associated with lipids. When 
apoE associates with lipids, lysine at position 143 and 146 becomes more exposed to 
the aqueous phase while amino acids 165-169 fonn a helix. This change results in 
enhanced positive electrostatic potential in the receptor-binding region, allowing for 
high-affinity binding to the LDL-receptor (95;96). The amino-terminal portion of 
apoE also contains a binding site for scavenger receptor class B type I (97). The 
physiological importance of this finding still needs to be determined. The interaction 
of apoE with HSPG, LRP and the LDL-receptor is a highly complex physicochemical 











in and around the apoE receptor-binding region decrease receptor-binding affinity and 
depending on the nature of the mutation, binding to the various receptor types may be 
differentially affected. Mutations that lie outside of the receptor-binding region may 
still affect receptor binding by secondarily altering the conformation of this region. 
This principle is illustrated by the altered receptor binding of apoE (RI58C) or apoE 
Leiden. 
The structure of the carboxy-terminus (residues 210-299) of apoE is less well 
understood than the amino-terminus. The carboxy-terminus contains the major lipid 
binding and self-association regions of apoE. It also contains a heparin binding site 
(92). The carboxy-terminus of apoE is believed to adopt an amphipathic a-helical 
conformation with a segment that adopts a coiled-coil helix formation at the 
lipoprotein binding site (98). Residues 267-299 are responsible for apoE self-
association (99), while residues 245-266 determine lipoprotein binding preferences 
(l 00; I 01). The various isoforms of apoE preferentially associate with different 
lipoprotein classes. ApoE4, for instance, is preferentially found in VLDL lipoproteins. 
The arginine at position 112 in apoE4 forms a salt bridge with a glutamic acid at 
position ] 09 resulting in the side arm of arginine 61 being displaced. This likely alters 
the interaction of arginine 61 with the carboxy-terminal of apoE (probably with a 
glutamic acid residue at position 255) and results in altered lipoprotein binding 
affinity (102). 











ApoE is a highly polymorphic protein. Primary polymorphism is due to genetic 
variations at the apoE gene locus, while secondary polymorphism is brought about by 
variable degrees of sialylation at position 194. There are three common primary 
isoforms of apoE, known as apoE2, apoE3 and apoE4 according to their IEF 
migration. The common isoforms are the product of three alleles (e2, £3 and £4) at a 
single gene locus. The three common isoforms differ at amino acid positions 112 and 
158. The amino acid substitutions that differentiate the various isoforms also account 
for the charge difference seen on IEF of apoE. ApoE4 has two positive charges and 
apoE3 one positive charge relative to apoE2. 
Table 1-2 Amino acid differences between the three common apoE isoforms 
i Isoform Amino acid 
i 
Position 112 Position 158 
ApoE2 Cysteine Cysteine 
ApoE3 Cysteine Arginine 
ApoE4 Arginine Arginine 
1.4.2.2.4 ApolipoproteinE population genetics 
The d allele is the commonest allele and is often considered the human ''wild-type'', 
although the £4 allele may be the true "ancestral" allele. Almost all animals, including 
higher primates (l03), have the equivalent of a e4 allele. One could speculate that 












Infectious diseases may also have exerted evolutionary pressure on apoE. There is 
evidence that apoE influences outcome in several infectious diseases rather than 
susceptibility to infection. In hepatitis C virus infection the presence of the £4 allele 
protects against severe liver disease (104), while patients with the £2 allele are more 
severely affected by herpes simplex encephalitis (105). The strongest evidence for 
infectious diseases exerting evolutionary pressure on apoE comes from the study of 
apoE genotypes in malaria. Gambian infants homozygous for apoE2 were infected 
with malaria at a younger age (106;107), while the apoE3/E4 phenotype was enriched 
amongst infants with severe cerebral malaria and malarial anaemia (108). As apoE2 
homozygosity is highly prevalent in Gambia (14%) the authors of one report (107) 
speculate that early infection with malaria when maternal antibodies are still present 
may protect against more severe infection later in life. As the studies examined 
relatively small numbers of patients and have as yet not been replicated in other 
populations their findings must be treated with caution. 
There are six possible apoE phenotypes when the three different genotypes are 
combined. They are in descending order of frequency for most populations E3/E3, 
E4/E3, E3/E2, E4/E4, E41E2, and E21E2. Certain alleles are more frequent in some 
populations than others. For instance the £4 allele is more common in Northern 
European (14-19%) populations compared to Southern European populations (7-12%) 
(l09). Many African populations, e.g. from Nigeria or Sudan, also have a high 
prevalence of the £4 allele. Table 1.3 illustrates gene and phenotype frequencies found 











Table 1·3 Frequencies of common alleles at the apoE gene locus and resultant apoE phenotypes 
-------
Population Selection Sample Sex Genotype: Relative Phenotype frequencies % Reference 
studied criteria size M: frequency 
F E2 E3 Ee4 E21E2 E3!E2 E31E3 E41E2 E4!E3 E41E4 
African Nigerians Unknown 176 0.028 0.662 0.310 0 3 46 3 37 II (110) 
African Americans Population based 1612 0.131 0.668 0.201 1 18 44 5 27 5 (Ill) 
American Indians Community based 4541 2:3 0.016 0.855 0.129 0 2.5 72.5 0.5 23.5 1 ( 1121 
C': Framingham, Community based 2258 1: 1 0.08 0.787 0.133 0.5 13.1 62.7 1.7 18.8 3.2 (113) 
USA 
C1: Munster, Factory workers 1557 0.082 0.782 0.136 0.9 11.7 62.2 2.9 19.9 2.2 (114) 
Gennany 
C l : Finland Youths 1577 0.039 0.767 0.194 0.3 5.4 58.7 1.8 30.6 3.2 (115) 
CI : France Random selection 504 0.081 0.802 0.117 0.8 13.09 64.28 1.6 18.65 1.58 (116) 
C : Italy Random selecti.on 260 0.073 0.827 0.1 0.4 12 68.4 16.5 1.5 1.2 (117) 
Chinese Labourers 141 1:0 0.074 0.844 0.082 1.4 12.1 70.9 0 14.9 0.7 (118) 
Japanese Population based 576 0.037 0.846 0.117 0.3 6.1 71.9 0.7 19.3 1.7 (119) 
Mexican Americans Community based 963 0.039 0.859 0.102 0.21 6.74 73.8 0.73 17.32 1.1 (12Ol 
~ona Pregnant females 678 0:1 0.159 0.616 0.225 3.7 17.4 40.0 7.1 25.8 6.1 (121) 
C=Caucasian population 











1.4.2.2.5 Apolipoprotein E polymorphisms and cardiovascular disease 
The apoE polymorphism is one of the most thoroughly studied genetic 
polymorphisms. The impact of apoE polymorphisms on lipids and cardiovascular 
disease risk has only been studied at the population level for the three common 
polymorphisms (E2, E3 and E4) and only these will be considered in this section. The 
homozygous E3 genotype, as the most common genotype, is used as the referent 
against which the influence of other alleles is evaluated. The E2 allele is generally 
associated with lower total cholesterol while the £4 allele elevates total cholesterol 
(122). The apoE polymorphisms have similar qualitative effects in most populations 
studied, despite significant differences in mean cholesterol concentrations, diet and 
exercise, although the magnitude of impact is variahle (122). The effect is also 
observable when studying children (123). The E2 allele is reported to decrease total 
cholesterol on average by 0.36 mmollL while the E4 allele is associated with an 
increase of 0.21 mmollL in the otal cholesterol (122). The apoE gene accounts for 
8.3% (124) to 1% (113) of the variance in population LDL-cholesterol (LDLC) levels 
and contributes more to normal cholesterol variability than any other gene identified 
thus far. 
The impact of apoE polymorphisms has also been studied directly at the level of the 
vessel, either by imaging studies such as angiography or measurement of carotid 
intima-media thickness (lMT) , or at autopsy. In a study of healthy non-diabetic 
Italians the £4 allele was associated with significantly increased lMT thickness after 
statistical adjustment for other atherosclerosis risk factors (117). In an autopsy study 











account for 5.7% of the variation in observed atherosclerotic lesions in the thoracic 
aorta after adjustment for lipid levels (125). In a more recent study the coronary 
arteries of 70.0. Finnish men were examined at postmortem. The 84 allele was found to 
be a significant risk factor for atherosclerosis in younger and middle-aged men but 
was not significant anymore in older age (126). 
Epidemiological studies have also addressed the role of apoE polymorphisms in 
cardiovascular disease (CVD). In the MONICA project (Monitoring of Trends and 
Determinants in Cardiovascular Disease) an increase of 0..0. 1 in the relative frequency 
of the 84 allele was associated with an increase of 0..114 mm l/L in the average total 
cholesterol and an increase in coronary heart disease (CHD) mortality of 24.511 0.0.0.0.0.. 
In a subset analysis of the 4S those patients in the placebo group who carried.a 84 
allele had a mortality risk ratio of 1.8, independently of other risk factors for 
atherosclerosis. In patients treated with simvastatin this difference was not observed 
(127). It is important to note that although apoE polymorphisms have important 
effects at the epidemiological level, there is as yet no evidence to suggest that apoE 
genotypes should be determined routinely when screening for CVD risk. In fact, most 
studies addressing this issue have found areas under the receiver-operating 
characteristic curve (ROC) of around 0..5 (128-130.), indicating that determining apoE 
genotypes adds no useful information in CVD risk screening for individuals. 
1.4.3 Lipoproteins 
As discussed previously lipoproteins are complexes of lipids and proteins. They are 











alternative classification systems based on identifYing lipoproteins by the apoproteins 
present. As a general rule, the density of lipoproteins decreases as their size increases, 
as larger lipoproteins contain proportionally more lipid, of lower density, and less 
protein. Lipoproteins are generally not found as a sharp band at any given 
ultracentrifugal density, but distributed broadly around one or several peaks of 
maximal concentration along the density gradient. 
Lipoproteins are spherical particles and vary in size from more than 1000 nanometers 
(nm) to around 5-12 nm. Lipoproteins can be visualized by electron microscopy, but 
accumulation of larger TGRL results in plasma having a turbid to milky appearance 
(lipaemia) that is visible to the naked eye. This effect is due to light being scattered by 
lipoprotein particles. The lipid constituents of the outer lipoprotein shell are mainly 
phospholipids with some free cholesterol. Triglycerides and cholesteryl esters make 
up the core lipids. Apolipoproteins perform the structural and metabolic roles 
previously discussed. The physical and chemical characteristics of the main 











Table 1-4 Physico-chemical characteristics of the major lipoprotein classes 
Lipoprotein Density Molecular mass Electrophoresis ~ Diameter Lipid Constituents % 
g/mL 1 kDa nm 3 Triglycerides 
Chylomicrons <0.95 400 xl03 Origin 75-1200 80-95 
VLDL 0.95-1.006 10-80 x 103 Pre-beta 30-80 55-80 
IDL 1.006-l.0 19 5-10 x IOj Broad-beta 25-35 20-50 
LDL 1.019-1.063 2.3 x IOj Beta 18-25 5-15 
HDL 1.063-1.210 1.7-3.6 x 102 Alpha 5-12 5-10 
g/ml= grams per milliliter 
2 Electrophoretic mobility, bands labelled according to Fredrickson's nomenclature 









ApoB48, ApoCI-III, ApoE, ApoAI+II 
ApoB100, ApoCI-III, ApoE 
ApoB100, ApoCI-III, ApoE 
. ApoBI00 
----











Lp(a) consists of a LDL particle covalently linked to a protein called apo(a). Apo(a) is 
an extremely polymorphic protein that has close homology to plasminogen. Lp(a) 
occurs in only a few species. Lp(a) levels in humans vary markedly. The 
physiological significance of Lp(a) remains unclear and there are still many 
unanswered questions regarding this enigmatic lipoprotein (131). 
1.4.4 Lipoprotein metabolism 
This section will briefly review lipoprotein metabolism with particular emphasis on 
remnant metabolism and clearance. Reverse cholesterol transport in HDL will only be 
considered where it is relevant to the understanding of the metabolism of apoB 
containing lipoproteins. 
Dietary triglycerides are hydrolyzed by luminal lipases in the intestines and the 
resulting glycerol, free fatty acids, mono- and acylglycerols are absorbed by 
enterocytes. In the enterocyte re-esterification of these components yields intact 
triglycerides again. Chylomicrons are assembled in the endoplasmic reticulum of the 
enterocyte. ApoB48 is the structural apolipoprotein and apoAI and apoAIV are also 
associated with nascent chylomicrons. Chylomicrons are exocytosed into lymphatic 
spaces following translocation to the Golgi apparatus. Chylomicrons enter the plasma 
compartment via the thoracic duct. In plasma chylomicrons rapidly exchange 
apolipoproteins with other lipoproteins, especially HDL, and acquire apoE and apoCI-
III. Circulating chylomicrons are depleted of triglycerides by the action of LPL. LPL 
is bound to glycosaminoglycans (heparan sulphate) on the luminal side of capillary 
endothelial cells and hydrolyzes a proportion of chylomicron triglycerides. The 











chylomicron undergoes triglyceride hydrolysis some phospholipids and A-
apolipoproteins are transferred to HDL. The conformational change in chylomicrons 
also decreases the binding affinity of the C-apolipoproteins, which then transfer to 
HDL. LPL reduces the triglyceride content of chylomicrons by about 80-90% before 
the particle circulates again. The particle is now a chylomicron remnant and is 
markedly enriched in cholesterol compared to nascent chylomicrons. Chylomicrons 
undergo rapid metabolism with an average residence time of 5-10 minutes for 
chylomicron triglycerides in the circulation. The further metabolism of chylomicron 
remnants will be discussed together with that ofVLDL remnants. 
VLDL are synthesized in hepatocytes and are quantitatively the most important 
pathway for triglyceride and cholesterol export from the liver to the circulation. 
ApoB I 00 is the structural apolipoprotein of VLDL, but small amounts of C-
apolipoproteins and apoE are found on nascent VLDL. The triglycerides in VLDL 
derive either from uptake of free fatty acids (FF A) bound to albumin and re-esterified 
in hepatocytes, endogenous de novo synthesis or delivery to the liver by remnant 
lipoproteins. The VLDL secreted by the liver is not uniform in size and lipid 
composition, but covers a range of species. For practical purposes two main types of 
VLDL are generally recognized. VLDL may be large and triglyceride rich (VLDLl) 
or smaller and denser with less triglyceride (VLDL2). In normolipidaemic individuals 
VLDLl particles are the major determinant of plasma triglycerides (132; 133). In 
situations where triglycerides are in excess such as diabetes, alcohol abuse or obesity 
the liver preferentially secretes an excess of VLDLl (134). Circulating VLDL bind to 
endothelial LPL where they undergo triglyceride hydrolysis. Because VLDL particles 











residence time in the blood for VLDL triglycerides is accordingly substantially longer 
at 15-60 minutes than that of chylomicrons. The action ofLPL results in the formation 
of VLDL remnants. VLDL remnants may be taken up directly by the liver or undergo 
further metabolism and eventually be converted to LDL. In humans about half of 
circulating VLDL remnants will undergo conversion to LDL. Small VLDL particles 
give rise to relatively small remnants that bind apoE less efficiently than larger 
remnants. Smaller remnants therefore have delayed clearance and are more likely to 
undergo conversion to LDL than larger remnants. Small remnants often have 
"intermediate" density between VLDL and LDL and are isolated as IDL. 
VLDL remnants are converted to LDL by further lipoprotein remodeling in the 
circulation. Further triglyceride hydrolysis, mainly mediated by HL, occurs and a 
small triglyceride-poor and cholesterol-rich particle is formed. Due to its different 
conformation, LDL loses its binding affinity for apoE and apoB 1 00 remains as the 
only apolipoprotein. LDL is cleared slowly from the circulation (approximate 
residence time is three days) and therefore makes up the bulk of circulating 
lipoproteins. Specific LDL clearance is mediated exclusively by the LDL-receptor. 
Non-specific clearance by mechanisms such as fluid endocytosis is quantitatively 
much less important than receptor mediated clearance. LDL has a lower affinity for 
the LDL-receptor than VLDL remnants and therefore is cleared slowly. The liver 
takes up the bulk of the circulating LDL, although extrahepatic tissues, such as the 











Figure \-\ Illustration of remnant metabolism 
REMNANT METABOLISM 












The letters C, E, B48 and B100 indicate the presence of apolipoproteinC, apolipoproteinE, apolipoproteinB48 and apolipoprotein B100 on the 
respective lipoprotein 
VLDL: very low density lipoproteins 
LDL: low density lipoproteins 
VLDLR: very low density lipoprotein remnant 
CMR: chylomicron remnant 
Rem: remnant lipoprotein 
LPL: lipoprotein lipase 
HL: hepatic lipase 
LDLr: low density lipoprotein receptor 
LRP: low density lipoprotein receptor related protein 











1.4.4.1 Remnant metabolism 
Remnant clearance is almost exclusively mediated by the liver. For remnant 
lipoproteins to be cleared by hepatocytes they need to come in direct contact with 
hepatocytes first. In the liver the capillary endothelium differs from the endothelium 
found in most other organs of the body in that it is fenestrated. This fenestrated 
sinusoidal endothelium is in effect a biofilter that separates the hepatic blood from the 
plasma found in the space of Disse (135). Nascent chylomicrons are too large to enter 
the space of Disse, while chylomicron remnants are small enough to pass through the 
fenestrations. VLDL and its remnants are small enough to freely enter and leave the 
space of Disse. Pseudocapillarisation of the endothelium occurs in ageing and results 
in loss of the normal fenestrations. This results in delayed chylomicron remnant 
clearance and postprandial hypertriglyceridaemia. This mechanism has been 
suggested as an important factor in the pathogenesis of age-related atherosclerosis 
(136). 
The space of Disse is rich in HSPG (137), apoE (138) and HL (139). Remnants 
entering the space of Disse may also carry some LPL, but the role of this protein in 
remnant clearance under physiological conditions is not well defined as yet (72). 
Mahley and coworkers (72) suggested that hepatic remnant clearance is a three step 
process. Rapid sequestration of remnants in the space of Disse is followed by further 











Remnant lipoproteins entering the space of Disse are rapidly sequestered there. HSPG 
playa very important role in this regard as they are able to bind HL (as well as LPL) 
and apoE, the other important proteins participating in remnant clearance (140). 
Heparinase removes the sulfated glycosaminoglycan side chain from proteoglycans. 
Cells treated with heparinase have significantly reduced remnant binding and uptake 
compared to untreated cells (141). Experiments during which heparinase is injected 
into the portal vein of rats followed by injection of labelled p-VLDL show marked 
reductions in both plasma clearance and hepatic accumulation of the labelled 
substrate. The affinity and activity ofthe LRP and LDL-receptor for other ligands was 
not altered (141). ApoE in the space of Disse may be bound to HSPG and by binding 
to remnants acts as a "bridge" between HSPG and remnants. This results in 
sequestration of additional remnants. In mice expressing rat apoE, apoE was mainly 
localized in the sinusoids in the fasting state. Infusion of remnant lipoproteins 
changed the distribution of the apoE, it was now mainly found over the hepatic 
parenchymal cells and less was found in the sinusoids (142). The distribution ofHL is 
similar to that of the extracellular matrix and HSPG in and around the space of Disse 
(143). HL is not only important because of its catalytic activity but also because of its 
role in enhancing remnant binding. Experimental evidence for this comes from 
experiments in which rat hepatoma cell lines were transfected with various forms of 
human HL. Wild type HL increased remnant binding and clearance. Catalytically 
inactive HL with preserved cellular binding affinity also increased remnant binding, 
although to a lesser extent than wild type HL. Transfection with catalytically active 
but binding defective HL reduced remnant binding when compared to wild type HL 
(144). In human HL deficiency P-VLDL is often found in addition to increased 











three patients with catalytically deficient HL significant differences in lipoprotein 
composition were found between the two patients who expressed no HL protein and 
the one patient that expressed a small amount of HL protein. All patients had 
triglyceride-enriched lipoproteins, but the patient with measurable HL protein did not 
have marked cholesterol-enrichment of VLDL and IDL, indicating that even 
catalytically defective HL plays a role in remnant clearance (148). 
Following capture and sequestration of remnants further lipolytic processing may 
occur in the space of Disse. There is some disagreement as to the relative 
contributions made by HL (144;149) and LPL (150;151) t  this process. Further 
studies examining the amount of LPL transported on remnants and the amount of LPL 
in the space of Disse under physiological conditions are needed to resolve this issue. 
The three receptors that mediate remnant uptake by hepatocytes are the LDL-receptor, 
LRP and HSPG (140). Both apoB and apoE are ligands for the LDL-receptor. ApoE 
in remnants binds to LDL-receptors with high affinity, leading to rapid endocytosis of 
remnants. Experiments with fluorescently labeled chylomicron remnants in LDL-
receptor deficient mice showed normal sequestration of remnants in sinusoidal spaces 
but delayed uptake into hepatocytes. This suggests that the LDLR-receptor mediates 
fast hepatic uptake of remnants but that there are alternative pathways of remnant 
uptake (152). In another series of experiments with LDL-receptor deficient mice 
marked accumulation of cholesterol in LDL was found but there was no remnant 
accumulation (153). This finding is also supportive of the existence of additional 
alternative pathways to the LDL-receptor for clearing remnants. The LRP is a 











The LRP molecule is escorted to the cell surface following intracellular synthesis by a 
chaperone protein called the receptor associated protein (RAP) (154) . Intravenously 
injected RAP blocks all ligands from binding to the LRP (155), while binding itself to 
HSPG. HSPG is important to the functioning of the LRP. In Chinese Hamster Ovary 
(CHO) cell experiments ~-VLDL binding is enhanced if the medium is enriched in 
apoE to mimic the conditions found in the space of Disse. This enhanced binding 
activity is due to the LRP/HSPG pathway, as LDL-receptor antibodies do not block it 
substantially. LDL-receptor antibodies block basal (non apoE enriched) binding 
substantially . Binding of ~-VLDL not enriched in apoE was quantitatively 
comparable in normal cells and cells with mutant HSPG. Enrichment of ~-VLDL with 
apoE increased binding 4-7 fold in nonnal cells but produced no measurable increase 
in the cells with mutant HSPG. Hep arinase treatment of nonnal cells eliminated the 
enhanced binding seen with apoE, while a2-macroglobulin binding was normal in the 
mutant cells and not influenced by heparinase treatment (144). Functional HSPG is 
therefore essential on the cell surface to mediate the enhanced binding observed in an 
apoE-enriched environment. Experiments with LRP-null fibroblasts showed enhanced 
binding and uptake of apoE-enriched ~-VLDL, although the enhancement was not as 
marked as that observed in wild-type cells. Heparinase treatment eliminated the 
enhanced binding, proving that HSPG alone can make a significant contribution to 
remnant uptake (156). 
A great deal of work has been done examining the relative contribution that each of 
these three receptors make to remnant metabolism. Much of this work has been done 











In summary, these studies (l 153;1 show that inhibition of 
either LDL-receptors or HSPG/LRP does not significantly influence remnant 
as there is excess capacity in the system. Inhibition all three 
results in severe remnant accumulation, as does the 
critical ligand for all three receptors. 
of 
Pathophysiology of dysbetalipoproteinaemia 
which is the 
The of is and only the last decade has 
brought a fuller understanding of the molecular mechanisms that result in the 
phenotype. In all cases of 
considered here dysfunctional apoE is the initial pathophysiological abnormality. The 
majority patients with aySbf~tallp()prote:m,len1Ia are homozygous for the £2 allele of 
(5), but mutants that are inherited as autosomal dominants and 
also need to be considered as causes. 
1.5.1 Precipitating factors 
for apoE2 IS the most common substrate for 
dysbetalipoproteinaemia, but less than J 0% of apoE2 homozygotes ever develop 
hyperlipidaemia. Most homozygotes are or even 
hypolipidaemic (50). Hyperlipidaemia is also not present at birth but develops in 
adulthood. homozygotes therefore additional "metabolic stressors" or 












Transgenic mice expressing human apoE2 at levels of 10-30 mg/dL were 
hypolipidaemic (158), as are most humans with this genetic makeup. Transgenic 
apoE2 mice that additionally overexpressed human apoB developed hyperlipidaemia 
characterized by low levels of LDL-cholesterol and remnant accumulation. This 
situation may perhaps be analogous to that seen in subjects who co-inherit apoE2 
homozygosity and another condition, such as familial combined hyperlipidaemia 
(FCH), that is characterized by the overproduction of apoB containing lipoproteins 
(159). Disorders such as diabetes or alcoholism are also often complicated by 
overproduction of apoB-containing lipoproteins. 
Changes in LDL-receptor availability may also precipitate hyperlipidaemia in 
genetically predisposed subjects. ApoE2 transgenic mice crossed with LDL-receptor 
null mice developed a dysbetalipoproteinaemic phenotype. In humans FH may be due 
to mutations in the LDL-receptor. Several studies have addressed the issue of co-
inheritance of apoE2 homozygosity and LDL-receptor mutations (160;161). Co-
expression of both defects in humans does not have a simple additive effect but results 
in complex modulation of individual gene expression. This issue will be addressed in 
more detail later in this thesis. Hypothyroidism affects human lipid metabolism in 
many ways and decreased availability of LDL-receptors may be a mechanism 
whereby hyperlipidaernia is precipitated . Ageing is also associated with a decrease in 
hepatic LDL-receptor numbers. Diets high in cholesterol may also downregulate 
hepatic LDL-receptor expression. 
It is most unusual for women homozygous for apoE2 to develop hyperlipidaemia 











In nV:,lolObUC,H amounts, therefore seems to be a protective factor. ApoE2 
transgenic rabbits show marked differences despite P¥.WP'oc comparable 
levels of Male rabbits hyperlipidaemia that was reversed by 
treatment with £\P,",."", •• ,.,o while female rabbits became hyperlipidaemic following 
ovariectomy. Oestrogen treatment was associated with increased lipolytic activity 
increased (l Other animal studies have also shown that 
doses of £\p,orrr,,,,,,,',, can increase In a 
human turnover study a postmenopausal female with dysbetalipoproteinaemia was 
treated with 1 !lg/kg/day. Turnover studies were performed before 
and after hormone supplementation. Hyperlipidaemia improved markedly, as seen in 
other cases of hormone supplementation (l and VLDL was 
accelerated significantly. VLDL-production was also increased by a factor of 60% but 
increased remnant clearance more than ('I"\rnn,'''' for this increase (l 
Renal disease can influence metabolism through 
mechanisms. Nephrotic range proteinuria is often associated with overproduction of 
lipoproteins while with chronic renal failure often have impaired lipolytic 
activity (1 165). Both these mechanisms may contribute to remnant accumulation. 
Several classes of 
mechanisms of 
are well known to influence lipid metabolism. The molecular 
induced hyperlipidaemia are varied (166; 167), but 
increased lipoprotein production or decreased lipoprotein clearance 
may be operative either alone or in combination. Dmgs such as steroids, HIV I.JI'-"""';>'" 
inhibitors (PI), retinoids or beta-blockers may therefore precipitate 











1.5.2 Defective receptor binding 
ApoE variants that are associated with the development of dysbetalipoproteinaemia 
are characterized by defective binding to hepatic lipoprotein receptors. There are, 
however, important differences between the various apoE mutants in their bindIng 
affinity to the hepatic receptors involved in remnant clearance (LDL-receptor, 
LRP/HSPG). ApoE2 has less than 2% of normal LDL-receptor binding. Although the 
amino acid change at position 158 from arginine to cysteine, that distinguishes apoE2 
from apoE3, lies outside of the direct LDL-receptor binding region it causes 
secondary structural changes that alter the binding region's conformation 
significantly. In apoE3 a salt bridge forms between Arg-158 and Asp-154. This does 
not occur in apoE2 and instead Asp-154 interacts with Arg-150 to form a new salt 
bridge. This dramatically alters the charge surface presented by apoE2 to its receptor, 
resulting in decreased receptor binding (168). 
The dominantly transmitted mutations in apoE also have reduced LDL-receptor 
binding (often around 20-50% of normal), but their binding activities are higher than 
that of apoE2 (50). Conceptually, it not intuitively obvious why these mutants with 
better LDL-receptor binding than apoE2 are able to cause hyperlipidaemia in a 
dominant fashion, while two copies of apoE2 and precipitating factors are necessary 
to cause disease. This phenomenon is partially explained if one considers not only 











ApoE2 has 50-90% of normal HSPG binding affinity while many of the autosomal 
dominant variants have very poor binding to HSPG (169). The importance of this 
receptor pathway is demonstrated by experiments with transgenic mice lacking both 
murine apoE and functional LDL-receptors. In mice expressing human apoE2 
cholesterol levels were approximately double normal, while mice expressing the 
dominant mutant apoE (ArgI42Cys) had cholesterol levels eight times higher than 
expected. The apoE2 mice were still able to use the HSPG/LRP pathway, but in the 
absence ofLDL-receptors the apoE (Arg142Cys) mice were unable to clear remnants 
because of their inability to use the alternative HSPG/LRP pathway (50). The 
HSPG/LRP binding affinity of apoE variants is therefore an important determinant of 
dominant versus recessive expression of dysbetalipoproteinaemia. The HSPG/LRP 
pathway is so important because defective function of this pathway impairs both the 
initial sequestration of remnants in the space of Disse and subsequent receptor-
mediated uptake. 
1.5.3 ApoE and lipolys s 
ApoE2 homozygotes characteristically have low levels of LDL-cholesterol. These low 
levels of LDL-cholesterol can be explained by several hypotheses. Poor uptake of 
remnants may lead to cholesterol depleted hepatocytes and upregulation of hepatic 
LDL-receptors. Remnants may also compete poorly with apoB 100 containing LDL 
for clearance at the LDL-receptor leading to enhanced LDL clearance. Most evidence, 
however, supports the hypothesis that impaired formation of LDL, due to decreased 
lipolytic conversion of VLDL to LDL, accounts for the low LDL levels. In transgenic 
apoE2 + LDL-receptor null mice the LDL-cholesterol levels are low, implying that 











(170). However, apoE2 enriched VLDL and lDL were poor substrates in an assay of 
lipolysis. Increasing concentrations of apoE2 resulted in progressively decreasing 
release of free fatty acids in the lipolytic assay (170). ApoE2 inhibits lipolysis by 
displacing apoCIl, an activator of LPL, from the lipoprotein and adding additional 
apoCIl to the medium partially corrects impaired lipolysis secondary to apoE2 
accumulation (170). ApoE also activates HL, but apoE2 is a less effective activator 
than apoE3 (171; 172). HL mediated lipolysis of lDL to LDL is therefore also 
impaired, leading to decreased LDL production. 
1.5.4 ApoE distribution in lipoproteins 
ApoE variants do not only differ in their binding affinity towards hepatic lipoprotein 
receptors but also preferentially associate with certain lipoprotein classes. ApoE2 
preferentially associates with HDL (173;174), while certain dominant mutants 
preferentially associate with VLDL. The presence of Arg-1l2 determines preferential 
VLDL association (173). Preferential distribution into VLDL has been documented 
for apoE-Leiden (175) and apoE (Arg142Cys) (176). In ~-VLDL from patients 
carrying the apoE-Leiden mutation the ratio of mutant to normal apoE approaches 7:1 
(175). Enriching VLDL in mutant apoE displaces more apoCII from the particle, 
impairing its suitability as a lipolytic substrate. The VLDL of transgenic mice 
expressing similar plasma levels of apoE was a much worse lipolytic substrate if the 
apoE (ArgI42Cys) mutation was introduced rather than apoE2 (50). 











ApoE plays an important role in the secretion of VLDL triglycerides. Hepatocytes 
from apoE-deficient mice secrete about 50% less triglycerides than hepatocytes from 
wild-type mice (177). Conversely overexpression of human apoE in rat hepatocytes 
was associated with increased VLDL triglyceride secretion that paralleled apoE levels 
(73). A similar, but more pronounced, effect has also been demonstrated in human 
apoE3 transgenic rabbits (178). Elevated levels of apoE characterize 
dysbetalipoproteinaemia and increased VLDL production therefore is an important 
component in the genesis of hyperlipidaemia (179). 
1.5.6 Pathophysiology of apoE deficiency 
Dysbetalipoproteinaemia is usually due to the presence of excessive levels of 
dysfunctional apoE, but occasionally apoE mutations may result in complete or partial 
apoE deficiency. Several kindreds with apoE deficiency have been described (180-
183). Human apoE deficiency is associated with severe hyperlipidaemia, but the 
phenotype differs from that seen in other forms of dysbetalipoproteinaemia. There is 
hypercholesterolaemia but hypertriglyceridaemia is not a prominent feature. 
Remnants are markedly cholesterol-enriched and the ratio of VLDL cholesterol to 
plasma triglycerides is higher than in dysbetalipoproteinaemia due to binding-
defective apoE mutants (183). Triglycerides do not accumulate significantly in apoE 
deficiency as VLDL-lipolysis is not inhibited and VLDL secretion is not stimulated. 
1.5.7 ApoE variants associated with dysbetalipoproteinaemia 












Table 1-5 ApoE variants associated with dysbetalipoproteinaemia 




Arg158-Cys <2% -50% ApoE2, homozygosity and precipitating factor required for 
phenotypic expression 
Arg145-Cys Common in South Africa, homozygotes described (184) 
Argl45-Cys Moderate Low ApoE Philadelphia (185;186) 
Glu13-Lys 
Arg145-His ApoE Kochi (187) 
Arg136-Ser Moderate Mutant apoE predominates in plasma, found in Spain (188;189) 

















Arg142----+Cys Low Very low Very severe hyperlipidaemia, early expression, very rare, used (176;191 ;192) 
'as model in transgenic animal work 
Arg142----+Leu Identified in single family (193) 
Lys 1 46----+Gln Moderate Large pedigrees studied (Dutch), variable phenotype, (194-197) 
(-40%) 
Lys146----+Glu Low Very low ApoE-l Harrisburg, highly penetrant (198-200) 
r-----" 
Lys 146----+Asn ApoE1-Hammersmith, onset in childhood, phenotype is severe (201) 
Arg147----+Trp 












Mutation Receptor·binding affinity Comments References 
LDL· HSPG/LRP 
receptor binding 
-- --- -- _. 
Glu244,245~Lys Apo E Suita, remnant accumulation demonstrated (203) 
Notes: 
1. Table based on references (50;204) and Online Mendelian Inheritance in Man (OMIM) 
2. The table does not aim to list all apoE mutants or variants 
3. ApoE variants that are associated mainly with hypertriglyceridaemia have not been included in this table 
4. The table does not variants associated with lipoprotein glomerulopathy 











1.5.8 ApoE and lipoprotein glomerulopathy 
Lipoprotein glomerulopathy is a very rare disorder (approximately 65 cases reported 
so far worldwide (205)) that was only officially recognized in 1995. Almost all cases 
have been reported from Japan with a few cases seen in China and Europe. 
Lipoprotein glomerulopathy is characterized histologically by lipoprotein thrombi in 
markedly dilated glomeruli. The histology of lipoprotein glomerulopathy is distinct 
from that seen in LCAT deficiency which is also a primary lipid disorder that causes 
renal failure secondarily. The renal histology of LCAT deficiency is characterized 
primarily by focal segmental glomerulosclerosis, mesangial expansion and 
"ballooning" of glomerular loops filled with foamy lipid-like material (206). 
The renal lesions of lipoprotein glomerulopathy cause mild to severe proteinuria and 
about half of the patients reported so far have progressed to renal failure. On 
biochemical evaluation serum levels of apoE are markedly increased (mean 17.1 
mg/dL; SEM 1.9 (205) in 40 cases) and hyperlipidaemia is common but not 
invariable. Mean (± SEM) TG are 3.53 ± 0.32 mmollL with TC 7.04 ± 0.41 mmollL 
(205). These lipid values are somewhat lower than those reported in most cases series 
of dysbetalipoproteinaemic patients (7;9;lO;207). The VLDL is cholesterol enriched, 
meeting diagnostic criteria proposed for dysbetalipoproteinaemia (208). 
Lipoprotein glomerulopathy by definition requires a mutation of apoE to be present. 











Table 1-6 ApoE mutations associated with lipoprotein glomerulopathy 
Mutation Common name Comments References 
Argl45-Pro ApoE Sendai Commonest mutation (209) 
I Cys25-Arg ApoEKyoto (210) 
Del Leu 141 to Lys 143 ApoETokyo (211) 
Del Gln 156 to Gly 173 Single patient reported (212) 
ApoE mutations are likely the causal factor in this disorder as murine apoE knock-out 
mice that express apoE Sendai develop an illness very similar to lipoprotein 
glomerulopathy (213). Recurrences of the disease following renal transplantation are 
also common. However, not all mice develop renal disease and human gene carriers 
without renal disease have also been identified (213-215), suggesting that other 
factors (intrinsic glomerular factors, environmental factors) are important in the 
pathogenesis of the disorder. Hyperlipidaemia seems to at least play an aggravating 
role in some cases as histological improvement following intensive lipid-lowering 
therapy has been described in a few patients (216). 
The pathogenesis of lipoprotein glomerulopathy is as yet incompletely understood. 
The receptor binding affinities of apoE Sendai have been investigated and the LDL-
receptor binding is less than 5% of normal but HSPG binding is well preserved at 
around 66% of that of apoE3 (217). It is speculated that lipoprotein particles carrying 
abnormal apoE may deposit in predisposed glomeruli where they induce multiple 











Interestingly histological findings characteristic of lipoprotein glomerulopathy have 
been reported in a few isolated cases of dysbetalipoproteinaernia due to homozygosity 
for apoE2 (218;219). Further study of the link between lipids, apoE and renal disease 
is required. 
1.6 The dysbetalipoproteinaemic phenotype 
The following section provides a very brief overview of the clinical phenotype of 
dysbetalipoproteinaemia. Clinical, diagnostic and therapeutic aspects of 
dysbetalipoproteinaemia will be discussed in greater depth in the relevant chapters of 
this thesis. This section only intends to provide a brief introduction to the topic. 
1.6.1 Clinical features 
Palmar crease xanthomata are the distinguishing clinical feature of 
dysbetalipoproteinaemia and have been regarded as pathognomonic. They are, 
however, only found in a minority of patients. The reported incidence varies widely 
amongst case series and is generally lower in more recent reports, where the diagnosis 
of dysbetalipoproteinaernia is more actively sought in a wider cohort of patients with 
mixed hyperlipidaemia (6-10;220). Tendon xanthomata, tuberous, tuboeruptive and 
eruptive xanthomata may also occur but are not unique to dysbetalipoproteinaemia. 
Dysbetalipoproteinaemia is a highly atherogenic disorder and premature 
atherosclerosis is common. The distribution of vascular disease differs from that seen 











prevalent (7-10;220). On occasions hypertriglyceridaemia may be severe enough to 
cause pancreatitis. 
1.6.2 Diagnosis of dysbetalipoproteinaemia 
There are no universally accepted laboratory criteria for the diagnosis of 
dysbetalipoproteinaemia. The diagnosis may be based either on analysis of the 
lipoprotein phenotype demonstrating remnant accumulation or on analysis of apoE. 
Dysbetalipoproteinaemia is usually suspected if both triglycerides and total 
cholesterol are raised and the mass ratio is I: I or the molar ratio 1 :2. 
1.6.2.1 Analysis of lipoprotein phenotype 
The lipoprotein phenotype can be determined either by electrophoretic, 
chromatographic or chemical techniques. Traditionally the diagnosis of 
dysbetalipoproteinaemia was based on the finding of a broad-beta band on agarose gel 
(initially paper was used) electrophoresis of plasma with p-mobility of 
ultracentrifugally isolated VLDL (13). Other suggested electrophoretic methods 
include immunoelectrophoresis (221), electrophoresis with selective precipitation of 
VLDL (222;223), isoelectric focusing of plasma (224), modified agarose gel 
electrophoresis (225), polyacrylamide electrophoresis (15) and polyacrylamide 
gradient gel electrophoresis (226). Recently the lipid laboratory at the University of 
Cape Town (UCT) has shown that non-denaturing polyacrylamide gradient gel 
electrophoresis is probably the best electrophoretic screening technique for 











dysbetaJipoproteinaemia has been described (228), but due to its labour-intensive 
nature, chromatography has not been used as a routine diagnostic tool. 
As electrophoretic techniques often require subjective interpretation, attempts were 
made to develop quantitative diagnostic techniques. These ultracentrifugal techniques 
all rely on demonstrating cbolesterol-enrichment of the VLDL fraction. Using the 
presence of ~-migrating VLDL as a diagnostic gold standard multiple ratios of 
cholesterol in VLDL to VLDL-TG or plasma-TG were suggested as being diagnostic 
of dysbetalipoproteinaemia (207;229-232). An alternative method that isolates 
remnant-like particles by differential antibody binding and then calculates the ratio of 
cholesterol in these particles to plasma-TG has also been described (233). The other 
described phenotypic approaches either rely on measurement of apolipoproteins 
(234;235) or selective lipoprotein precipitation (236). 
1.6.2.2 Analysis of apoE 
Utermann (41) was the first to report the specific deficiency of the apoE3 isoform in 
the VLDL of dysbetalipoproteinaemic patients using lEF. lEF techniques 
subsequently underwent multiple modifications, including neuraminidase treatment to 
remove sialic acid residues and so remove "minor isoforms" of apoE from the gel. 
lEF is still used in some laboratories to phenotype apoE, but in general it has been 
replaced by polymerase chain reaction (peR) based techniques that can distinguish 
between the major isoforms of apoE in a single assay. The method described by 
Hixson and Vernier (237) remains popular. Routine genotyping using this method 











demonstrate homozygosity for the t2 allele therefore does not exclude the diagnosis 
of dysbetalipoproteinaemia entirely. Dominant apoE mutants may be suspected when 
the phenotype as determined by IEF and the genotype determined by peR are 
discrepant. 
1.6.3 Treatment of dysbetalipoproteinaemia 
The treatment of dysbetalipoproteinaemia is generally very rewarding with most 
patients achieving good control of their hyperlipidaemia. The principles of treatment 
are to identify and control possible precipitating factors, e.g. diabetes, 
hypothyroidism, obesity, as best as possible. A diet low in total fat with particular 
emphasis on the reduction of saturated fat is advised. Depending on the body mass 
index (BMI) additional caloric restriction may be necessary. In the lipid clinic 
experience most patients require additional lipid-lowering medication. Fibrates, 
statins and nicotinic acid are all effective (238-240), but cholestyramine should be 












2 Chapter Two: Methods 
This chapter describes the methods used in the retrospective review of the lipid clinic 
case series of dysbetalipoproteinaemia. Specialized methods such as sequential 
ultracentrifugation of lipoproteins or studies of remnant metabolism by stable isotope 
breath test are described in the appropriate chapters. 
2.1 Clinical methods 
The patients described in this thesis were all seen at the lipid clinic of Groote Schuur 
Hospital (GSH) in Cape Town, South Africa. GSH is the tertiary teaching hospital 
affiliated to the UCT. The hospital mainly serves the indigent local popUlation but 
patients may also be referred from the private medical sector for superspecialist 
advice. Most patients treated with lipid-lowering therapy continue to attend the clinic 
in the long-term as until very recently (2005) lipid-Ioweri~g therapy could only be 
dispensed to public sector patients on a script from the lipid clinic that required six-
monthly renewal. 
The Division of Lipidology of the Department of Medicine comprises the lipid clinic 
and the associated laboratory at UCT. Currently the lipid clinic at GSH is the only 
facility in South Africa that has access to the full range of diagnostic services 
necessary to diagnose dysbetalipoproteinaemia. The clinic has a particular interest in 












2.1.1 Clinical documentation 
Almost all patients referred to the lipid clinic are initially seen by a consultant. 
Patients not personally seen by a consultant at their first visit are presented to a 
consultant by junior physicians. From 1990 onwards patient data has been captured in 
standardized admission forms, to ensure completeness of data collection. All data.are 
prospectively captured in a Paradox (Corel ®) database. Clinical data are generally 
complete for patients seen after 1990. Before 1990 a standardized clerking sheet was 
also used but less information was collected and there was not a strong emphasis on 
ensuring completeness of data collection. Follow-up visits are also recorded using a 
standardized format. The lipid clinic notes are kept in duplicate; the original remains 
in the lipid clinic file (held at the lipid laboratory) while a carbon copy is filed in the 
patient's folder held by the hospital. This system facilitates rapid access to notes for 
research and enquiries and guards against data loss due to mislaid or lost hospital 
folders. 
2.1.2 Collection of clinical data 
History taking and physical examination generally follow well-established traditions. 
When taking the history special attention is paid to the following points, which are 
often neglected in standard medical histories: 
• Clinical manifestations of atherosclerosis 
• Dietary history by non-quantitative food recall and description 











• Evaluation of physical activity 
The physical examination particularly emphasizes the following points: 
• Physical stigmata of dyslipidaemia 
• Evidence of vascular disease 
Following the initial consultation a letter detailing the patient's history, physical 
findings, diagnosis and the recommended treatment is sent to the referring doctor. 











Figure 2-1 Page 1 of initial visit data sheet 
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Figure 2-2 Page 2 ofinitial visit data sheet 
GSH UPlD CUNIC ADMISSION FORM (2) I .ATEIm ~ '~I 



















Walst __ Hip ___ WHR __ 
BPEr&CI Supine 
I~I IPIlpiit ldam pad I_lib IMrIoId 
I~l RENAL 
AUSCULT 
I 'I§ I 
11=1 











Figure 2-3 Page 3 of initial visit data sheet 
GSH UPID CUNIC ADIUSION FORM (3) PATIENT 
RISKS ASSESSMENT 
I¥-I IfE~ 15§J I 
UPID DISORDER· 




























Figure 2-4 Page 1 of follow-up visit data sheet 
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Figure 2-5 Page 2 of follow-up visit data sheet 
PDl143 
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2.1.3 Consent for DNA extraction and storage 
The lipid clinic at GSH not only aims to provide expert clinical care to patients but 
actively engages in research. All patients are therefore given the opportunity to 
consent to storage and analysis of their DNA. The consent covers specific genetic 
tests that may be necessary diagnostically, e.g. genotyping of apoE in patients with 
mixed hyperlipidaeruia and further research investigations. The University Research 
Ethics Committee has approved the "DNA consent form". More than 98 % of patients 











Figure 2-6 DNA consent form 
THE LIPID CLINIC AND THE LIPID LABORATORY AT THE 
UNIVERSITY OF CAPE TOWN & GROOTE SCHUUR HOSPITAL 
CONSENT FOR DIAGNOSTIC & RESEARCH INVESTIGATION 
Please read carefully and feel free to ask any questions you may have. If you agree, 
place a check (T) in the relevant block; if you disagree, delete the relevant clause . 
1, ........................................................... .. ......................................... hereby consent to the removal of blood 9, skin 9, or 
other tissue (specify) from myself andlor 
to whom am the (relationsb ip) 
The purpose of the investigation is to perform 
9 diagnostic tests for dyslipidaemia or other metabolic disease that may predispose to atherosclerosis 
9 research investigations currently and in future, but subject to the conditions of the institutions above and the ethics review tilat 
govern tile research at these institutions. This may mean the determination of alternative inherited defects to explain my 
condition, or other factors which may have a bearing on the outcome of my condition, or for testing of any other gene that may 
be under research. 
The result(s) of the analysis carried out on the sampJe(s) will be made known to me, via my doctor, in accordance with the 
relevant protocol if and when available. The doctor(s) to be informed: 
Additionally, I authorise that the results be made known to the following family member(s): 
After due explanation by .......................................... , I understand that 
(l) Conventional procedures and techniques are employed by trained staff to obtain and process the samples and that 
consequently the risk to my health is minimal. 
(2) Confidentiality and anonymity ofthe sample(s) is(are) respected: the samples are coded by numbers. My written permission is 
required for release of identifiable information to any other party. 
(3) Precise diagnoses may not always be possible because of limited knowledge about the cause(s) of the condition(s). Even 
under the best conditions, current understanding and teehnology are imperfect. The research may thus be of no direct benefit to 
me but the samples may provide general insight into disease and health. 
(4) The cost involved for me will be determined according to scheduled tariffs, or borne by research budgets, and that no tests for 
which payment is required will be undertaken without prior consultation. 
(5) No commercial claims can be made on developments from these investigations by myself. 
(6) Permission to investigate may be withdrawn at any time by me, without prejudice to my future medical care. 
Signed .... ........... ....................................... Date ................................. . 
Witnessed by (Signatures) .......................................... . 












2.2 Special investigations 
2.2.1 Routine biochemical investigations 
Following a twelve-hour fast all patients routinely attend for venesection 
approximately a week before their initial consultation. All investigations listed below 
were performed in the chemical pathology laboratory of GSH using automated 
analyzers. Standard laboratory quality control procedures were followed to ensure 
reliability and reproducibility of the results. Cholesterol and TG were measured by 
standard enzymatic methods. High density lipoprotein cholesterol (HDLC) was 
initially measured after precipitation with phosphotungstic acid but in 2004 the 
laboratory switched to a homogenous method using polyethylene glycol modified 
enzymes (Roche Diagnostics). ApoB was measured by a commercially available 
immunoturbidimetric assay (Roche Diagnostics). The following investigations were 
done in all patients: 
Lipid investigations: 
• Triglyceride 
• Total cholesterol 
• HDLC 
• LDLC is calculated using Friedewald's equation (242) provided TG is less 
than 4.5 mmollL 
Note: The Friedewald equation should not be used in patients with dysbetalipoproteinaemia and nO values/or LDLC are 













• Lipoprotein (a) 
Other investigations: 
• TSH, T4requested ifTSH is abnonnal 
• Glucose 
• Renal function: urea, creatinine 
• Liver function tests: albumin, bilirubin, AST, ALT, GGT, ALP 
• Urate 
• Creatinine kinase 
2.2.2 Electrophoresis 
2.2.2.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was perfonned utilizing the Beckman Paragon Lipo ® 
system according to the manufacturer's instructions. Briefly, 5 /J.I of plasma (or serum 
on occasions) was applied to the agarose gel using the template supplied by the 
manufacturer. Gels were electrophoresed at 100V for 30 min in a barbital buffer (PH 
8.6). Following electrophoresis gels were fixed in an acetic acid solution, dried and 
then stained with Sudan Black followed by destaining in ethanol solutions. 
All gels were reviewed by a single observer (ADM) at the time of the patient's initial 











of 2.3 mmol/L was used to differentiate between IIa and llb patterns. Gels that 
showed unifonn staining from the p-area to the pre-p area were classified as Type 1II. 
Routine agarose gel electrophoresis was perfonned at the chemical pathology 
laboratory. The agarose gels for the Bayer W 622811 0 176 (hereafter referred to as 
Bayer Study) were done at the lipid laboratory. These gels were scanned with the 
GelDoc system (Bio-Rad Corporation) and densitometric analysis was undertaken. 
2.2.2.2 Polyacrylamide gradient gel electrophoresis (PGGE) 
Non-denaturing polyacrylamide gradient gel electrophoresis was undertaken in 2-8% 
polyacrylamide gels with a 3% acrylamide concentration in the stacking gel. The 
higher acrylarnide concentration in the stacking gel is necessary to allow safe 
handling and loading of the gels. Lipoproteins are prestained with Sudan Black, so 
that gels can be inspected immediately after electrophoresis and require no further 
processing. 
Technigue: 
Polyacrylamide mini-gels (6 cm long) were freshly cast prior to each electrophoretic 
run. A 30% stock solution of acrylamide with 2.7% bisacrylamide was used to prepare 
an 8% solution of acrylamide in a buffer containing 13.6 g% Tris and 30% (v/v) 
glycerol at pH 8.8. A 2% acrylamide solution was prepared in Tris 13.6 g%. 
Polymerization was activated in 4 ml of each solution by adding 30 I,d of ammonium 
persulphate (100 mg/ml) and 15 III of tetramethlylethylenediamine (TEMED). The 
activated solutions were placed in the two chambers of a gradient maker with a small 











containing the 8% acrylamide solution. The stacking gel contains 3% acrylamide 
stock in 1.68 g% Tris at a pH of 6.8. Once the separation gel has set, the stacking gel 
solution is polymerized by adding 100 III of ammonium persulphate and 4.0 III of 
TEMED. Using this solution and a comb 15 lanes are prepared for electrophoresis. 
Fasted EDTA- plasma samples were prestained for lipids with Sudan Black using a 
similar method to Gambert et al (244). Briefly, 100111 of plasma was incubated with 
50111 oflipid stain (1 % w/v Sudan Black in ethylene glycol) for an hour at 4 °C and 
then spun for 20 min at 10000G. Equal volumes of supernatant and saturated sucrose 
were mixed and 12 III of the resultant solution was loaded per well. 
Gels were run for 12-18 hours at 130 V at 4° C in a Tris Glycine (pH 8.3) buffer 
utilizing the Bio-Rad Minigel apparatus. The gels were subsequently analyzed without 
any further processing. 
The gels were visually inspected and reports used a simple terminology that avoids 
inferring lipoprotein separation by density. The bands corresponding to LDL species 
usually appeared sharp and well defined and migrated to the distal fifth of the gel 
(anodal end). Migration of lipoproteins on successive gels was assessed relative to 
two control lanes, in which previously selected plasma with a known large (A) and 
small (B) LDL species were run. 











Gels were calibrated with lipoprotein fractions (VLDLl, VLDL 2, IDL and LDL) 
isolated by sequential density-gradient ultracentrifugation, according to a previously 
described method (245). These fractions were prestained for lipids as described above 
and then electrophoresed on the same geL Optical density profiles were obtained by 
video densitometry and the migration range of each lipoprotein fraction was expressed 
in terms of the retardation factor (Rt), for which the beginning of the separation gel 
was taken as zero and the peak of small dense LDL (B species) as LO, as this is the 
apo-B-containing lipoprotein that migrates furthest in this system. VLDLl (Sf 60-
400) has a RfofO.2-0A5, VLDL2 (Sf 20-60) has a RfofOA5-0.7, IDL (Sf 12-20) has 
a Rf of 0.7-0.85 and LDL (Sf 0-12) has a Rf of 0.85 to 1.0. Chylomicrons are found at 
Rf<0.2. 
Figure 2~ 7 Calibration of PGGE 
Rf 0.2-0.45 
- VLDL 1 Sf 60-400 
RfO.45-O.7 
- VLDL2 Sf 20-60 
Rf 0.7-0.85 
-IDL Sf 12-20 
-LDLSfO-12 












Gels run after June 1998 were electronically captured with the Bio-Rad GelDoc 1000 
system (Bio-Rad, USA). Gels are placed in a photographic chamber and images are 
captured by a mounted video camera. The image is digitalized and transferred to a 
personal computer for further analysis with the Bio-Rad MultiAnalyst software (Bio-
Rad, USA) or alternatively raw optical density and migration distance data can be 
exported for analysis with other software. Baseline optical density was measured for 
each gel at the beginning of the separation gel between lanes. The value obtained was 
subtracted from the optical density readings for the lanes. 
2.2.2.2.2 PGGE terminology 
Gels are described using an "in-house" terminology that allows for rapid and 
reproducible description of gels. The following section explains this terminology. 
As PGGE separates lipoproteins according to SIze, with sIze being inversely 
proportional to migration distance, the largest lipoproteins are found at the origin. 
Chylomicron sized particles do not migrate into the gel and remain at the origin. Such 
staining is referred to as O. Particles migrating further than the origin but not into the 
"LDL area" stain in the midzone of the gel and are termed M. The M region is quite 
large, making up about two thirds of the gel. Therefore lipoproteins migrating to the 
beginning of the M zone are termed M-early (M-e) while those migrating further are 
termed M-late (M-l). Remnant particles are found in the M-l zone. Particles that 
migrate to the lower third of the gel are termed to be in the "LDL" area. The largest 
particle is assigned the letter A while the smallest particle is termed B. Faintly 











letters in the reporting is subjective by nature, but as all reports have been given by a 
single observer the problem of inter-observer variability is minimized. I is found in an 
intermediate position between A and B and further subdivisions are made- termed 
Aearly (Ae), All and liB. Particles that migrate further than the B marker are termed 
B-post. Unusually an extraordinary large LDL-sized particle may be seen above A, 
and is termed pre-A. It represents Lp (a). The figures illustrate the naming convention. 
Figure 2-8 Naming convention for PGGE 
Origi.l1 
tor-late 











Figure 2-9 LDL species size on PGGE 
- A 
A 
0.6 0.7 0.8 
Retardation factor 
2.2.3 VLDL compositional analysis 
I 
1.2 
For VLDL compositional analysis 5.5 mt offasted plasma was adjusted to a density of 
1.3 g/ml by addition of 2.74 g of KEf. A saline solution of density 1.0063 g/ml is 
prepared. Five ml of the density-adjusted plasma is loaded in a Beckman SW40 rotor 
tube. Using a peristaltic pump saline is layered over the plasma to 2 mm below the 
rim of the tube. The tubes are balanced in the SW40 rotor and then spun at 33000 
revolutions per minute (rpm) for 17 hours at a temperature of 15° Celsius. 
Following ultracentrifugation the VLDL supernatant is aspirated quantitatively and 
assayed for cholesterol and triglycerides together with the unused density-adjusted 
plasma. The ratio of cholesterol to triglyceride in VLDL is calculated 
(CvLDd TGvLDL). The ratio of cholesterol in VLDL to plasma TG is also calculated 
CvLDUTGPlasma). These two ratios were initially repol1ed as mass ratios and this 











with previously work. All of 
VLDL in this thesis are therefore mass ratios. 
2.2.4 Genotyping 
2.2.4.1 DNA extraction and "' .. "" .. .,.'" 
Genomic DNA was extracted from coats using the described by Parzer 
This method good (about 2S0 ~lg of DNA from Sml of whole 
blood) of relatively pure DNA. Extracted DNA is labelled with a unique 'rlPMr.1", 
number and stored at -200 C. The "DNA number" allocated to each IS 
used in all databases and allows for easy across multiple 
databases. 
Determination of common apoE isoforms 
The common .cnj"nrnn<: were (1ptprrrHn according to the method first described 
by Hixson and Vernier (237) with some minor modifications. The PCR is nprt{\'-nn 







































PCR conditions: 1 cycle at 95° C for 5min 
35 cycles of 94.5° C for 45 seconds and finally 60 ° C for 1 
minute 
Post PCR 10 III of product is run on an agarose gel to confirm that amplification was 
successful. Thirty III of PCR product is digested with 10 units of Hhal at 37° C 
overnight. Digested product is loaded and run on a 12% polyacrylamide gel utilizing a 
sucrose loading buffer. The gel is stained with ethidium bromide and photographed 
under UV light in the GelDoc apparatus. 
The various apoE isoforms have differing numbers of Hhal cleavage sites, resulting in 











Figure 2-10 Hhal cleavage sites 


















Figure 2-12 Example of gel used to determine apoE isoforms 
Lanes 1,2 and 3 are loaded with samples of known genotypes: £21£2, did and £41£ 4 
2.2.4.3 Determination of apoE (Arg14S-+Cys) mutation 
Two methods are in use at the lipid laboratOlY to test for this mutation. The methods 
are used interchangeably and show excellent agreement with each other. 
2.2.4.3.1 Method 1 
The restriction enzyme BbvI cuts at the sequence: GCAGC. In the wildtype the 
following fragments are generated (from 5' to 3'): 25, 108, 33 and 78 bp. The 











The same DNA fragment that was amplified for determination of apoE isoforms is 
used for this assay. The fragment is cut for two hours at 65° C using 2 U of Bbvl 
(Fermentas). Cut products are separated by electrophoresis on a 12% polyacrylamide 
gel (4 hours at 110 V) and stained with ethidium bromide. Visualization is under UV 
lighting. 
Bands seen following Bbvl digest: 
Homozygote for ApoE (RI45C): 111,108 and 25 
Heterozygote for ApoE (R145C): 111,108,78,33 and 25 
Wildtype: 108, 78, 33 and 25 
Figure 2-13 BbvI digest for ApoE (R14SC) 
Lane I: Wildtype 
Lane 2: Heterozygote 
Lane 3: Homozygote 
Lane 4: Wildtype 
Lane 7: Heterozygote 











2.2.4.3.2 Method 2 
The ApoE (R 145C) mutation can also be detected by usmg a mismatch assay 
(Amplification Refractory Mutation System -ARMS) developed in the lipid 
laboratory with the help of Professor Howard Henderson of the Department of 
Chemical Pathology at UCT. 
Two sets of PCR are perfonned- one set with a primer that will amplify wildtype 
DNA and one set with a "mutant" primer that will yield product only if the apoE 
(R 145C) mutation is present. 
Nonnal: (5'- ATCGCTGAGGAGCCGCTTTCG-3') 
Mutant: (5'-ATCGCTGAGGAGCCGCTTTCA-3') 
Opposite Primer F6: (5'-TAAGCTTGGCACGGCTGTCCAAGGA-3') 
DNA denatured in 10% DMSO is used for this assay. The PCR cycles are: 
1 cycle at 95° C for 35 seconds 
35 cycles of 94.5 °C for 45 seconds, 60° C for 60 seconds, 72° C for 60 seconds 
1 cycle at 72° C for 3 minutes 
The amplified product is run on a 10% polyacrylamide gel. PCR products from the 
two PCR reactions per patient are loaded in a single lane separated by a time interval 












Figure 2-14 ARI\1S assay for apoE (RI4SC) 
') 1 4 'i () 7 R 
Lane 1: Heterozygote Both prImers have successfully amplified and two 
bands of product are visible. 
Lane 2: Homozygote Only the mutant primer has yielded product and a single 
band is visible that has migrated further into gel due to earlier loading. 
Lane 3: Wildtype 
Lane 8: Heterozygote 
Only the wildtype primer has yielded product. 
2.2.4.4 Determination of apoE (Lys146-----'>Gly) mutation 
This mutation is also screened for using an ARMS assay. The primers were designed 
in the lipid laboratory with the assistance of Professor Howard Henderson of the 
Department of Chemical Pathology at UCT. The PCR conditions are identical to those 
used for the apoE (RI4SC) mutation. The PCR products are also run on a 10% 
polyacrylamide gel with double, time-delayed loading of lanes. The RCR product 
obtained with the mutant primer is again loaded first. 











Mutant: (5 ' -GGCATCGCGGAGGAGCCGA TG-3') 
Wildtype: (5'-GGCATCGCGGAGGAGCCGATT-3') 
Opposite Primer F6: (5'-TAAGCTTGGCACGGCTGTCCAAGGA-3') 
Figure 2-15 ARMS assay for ApoE (KI46Q) 
1 ') 1 4 'i 
Lane 1: Heterozygote Both primers have been amplified and two bands are 
visible. The bands are separated not by size but by delayed loading. 
Lane 2: Wildtype 
is visible. 
The mutant primer has not amplified and only one band 
Lane 3: Heterozygote 
2.2.4.5 ApoE sequencing 
In patients with cholesterol-enriched VLDL meeting the diagnostic criteria set out in 
this thesis, but with no identified apoE mutation, a portion of the apoE molecule was 











Due to limitations of funds it was not possible to sequence the entire molecule, 
but the focus was on the TPf'pnl{'Ir_h. region of as most identified mutations 
have been found in this The PCR obtained determining the 
common isoforms by the method of Hixson (237) was 
was not performed but ouL<;ourced to a commercial 
biotechnology company (lnqaba Biotechnological Industries . Pretoria, South 
Genomic DNA was amplified as described in section 2.2.4.2. PCR products were 
in agarose the relevant bands were cut from the gel and submitted to 
Industries. The DNA was purified at lnqaba 
Biotechnological Industries and the 
by the chain termination method with 
was Fragments were 
"r~·<(',~nt labels on an automated 
sequencer. Inqaba Biotechnological Industries e-mailed completed sequences to the 
laboratory review. 
were bidirectionally 
All sequences were reviewed 
previously published sequence. 
Statistical Methods 
2.3.1 Management 
inadequate sequences were 
+ 
two observers and compared with the 
Clinical data were captured from original source documentation held at the lipid 











had gone missing from the folder held at the lipid laboratory the patient' s hospital 
folder was requested. Results of special investigations performed at the lipid 
laboratory were captured by linkage of multiple databases held in the laboratory (e.g. 
genotyping results) to the main database using the unique "DNA number" of each 
patient. Data preceding the computerization of the laboratory was extracted from 
archived laboratory records and entered manually. 
2.3.2 Data Analysis 
Data to be analyzed was transferred either to Quattro Pro (Corel ®) or to Graph Pad 
Prism (GraphPad Prism version 4 .00 for Windows, GraphPad Software, San Diego 
California USA, www.graphpad.com). All graphs were generated using Prism. Where 
box and whiskers plots are presented they are all of the following type. 


















The data were analyzed usmg standard statistical methods. Normally distributed 
variables were analyzed using parametric tests. Non-parametric tests were used for 
skewed data or logarithmic transformation was performed. Categorical variables were 
analyzed in contingency tables. The statistical methods used for each analysis will be 
indicated in the individual sections. 
2.4 Reviewing the Cape Town experience of 
dysbetalipoproteinaemia 
2.4.1 Dysbetalipoproteinaemia: definition for this study 
For the purposes of this study dysbetalipoproteinaemia was defined by both 
phenotypic and genotypic criteria. Patients were classified as dysbetalipoproteinaemic 
if they fulfilled one or both of the criteria below. 
Phenotypic Criteria: 
The demonstration of cholesterol-enriched VLDL has been the phenotypic diagnostic 
test of choice for patients with suspected dysbetalipoproteinaemia for many years. 
Fredrickson himself suggested it should replace agarose gel electrophoresis of 
ultracentrifugally isolated VLDL (207). Within the literature there is not universal 
agreement as to the level of cholesterol-enrichment of VLDL that should be regarded 
as diagnostic. In this study we defined dysbetalipoproteinaemia using the mass ratios 











specificity. at the cost of reduced sensitivity, when compared to other U1a5'1\"> 
ratios. 
Cholesterol vLorJTriglyceride VLOL (CV ffV) :::: 0.42 
or 
Cholesterol VLOLI Triglyceride Plasma :::: 0.30 
VLDL compositional on multiple occasions in some 
A single result was sufficient for inclusion in the 
Patients were also diagnosed with dysbetalipoproteinaemia if one of the following 
<ypy" ... ,.,,, .. ,,,,, was documented in the presence of mixed 
It Homozygosity for the e2 isoform 
It ApoE (RI45C) mutation detected 
It ApoE (K146Q) mutation detected 
Based on these criteria the dysbetalipoproteinaemic 
into several groups. 






















of apoE for mutations known to be associated with 
analysis 
Patients with positive VLDL compositional but no detected apoE mutation 
are referred to as "genotype negative" in this thesis. In this specific eon text 
the term negative must be taken to indicate that no mutations in apoE were 
detected a limited array of genotypic tests. mutations may still be present, 
but the are rp1".orrc'''' to as for the purpose of this thesis. 
finding 
As the diagnosis of dysbetalipoproteinaemia was based on laboratory criteria all 
laboratory records of apoE and VLDL compositional analysis were 
reviewed for patients that met the inclusion criteria. Additionally the clinical database 
was for patients that had been labelled as dysbetalipoproteinaemic or where 











Historically the policy from about 1985 onwards has to perform VLDL 
compositional analysis in all with possible dysbetaiipoproteinaemia. Patients 
seen prior to 1985 were often not investigated further. In these apoE 
genotyping was done if a DNA sample was VLDL compositional 











3 Chapter Three: Clinical and laboratory findings 
1 Demographics 
One hundred and patients with dysbetalipoproteinaemia were included in 
the database. The first 
in February 2004. 
1969 and the database was closed 
Table 3-1 Ethnic and sex distribution of dysbetalipoproteinaemic patients 
Males (%) Females (%)1 
Caucasian 27 ( 19 (1 
Mixed Race 37 (27.2) 40 (29.4) 77 
Indian 1 (0.7) 0 
African 10 12 
All 75 61 136 
I The indicated is relative to all ,,,,,,n?>,,, m,nnr'ntp patients in the 











Table 3-2 Ethnic and sex distribution of all other patients seen at the GSH lipid clinic up to 
February 2004 
Ethnicity Males (%) I Females (%) I Sum (%) I 
Caucasian 866 (20.1) 814(18.9) 1680 (39.0) 
Mixed Race 1027 (23 .9) 1424 (33 .1) 2451 (56.9) 
Indian 59 (1.4) 26 (0.6) 85 (2.0) 
African 54 (1.3) 36 (0.8) 90 (2.1) 
All 2006 (46.8) II 2300 (53.2) 4306 
I The percentage indicated is relative to the total number of patients 
Percentages have been rounded 10 the first decimal 




Chi-square test P<O.OOOI 
The proportion of patients with dysbetalipoproteinaemia at the lipid clinic within each 
ethnic group ranges from 1-3% for all ethnic groups, except for African patients in 











laU,llHJU;:) for the high of in African 
U"',UY"'IS the clinic. African patients historically had worse access to medical services 
than other population groups and thus would often only be referred to a tertiary center 
if they had obvious 
preferentially select patients with 
obvious cutaneous xanthomata. The 
a lipid This referral would 
that are associated with 
(Rl mutation in 
the African population also contributes to the high of the disorder 
below). 
1.1 Comparison with previously published case ",,,,,r""'''' 
Most published case series from (6;9;10) or the United States of 
America It is therefore difficult to compare the ethnic mix in the case series 
due to the different populations studied. All case series reviewed 10;220) 
reviewed a excess of male with a pooled 0) 
distribution of 3:2 for male: female. We recorded a very similar gender distribution 
with a moderate excess of male As the of 
are not the male excess reflects the influence of environmental and 
biological factors, of which 
females. 
3.2 ApoE genotypes 
is likely the most important in pre~m<:no,pal11sa 
In the 136 with dysbetalipoproteinaemia apoE mutations were identified in 99 











dysbetali poproteinaemia (71 % of identi fied mutations). Locally the apoE (R 14SC) 
mutation was also highly prevalent and accounted for 27% of identified mutations. 
The apoE (R14SC) mutation was found in all population groups studied. However, 
three of the four apoE (R 14SC) homozygotes were African. None of the homozygous 
subjects had a family history suggestive of consanguinity. This suggests that the 
background frequency of the apoE (R14SC) mutation may be relatively high in the 
black population. The apoE (KI46Q) mutation was identified in two patients. Both 
patients had Dutch/Belgian ancestry. This mutation was also first described in Dutch 
and Belgian patients (194) . 
Table 3-3 ApoE genotypes in the dysbetalipoproteinaemia cohort 
Genotype Sex Ethnicity Total 
I 
Male Female Caucasian Mixed Indian Black 
race 
ApoE2/E2 39 31 28 36 I S 70 
ApoE Heterozygote IS 8 6 14 0 3 23 
(R145C) Homozygote 2 2 0 I 0 3 4 
ApoE (KI46Q) 2 0 2 0 0 0 2 
Genotype not identified 17 20 10 26 0 1 37 
3.2.1 ApoE (R14SC) mutation 
The apoE (RI4SC) mutation was first described in 1982 by Rail (47). Rail identified 











apoE cOlnpeted unusually well with iodinated LDL in human fibroblasts. One patient 
for this mutation while the other was heterozygous (18;47), Emi and 
Hsia further cases secondary to 
this mutation, also in African American patients (18;47;247;248). In 1997 de Villiers 
described 10 including 4 with this mutation (I The 
patients all attended the lipid clinic at Groote Schuur Hospital. The mode of 
inheritance was shown to be autosomal dominant with incomplete penetrance. There 
IS no effect and " AY"" A,,,, and heterozygotes are affected similarly. 
In 1991 Lohse described a 24 year-old woman with severe 
whose migrated as apoE4 
homozygous carrier of R 
IEF. The patient was found to be a 
The allelic variant was named 
Philadelphia (1 When the kindred were subsequently traced, six hpl'PFf'7" 
mutation carriers were identified. 
was associated with "a moderate 
for the apoE4-Philadelphia allele 
of dysbetalipoproteinaemia (186). 
Heterozygotes had various degrees of hyperlipidaemia (less severe than the 
patient) in the presence of cholesterol-enriched VLDL. None of the 
heterozygotes had cutaneous manifestations of hyperlipidaemia. For the apoE4-
mutation there is therefore a suggestion that a 
apply and that the inheritance is partially dominant. 
The apoE4-PhiladeJphia mutation was excluded in the 
145C) patients reported from Town by Ava} 
effect may 
cohort of apoE 
of peR products 
generated exon 3 primers (184; 186). Two of the (R145C) 











3.2.1.1 ApoE (R14SC) population distribution 
The apoE (RI45C) mutation has been identified in patients with diverse ethnic and 
geographic origins. The GSH lipid clinic has identified Caucasians (with ancestry 
from the United Kingdom), Africans and Mixed Race patients with this mutation. The 
identification of three unrelated African homozygotes suggests that the background 
prevalence of the apoE (RI45C) allele in the African population may be high. This 
has not been formally examined as yet, but information is available from two studies 
examining lipoprotein metabolism in pregnancy. 
In the first study apoE genotypes and the presence of the apoE (R l45C) mutation 
were determined in pregnant patients presenting to the GSH obstetric unit with 
gestational proteinuric hypeltension (pre-eclampsia) and In women with 
uncomplicated pregnancies. All participants In this study were African and were 
almost entirely of Xhosa extraction. DNA extraction and amplification was successful 
in 180 of 184 subjects. The apoE (R145C) mutation was found in 11/180 (6%) of 
patients. All subjects were heterozygous for the mutation . There was no association 
between apoE genotypes and the occurrence of gestational protein uric hypertension 
(249). 
Tanyanyiwa studied lipid profiles, PGGE and apoE genotypes in 690 pregnant women 
attending two large public health care facilities in Harare, Zimbabwe. Almost all 











for the (R145C) mutation and 564 women were successfully tested for 
this mutation (12]). 
Table 3-4 ApoE (R145C) mutation in Zimbabwean patients 
N % 
29 5.15 • 
G 
IJ') 




No mutation detected 533 94.5 • 0 Q.. 
-< 
The total of 5.5% for mutation is very similar to that observed in the 
previous study, although the two studies were conducted In geographically and 
ethnically Town, South Africa and Zimbabwe. The 
detection of two homozygotes again supports the contention that there is a high 
of this mutation in Africans with Zimbabwean 
3.2.1.2 ApoE (R14SC) and the common apoE isoforms 
All carriers of the (R145C) mutation had at least one £3 allele when genotyped 
to Hixson The genotype was dl 83 in all 











Due to the small number of subjects not homozygous for the c:3 allele, the influence of 
the other apoE allele on clinical and laboratory characteristics was not examined. 
3.2.1.3 Haplotype analysis of the apoE (R14SC) gene 
Haplotype analysis of the apoE (R14SC) mutation in patients attending the lipid clinic 
at GSH has been undertaken previously. This work was done by a student (Aron 
Abera) for a BSc (Hons) degree in the Depattment of Genetics under supervision of 
Professor Howard Henderson of the Department of Chemical Pathology and Professor 
A. David Marais of the Department of Medicine (250). 
DNA from 47 subjects who either carried the apoE (RI4SC) mutation or were 
relatives of mutation calTiers was examined. DNA from 30 healthy normolipidaemic 
controls of African ethnic origin was also studied. Two microsatellite markers and one 
intragenic single nucleotide polymorphism (SNP) were selected for study. The two 
microsatellite markers were (di tance from apoE gene given in brackets): 
• D19S417 
• D19S408 
(5 .9 Mb) 
(1 .3 Mb) 
The SNP was located in intron 2 of the apoE gene. 
PCR products for the microsatellite markers were analyzed on 9% non-denaturing 
polyacrylamide gels. The SNP was analyzed in agarose gels following restriction of 











Haplotypes were constructed using the common isoforms of apoE and the three 
markers described above. 
The figure below illustrates the haplotypes constructed in the largest kindred with the 
apoE (RI45C) mutation. 
Figure 3-2 Haplotypes in a kindred with the apoE (R14SC) mutation 
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Of the three kindreds studied, two had similar haplotypes for the mutated allele. All 
three kindreds studied were of Mixed Race. DNA amplification was only successful 
in two African patients homozygous for the apoE (RI45C) mutation. These 











the 8 possible repeat lengths (see figure 3.6). There were no differences in the SNP 
genotypes. 
Table 3-6 Microsatellite markers in two African patients homozygous for the apoE (R14SC) 
mutation 
D I 9S408 Genotype D 19S417 Genotype 
("CA" repeat length) (HeA" repeat length) 
Patient 1 (15,17) (8,12) 
Patient 2 (17,21) (6.16) 
The allele frequency of the two microsatellite markers in the control samples of 
African origin was also compared to that observed in all African mutation carriers. 
Significant differentiation was found at both microsatellite markers, but due to the 
small number of specimens studied and the relative distance of the chosen markers 
from the apoE gene locus the study was unable to conclusively differentiate between a 
single origin and multiple origins of the mutation in African patients . 
However, given the diverse ethnic origins of individuals carrying the apoE (R145C) 
mutation it is likely that the mutation is recurrent. The C-T change observed at 
position 403 J of the apoE gene with the apoE (R145C) mutation is an example of a 











3.2.2 ApoE sequences in patients with no identified apoE 
mutations 
The binding region of apoE was sequenced in all patients without an identified apoE 
genotype as detailed in section 2.2.4 .5. Adequate quality forwards and reverse 
sequences were obtained in all subjects. No mutations were identified in any of the 
patients. The apoE genotype as determined by the Hixson method (237) was 
confirmed by sequencing in all patients. 
Figure 3-3 ApoE sequence in a genonegative patient (E3/E3) 
Codon 112 
T G C (CYS) 
~ t ft ft 
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Although this investigation did not find any mutations in apoE, it is of course still 
possible that subjects may have mutations outside the sequenced fragment. Large 
deletions or insertions may also have been missed. 
Samples from patients with the apoE (RI45C) and apoE (KI46Q) mutations were also 
submitted for sequencing and the mutations were confioned. The apoE (R145C) 











Figure 3-4 Heterozygous apoE (R145C) mutation carrier 
Codon 145 
C G T (ARG) 
T G T (CYS) 
II fI 
A 
~ ~ fI 
1\ 
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3.3 Total clinical experience 
All patient records were reviewed in February 2004 and the date of the last 
consultation was noted. The duration of follow-up was calculated as the difference 
between the date at presentation and the date of the last consultation. Where available, 
infonnation on the final outcome was collected. 
3.3.1 Follow-up 
The mean duration of follow-up was 4.74 ± 5.16 years (median 3.55) with a range 
from 0 to 23 .14 years. Sixteen patients were either lost to follow-up or referred 











follow-up visit are available. The mean age at the last documented visit was 55.00 ± 
12.47 years with a range of 10.54 to 85 .21 years. 











NOle: DOlo censored February 20(14 
Median 
+ 
The total cumulative experience is 640 patient-years. 
3.3.2 Final outcomes 
In February of 2004 75 patients were known to be alive (as judged by a clinic 
attendance less than six months previously or personal contact), 15 patients had died 
and the final outcome could not be determined with certainty in 46 patients. Many of 
the patients with unknown outcome are presumed to have died, considering their age 
and morbidity when last seen at the clinic. They may have died at home or at other 
medical facilities with no formal documentation regarding their death available in 











Of the 75 patients known to be alive, 67 regularly attend the lipid clinic for treatment 
and monitoring while 8 
hospitals. 
3.4 Age at presentation 
their treatment in the private sector or at other 
Information the age at initial presentation was available for 135 patients. 
The interval between the onset of and to the lipid clinic 
is obviously highly variable and cannot be determined reliably. The age at 
v;:'~;lIli:1L'\'IH is therefore the best approximation available and allows for vVl"fJ"" 
to be made between different groups of dysbetalipoproteinaemic patients. Table 3.7 











Table 3-7 Ages at ... ro'.o"'" ..... ," 
Patient categories Age at presentation (years) 




All patients ! 135 50.19 51.36 11.39 6.93-80.80 I 
Males 74 47.37 47.84 11.30 6.93-67.20 
Females 61 53.62 53.76 10.53 22.6-80.80 
All 98 49.95 50.78 10.71 6.93-71.27 
E2/E2 69 49.93 5 . 9.77 23.18-71.27 I 
i E (R145C) All I 27 50.00 53,47 13.15 6.93-65.15 
0 r:: E (RI45C) hetero 23 50.56 54.27 13.42 6.93-65.15 <l,) 
C? 
E (RI45C) homo 4 46.81 44.83 12.71 33.82-63.76 
E (K146Q) 2 49.87 49.87 12.29 41 18-58.56 
Geno (-) 50.83 51.67 13.17 22.60-80.80 
There was a very wide range in age of presentation. The two youngest (6.93 
and 22.60 years at .... "'-'aaUVlll) both had severe renal disease with nephrotic range 
which may cause severe even in the absence of 
errors in lipid metabolism The oldest patient (80.80 years old at 
with ischaemic heart disease and the of dysbetalipoproteinaemia 
was made when her severe mixed hyperlipidaemia was investigated. 











The factors were examined for their influence on the age at initial 
presentation. 
3.4.1.1 
Males at a younger age than females. When analyzed by subgroup this 
was confirmed in the groups: 
• Cohort as a whole 
• 
• 
In the smaller (R145C) mutation and 
prpnr,'<: did not reach statistical females also presented later than men but the 
significance. This may be due to the smaller number of and the wide scatter 











Table 3-8 Gender differences in age at presentation 
Category Sex Number Mean SD Difference P value I 
Males 74 47.37 J 1.30 
All Patients 6.25 0.0013 
Females 61 53.62 10.63 
Males 57 47.48 11.65 
Geno (+) 5.90 0.0065 
Females 41 53 .38 8.22 
Males 38 47 .01 10.16 
E2/E2 6.49 0.0051 
Females 31 53.51 8.06 
E (R145 C) Males 15 47.65 15.38 
8.35 0.16 
Hetero Females 8 56.00 6.12 
Males 17 46.98 J 0.43 
Geno (-) 7. 1 0.10 
Females 20 54.09 14.63 
I Unpaired t-test 
3.4.1.2 ApoE Genotype 
There were no differences in age at presentation when patients were compared by 
genotypic status (mean age 49.95 ± 10.71 vs. 50.83 ± 13.17, P=0.69 for genopositive 
vs. genonegative patients by unpaired t-test). Amongst patients with identified apoE 
mutations the nature of the mutation did not influence the age at presentation (mean 
age 49.93 ± 9.77 vs. 50.56 ± 13.42, P=0.81 by unpaired t-test-for apoE2 homozygotes 











small and their mean age of 46.81 12.71 years at presentation was not 
different from heterozygous mutation carriers (P=0.61, unpaired 
3.4.1.3 Ethnicity 
The age at presentation was very similar for Caucasian and mixed race (51.73 
± 11.52 years vs. 50.20 ± 10.20 years, P=0.44 by unpaired t-test) but Africans 
on average about 7 years earlier at a mean age of 42.96 ± 16.89 years, 
there was a wide range of ages at from 6.93 to 65.10 years. 
in a study of FH at the lipid clinic Caucasian patients presented the 
earliest and African patients the latest. African patients were generally seen 
following a complication of atherosclerosis 
awareness of FH and better access to 
Tbis finding probably 
in the Caucasian 
with the often less obvious ofFH. 
3.4.1.4 Physical signs of a lipid disorder 
Cutaneous xanthomata (tuberous, tuboeruptive and 
the most dramatic external signs of "",,,,,Pt<, , .. ,,,n.,,t,,,, 
by the and the physician, although in the GSH 
referral is often to a dennatologist rather than a 
xanthomata) are probably 
and are readily noticed 
clinic experience the initial 
Palmar crease 












Patients with eruptive/tuboeruptive xanthomata were significantly younger at 
presentation than patients without these xanthomata (42.90 ± 12.06 years vs. 52.23 ± 
10.44 years, P<O.OOOI , unpaired t-test). The high prevalence of eruptive/tuboeruptive 
xanthomata in younger patients is well illustrated if patients are divided into quartiles 
by age of presentation. 
Figure 3-6 Eruptive/tuboeruptive vs. quartiles of age at presentation 
45 
til 40 -c::: 35 Q) 
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Q1 Q2 Q3 Q4 
Quartiles of age at presentation 
Chi-square test 
Quartile I: 6.93-43 .7 1 
Quartile 2: 43.72- 51.51 
Quartile 3: 51.52- 57.68 
Quartile 4: 57.68-80.80 
P=0.005 
[IT)] Eruptive/tuboeruptive 
E:J No eruptive/tuboeruptive 
xanthomata 
The finding of palmar crease xanthomata did not influence the age of presentation to 
the lipid clinic (48.15 ± 9.17 years vs. 50.90 ± 12.04 years, P=O.22 by unpaired t-test 
for palmar crease xanthomata vs. none). The same was true for tendinous xanthomata 
(50.98 ± 9.44 years vs. 50.05 ± 11.05 years, P=O.72 by unpaired t-test for tendinous 











presentation (49.89 ± 7.59 years vs. 50.24 ± 11.74 years , P=O.92 by unpaired t-test for 
xanthelasmata vs. none). As expected the prevalence of arcus corneal is increased with 
age (56.16 ± 9.01 years vs . 48.64 ± 11 .52 years, P=O.OO 17 by unpaired t-test for arcus 
vs. none). 
Figure 3-7 Arcus cornealis by quartiles of age at presentation 
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Quartile I: 6.93-43 .7 1 
Quartil e 2: 43 .72- 51 .51 
Quartile 3: 51 .52- 57.68 
Quartile 4: 57.68-80.80 
02 03 04 
Quartiles of age 
[[Il] Arcus cornealis 
E3 No arcus cornealis 
P=O.009 
Chi-square test 
3.4.1.5 Metabolic precipitants of dysbetalipoproteinaemia 
Dysbetalipoproteinaemia is often unmasked by clinical conditions such as alcoholism, 
diabetes or hypothyroidism. We compared the ages at presentation of patients 
categorized by the clinical disorder thought to be the dominant precipitating factor by 
the admitting clinician . Alcohol abuse was associated with a significantly younger age 
at presentation when compared to those patients in whom no secondary cause was 











habits and may not always truly reflect actual alcohol consumption. The fact that 
patients who abuse alcohol are younger at presentation than other patients may simply 
be due to alcohol abuse often setting in at a younger age than the other clinical 
conditions considered. 
Table 3-9 Ages at presentation by metabolic precipitants 
Number Mean Median SD Range P value 4 
Diabetes I 36 52.19 54.24 10.48 27.40-71.27 0.88 
Hypothyroidism 6 56.02 54.17 13 .71 39.75-80.80 0.20 
Alcohol abuse 2 6 39.00 38.99 8.41 29.49-49 .38 0.01 
Renal disease ~ 13 48 .39 52 .62 18.31 6.93-60.39 0.57 
None of above 74 50.35 50.00 10.16 23 .]8-75 .97 
I Diabetes previously diagnosed or diagnosed at the first consultation 
2 Alcohol abuse was defined as consumption of more than 140 grammes of alcohol per 
week for females and 210 grammes per week for males 
3 Chronic renal failure , proteinuria (> I + on dipstick), nephrotic syndrome 
4 Compared to patients with none of the above conditions (unpaired t-test) 
Obesity was highly prevalent. Thirty-three % of patients had a BM! of more than 30 
kg/m2 and the waist circumference exceeded the values recommended (men< 102 cm, 











(NCEP III) (254) in 50% of patients. Obesity was analyzed without reference to other 
metabolic precipitants due to its high prevalence. 
, 
Table 3-10 Age at presentation and obesity J 
Age at presentation • 
Measure of obesity Number I P value 2 
Mean Median SD Range 
BMI :::: 30 43 49.98 51.66 12.33 6.93-80.80 
0.69 
(kg/m2) < 30 84 50.66 52.67 9.77 27 .04-66.92 
Waist 3 > NCEP 54 51.39 52.67 9.57 27.04-68.43 
0.04 
(cm) < NCEP 54 47.16 49.06 12.80 6.93-80.80 
I Incomplete data for some patients 
2 Data not normally distributed , Mann Whitney test 
3 Men > 102 cm, women >88 cm 
The finding that an increased waist circumference was associated with a higher age at 
presentation is somewhat surprising. Abdominal obesity is predictive of insulin 
resistance and would be expected to accelerate the phenotypic expression of 
dysbetalipoproteinaemia. 
3.4.1.6 Comparison with previous case series 
All previous case series report a younger age at presentation in males than females 
(6;7;9;10), with the mean reported difference ranging from 5 (10) to 17 years (6). 











(9 ; 10). This may well reflects ascertainment bias as Borrie (6) studied patients seen at 
a dermatology clinic for xanthomata and Morganroth (7) reports on patients referred 
to the National Institute of Health. It is likely that younger and more severely affected 
patients would be referred to such centers. Feussner (10) describes 64 hyperlipidaemic 
apoE2 homozygotes identified at a single tertiary center by systematic screening of 
patients referred with mixed hyperlipidaemia. The setting of Feussner's study is 
therefore very similar to the GSH lipid clinic and the mean ages at presentation are 
very similar to those seen in this study (values in brackets) at 48.9 years (47.37) for 
males and 53.2 (53.62) years for females. There are no published reports examining 
the influence of physical stigmata, apoE genotype and comorbidities on the age at 
presentation. 
3.5 Lipid investigations 
There was a very wide range of lipid values at initial presentation. 
Dysbetalipoproteinaemia may present with " moderate" dyslipidaemia in a few 
patients but on occasions may also causes extremely severe dyslipidaemia. Table 3.11 
illustrates the lipid values at presentation. Patients who were referred on treatment and 
for whom untreated lipid values could not be traced were excluded from this analysis. 
Triglyceride values were not normally distributed and analytic statistics were 











Table 3-11 Untreated lipid values at presentation 
All Patients Number Mean Median SD Range 
TG 131 8.28 1 4.90 9.39 1.6-63 .20 
TC 133 11. 79 1 10.42 5.04 4.8-34.30 
HDLC 118 1.07' 1.00 0.37 0.5-2.1 
I All values in mmol/L 
3.5.1 Triglycerides 
In patients with FH (253) and the general population (255) triglycerides increase with 
age. In dysbetalipoproteinaemic subjects hypertriglyceridaemia is often associated 
with cutaneous xanthomata (see below) and may lead to acute pancreatitis. There is 
therefore a positive bias towards earlier referral of hypertriglyceridaemic patients. 












Figure 3-8 Triglycerides vs. age at presentation quartiles 
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The scatter plot (-- geometric mean) shows that most patients with severe 
hypertriglyceridaemia (here defined as TG> 15 mmollL and indicated by the broken 
line) present at a younger age. 
The nature of apoE mutations influences remnant metabolism differentially. TG levels 












Table 3-\2 Triglycerides by apoE mutation 
Triglyceride 
Genotype Number mrnoliL 
Mean Median SD Range 
E2/E2 I 
.:,.{ 
c 67 4.9 7.8 7.0 1.6-41.3 
All 26 6.7 5.6 4.3 2.2-19.7 
,-.. 
+ U V) 
Hetero 23 6.9 5.6 4.6 2.2-19.7 0 <:t c:: -Q) 
~ 0 
U.l Homo 3 5.3 5.5 0.48 4.8-5.7 
E (KI46Q) 2 5.7 5.7 2.5 3.9-7.4 
Geno- 37 10.3 4.8 14.4 2.2-63 .2 
















All E2 E145 all E145 het E145 homo E146 Geno-
There were no significant differences in TG values at presentation between apoE2 
homozygotes and heterozygous carriers of the apoE (RI45C) mutation (P=0.81, 
unpaired t-test). Homozygosity for the apoE (R 145C) mutation was not associated 











an identified mutation had similar TG to those in whom an apoE mutation had 
been identified (P=0.67, unpaired There were no ,u,,",",u,",,.,, in TG 
between males and females (geometric mean 6.45 vs. 5.55 for males vs. females; 
P=0.23 unpaired !-test). 
Patients with severe "".,PrY,., 15 are particular concern 
because they are at high risk of acute examination was done to 
determine whether any factors were particularly associated with severe 
hypertriglyceridaemia. There were 17 with severe hypertriglyceridaemia. 
genotypic status exact Diabetes (P=0.78, Fisher's exact 
BMI (30.17 ± 5.30 vs. 28.52 ± P=0.19 by unp ired t test for TG > 15 mmollL vs. 
TG <15 mmollL) and waist circumference> NCEP Criteria (P=0.10, Fisher's exact 
test) were not associated with severe hypertriglyceridaemia. However, severe 
was associated with alcohol abuse 
























TG >15 TG <15 
Triglyceride in mmoUI 
In this cohort men were more likely than women to present with severe 
hypeltriglyceridaemia . Although alcohol abuse was more frequent amongst males 
(data not shown) the absolute number of patients with severe hypertriglyceridaemia 
that abused alcohol was only three. 
3.5.1.1 Comparison with previously published case series 
The mean TG of 8.28 rrunol/L in our series lies within the range of 5.7 mmollL (256) 
to 8.1 rrunol /L (l0) reported in previous studies. The association of plasma 
triglycerides with physical stigmata of dyslipidaemia and comorbid conditions has not 
been systematically reported previously . 











The levels of total cholesterol and triglyceride are correlated (r2=O.54 by linear 
regression, P<O.OOOl) and it is therefore not surprising that these lipids have similar 
associations with clinical and metabolic features . 
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Figure 3-12 Total cholesterol vs. age at presentation quartiles 
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Table 3-13 Total cholesterol by apoE mutation 




Mean Median SD Range 
E2/E2 68 12.02 11 .20 4.60 4.8-34.30 
All 26 10.72 10.55 4.25 6.2-27.20 
~ 
+ U tr) 
0 ~ Hetero 23 10.66 10.20 4.48 6.2-27.20 
0 -(1) eo::: 
0 '-' 
L.Ll Homo 3 11.18 11.40 2.23 8.84-13.30 
E (KI46Q) 2 10.50 10.50 1.69 9.30-11.70 
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All E2 E145 all E145 het E145 homo E146 Genoneg 
There were no significant differences between the total cholesterol at presentation 
between E2 homozygotes and heterozygous carriers of the apoE (RI45C) mutation 
(P=O.13 , unpaired t-test). Homozygosity for the apoE (R] 45C) mutation was not 
associated with higher total cholesterol than the heterozygous state (P=0.64, unpaired 
t-test). Patients without an identified apoE mutation had similar total cholesterol to 
those in whom an apoE mutation had been identified (P=0.88, unpaired t-test). There 
was no significant difference in total cholesterol between males and females 
(geometric mean ]0.8] vs. 11.22, P=0.96, unpaired t-test). 
3.5.2.1 Comparison with previously published case series 
The mean TC of J 1.79 mmollL is similar to that reported in previous case series 
where the aggregate mean of 4 series (6;7;9; 10) is 11 .84 mmollL. Factors influencing 
TC levels have not been reported on previously. 











The ratio total cholesterol to triglycerides approaches unity when pvrlr,."", 
by mass or 2: I if lipids are .. ,,"'·oo~,u in molar terms (5). In our series the mean 
molar ratio was 2.07 1.03 (Median 1.96, 0.39-7.63). There were no 
significant differences in this ratio between any subgroups of dysbetalipoproteinaemic 
(data not shown). Because the high variability of the ratio of total cholesterol 
to in dysbetalipoproteinaemia a ratio that significantly differs from 2 does 
not exclude the diagnosis. The mean molar ratio was 4.45 ± 3.21 (Median 
0.11-34.50) in the total u"wc<ua" .. of 5952 lipid patients. 38 .... (U1\Al,.:> with a 
ratio of exactly 2: 1, 2 were aVimetalllpopr 
3.5.4 HDL Cholesterol 
HDLC levels are highly variable in with dysbetalipoproteinaemia. In our 
cohort the HDLC range was from 0.5-2.1 mmolJL. HDLC levels did not show a 











Figure 3-14 HDLC vs. age at presentation quartiles 
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The HDLC level varied significantly when analyzed by apoE mutation . 
Table 3-14 HDLC by apoE mutation 
HDL Cholesterol 
Genotype Number mmollL 
Mean Median SD Range 
E2/E2 63 1.18 1.19 0.41 0.5-2.1 
All 24 0.88 0.91 0.25 0.5-1.4 
,,-.. 




UJ Homo 2 0.86 0.86 0.08 0.8-0 .92 
E (K146Q) 1 1.8 























E145all E145 hel E145 homo E146 Genoneg 
There were differences between the HOLe at presentation between 
homozygotes and carriers of the (RI45C) mutation 
unpaired 10rnO:i:Y}~OSHY for the mutation was not associated 
with altered HOLe levels compared to the hplpr(Vn! state I, t-
test). Patients without an identified mutation had similar HOLe to those in 
whom an mutation had been identified 16, unpaired HOLe levels 
are generally in women than men. This was also true in our cohort although the 
difference was not (1.03 ::=0.36 mmol/L vs. Ll2 ::= 0.38 
mmolJL for male vs. female, P=0.15, 
Hypertriglyceridaemia is often associated with low levels of HOLe. In our series 
mean HOLe levels were highest in those in the lower of triglyceride 
levels. HOLe levels may have been overestimated in some hypertriglyceridaemic 











Figure 3-16 HDLC by triglyceride quartiles 
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ANOVA (Kruskal-Wallis test) P=O.003 
3.5.4.1 Comparison with previously reported case series 
Not all previous case series report HDLC, but where reported, values are similar to 
the mean value seen in our series. There have also been significant changes in the 
methodology used to determine HDLC over the years and this may affect the 
comparability of results (257). 
3.5.5 Apolipoproteins 











Apolipoprotein B levels reflect the number of circulating apoB-containing 
lipoproteins. Larger lipoproteins contain proportionally less apoB and more lipid than 
smaller lipoproteins. Remnant lipoproteins are larger than LDL and are relatively 
cholesterol-enriched. In patients with equivalent elevations of TC, assuming no major 
differences in HDLC, one would thus expect to find lower levels of apoB in patients 
with remnant accumulation. The mean apoB level in our cohort was 1.24 ±0.34 giL. 
Table 3.15 shows the mean apoB levels by apoE genotype. 
Table 3-15 ApoB (giL) levels by apoE genotype 
Apolipoprotein B (giL) 
Genotype Number 
Mean Median SD Range 
E2/E2 58 1.15 1.08 0.48 0.32-3.19 
All 23 1.21 1.22 0.36 0.55-1.97 
~ 
+ U V) 
Hetero 19 1.25 1.27 0.34 0.62-1.97 0 -<:t 
C -II) ~ 0 '-' 
W Homo 4 1.00 1.00 0.39 0.55-1.46 
E (K146Q) 2 1.24 1.24 0.28 1.04-1.43 
Geno- 30 1.60 1.58 0.54 0.6-2.8 
ANOV A for data sets apoE21E2, apoE (RI45C) heterozygotes and genonegative 
P=0.0003 
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ApoB levels were significantly higher in patients without a known apoE mutation 
than in apoE2 homozygotes and apoE (R 145C) mutation carriers. The apoB levels did 
not differ significantly between apoE2 homozygotes and apoE (R 145C) mutation 
carriers. In a cohort of 916 patients with FH seen at the GSH lipid clinic and evaluated 
in the same laboratory, the mean apoB level was 1.56 ± 0.39 giL with a mean TC of 
9.10 ± 1.68 mmollL. The TC was 11.0 ± 3.96 mmollL (P<O.OOOI , Mann-Whitney 
test) in the dysbetalipoproteinaemic patients for whom apoB levels were available . 
The ratio of apoB/TC was significantly lower In patients with 
dysbetalipoprotei aemia than those with FH (0.13 ± 0.05 vs . 0.17 ± 0.04, P<O.OOO 1, 
Mann-Whitney test for dysbetalipoproteinaemia vs . FH). On subgroup analysis 
patients with no known apoE mutation have significantly higher apoB/TC ratios than 
those with identified apoE mutations and more closely resemble patients with FH. 
This could be due to the concurrence of LDL hypercholesterolaemia and cholesterol-
enriched VLDL in genonegative patients. A detailed ultracentrifugal analysis would 



























Kruskal-Wallis test P<O.OOO I 
Post-test 
* P<O.OOI vs. genopositive patients 
+ P<O.OOI vs. patients 
The di}jerence benveen genonegalive and FH patients was not slalislical(v sign~flcant 
ApolipoproteinAI 
levels from 0.29-2.49 with a mean 1.17 ± 0.33 giL. ApoAl 
levels did not by not ApoAI levels 
did not differ ~''''''H'~'''' between patients with and patients 
with FH (1.17 ± 0.33 vs. 1.15 ± 0.32 P=0.55 by Hest for 











Comparison with previously published case series 
published case series have not reported details on 
are therefore not possible. 
VlDl compositional analysis 
VLDL ""',.,.,.,,"',, analysis was done at least once in 1341136 
levels and 
of In 
total 258 VLDL compositional analyses were n", .. tr\l-rn~·t1 
per patient. In this section the data are 
with a mean number of 1.9 
to the results of those 
analyses performed when patients were not 
medication. VLDL compositional analysis was 
untreated state. 
in 98 III 
Ratio of cholesterol vwt/triglyceride VWL (CV/TV) 
The ratio of CV lTV is generally elevated in patients with dysbetaiipoproteinaemia, 
but not always reach the proposed 
in patients with severe n'IT'PrTn 
threshold of 0.42 (230), 











Table 3-16 CV/TV ratio by apoE genotype in untreated patients 
Ratio CV/TV 
Genotype Number 
Mean Median SD Range 
E2/E2 50 0.53 0.51 0.19 0.21-1.34 
k, 
All 17 0.52 0.43 0.35 0.16-1.76 
,--.., 




i.J..l Homo 1 0.68 
E (KI46Q) I I 0.37 . 
Geno- 28 0.49 0.47 0.15 0.20-1 .02 
Note: For technical reasons this ratio could not be determined in one patient. thereJore Slim of all patients is only 97 
The CV/TV ratio did not differ significantly by apoE genotype (data not shown). 




















Table 3.17 illustrates in how many patients the diagnosis of dysbetalipoproteinaemia 
would have been made purely on phenotypic criteria using a diagnostic threshold of 
either 0.42 (230) or 0.35 (231) for the ratio CV/TV. 
Table 3-17 Patients meeting phenotypic diagnostic criteria (CV lTV) in the untreated state 
Ratio CV/TV 
Genotype Number 
~ 0.42 ~ 0.35 
E2/E2 ~,ti:.i;'.! 
" .. :; 
50 37 46 
All 17 10 12 
~ 
+ U <n 
0 -.::t Hetero 16 9 11 
s::: -<!) 0::: 
0 '-' 
'-Ll Homo I I I 
E (KI46Q) I 0 I 
" 
Geno- 28 22 25 
3.5.6.2 Ratio of cholesterol vLDdtriglyceride Plasma (CV/TP) 
The ratio of CV ITP ranged widely from 0.1 0 to 0.71. The ratio was significantly 
higher in apoE2 homozygotes than in patients with no identified genotype (Kruskal-
Wallis test P=0.002, Dunn's multiple comparison test for apoE2 homozygotes vs. 
genonegative P<O.O 1; Columns analyzed apoE2 homozygotes, apoE (R 145C) 











Table 3-18 CV{fP ratio by apoE genotype in untreated patients 
Ratio CV/TP 
Genotype Number 
Mean Median SD Range 
E2/E2 
.: 
51 0.36 0.35 0.1 0.14-0.66 
, ; 
All 17 0.33 0.30 0.16 0.1-0.71 
~ 
+ U V) 
Hetero 16 0.33 0.30 0.16 0.1-0.71 0 -.;t 
t:: -(]) et:: 
0 '--' 
u.:! Homo 1 0.37 
, 
E (KI46Q) 1 0.37 : 
Geno- 28 0.28 0.28 0.08 0.14-0.46 
Table 3.19 shows how many untreated patients reached the diagnostic threshold of 
0.30 (207) or 0.25 (231) for the CVITP ratio. 
Table 3-19 Patients meeting phenotypic (CV/TP) diagnostic criteria in the untreated state 
Ratio CV/TP 
Genotype Number 
::: 0.30 ::: 0.25 
E2/E2 51 41 44 
All 17 9 10 
~ 
+ U V) 
0 -.;t Hetero 16 8 10 
t:: -(]) et:: 
0 '--' 
w Homo 1 I 1 
E (KI46Q) 1 1 I 











3.5.6.3 Comparison with previously published case series 
Most of the previously published case series do not report the degree of VLDL-
cholesterol enrichment found in their patients, but simply use VLDL-compositional 
analysis as a diagnostic criterion. Where the results are reported, they are similar to 
those in this cohort (10). 
3.5.7 Agarose gel electrophoresis 
The interpretation and classification of agarose gel electrophoresis always involves a 
measure of judgment and subjectivity and is therefore not fully standardizable. 
However, all agarose gels in this series were reviewed and classified by a single 
observer, eliminating intra-observer variability. Reports on agarose gel 
electrophoresis were available for 113 patients. 
Thirty-two % of patients had agarose gel electrophoresis "typical" of 
dysbetalipoproteinaemia, i.e. broad-beta bands. Amongst genopositive patients 41 % 
of patients had a broad-beta band. In an additional 27% of patients the suspicion of 
dysbetalipoproteinaemia was raised on review of agarose gel electrophoresis, but the 
pattem observed was not entirely characteristic. By way of example, patients with 
severe hypertriglyceridaemia at presentation and staining of chylomicrons at the 
origin in addition to staining of the /3 and pre-/3 areas were classified as having a Type 
V pattem. If lipoproteins stained relatively uniformly in the /3 and pre-/3 areas without 











Table 3-20 Fredrickson classification of agarose electrophoresis 
Fredrickson Nt % 
I 0 0 
IIa 2 2 
• lIb 
28 20 
III 36 32 




! III <;:1 L 
K 
31 127 
Not classified j 1 1 
Other 4 4 4 
N umber of patients 
Broad-beta band sm:pe,cted. but electrophoretogram not characteristic, see 
table 3.21 below for more details 
3 Gels not classifiable (technically inadequate) 












Table 3-21 Final Fredrickson classification of agarose gels suggestive of dysbetalipoproteinaemia 




Of the 36 patients with typical broad-beta bands on agarose gel electrophoresis 32 
were genopositive (Fisher's exact test P=0.004 comparing the prevalence of typical 
broad-beta band by genotypic status). In patients without a typical broad-beta band the 
most common pattern was Type lIb (381113), followed by Type V (151113) and Type 
IV (81113). 
As is to be expected mean TG levels were highest in the patients with Type V patterns 
and lowest in those with IIa patterns (data not shown). Patients with a typical broad-
beta band had significantly higher mean TG levels than those patients ultimately 
classified as having a Typ  lIb pattern with the suspicion of an underling broad-beta 
band (TG for typical Type III pattern 8.54 ± 10.24 mmoV vs. 4.74 ± 3.59 mmollL for 
patients classified as Type lIb pattern with suspicion of underlying broad-beta band; 
P=0.0007 by Mann Whitney test). TG levels did not differ significantly between 
patients with Type lIb patterns, whether an underlying broad-beta band was suspected 
or not (TG for typical Type IIb 4.49 ± 1.78 mmoVL vs. 4.74 ± 3.59 mmoVL for 
patients with possible underlying broad-beta band; P=0.43 by Mann-Whitney test) . 
TC levels were higher in patients with typical broad-beta bands than those classified 











difference was not statistically significant for typical 1lI 12.05 ± 
5.75 mmoliL vs. 9.58 ± 2.38 mmol/L for 1""11'<::11"" classified as llb pattern with 
of underlying broad-beta P=0.058 by Mann Whitney 
more cholesterol-enriched VLDL or of dysbetalipoproteinaemia 
(palmar crease cutaneous or tendinous xanthomata) was not 
with a higher of agarose electrophoretograms characteristic of 
dysbetalipoproteinaemia not shown). 
There were 8477 records of agarose nr.,'pe,'e in the database at the 
time that the dysbetalipoproteinaemia was closed. Of these 78 had been 
classified as Type III without a of 
having been made Not all patients had continued at the lipid 
clinic, and therefore investigations for dysbetalipoproteinaemia were not 
completed in all Of the 78 patients were available for 65. 
Table 3-22 ApoE genotypes in patients with Fredrickson T)'pe 111 pattern who were not 
UlllglIlJl~CU with d),sbetalipoproteinaemia 
ApoE 4 E3/E3 E3/E4 E4/E 
N 8 4 31 20 2 
54 patients had been evaluated for the (RI mutation and all were 
VLDL .... v.,uvv',;,,,'vu'" had been undertaken on 51 occasions in 34 
None of the ratios were considered diagnostic dysbetalipoproteinaemia. Although 











for dysbetalipoproteinaemia this does indicate that agarose 
electrophoresis is not for dysbetalipoproteinaemia. 
3.5.8 Polyacrylamide gradient gel electrophoresis 
Non-denaturing PGGE is np'-T'-""""~'rl routinely on all the clinic 
for the first time. the total expcrience is of about 26000 lanes run 
over the last fifteen years. PGGE separates by size and the ""u,~"'u 
chosen in the UCT laboratory retains only apoB-containing within 
the is characterized by the accumulation of remnant 
lipoproteins and low levels of LDL. lipoproteins by size one would 
therefore expect to see little or no LDL-sized material but an excess of 
lipoproteins of IDL and VLDL2 size. The dysbetalipoproteinaemic phenotype is 
highly variable and in cases where metabolism is 
especially when TG levels are markedly elevated - chylomicron and VLDLl-sized 
lipoproteins may also accumulate. The abnormal distribution of by size in 
dysbetalipoproteinaemia had already been observed by Shepherd In 1975 
agarose column chromatography (228). 
The observation that many patients with t1""hp't<l 
PGGE profile led to further investigation. It was found that a 
had an unusual 
characterized by 
accumulation of IDL-sized lipoproteins and the absence of LDL-sized lipoproteins 
was highly (95%) and sensitive (72%) for the diagnosis of 
(227;258). The control group for this study was made up of 











excluded by VLDL compositional analysis and genotyping for the conunon apoE 
isoforms and locally prevalent dominant apoE mutation. Analysis of the area under 
the curve (AUC) of densitometric tracings further improved diagnostic accuracy. A 
ratio of AUC of more than 0.5 for IDLILDL area was 100% specific and 89% 
sensitive for the diagnosis of dysbetalipoproteinaemia. 
PGGE patterns were divided into four arbitrarily named categories: 
A=VLDL and IDL only (Rf0.45-0.85) 
B=VLDL and IDL, faint staining in LDL region (Rf 0.85-1.0) 
C=VLDL and IDL, prominent staining in LDL region (Rf 0.85- 1.0) 
D=LDL only (RfO.85-1.0) 

























Note: The relative OD scales have been adjusted for the various tracings to 
emphasize TGRL. 
Figure 3-21 PGGE patterns 
A B c o 
Note: The photograph above is a composite of several gels. It has been electronically 
altered to increase contrast and sharpness, but no other changes have been made to 
the images. The densitometric tracings in Figure 3.20 are not those of the lanes 
above. 
The publication of the above findings described pattern A in 72% of untreated patients 
with genopositive dysbetalipoproteinaemia. Pattern B was found in 20% of subjects, 
while 8% had pattern C. None of the patients studied in the untreated state had pattern 
D (258). If treated patients are included in the cohort as many as 8% may have pattern 
D. PGGE patterns may therefore undergo substantial change in individual patients as 











will be discussed in detail in " .. "'.., ..... , 4 in the context of the controlled 
conditions of a clinical trial. The next section reports on the experience with PGGE in 
the full cohort of dysbetalipoproteinaemic 
3.5.8.1 PGGE patterns 
PGGE were available for 135 of the patients. About half of all patients had a 
PGGE pattern considered highly characteristic of dysbetalipoproteinaemia (A 
In 69% of the PGGE pattern was very 
dysbetalipoproteinaemia or B pattern). 
Table 3-23 PGGE reports in dysbetalipoproteinaemia 
Pattern A B C D 
. Number 67 26 31 11 












Table 3-24 PCCE patterns by apoE geno type 
PGG E pattern 
Genotype Number 
A B C D 
E2/E2 69 54 8 1 6 
All 28 8 9 10 1 
+ G If) 
Hetero 24 7 7 9 I 0 '<t 
c: -II) e::: 0 '-" 
W Homo 4 1 2 I 0 
E (KI46Q) 2 0 0 2 0 
Geno- 36 5 9 18 4 
Genopositive patients were significantly more likely than genonegative patients to 
have an A pattern with no LDL-sized lipoproteins visible on staining (P<O.OOOI by 
Fisher ' s exact test) . 
Figure 3-22 PCCE with no visible LDL by apoE genotypic status 
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1/1 -I:: 




















PGGE patterns also to the underlying apoE mutation. Patients with 
the (R145C) mutation were more to have visible LDL-sized 
lipoprotein particles than hornoz:VQ()tes (P<O.OOOI by Fisher's exact 
















mutation LDL-sized were seen more 
frequently in patients with TG levels in the lower two quartiles (P=O.005 by Chi-
square test). In TG levels (quartiles) did not have a statistically 












Figure 3-24 PGGE patterns by TG quartiles in patients with the apoE (RI4SC) mutation 
1/1 ... c: 
Q) ... 























All laboratory records of PGGE were reviewed for reports that would be highly 
suggestive of a diagnosis of dysbetalipoproteinaemia. There were 26026 PGGE 
reports in total. There were 333 reports of patients with visible staining only in the 
range of VLDL and lDL-sized particles with no staining of LDL-sized particles. Of 












Table 3-25 Origin of specimens with PGGE reports suggesting dysbetalipoproteinaemia 
Source Details N 
ART In 4 
children I 
>-. Coronary 4 "0 
3 
Vl 








'" Population 5 u 
OJ) 
4 .3 screen 
0 
·5 
<l) NAFLD 5 6 "0 
0.. 
LL.l 
PET 6 15 
Other I 11 
Referred by 5 
other labs 
Lipid clinic ~ 47 
Origin unclear 11 
I Specimens from a study investigating the effects of antiretroviral therapy (ART) on 
the lipid profile of lIlY -infected children. No clinical data available. 
2 Specimens received from the coronary care unit. No clinical data available. 
3 Specimens from a study investigating lipid abnormalities in patients with polycystic 
ovarian syndrome (PCOS). No clinical data available. 












5 Specimens received and processed during the course of a study investigating non-
alcoholic fatty liver disease (NAFLD). No clinical data available. 
6 Specimens from a study examining lipid abnormalities III patients with 
preeclampsia. DNA was available for these patients and 5 patients were homozygous 
for apoE2 and the apoE (R 145C) mutation was detected in two. Unfortunately no 
clinical details are available. 
7 Specimens from various other sources. 
8 Specimens that had banked DNA. Most, but not all, of the patients with banked 
DNA would have been seen as patients at the lipid clinic. 
On the 47 specimens linked to the lipid clinic by DNA numbers the following data 
were available: 
Table 3-26 Genotypic and phenotypic results in patients with PGGE patterns suggestive of 
dysbetalipoproteinaemia 
ApoE Isoform 
E2/E2 E2/E3 E3/3 E3/4 E4/E4 NT' 
9 7 I 14 5 11 
ApoE (R 145C) mutation L 
POS NEG NT 











VLDL compositional analysis 
s NEG 
18 28 
I NT= Not tested 
2 Patients with apoE2 homozygosity were not tested for this mutation 
There were 11 patients in who no further to U'''F','''J'''' 
dysbetalipoproteinaemia had been These were mainly seen in the 
first few years following the establishment of the clinic. The clinic's interest in 
dysbetalipoproteinaemia was not fully at that and there was less 
experience in the interpretation of PGGE. Ten of the 47 (21 %) patients were found to 
have apoE with the of dysbetalipoproteinaemia. 
These patients were not included in the dysbetalipoproteinaemic cohort studied here 
because they had been after the database had been locked (6), their records 
could not be retrieved (1) or had been sent PGGE and DNA analysis, but 




had all had 
exclusion of the (R 
for dysbetalipoproteinaemia. 
to determine the common apoE 
mutation and VLDL compositional analysis. In many 
narlenrs the VLDL vV'"F'''''''V''''' had been repeated on several occasions. 











It is conceivable that many of the patients with PGGE suggestive of 
dysbetalipoproteinaemia but without clinical details may well have had this disorder. 
ART, particularly if PI are used, is known to precipitate dyslipidaemia and 
dysbetalipoproteinaemia may well occur in genetically susceptible individuals 
(260;261). Patients in coronary care units have manifest atherosclerosis and this 
population may therefore also be enriched for dysbetalipoproteinaemia. PCOS is 
commonly associated with obesity and insulin resistance (262), both factors that may 
precipitate dysbetalipoproteinaemia. Similar considerations apply to patients with 
NAFLD (263). In the population survey about 1000 people were screened (259). A 
rate of dysbetalipoproteinaemia of 5: 1000 is higher than previously reported (1), but it 
must be considered that lipid levels were not known for these patients and that some 
samples may have originated from individuals with normal or even low lipid values. 
The high rate of PGGE patterns suggestive of dysbetalipoproteinaemia in patients 
with preeclampsia is of interest. In a recent antenatal study in Zimbabwe using the 
same PGGE method as described here, 30 of 660 (4.5%) participants had a pattern 
highly suggestive of dysbetalipoproteinaemja. Of these 30 subjects 14 had apoE 
mutations (8 apoE (R145C); 6 apoE2/E2). The dysbetalipoproteinaemia pattern only 
persisted in two subjects in the postnatal state, strongly suggesting that pregnancy is a 
sufficient metabolic stressor in genetically predisposed subjects to tilt lipid 
metabolism towards remnant accumulation (121). Pathology laboratories in the 
private sector often referred samples with "unusual" lipid values to our laboratory. A 
common reason for referral was marked discrepancy between the directly measured 












Although an A on PGGE is not entirely for dysbetalipoproteinaemia, 
PGGE remains a very useful investigation. The pattern was uncommon 
(333/26026 or 1 and was associated with oy:soctallpo,pr()tel In 
238 instances. In the 95 instances where dysbetalipoproteinaemia was SU~;DeCle:a but 
could not be proven clinical information was not available and further 
could not be done in 61 cases. these had 
are positively associated with the development of dysbetalipoproteinaemia. 
3.5.8.1.1 particle by 
LDL size, when studied in non-dysbetalipoproteinaemic 
Hypertriglyceridaemia is strongly 





cholesterol ester transfer protein, oestrogen levels (266) and activity of plasminogen 
activator inhibitor-l (267) also influence LDL size. LDL size IS 
further influenced by factors that interact In a complex fashion with 
environmental and hormonal influences From an eOIOerni 
view age, male sex, obesity, hypertension, diabetes and the metabolic 
associated with an increased prevalence of small dense LDL particles 




This is not surprising as low levels of LDL and aceumulation of remnants of TGRL 
characterize this disorder. The little LDL formed in dysbetaiipoproteinaemia is likely 
to be small and dense as there are high levels of remnant lipoproteins that 











leads to the formation of small dense LDL. Conversely apoE2 does not activate HL as 
well as apoE3 (171; 172) and low HL levels are associated with larger LDL species. 
In those patients of our cohort with visible LDL-sized particles the particle size, 
determined relative to the two control LDL species - A (large) and B (small) - loaded 
on every gel, was predominantly, but not exclusively, small. 
Figure 3-25 LDL particle sizes by PGGE (proportional representation) 
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Note: Capital letters in this instance only indicate LDL-size and do not refer to the 
intensity of staining (see PGGE terminology for more details) 
Lipoproteins that migrated further than I (i.e. liB , Band Bpost) were classified as 





















E21E2 Geno+ Geno E145 
Patient Group 
of 




patients have small dense LDL, the 
In without identified apoE 
mutations than those with known mutations (P=0.006, Fischer's exact test). 
Patients with (R145C) mutations also had a higher of small LDL 
than homozygotes but the difference was not statistically significant 
(P=0.28, Fischer's exact test). Patients without identified mutations are very 
unlikely to have LDL 
Table 3-27 LDL size by apoE genotype 
'-JvUV ,~ 22 
Genotype 
Geno- 2 29 













As the vast majority of patients without identified apoE mutations had small dense 
LDL it was not feasible to investigate the effect of hypeliriglyceridaemia on LDL size 
in this subgroup. In genopositive patients the proportion of patients with large LDL 
species declined progressively in the higher quartiles of TG levels, but the change was 
not statistically significant (P=O.21 by Chi-square test with 9 patients in each 
quartile ). 
Figure 3-27 LDL species size in genopositive patients by quartiles of TG values 
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Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Quartiles of TG 
_ Small LDL 
_Large LDL 
Griffin (271) has previously suggested that 1.5 mmollL is the TG threshold above 
which increasing levels are strongly positively associated with the presence of small 
dense LDL. It is therefore not surprising that the majority of patients with visible LDL 
sized lipoproteins had small dense LDL. Of interest is that large LDL species were 
found in a few patients despite the presence of multiple factors associated with the 
formation of small dense LDL. This phenomenon was also observed in a few patients 
with FH (253) and remains as yet unexplained. Speculatively, differences in HL and 











Physical stigmata of dyslipidaemia 
3.6.1 Palmar crease xanthomata 
Palmar crease xanthomata also called xanthoma striata palmaris) are 
characteristic deposits of lipid in the palmar and digital creases. In rare cases 
the feet may be involved in a similar fashion. Palmar crease xanthomata are 
planar but may on occasions contain small nodules. The lipid clinic of 
palmar crease xanthoma is that they are usually not symptomatic and are 
often unaware of them. are usually but unilateral involvement of the 
dominant hand has been seen. Typically crease xanthomata resolve completely 
once hyperlipidaemia has been controlled. The pathophysiology of palmar 
crease xanthomata is not well understood or but as these are 
pathognomonic of dysbetalipoproteinaemia it seems reasonable to assume that 
renmant differ from other lipoproteins in their ability to extravasate in 
defined anatomical microcirculations and induce xanthoma formation. Lesions similar 
to palmar crease xanthoma may be seen in patients with high concentrations of 
lipoprotein X (LpX). With LpX the infiltration of the palmar creases lacks the 
characteristic colour seen in dysbetalipoproteinaemia, as carotene is 











Figure 3-28 Hand with palmar crease xanthomata 











Figure 3-30 Digital crease infiltration 











Figure 3-32 Palmar crease infiltration with LpX 











lnfonnation on palmar crease xanthomata was available in 134 patients and palmar 
crease xanthomata were found in 34 patients (25%). Palmar crease xanthomata were 
not associated with a younger age at presentation (see above). Palmar crease 
xanthomata were significantly more common in patients homozygous for apoE2 than 
in carries of the apoE (R145C) mutation or patients with no identified apoE mutation 
(P<O.OOO I , Chi-square test). Only one of the genonegative patients had palmar crease 
xanthomata. 
Table 3-28 Palmar crease xanthoma by apoE genotype 
Palmar crease xanthomata 
Genotype 
Present Absent 
E2/E2 28 39 
All 4 22 
~ 
+ U <n Hetero 3 19 0 "'<t 
C -II) 0::: 0 '--' 
!.Ll Homo I 3 
E (KI46Q) 0 1 I I 
·0 
; 
Geno- I 35 
Palmar crease xanthomata were found in 33% of female patients and 23% of males 
but this difference was not statistically significant (P=0.07, Fisher's exact test). The 
presence of palmar crease xanthomata was associated with higher levels of total 











Table 3-29 Palmar crease xanthomata and lipid values 
Lipid value Palmar crease xanthomata P value I 
Present Absent 
TG 8.06 ± 10.02 8.49 ± 7.02 0.25 
TC 13.55 ± 5.83 11.19 ± 4.63 0.02 
HDLC 1.06 ± 0.35 1.15 ± 0.43 0.22 
Ratio CV/TV L 0.55 ± 0.13 0.48±0.12 O.OJ 
Ratio CV ITP j 0.36 ± 0.09 0.31 ± 0.09 0.005 
I Unpaired t-test, skewed data was log transformed before analysis 
2 Cholesterol vLDdTriglyceride VLDL 
3 Cholesterol VLDU Triglyceride Plasma 
The finding that palmar crease xanthomata are associated with VLDL that is highly 
cholesterol enriched lends some support to the speculation that the size, composition 
and nature of remnant particles determine their propensity towards forming palmar 
crease xanthomata. 
3.6.1.1 Comparison with previously published case series 
The reported prevalence of palmar crease xanthomata is highly dependant on the 
initial criteria used to diagnose dysbetalipoproteinaemia. Thus it is not surprising that 











dermatology clinic. Similarly (7) reports crease xanthomata in 
64% of seen at the NIH. Feussner (10) found palmar crease xanthomata in 
39% of their less highly selected Overall the clinic is of 
palmar crease xanthomata in 25% of patients, but the occurrence 
crease xanthomata was strongly linked to the genotype (see above). The 
In of 28/67 is very similar to that rpr'Artp" by 
Feussner. 
3.6.2 Eruptive and tuboeruptive xanthomata 
and xanthomata are not characteristic of 
dysbetaiipoproteinaemia but may occur whenever there is severe 
xanthomata are usually the first cutaneous 
of severe while 
generally associated with hyperlipidaemia of '~H""."'" 
xanthomata are 
duration. These two 
of cutaneous xanthomata are considered together here as the distinction between 
and tuboeruptive xanthomata In is somewhat subjective and the 
clinical do not allow for these 
xanthomata are usually n'lntr.M""t.f' they are dramatic to 











Figure 3-34 Eruptive xanthomata on the trunk and buttocks 











Figure 3-36 Tuboeruptive xanthomata in an African patient 
Eruptive or tuboeruptive xanthomata were found in 30 of 133 (23%) of patients. As 
previously shown the presence of these xanthomata was associated with a 
significantly younger age at presentation . The highest incidence of 
eruptive/tuboeruptive xanthomata was found in patients homozygous for apoE2. 
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u.l Homo 3 1 
E (K146Q) lJlihb:::~~ 1 1 












Eruptive/tuboeruptive xanthomata were found in 20% of female patients and 24% of 
males (P=0.54, Fisher's exact test) . 
Table 3-31 Eruptive/tuboeruptive xanthomata and lipid values 
Lipid value Eruptive/tuboeruptive xanthomata P value I 
Present Absent 
TG 14.30 ± 11.80 6.58 ± 7.89 <0.0001 
TC 16.01 ± 6.54 10.64 ± 3.90 <0.001 
HDLC 1.13 ± 0.52 1.07 ± 0.33 0 .94 
Ratio CV /TV 2 0.54 ± 0.27 0.50 ± 0.13 0.20 
Ratio CV /TP j 0.36 ± 0.12 0.32 ± 0.08 O.oI 
I Unpaired t-test, skewed data were log transformed before analysis 
2 Cholesterol vLDJTriglyc ride VLDL 
3 Cholesterol VLDU Triglyceride Plasma 
In our series the finding of eruptive/tuboeruptive xanthomata was generally associated 
with severe hyperlipidaemia. VLDL cholesterol-enrichment was also higher in 
patients with such xanthomata, but the difference was only statistically significant for 











3.6.2.1 Comparison with previously published case series 
Similar to palmar crease xanthomata, the reported prevalence of eruptive/tuboeruptive 
xanthomata is highly variable and higher in the older studies. The prevalence of 29% 
in apoE2 homozygotes is higher than the 11 % recorded by Feussner (lO), but lower 
than that reported in all the other series. 
3.6.3 Tendinous xanthomata 
Tendinous xanthomata are firm subcutaneous nodules attached to or forming an 
integral part of the tendon. Tendinous xanthomata always indicate serious errors of 
lipoprotein metabolism. They are seen most commonly in patients with FH but also 
occur in patients with cerebrotendinous xanthomatosis, phytosterolaemia and 
dysbetalipoproteinaemia. Tendinous xanthomata most commonly involve the Achilles 
tendon followed by the extensor tendons of the hand. 











In our senes of dysbetalipoproteinaemic patients all tendinous xanthomata were 
located in the Achilles tendons. Seventeen % (23/134) of patients had tendinous 
xanthomata at presentation. Tendinous xanthomata were most prevalent amongst 
apoE2 homozygotes. 




E2/E2 17 52 
All 25 
,-.., 
+ U V) 




u.l Homo 3 
E (KI46Q) 
Geno- 4 32 
Chi-square test P=O.04 
There was no significant difference (P=O.65, Fisher's exact test) in the prevalence of 
tendinous xanthomata between males (I9%) and females (15%). None of the lipid 
values analyzed was predictive of the presence of tendinous xanthomata, although 











Table 3-33 Tendinous xanthomata and values 
Lipid value 1 P value I 
Present Absent 
TG 5.45::: 3.29 8.87 ± 10.17 0.1 I 
TC 
HOLC 0.91 
Ratio CV/TV L 0.49 ± 0.11 0.51 ±O.lS 0.S6 
7 0.32 0.10 0.15 
Hest, skewed data were log transformed before 
2 Cholesterol vLDuTriglyceride VLDL 
3 Cholesterol VLOU Plasma 
3.6.3.1 Comparison with previously published case series 
The of tendinous xanthomata in 
variable. Feussner (10) and (9) respectively 
published case series is highly 
tendinous xanthomata in only 
1 % and 3% of their study populations. Morganroth (7) found tendon xanthomata in 
23% of in his This is similar to the 17% prevalence in the CUlTent 
series and the 25% In The in the 
of tendon xanthomata cannot be I..cAIJlalH'vU easily, the 
difference observed between this series and that of Feussner (10). Tendon xanthomata 











abnormalities are subtle clinicians do not always agree on the clinical significance of 
these abnormalities . 
3.6.4 Xanthelasmata 
Xanthelasmata are soft yellow-orange papules or plaques found around the eyes and 
lids. Their prevalence increases with age and is generally higher in women than men. 
They may occur in normolipidaemic individuals but are often associated with subtle 
derangements of lipid profiles such as higher VLDL and lower HDL levels (272) . 
Xanthelasmata are not useful in the differential diagnosis of lipid disorders and 
generally only alert the clinician to the need for performing lipid analysis . 
Figure 3-38 Xanthelasmata 
Xanthelasmata were found in 8% (l1 1l 33) of patients. No difference in the occurrence 
of xanthelasmata was observed between the various apoE genotypes. Xanthelasmata 
were significantly (P=O.02, Fisher's exact test) more common in female patients 















E2/E2 .• ;1iL:;1!j1 7 61 
..:il.Wml@i~ 
All 2 25 
~ 
+ U V) 
Hetero 2 21 0 '1" 
C -<l) cG 
V '-' 
!..Ll Homo 0 4 
E (KI46Q) J "j; 1 I 
~::. 
Geno- I 35 
Chi-square test P=0.14 
In this series of patients there were no significant differences in lipid values between 
patients with and without xanthelasmata. However, there were only I I patients with 
xanthelasmata, limjting the statistical power of this analysis . 
Table 3-35 Xanthelasmata and lipid values 
Lipid value Xanthelasmata P value I 
Present Absent 
TG 6.44 ± 2.53 8.33 ± 9.71 0.97 
TC 11.82 ± 2.63 11.73 ± 5.20 0.59 
HDLC 1.18 ± 0.43 1.07 ± 0.36 0.41 
Ratio CYITY L 0.53 ± 0.12 0.51 ± 0.18 0.44 











I Unpaired t-test, skewed data were log transformed before analysis 
2 Cholesterol vLDJTriglyceride VLDL 
3 Cholesterol VLDLI Triglyceride Plasma 
3.6.4.1 Comparison with previously published case series 
The prevalence of xanthelasmata is generally low, at 3-6 % (9;10), in previously 
published series. The 8% prevalence in this series is in accord with this finding. 
3.6.5 Arcus cornealis 
Arcus cornealis is an opaque (white) arc or circle seen at the periphery of the cornea. 
In its early stages it may not be circumferential as it generally develops superiorly and 
inferiorly before becoming circumferential. Age is the dominant influence on the 
prevalence of arcus corneal is, with the prevalence approaching 100% at the age of 80 
years (273). Arcus corneal is is generally not useful in the differential diagnosis of 
lipid disorders. Its main utility is in alerting the physician to the possible presence of 
hyperlipidaemia if found in a young «40 years of age) subject. In this series there 












Figure 3-39 Arcus cornealis in a patient with dysbetalipoproteinaemia 
Arcus cornealis was found in 21 % (28/132) patients. The prevalence of arcus 
cornealis was not affected by apoE mutations. 
Table 3-36 Arcus cornealis by genotype 
Arcus corneal is 
Genotype 
Present Absent 
E2!E2 15 52 
All 4 23 Chi-square test P=O.61 
~ 
+ U If) 
Hetero 4 19 0 "<:I" 
t: -tU ez:: 
0 '-" 
L.L.l Homo 0 4 
E (K146Q) 0 2 











The prevalence of arcus cornealis was 22% in males and 24% in females (P=0.83, 
Fisher's exact test). In this small group of patients no changes in the prevalence of 
arcus corneal is according to lipid values at initial presentation was demonstrable. 
Table 3-37 Arcus cornealis and lipid values 
Lipid value Arcus corneal is P value I 
Present Absent 
TG 6.33 ± 4.96 8.67 ± 10. 16 0.32 
TC 10.91 ± 5.41 11.96 ± 4.93 0.18 
HDLC 1.09 ± 0.38 1.08 ± 0.37 0.92 
Ratio CV/TV 2 0.51 ± 0.10 0.51 ±0.19 0.67 
Ratio CV ITP J 0.32 ± 0.09 0.33 ± 0.09 0.93 
I Unpaired t-test, skewed data were log transformed before analysis 
2 Cholesterol vLDuTriglyc ride VLDL 
3 Cholesterol VLDU Triglyceride Plasma 
3.6.5.1 Comparison with previously published case series 
Arcus cornealis is not a useful physical sign In the differential diagnosis of 
dyslipidaemias and increases in prevalence with age. Information on its prevalence is 











1.6-11% 10). A prevalence of arcus comealis was found in this series 
(21%), hut a mean age of our cohort may be partially explanatory 
3.6.6 Clustering of physical signs of dyslipidaemia 
The physical of dyslipidaemia cluster in patlenlts. In this analysis only those 
indicative of severe disturbances in lipoprotein metabolism have been 
considered. There were 54 patients with tendinous, eruptive/tuboeruptive or palmar 
crease xanthomata and 22 n<>tlpnt" had at least two these while all three signs 











3-40 of physical signs in complete cohort 
Tendon xan. Eruorruhoeruotive xan. 
81 
Palmar crease xan 
The numbers indicate the number of patients with the physical 
Most of the of dyslipidaemia were found in ..,0."'"'''''' tl,(\ml(\7v{)',m for 











Figure 3-41 Clustering of physical signs in apoE2 homozygotes 
Tendon xan. Erup/Tuboeruptive xan. 
31 
Palmar crease xan 
3.7 Atherosclerotic complications 
All clinical records were reviewed to gather data on atherosclerotic complications. 
Data were collected on atherosclerotic complications present at diagnosis as well as 
those that set in during follow-up at the clinic. The duration of follow-up at the clinic 
was very variable and consequently the total atherosclerotic burden in this population 
cannot be estimated accurately. The approximate age of the patient when the 
atherosclerotic complication set in was calculated. Comparisons were made with FH 











Ischaemic heart disease (IHD) was defined as a history of myocardial infarction , 
percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) or 
a convincing clinical history of angina pectoris. PVD was defined by a history of 
surgery for PVD (amputation, bypass surgery), angiographic intervention or by a 
convincing history of peripheral claudication. Cerebrovascular disease (CerVD) was 
defined as a history of a previous stroke or transient ischaemic attack (TIA). 
3.7.1 Ischaemic Heart msease 
At presentation 481135 (36%) patients had IHD and during follow-up another 11 
developed IHD. Therefore 591135 (44%) of patients are known to have developed 
IHD. As previously stated, this figure likely underestimates the true burden of IHD 
due to incomplete follow-up. 
The apoE genotype did not influence IHD status either at presentation or at final 
follow-up (data not shown). The prevalence of IHD did not differ between males and 
females (32% vs. 39%, P=0.47; Fisher's exact test for male vs. female). 
Table 3.38 illustrates the prevalence of IHD in relationship to other cardiovascular 












Table 3-3SIHD and other cardiovascular risk factors 
IHD 
P Value I 
Absent 
Present 24 12 
Diabetes 0.0007 
Absent 31 63 
Present 42 32 
Hypertension 0.0009 
Absent 17 45 
Present 133 40 
0.47 
Absent 20 33 
Nole: Complele data was no/ available on all risk factors for all palienls: IfU'.!Y>/nI"P the number of 
patients with IHD is nOI a/ways 
I Fisher's exact test 
2 Smoking is defined as any 
Diabetes and hypertension were strongly predictive of but in this analysis 
smoking was not associated with IHD. The total number of pack years smoked at the 
time of presentation was derived multiplying the number of years smoked by the 
average number of 
difference in 
smoked per day and dividing by There was no 
exposure between with and without IHD (mean 
years 26.8 ± 11.6 vs. 26.8 
patients). Increased IHD 
exposure (data not shown). 
P=O.61 by Mann-Whitney test IHD vs. no HID 











The mean age at which IHD became clinically overt was 52.2 9.5 32-75) 
years. The mean age of onset of IHD was not significantly influenced by apoE 
(data not shown). IHD was, however, diagnosed at a younger 
age in males than "' .... ,,«\ .. '" lOA vS.56.6 ± 7.6, P=0.004 unpaired Hest for male 
vs. female). Table 3.39 shows the mean ages at which IHD was in the 
presence of other cardiovascular factors. 
Table 3-39 Age at diagnosis of IHD in the presence of other cardiovascular risk factors 




Diabetes 52.8 ± 8.3 52.7 ± 10.8 0.98 
H YpCllCIl:> 54.3 ± 8.6 48.4 ± 10.6 0.03 
Smoking 0.007 
In patients who had never smoked the diagnosis of IHD was made on average seven 
years later than in smokers. Diabetes increased the of IHD but did not 
further accelerate its Hypenension was somewhat paradoxically 
associated with more advanced age at the time IHD was 











In a cohort with FH the same clinic the of rHO at 
nrp'cpr,t<>tlAn was 43%. The mean age at onset of lHO was 43 years for males and 49 
years for females (253). Although with FH were on average 6 years younger 
when IHO set in, they would have been from bil1h while 
would have become 
a fairly V'VUI;"U period of normo- or even hypolipidaemia. 
The of IHO cannot be directly across several case series as 
diagnostic criteria may vary and are not always disclosed. Additionally 
clinics may introduce selection bias. The final 
of 44% for IHO in this cohort is the highest as yet, but does include 
prolonged follow-up in many The prevalence diabetes is also In 
this series than that reported m most other series below). This may have 
contributed to the higher of IHO together with a positive selection bias 
towards IHO in referrals to the GSH clinic. 
Morganroth reports a difference of 11.6 years in the mean age of onset lHO 
between males ) and females This series documents earlier onset in males 
(49.4) than females (56.0) but does not find the same of prematurity of lHO. 
Stuyt (9) risk factors for IHO in 39 patients and only higher levels of total 
cholesterol and smoking were of rHO. The small number of 
(21 and diabetic in Stuyt's did not allow for 











3.7.2 Peripheral vascular disease 
At their first evaluation 371134 (28%) of patients had evidence of PVD. During 
follow-up PVD was diagnosed in one additional patient. 
The apoE genotype did not influence the prevalence of PVD either at presentation or 
at final follow-up (data not shown). The prevalence of PVD did not differ between 
males and females (23% vs. 30%, P=0.43 ; Fisher 's exact test for male vs. female) . 
Table 3.40 illustrates the prevalence of PVD in relationship to other cardiovascular 
risk factors. 
Table 3-40 PVD and other cardiovascular risk factors 
PVD 
P Value I 
Present Absent 
Present 21 24 
Diabetes 0.001 
Absent 17 74 
Present 30 44 
Hypertension 0.0005 
Absent 8 54 
Present 24 49 
Smoking 2 0.10 
Absent 10 43 
Note: Complete data was not available on all risk factors f or all patients; therefore the number of 











1 Fisher's exact test 
2 Smoking is defined here as any history of smoking 
As seen with the analysis of IHD diabetes and h\/t""rtpn,Clrm were 
associated with a diagnosis of PVD. The estimated smoking exposure did not 
differ between patients with and without PVD (28.6 vs. 25.9 pack years, P=0.47 by 
unpaired Hest for PVD vs. no PVD). 
The mean age at which PVD was ''''',''"u'v" ... · .... was 56.42 ± 7.87 years with a range from 
36 to 70 years. The mean age of diagnosis of PVD was not influenced by apoE 
(data not shown) or ± 9.3 vs. P=O.77 by unpaired t-test 
for males vs. 
Table 3-41 Age of diagnosis of PVD in the presence of other cardiovascular risk factors 
I 




Diabetes 55.0 ± 8.5 57.9 ± 8.2 0.29 
H 56.8 ± 8.8 56.4 ± 4.7 0.49 
Smoking 57.0 6.5 55 ± 12.2 0.54 
None of the cardiovascular risk factors examined was associated with an earlier 











~~" .. ,v"'-' of a diagnosis of PVD. The number 
smaller than those with IHD. IHD diagnosis 
ofPVD. 
with diagnosed PVD was 
tended to predate the diagnosis 
Comparison with previously published case series 
The incidence of PVD is very high in dysbetalipoproteinaemia when compared to 
other dyslipidaemias. In patients with FH attending the GSH lipid clinic the 
using the same was only 4% (253) compared with 28% 
In The two most recently published case series 
a higher prevalence of PVD than IHD with ratios of 1.81: 1 (10) and 
1.21: I (9). The two earlier series (6;7) ratios 0.78: 1 (7) and 0.5: I The 
ratio 0.77: I in this series is very similar to that reported by Morganroth (7). Both 
later series also report a high absolute of PVD (31.1 and 46%). 
criteria for PVD are not disclosed in all papers and where physical findings as 
absent or reduced pulses are used to PVD significant observer bias may be 
this series did not a significant difference in age 
onset PVD between males and PVD, contrary to the findings in IHD 
and paper (7). 
Cerebrovascular 
There were only 61134 (4%) patients with clinical evidence of CerVD. Four pac.""", 
had a of a cerebrovascular accident and TIA's had been diagnosed in 2. Three 
2 carried the apoE (RI45C) mutation and in one 











The mean age at diagnosis was 56.9 ± 10.6 with a range of 38-68 years. Two patients 
were diabetic and all patients were hypertensive. The small number of patients with 
CerVD precludes formal assessment of the influence of other cardiovascular risk 
factors. 
3.7.3.1 Comparison with previously published case series 
In all previous studies CerVD is the least common atherosclerotic complication of 
dysbetalipoproteinaemia. The reported prevalence ranges from 0-11 % but the series 
with the highest reported prevalence included data on ultrasonographically detected 
carotid artery stenosis in the definition of CerVD. 
3.8 Pancreatitis 
Severe hypertriglyceridaemia is a well-known precipitant of acute pancreatitis. The 
pathogenesis of hypertriglyceridaemic pancreatitis is imperfectly understood. The 
level of hypertriglyceridaemia required to trigger an episode of acute pancreatitis can 
vary markedly between patients and even for an individual patient. In the GSH lipid 
clinic the experience is that hypertriglyceridaemia of less than 15 mmollL is seldom 
associated with acute pancreatitis (274;275). 
Two of the patients included in this case series presented to the lipid clinic following 
episodes of acute pancreatitis. Pancreatitis was attributed to hypertriglyceridaemia in 












Patient I: This was a 50 year old man seen following an episode of acute 
pancreatitis. Unfortunately TG values at the time of pancreatitis were not 
available, but the TG was still 5.5 mmollL after being kept nil per mouth for 
several days in hospital. Original laboratory records could not be traced to see 
whether lipaemia had been commented upon at any stage. ApoE2 homozygosity 
was subsequently documented, but no further follow-up information is 
available. 
Patient 2: This 34 year old lady presented following an episode of severe 
pancreatitis requiring prolonged hospital admission. The TG level was 7.5 
mmollL following several days of fasting. The patient had eruptive and 
tuboeruptive xanthomata suggesting prolonged severe hypertriglyceridaemia. 
Type 1I OM had been diagnosed several months prior to admission. No 
mutations in apoE could be identified. Several further episodes of acute 
pancreatitis have occurred subsequently resulting in the formation of a 
pancreatic pseudocyst. During times of non-compliance with lipid-lowering 
therapy the TG value has been as high as 30 mmol/L. 
Although acute pancreatitis is an unusual complication of dysbetalipoproteinaemia, 
patients with severe hypertrigJyceridaemia must be made aware of this risk. 
Immediate institution of a very low fat diet « I Og/day of triglycerides) for several 
days helps to rapidly lower triglycerides. Any factors such as uncontrolled diabetes, 
alcohol abuse or medications that may be exacerbating the hypertriglyceridaemia 











fasting may drop substantially, the diagnosis of hur",rtn 
pancreatitis may be dismissed inappropriately if only moderately elevated TG levels 
are found. 
3.9 Disorders precipitating dysbetalipoproteinaemia 
is not evident at birth and often becomes 
overt in the of "metabolic stressors". mutations differ in 
their metabolic cofactors. In the GSH lipid clinic series 33% 
medical excluding obesity, which may have 
waist 
or a Including obesity, defined either by BMJ>30 




factor. 1n the patients with unknown medical 
more frequently, this was attributable to the 
below). In apoE (R 145C) mutation carriers metabolic 
were identified in 38 % of to 17% of 
Fisher's exact test). Obesity was the commonest 
factor and abdominal was 
Diabetes is a well-known precipitant of and thus it is not 
that this disorder was highly prevalent in this series. All were 
clinically classified as U based on features such as age at onset, association with 
obesity, presence of other markers of the metabolic syndrome and presentation 











the lipid clinic but generally received lifestyle and nutritional advice followed 
by oral hypoglycaemic therapy with either 'Yl"tTnnTIm or or both. Insulin 
was generally when combination oral hypoglycaemic therapy failed to 
achieve a haemoglobin (HbArc) value of less than 7%. No patients were 
prescribed thiazolidenediones as these were never on the GSH 
fonnulary. 
At initial 36/l35 (27%) of were diabetic. 
diabetes was in a further 9 resulting in a 
with some mal!!nose:s of diabetes likely not recorded due to ,""n,...,,., 
Diabetes was more common in without an 
follow-up 
of at least 33% 
follow-up. 
mutation in 
than in those with known mutations. Diabetes was more common 
in apoE (R145C) mutation carriers (30%) than in apoE2 homozygotes (16%), but the 
significant 16, Fisher's exact Assessing difference was not 
diabetic status at final confirmed the excess of diabetes seen in patients 
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At the initial clinic visit 33% of females and 22% of males were diabetic (P=O.l7, 
Fisher's exact test). Diabetes was positively associated with higher BMI and WHR. 
Analyzing patients according to their fmal diabetic status showed even more marked 











Table 3-43 Diabetes at initial presentation and measures 
BMI 
Waist I 
Male 1.00 ± 0.04 0.95 ± 0.07 0.05 
Female 1.00 ± 0.08 0.88 ± 0.08 <0.0001 
I Waist circumference in cm 
2 ratio 
The relatively small number of patients (9) that developed diabetes 
did not allow for further comparative analysis, as full th,·n,."ntl1,ptr'.I' data were 
for six of these patients. 
is a common comorbidity of diabetes and in this series 80% of diabetic 
were hypertensive compared to 42% of the non-diabetic population 
, Fisher's exact There was no difference (P=0,70, Fisher's exact 
in the rates between diabetic (61%) and non-diabetic patients 











This study found a diabetes prevalence 27%. This is much than 
that in all other series. Even when considering only those patients with an 
identified apoE mutation the 
(R145C) carriers had a 
of diabetes at 24% remains very high. 
of diabetes (30%) and when 
considering only homozygotes the prevalence of diabetes at 1 was similar 
to the 14% reported Feussner (l Yet (9) only a 
(3%) with The may possibly be partially ",,,,~,,at:ll"'U by 
differences in the criteria used to diagnose diabetes and the intensity of surveillance 
for this disorder. Morganroth (7) reports that 55% of tested had an abnormal 
glucose tolerance test. Using the more stringent criteria currently applicable to the 
of II DM it is conceivable that diabetes may have been identified in 
more of these patients. Type II DM is asymptomatic in its early phases and 
several years may pass between the onset of and symptoms. All the 
GSH lipid clinic patients with dysbetalipoproteinaemia are screened for 
by means a yearly Additionally all patients with severe 
mixed byperlipidaemia are evaluated for dysbetaiipoproteinaemia and the 
f..!lUCUOl111a is not ascribed to diabetes before dysbetalipoproteinaemia has been 
excluded. 
3.9.2 Hypothyroidism 
Hypothyroidism was identified in 61136 
dysfunction was thought to be the main 
of In 4 patients thyroid 
of hyperlipidaemia, while 2 
had renal disorders in addition to the thyroid dysfunction. All were 











available achieved adequate control of hyperlipidaemia without lipid-lowering 
medication. 
3.9.2.1 Comparison with previous case series 
The prevalence of hypothyroidism (4%) in this series is very similar to the reported 
rate 1-5% 10). 
3.9.3 Renal disease 
Clinically significant renal disease was identified in 13/136 (10%) patients. There 
were 8 patients with diabetic 3 with 
secondary to primary glomerulonephritis, I patient with autosomal dominant 
polycystic disease and I patient with hypeltensive nephropathy. 
remission of renal pathology was only achieved in one patient. This was a young 
(7 years old at presentation) with membranous nephropathy secondary to chronic 
B infection and heavy His TC at was 
26.7 mmoUL with a TG 3.5 mrnoUL. He had extremely cholesterol-enriched VLOL 
(CVITV 1.76, CV/TP 0.71) and was to be heterozygous for the (R145C) 
mutation. He was treated successfully with lamivudine for his B infection 
and the membranous nephropathy resolved. Following remission of the 
patient's lipids normalized and medication was discontinued. 











It is difficult to quantify the UI\CWU'Ul of renal disease in the other patients as 
were t'\rP'Cp"t in many and the renal pathology was co-morbidities such as 
irreversible. 
Comparison previously published case series 
Feussner (I documents renal disease in of patients but presents no detailed 
on the nature of the renal disease. This series found renal disease in 10% 
of diabetic nephropathy. As the of patients with a 
OI::lDetes was also in our series the of renal disease 
in our series may be related to excess cases of diabetic nephropathy. 
(7;9) did not 
3.9.4 Obesity 
renal disease as a significant 
in any of their patients. 
""alH vw and 
of 
% of with dysbetalipoproteinaemia were overweight (BMI 25-
30 and 33% obese (BMI >30 kg/m\ The mean BMI for all was 28.68 
± 4.54 
vs. 
. The BMI of patients was significantly higher than that of 
4.6\ 27.89 ± 4.37 kg/m2, P=O.04 unpaired Hest for 
There were no differences in BMI between 
not shown). In 50% of 
with 
the waist 
circumference exceeded the gender-specific threshold the NCEP 
ATP III Abdominal obesity was highly 
while the rate was significantly (P<O.OOO I, Fisher's exact 
in females 
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P<O.04 by unpaired I-test 
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Females 
The hal's indicate the NeEP ATP III recommended maximal waist circumference by gender. 
The prevalence of as defined by a BMI of more than 30 kg/m2 did not increase 











did not differ between the quartiles (data not shown). Waist circumference was 
analyzed separately for males and females. There were no changes in 
circumference with age either sex (data not 
3.9.4.1 Comparison with previously published case series 
Rates of overweight and are also very high in 
series. In Feussner's series (10) of patients were "",p'r\11P 
published case 
while Stuyt 
ideal body (defined as a weight higher than 120% 
to insurance in 62% of patients. All except Feussner (10), 
report higher levels of obesity in female compared to male patients. None of the 
studies report data on circumference, as the deleterious metabolic 
of abdominal have only been more 
Alcohol abuse 
Alcohol abuse was identified in 61134 (4%) patients. These 
you g. the lipid response to 
were all male and 
alcohol intake could 
not be evaluated accurately, as all patients received dietary and lipid-lowering therapy 
in addition to advice their alcohol intake. 











None of the previously reported series include data on the prevalence of alcohol 
abuse, although the link between excessive alcohol intake and hypertriglyceridaeroia 
is well established (I 
3.9.6 Human immunodeficiency virus (HIV) infection and 
antiretroviral therapy (ART) 
In the era it was known that HIY infection and AIDS were associated with 
dyslipidaemia. The dyslipidaemia was characterized by low levels of 
moderately severe n'IY'F'nTl and the presence of small dense LDLC 
281 ). levels of inflammatory were to account for the 
dyslipidaemia (281). 
the introduction of ART a lipodystrophy syndrome was first described in 
1998 The lipodystrophy syndrome is a complex constellation of fat 
distribution, dysJipidaemia and insulin resistance. Antiretroviral differ 
in their potential to cause dyslipidaemia. the protease inhibitors ritonavir 
causes the most hypertriglyceridaemia, while stavudine is the nucleoside 
reverse transcriptase inhibitor that affects lipid metabolism the most (285;286). The 
mechanisms of ART-associated have not been elucidated 
conclusively, but may involve alteration in SREBP signalling of 
from proteasomal degradation (290), endocrine (291 and 
mi tochondrial (293). Cardiovascular disease and diabetes are increasingly of 











In 1999 a case report of severe hyperlipidaemia (TC 29.5 mmolJL and TG 27.3 
mmollL) associated with cutaneous xanthoma in a patient receiving ritonavir based 
AR T was published in the Lancet (260). The apoE phenotype was E2/E2 and the 
response to a fibrate was excellent. Following this initial case report there has been 
increased interest in the role that apoE plays in modulating the hyperlipidaemic 
phenotype induced by ART (261 ;295). 
In the GSH lipid clinic experience there were no patients with 
dysbetalipoproteinaemia solely due to HIV infection. The series includes one patient 
with ART associated dysbetalipoproteinaemia. This was a young male with apoE2 
homozygosity and no other metabolic risk factors except for ART. 
ART, on a meaningful scale, has only been available to patients in the South African 
public health care sector since late 2004. Owing to the interest in this subject an 
additional review was done of ART -associated dysbetalipoproteinaemia from the 
close of the main database up to December 2006. 
There were four additional cases of ART-associated dysbetalipoproteinaemia. The 
patients were all receiving "second-line" PI (Ritonavir boosted Lopinavir) based ART 
after failing or not tolerating the "first-line" non-nucleoside reverse transcriptase 
inhibitor based therapy. Three of the patients were apoE2 homozygotes and one had 
the apoE (R145C) mutation. DysJipidaemia was discovered incidentally in at least two 











Only a small fraction of ART-associated dyslipidaemia is likely seen at the lipid 
because lipid testing is not included in the routine monitoring of patients 
"first-line" ART and many also lack awareness of the 
metabolic complications of ART. Treatment currently recommend 
dysJipidaemia only after PI-based has been initiated. Currently there are 
few patients taking PI based <"", .. <:or", but this number will 
of time. 
increase as more 
receive ART for 
3.9.6.1 Comparison with n"-'"flC''' published case series 
HIY has only become in the last two decades and 
bas been available for an even shorter time. None of the 
could therefore include any data on HlY infection and ART. 
10 Treatment experience 
ART 
series 
This section presents 
dysbetalipoproteinaemia over a 
data regarding the treatment of 
of more than 20 years. The data should be 
interpreted cautiously as it is observational in nature and may be to 
bias. It does, hAl,"""J"'r a "real-world" ""v • .,,,,,.,,,," 
dysbetalipoproteinaemia in a resource limited setting. 
stat ins, were usually 
constraints. 











were by as analysis individual ","V,i"I)'VUllU would result in the 
formation small subgroups. Figure 3.44 illustrates the with 
which the various drug classes were prescribed. 




Nofe: No treatment indicates Ihal no Irealment dolo was mJnIJ/U11P 
The of treated patients (97 of 118 were fibrates, either as 
or in combination with a statin. The very usage of fibrates 
the prescribing practice at the GSH lipid clinic, where patients with mixed 
hyperlipidaemia suspicious of are initially started on a fib rate 
following lifestyle modification and control of precipitating factors. Patients that are 











poor a low dose statin is ",", __ nr,"c The 18 patients classified as not 
received treatment were either not drug therapy at their initial visit and 
then lost to follow-up or did not have follow-up data to evaluate the response to lipid-
medication. 
There were no significant (P=O.22 by m the classes 
to patients according to whether thcre was a known mutation or not. 
3-45 Relative proportion of classes prescribed to patients by genotype 
0.75 
~AII 
Stalin Fibrate Combination Niacin No treatment 
P=O.22 by Chi-square analysis for genopositive vs. genonegative 
Increasing duration of treatment was associated with increasing use of combination 
This may well reflect some loss of control as compliance wanes, 
age and additional medical problems such as diabetes set in or diabetic 
control deteriorates with time. After five years of significantly more 











3-46 Treatment of dysbetalipoproteinaemia to duration of 
~ Monotherapy 
B83 Combination therapy Duration of treatment 
3-47 Treatment of dysbetalipoproteinaemja after live years of follow-up 
<: 5 years > 5 years 
Duration of follow-up 
~ Monotherapy 
1m3 Combination therapy 











3.10.1 lipid responses to therapy 
The lipoprotein that in the view of the author was the most 
as "best profile") was sought in the records. The lipid response was 
assessed in that had been followed-up at the GSH lipid clinic at least two 
years, so there was opportunity to adjust medications. 
would have been seen a minimum of four times as prescriptions have to be renewed 
every six months to South African law. Additionally the 
was restricted to lipid clinics for the majority of the study 
In that had been followed-up for more than two years the absolute 
seen in TG and TC values scattered widely when analyzed duration of 
duration of follow-up beyond 2 years was not with further 
in lipid control. It is therefore reasonable to with more 




































therapy and duration of follow-up 
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Days of follow-up 
The mean decrease in TG from untreated values to the "best recorded level" was 6.11 
mmol!L range 0-55.6). The absolute decrease in TG was for 
those TG at baseline (r2=0.98 for linear 
in TG vs. """,,,")H'''" The mean percentage reduction in TG from baseline was 62% 
range 0-92%). On lipid-lowering therapy the mean achieved TG was 
2.43 mmol!L 2.0 range 0.3-12.4 mmoI!L). The baseline TG and 
"best" TG were different (P<O.OOOI by Wilcoxon rank 
A TG<2.3 mmol/L was achieved in 64% 
Patients with fibrates (9.26 ± 10.28 mmol/L) or statin combination 
rnp'r!'lr,v (9.71 8.90 mmol/L) tended to have higher baseline TG values 












reach statistical significance (P=0.06 by Kruskal-Wallis test). This trend likely simply 
reflects the fact that clinicians are more likely to prescribe fib rates as the degree of 
hypertriglyceridaemia increases. 
Figure 3-49 Baseline TG values and lipid-lowering therapy 
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Drug Therapy 
ANOVA (Kruskal-Wallis) P=0.06 
The "best" TG levels achieved did not differ by which therapy was prescribed (fib rate 
2.26 ± 1.50 mmol!L, statin 2.14 ± 1.03 mrnol!L, combination therapy 2.71 ± 2.20 
mmol!L; P=0.67 by Kruskal-Wallis test); this likely reflects ongoing adjustment of the 
treatment to achieve optimal lipid control. 
The absolute and relative decrease in TG achieved as well as the "best" TG levels did 
not differ between patients with and without identified mutations in apoE (data not 
shown). Diabetic patients responded less well to treatment than non-diabetic patients 











mmol/L vs. 2.18 ± 1.29 P=0.04 Mann-Whitney test for diabetes vs. non-
although there was no difference in baseline levels 8.50 
mmol/L vs. 8.64 ± 9.49 mmol/L; P=0.59 by Mann-Whitney test for diabetes vs. non-
diabetic). Similarly, patients with defined by a BMI>30 had 
treated levels than non-obese ± 2.38 mmol/L vs. 2.18 ± 1.32 
P=0.03 by Mann-Whitney test obese vs. non-obese), despite similar baseline levels 
8.53 mmolJL vs. 8.57 ± 9.62 P=0.88 by Mann-Whitney test for obese 
vs. When was 
NCEP A TP III recommendations 
by a waist circumference that exceeded the 
similar TG values were achieved (2.90 2.22 
mmolJL vs. 2.18 ± 1.34 P=O.lO by Mann-Whitney test for obese vs. non-
obese). Baseline differences were not """"H',","" significant (7.78 ± 
1 0.32 ± 13.32 mmolJL; P=0.85 by test for obese vs. no"_"np,,," 




with the least abdominal achieved significantly lower "best" TG 
levels than those in the (1.92 ± 1.80 mmol!L vs. 3.82 ± 2.68 
P=0.002 Mann-Whitney test for I vs. quartile 4) 
baseline levels (8.21 ± 7.49 mmol/L vs. 10.05 9.70 P=0.41 
Whitney test for quartile 1 vs. 
3.10.1.2 Total cholesterol 
The mean decrease in TC 
28.80 The mean 
baseline was 6.84 mmol/L (median 
reduction in TC was 52.4% 
Mann-
range 1.0-
range 15.2-85.8%). Patients with the 
absolute reduction in TC values 
cholesterol at baseline had the largest 











cholesterol vs. cholesterol). The mean TC on lipid-lowering was 5.15 
mmol/L (median 5.05 mmol/L, range 3.10-10.0 mmoIlL), which was significantly 
lower (P<O.OOOI by Wilcoxon signed rank test) than the baseline TC value of 11.98 ± 
5.39 mmollL in those patients whose response to treatment could be TheTC 
was less than or equal to 4.5 mmollL in a third of patients and 5.0 mmol/L or less in 
49% of .... """',.,,0 
The TC at baseline did not differ by the lipid lowering therapy chosen therapy 
11.88 ± 5.21 nunollL, therapy 12.57 ± 6.93 combination therapy 12.15 
± 5.58 mmollL; P=0.90 by Kruskal-Wallis The "best" TC also did not 




therapy 4.82 ± mmollL, combination 5.42 ± 1.21 
by Kruskal-Wallis test). When analyzing treatment response by the 
or combination therapy, the with combination 
therapy had significantly higher "best" TC levels ± 1.40 mmol/L vs. 5.42 1.21 
P=0.02 by Mann Whitney test monotherapy vs. therapy). 
This does not imply that vV,UV.U'''.VH therapy is inferior to mcmomera[)y but indicates 
that that fail initial monotherapy are to be treated with combination 
Patients failing may be less to for a 























vs. combination therapy 
O'~----~------------~-------
Monotherapy Combination therapy 
P=O.02 by Mann Whitney test 
While the presence of an mutation did not affect TG response to 
therapy it did the reductions seen in TC. Patients with identified 
apoE mutations achieved better reduction in TC than those in whom no 











Table 3-44 TC response to therapy by apoE genotype 
Genotypic Status Mean Median SD P Value I 
Geno+ 12.42 11 .20 5.12 
Baseline TC 0.02 
Geno- 10.89 9.30 5.97 
Geno+ 4.99 4.70 1.30 
Best TC 0.03 
Geno- 5.54 5.30 1.31 
Geno+ 7.44 6.80 4.90 
Absolute reduction <0.0001 
Geno- 5.34 3.8 5.32 
Geno+ 56 58 15 
Relative reduction (%) 2 0.0005 
Geno- 44 42 14 
I Mann Whitney test 
2 Percentage reduction 
Diabetic patients responded less well to therapy than non-diabetic patients. This 
finding may, however, be partially explained by the fact that proportionally more 











Table 3-45 TC response to therapy by glycaemic status 
Glycaemic Status Mean Median SD P Value I 
Diabetes 10.35 9.20 3.56 
Baseline TC 0.04 
No diabetes 12.56 10.90 5.82 
Diabetes 5.68 5.60 1.33 
Best TC 0.01 
No diabetes 4.96 4.7 1.27 
Diabetes 4 .67 3.80 2.97 
Absolute reduction 0.005 
No diabetes 7.61 6.20 5.43 
Diabetes 42 43 14 
Relative reduction 0.005 
No diabetes 56 58 15 
I Mann Whitney test 
Patients with a BMI>30 kg/m2 responded similarly to lipid lowering therapy to 
patients with a BMI<30 kglm2 (5.45 ± 1.31 mmollL vs. 5.05 ± 1.35 mmollL, P=0.21 
by Mann Whitney test for the "best" TC in obese vs. non-obese patients) . Patients 
with a waist circumference exceeding NCEP ATP III recommendations (254) tended 
to have higher TC levels on treatment (5 .36 ± 1.15 mmollL vs. 4.88 ± 1.35 mmoIlL, 
P=0.07 by Mann Whitney test for excessive waist circumference vs . normal waist 
circumference). Assessing abdominal obesity with the use of the WHR showed that 
patients in the lowest quartile of WHR (with the least abdominal obesity) had lower 
"best" TC levels than those in the highest quartile (4.60 ± 0.89 mmollL vs. 5.68 ± 











similar baseline levels ofTC (14.00 ± 8.12 mmol/L vs. 11.13 ± 4.38 mmollL, P=0.36 
by Mann Whitney test for quartile 1 vs. quartile 4). 
















Quartile 1 Quartile 4 Quartile 1 
Ouartiles of WHR 
I Baseline I 
Nole: The Y-axis is disconlinuous 
3.10.1.3 High density lipoprotein cholesterol 
Quartile 4 
Lipid lowering therapy was associated with an increase in HDLC from baseline in 











to 1.9 mmoI/L). The correlation between baseline HDLC and the observed increase 
was weak II by linear with lower HDLC levels tending to 
increase more than higher levels of HDLC. The baseline HDLC and "best" HDLC 
were significantly different (1.01 mmollL 0.35 mmo]/L vs. 1.29 ± 0.44 
P<0.0001 Wilcoxon rank test for baseline vs. "best" HDLC levels). The 
mean increase in HDLC was 34% (median range -43 to 271 On 
the mean HDLC was 1.29 mmollL (median 1 range 0.7-2.6 mmoI/L). On 
therapy 76% patients had a HDLC 1.0 mmol/L and in 43% of the HDLC 
was 2: 1.3 mmollL. 
HDLC did not differ significantly at baseline according to tlnal treatment allocation 
(fibrate 1.03 ± 0.36 statin therapy 1.04 0.18 mmollL, combination 
therapy 0.99 ± 0.40 mmollL; P=0.55 by Kruskal-Wallis The "best" HDLC did 
not type lipid lowering therapy (fibrate therapy 1.31 ± 0.48 
mmollL, statin therapy lAl 0.52 mmoliL, combination therapy 1.22 ± 0.33 
P=0.59 Kruskal-Wallis 
HDLC showed increases the presence of an identified apoE 
mutation (data not shown). HDLC also did not differ at baseline or on therapy 
between diabetics and non-diabetics (1.16 ± 0.31 mmollL vs. 1.34 0.47 mmol/L, 
P=0.15 by test for "best" HDLC in diabetics vs. non-diabetics). 
Obesity assessed either by BMl>30 kglm2 or waist circumference ,-,,,,,_,-,,",uU,'F, NCEP 
A TP III recommendations (254) did not HDLC levels or the 
change with therapy 
HDLC response when 
not shown). There were, however, significant differences in 











0.30 mmoVL, P=O.Ol by Mann-Whitney test for "best" HOLC in 
vs. quartile 4). 











Quartile 1 Quartile 4 Quartile 1 Quartile 4 
Quartiles of WHR 
The baseline HOLC levels were also in the quartile of lowest WHR, although 
the difference did not meet fonnal criteria for statistical (1.17 ± 0.48 
mmollL vs. 0.84 ± 0.24 P=0.07 by Mann-Whitney 
3.10.1.4 Apolipoproteins and PGGE 
ApoB and apoAl were only measured routinely at presentation and therefore it is not 
to examine in these variables with treatment. was not 











at so that it is not to discern changes In 











4 Chapter Four: A clinical trial evaluating lipid-
lowering therapy for dysbetalipoproteinaemia 
was evaluated in a clinical trial 
sponsored Pharmaceuticals. The trial was both the Medicines 
Control Council of South Africa and the Humans Research Ethics Committee of the 
University of Town. The trial enrolled dysbetalipoproteinaemic subjects from 
the lipid clinic at Groote Schuur and was conducted on the premises of the 
University Town. Permission was obtained from the sponsors to use trial data 
in this thesis. The results of this trial were never published due to the worldwide 
withdrawal of cerivastatin when was found to have a higher rate of 
muscle than other statins. 
4.1 Study Bayer W6228110176 
Title: A center, randomized, double-blind, cross-over to compare the 
and of cerivastatin 0.4 mg, fenofibrate 200 mg and 
combination of both once a in the treatment with Type HI 
hyperiipoproteinaemia. 
4.1.1 Study and pr()tolcOI 
The Bayer W6228/10176 study (hereafter referred to as the Bayer study) was a 











both. The inclusion criteria specified a phenotypic diagnosis (cholesterol-enriched 
of dysbetalipoproteinaemia and could be even if no 
in had been 
• Males or 18-60 years 
• Previously ultracentrifugally proven dysbetalipoproteinaemia with 
o CV/TV 0.42 or 
o CV ITP 2: 0.30 
• Patients with American Heart Association I diet 
• Written informed consent provided 
Patients were excluded if had medical conditions that could influence lipid 
metabolism significantly. These included: 
• I DM 
• II DM with a 
• Hypothyroidism unless adequately with thyroxine 
• Nephrotic syndrome or creatinine> 176 /lmol/L 
• Consumption of more than 14 alcoholic per week 
• cardiac (NYHA III or IV) 
• HIV infection or ART 











.. TG >25 at any stage of the or a history 
.. Severe hypertension BP > 180 or diastolic BP> 110 
.. event (MI, CV A, PCI) within 6 months of study 
enrollment 
.. arrhythmia or conduction disturbance 
.. creatinine kinase (CK) > 3x upper limit of normal (ULN) 
.. Active liver disease or AST and/or ALT > 3x ULN 
UH'_""U," disease that may affect absorption 
.. Severe psychiatric disease 
.. Use of that interfere with cerivastatin or fenofibrate metabolism 
.. Intolerance of statins or fibrates 
The design was that of a double-blind randomized crossover trial. The trial 
consisted of 4 treatment of 6 weeks duration each. The first treatment 
was identical for all trial participants and was a 'J"."~ V'HUU placebo washout period 
to obtain untreated lipid values. Patients were then randomly allocated to one 
of three possible treatment arms: The enrollment target was 36 patients. 
.. Arm A: Cerivastatin 0.4 Fenofibrate 
.. Arm B: Cerivastatin placebo, 200 mg/d 
.. Arm C: Cerivastatin 0.4 mgld, Fenofibrate 200 mgld 
Patients were randomized in blocks of six according to a schedule generated by the 











over to the next treatment arm, till they had been exposed to all three possible 
treatment "n'c,""C Patients were evaluated at the completion each treatment 
in the state. There was no wash-out between the treatment periods. 
Figure 4-1 W6228/10176 trial design 
6 weeks 
i 
4.1.2 Laboratory evaluation 












• Fasting TC and HDLC 
• * VLDL "roy,..,,,,,,,, analysis 
• * and complete 
analysis 
• * PGGE 
• Remnant turnover by means of stable breath test (in ~"'''_''''~, .... subset of 
patients i)«llll-'''_'' analyzed at the University of Western Perth) 
Safety 
• Full blood count 
• Urinalysis dipstick 
• Serum potassium, phosphate, uric acid, urea 
• Serum total albumin, ASTand ALT 
• Serum amy lase 
• Serum CK 
• Serum 
• hormone and free (initial visit only) 
• Pr,,'an'~nr'\J test (initial visit only in women of childbearing 
All laboratory tests those marked with * were in the chemical 
pathology of Groote Schuur Tests marked with * were performed 












4.2.1 Bayer Study 
4.2.1.1 Study course 
The study was terminated prematurely due to the worldwide withdrawal of 
ceri vastatin in 2001 
taking cefi vastatin 
reports of 
m particular when 
(296;297). None of the enroHed patients 
'-H.laUAl IV tennination of the study 
rates of rhabdomyolysis in 
was taken 
all three treatment arms of the 
limits statistical power, but a study. The 
limited of the results will be presented. Study data were analyzed by the 
author by means of a per protocol analysis. 
All patients that had at least one treatment arm while being at least 80% 
compliant with medication (assessed by count of returned were included 
in the analysis of that arm. The order in which medications had been allocated was not 
considered, as treatment carryover effects were not 
Thirty-five patients were screened and enrolled in the None of the ~a'lvH'" 
completed the study. 
medication. Three pal',-""" 
patients completed at least one six-week period on 
consent; two of these patients were less than 
80% compliant on due to adverse events to study medication. One 











Table 4-1 Study arms completed and reasons for early discontinuation 
Enrolled Placebo wash-out Treatment periods I 
I 2 3 
Male 20 16 12 10 0 
Female 15 12 8 7 0 
Total 35 28 20 17 0 
Attrition (per period) 0 7 8 3 17 
Reasons for non-completion 
Study terminated 5 6 I 17 
l':j, 
TG too high I 0 0 0 
i ;', 
Prohibited drug ': i~ I 0 0 0 
, 
Death following MI 0 I 0 0 
" 
Consent withdrawn L :" 0 I 2 0 
I Number of six-week periods on study drug that were completed 
2 Reasons given for withdrawing consent were myalgia, panic attacks and no reason 
given 
Table 4-2 Medication arms completed 
Cerivastatin F enofibrate Cerivastatin + Fenofibrate 
Allocated 29 28 26 
Completed 13 14 10 
Non-compliant I 0 I I 











I Compliance < 80% as assessed by counting returned medication 
4.2.1.2 Patient characteristics 
The data ..."",,,,,,u here is that of the 20 that at least one treatment 
arm, as these are the that contributed data to the analysis reported below. Of 
the 20 patients 8 were overweight (BMI > 25 and < 30 kg/m2) and 5 were obese 
(BMI >30 kg/m2). mutations were in 16/20 (80%) of patients. 
Table 4-3 Clinical characteristics of the patients that COnlDII!ted at least one treatment arm 
:Male Female All patients 
n 12 8 20 
J , . 7 
~ 
53.13 ± 4.15 52.35 ± 5.34 
.V V.IV 
Weight (kg) 82.13 ± 8.54 68.1 .59 
;>., 
'-...... 




85.13 ± 9.45 0 Waist (cm) 93.25±10.18 90.00 ± 10.47 ..a 
c 
<t: Hip (cm) 99.75 ± 8.20 100.00 ± 9.32 99.85 ± 8.42 
IWHR 0.94 ± 0.07 0.85 ± 0.04 0.90 ± 0.07 
13 14 




u IHD 4 1 5 
<= 
;:;! 















Values are given as mean ± SD 
I CerVD: Cerebrovascular disease 
Table 4-4 ApoE genotypes in that completed at least one treatment arm 
4.2.1.3 Lipid results 
The lipid results reported in this section are those of the 20 patients that completed at 
least one treatment arm of the study. The results of the two patients that were 
non-compliant with active treatment are included, because there is no reason to 
that did not discontinue their usual lipid-lowering therapy as instructed 
and were compliant on double placebo in the wash-out phase. Of the patients 
analyzed in this section 16 had an identified mutation (12 E2/E2 and 4 
(RI The group of ua"'-'ll'" with no identified mutations was too small (3 
anaJyzable patients treatment to allow an adequately powered statistical 
analysis of in responses to to the presence or absence of 
mutations. 
4.2.1.3.1 Total cholesterol 
the washout period the mean total cholesterol was 
10.56 3.46 mmollL (median 9.50 mmoVL, range 6.90- 20.90 mmollL). The TC was 











Combination therapy was significantly more effective than cerivastatin alone (P<O.OS, 
Tukey's post test) in lowering the total cholesterol. 
Table 4-5 TC during lipid-lowering therapy 
Total cholesterol Tukey's multiple comparison test 
Mean Median SD N Range P vs. Combination 
Baseline 10.56 9.5 3.46 20 6.90-20.90 
5.4 2.03 13 4.20-12.20 
Fenofibrate 5.46 5.40 0.64 13 4.40-6.50 
Combination 4.26 4.30 0.79 9 3.00-5.40 
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* * * 
O .O~---------------------------------------------
Baseline Cerivastatin Fenofibrate Cer + Feno 
Treatment allocated 
Legend: * P <0.001 vs. baseline 
/\ P <0.05 vs. cerivastatin 
The mean reduction in TC from baseline was 37.2 ± 10.6 % for cerivastatin, 44.07 ± 
16.68 % for fenofibrate and 53.43 ± 12.11 % for the combination of fenofibrate and 












4-3 TC reduction from baseline 
75 • 
• •• • ••• III • • 
E 50 • III 
0 .... • i- .' - ••• • • .. • 




Cerivastatin Fenofibrata Car + Feno 
Treatment allocation 
mean 
development report a 26 % decrease in TC with the 0.4 mg dose of 
cerivastatin with As 
dysbetalipoproteinaemia ly responds well to it is not 
that a more profound reduction in cholesterol was seen in this study. 
Trig/ycerides 
The mean TG in the untreated state following the wash-out period was 7.11 5.48 
mmoVL (median range 3.00-22.90 mmoVL). decreased in all 
treatment arms (ANOY A, P<O.OOO I), but the change from baseline was 











Table 4-6 TG during lipid-lowering therapy 
Triglycerides Tukey's multiple comparison test 
Mean Median SD N Range P vs. Cerivastatin P vs. Fenofibrate P vs. Combination 
Baseline 7.11 4.3 5.48 20 3.0-22.9 >0.05 <0.001 <0.001 
Cerivastatin 4.15 3.6 
Fenofibrate 2.23 2.30 
Combination 2.04 1.90 
2. 17 13 2.3-10.7 
0.93 13 0.8-3 .9 
1.19 9 0.9-4.8 
"':"'--"'-I , I, I I , I I,ll II II' 'II __ I :t; ~ 1_. '11 ).~ olj1'-=- _ ~, 
























Baseline Cerillaslatin Fenofibrale Car + Feno 
Treatment allocated 
* P< O.OOJ vs. baseline 
N\ P<O.OJ VS. cerivastalin 
1\ P<0.05 vs. cerivastatin 
The mean reduction in TG with cerivastatin was 20.2 ± 23.2 %, 61 1 ± 20.7 % with 
fenofibrate and 65.8 ± 15.3 % with combination therapy (ANOYA P<O.OOOI, Tukey's 
post test P<O.OOI for cerivastatin vs. fenofibrate and cerivastatin vs. combination 
therapy). The TG response to cerivastatin monotherapy was highly variable with 5 
patients either an rueT'.."""..., or a less than 1 0% decrease in TG while 
one patient reduced his TG by more than 70% from a very high baseline value of 
22.90 mmol/L. Fenofibrate and combination therapy consistently reduced 












Figure 4-5 TG reduction from baseline (%) 
90 
Q,I 80 c: .' 
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Cerivastatin Fe nofibrate Cer + Feno 
Treatment allocation 
Note: Negative values indicate an increase in TG values 
4.2.1.3.3 HDLC 
The mean HDLC following discontinuation lipid-lowering therapy was 1.24 ± 0.28 
mmolJL (median 1.10 mmol/L, range 0.90-1.70 mmolJL). Mean HDLC increased 
when fenofibrate was prescribed, but none of the '-'Weill,;"''' in HDLC reached statistical 











Table 4-7 HOLC during lipid-lowering therapy 
HDLC Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 1.24 1.10 0.28 20 0.90- >0.05 >0.05 >0.05 
1.70 




F enofibrate 1.37 1.30 0.35 13 0.80- >0.05 
2.0 , 
Combination 1.24 1.20 0.43 9 0.7-
2.0 




...J 1.75 -- g (5 1.50 B E E 1.25 c: 1.00 
U 0.75 ...J 
C 0.50 ::I: 
0.25 
0.00 
Baseline Cerivastatin Fenofibrate Cer + Feno 
Treatment allocated 











The mean change in HOLC with cerivastatin was a 1.4 9.3 
fenofibrate increased HDLC 10.4 ± 20.3 % while combination resulted in a 
mean decrease of 0.5 ± 25.0 P=O.25). The in HDLC were 
highly variable, from of about 40% to reductions of 35%. 
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'" J:: ,,-0 
;f!. Cerlvastalin Fenofibrate Cer + Feno 
Treatment allocation 
Hypertriglyceridaemia is often ass:oclatc:d with low levels of HOLe. The relationship 
between TG levels and HOLC was at baseline and rr,pn.r", with 
lipid lowering medications. At baseline there was no clear-cut between 
TG levels and but in on fenofibrate or combination th",..",..", HDLC 
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4-10 Relatiollship between TG and HDLC Oil fenofibrate 
2.2 
2. .. 











0 5 10 15 20 25 
TG in mmol/l 
Linear / =0.62 











0 5 10 15 20 25 
TG in mmollL 
It was noted that some patients with marked had HOLC 
cholesterol levels that seemed inappropriately high and that the HDLC actually 











and HDLC levels in the and bottom quartiles were compared on and off 
treatment. Patients in the qUaJ1ile with the highest TG (mean TG 15.98 ± 5.58 
mmollL) had a mean HDLC 1.28 ± 0.29 mmollL in the untreated which 
decreased to 1.00 0.28 mmollL when lipid-lowering therapy was given. Conversely 
patients in the lowest qual1ile of TG (mean TG 3.23 ± 0.17 mmollL) had untreated 
HDLC values of 1.25 ± 0.24 mmollL that increased to 1.28 ± 0.32 mmollL with 
treatment. It is thprpt,r\rp likely that the assay used to measure HDLC in this study 
gives readings in some patients with marked 
This phenomenon obviously also obscures changes in HDLe brought about 
medication. 
Previously published data on treating dysbetalipoproteinaemia 
(plasma lipids) 
4.2.1.3.4.1 Historical overview 
The atherogenicity dysbetalipoproteinaemia was soon after the initial 
of the disorder. It is therefore not that at 
dysbetalipoproteinaemia dietary modification were made as soon as lipid-
medication became available. The first reports of successful treatment of 
dysbetalipoproteinaemia describe the beneficial response observed with 
In (l 164). Two studies 
with hormone replacement therapy (HRT); in one study 
was (300) while the other study utilized tibilone (30 I), a 
synthetic steroid with weak oestrogenic, progestogenic and androgenic properties. The 











the two males ,au',,,,",'u. one responded by developing severe 
while withdrew due to the effects of r.""'fi"""''',,, on sexual 
habitus (I 
studies describe the use of nicotinic acid (302) (or the 





statins is described for the first time in a case report from 1986 (304). The use of bile 
acid sequestrants, colestipol in this case, was soon abandoned when TG 
were """OlJll""',U (305). Subsequent studies have documented the responses to 
newer (306-312) or explored treatment various statins 
There are only few reported direct comparisons of 
] 8) and there are no published reports of direct 















4.2.1.3.4.2 Overview of drug trials in 
Note: Trials may be listed more than once if included more than one treatment arm. 
Table 4-8 First attempts at 
.. -
,..... (mmollL) % Change 0 ApoE Basehne Values 
Author Year N 1 Oi"",. 3 Dose 
4 
Duration Commenl~ Ref 
E2/E2 TC TG HDLC LDLC TC TG HDLC LDLC 
Kushwaha 1977 6 AG+UC NA NA OES Illg!kg I (\63) 
Falko 1979 3 UC+IF 3 0 OES 1 !lg/kg 8w 10.54 5.95 1.04 3.41 53 23 48 53 2 (164) 
... - (--... 
~ Stuy! 1981 1 tJC+IF I 0 PLA 500ml 24<1 8.01 5.84 16(J) 6(I) 3 
T .c 1984 5 UC+IF 
2 ...... ~ 
3 NA 3g '"Ti"w 9.17 4.90 1.04 3.86 28 43 28 II 4 (302) '~Vb ,~. 
Sluyt 1985 10 ·IF 10 0 ACP 750mg 6w 10.00 7.99 0.91 3.05 30 48 7 10 (303) 










f-UB+IF r-z"" 5 C+C 8w 7.51 3.91 0.96 3.78 21 35 30 15 5 (305) 
Dallongeville 1991 9 UB+GE 6 0 OM3 6g 12w 8.57 6.34 1.92 0.78 26 57 14 21(0 


















UC Ultracentrifuf!ation with 
ACP A cipimox 
C+C 
OM3 Omega-3 fatly in capsule form 













5 Indicates the from the baseline untreated value 
where indicated the 
Increase= 
in TC and LDLC is a decrease while in HDLC refer to increases uecrease= (0), 
L were studied in a metabolic unit under different conditions and to for of time. One male 
exposure. The ad hoc was included in the Lipid mnrll\li'rl in all at times 
nature of this does not allow for calculation ot responses. 
2. The included one male who had of his on IIP"trllopn The baseline data is 
that of all 3 but the response is the III in the two female 
3. infusion was not 
4. The ,.1Ia~lIV~ of 
of 5. The 
6. The authors do not 
the reflects the normal In levels of 
seems uncertain in at least two natlents on review the data 
seems uncertain in some 











Table 4-9 Fibrates for dysbetalipoproteinaemia 
ApoE Baseline Values (nunollL) % Change ) 
Author Year N 1 Diagnosis 2 Drug 3 Dose • Duration Comments Ref 
E21E2 Other TC TG HDLC LDLC TC TG HDLC LDLC 
Hoogwerf 1984 5 UC+IF 2 3 CLO 2g 12w 9.17 4.90 1.04 3.86 23 40 22 2 1 (302) 
Hoogwerf 1984 4 UC+IF 2 2 GEM 1200mg 12w 9.14 4.98 1.04 3.68 23 56 35 1 2 (302) 
Stuyt 1985 10 UC+IF 10 0 CLO 2g 6w 8.88 5.7 0.93 3.14 24 34 10 II (303) 
Hoogwerf 1985 7 UB+IF 2 5 CLO 2g 8w 7.51 3.91 0.96 3.78 11 37 25 6(1) (305) 
Packard 1986 6 UC+IF 6 0 BEZ 600mg 8w 11.13 6.69 1.14 3.46 47 68 28 19 (307) 
Fruchart 1987 9 UC+UB+IF 9 0 FEN 100mg 12w 9.29 5.51 0.83 3.11 37 56 25 7 (320) 
Houlston 1988 13 UC NA NA GEM 1200mg 16m 12.6 10.2 1.1 40 70 45 3 (310) 
Kuo 1988 8 UC+IF 8 0 GEM 1200mg 24+18m 9.84 5.16 0.96 4.95 46 65 54 41 4 (309) 
Lussier-Cacan 1989 9 UC+UB+IF 9 0 FEN 300mg 12w 9.30 5.51 0.83 3.11 37 56 25 7 5 (308) 
Illingworth 1990 12 UC+IF 10 2 CLO 12.95 8.77 0.91 3.60 40 52 32 I (316) 
Larsen 1994 6 UC+IF 6 0 CLO 2g 8w 11.27 7.18 1.11 3.57 40 48 9 12 (321) 
Larsen 1994 6 UC+IF 6 0 GEM 1200mg 8w 11 .27 7.18 1.11 3.57 54 70 7 22 (32 1 ) 











ApoE Baseline Values (mmolfL) % Change 5 
Author Year N ' Diagnosis 2 Drug J Dose 4 Duration Comments Ref 
E21E2 Other TC TG HDLC LDLC TC TG HDLC LOLC 
I 
I 
Zhao 1994 8 UC+UB+IF 8 0 GEM 1200mg 11.87 6.08 0.95 1.87 45 63 . 28 0.5 (306) 
Feussner 1997 23 GEM 26 27 15 (312) 
Feussner 1997 23 FEM 39 39 28 (312) 
Civeira 1999 10 UE+UC I 9 GEM 1200 4w 8.37 3.64 0.99 4.53 17 55 2 5 6 (322) 
I Number of patients in study 
2 Indicates the criteria on which the diagnosis of dysbetalipoproteinaernia was based 
GE Genetic analysis of apoE 
IF Iso electric focusing 
UB UltracentrifUgation and demonstration offJ-migrating VLDL 
















FEM Fenofibrate (micronized) 
GEM Gemfibrozil 
4 Total daily dosage 
5 Indicates the percent change from the baseline untreated value 
Except if indicated the change in TG, TC and LDLC is a decrease while changes in HDLC refer to increases (Decreases= (D), Increases+ (I)) 
Comments 
I. The diagnosis of dysbetalipoproteinaemia seems uncertain in some patients. 
2. One patient did not complete this arm of the study. 
3. LDLC values were not reported. 
4. Patients were treated for two prolonged periods interrupted by a drug-free interval. The results reported are those at the conclusion of 
the first treatment period. 
S. This article reports on further analysis of lipoproteins in a cohort of patients initially reported by Fruchart (320). 











Table 4-10 Statins for dysbetalipo 
.--~~~ ,--~~~ ~ ~~ -~~~ ~~~~~~ ,---~~ 
% Change' Baseline Values(mmo!/L) 
Author Year N 1 ni~"nn<i, 2 Dose 4 Duration Comments Ref 
~'" ~~~ 
E21E2 01 TC TG HDLC LDLC TC TG HDLC LDLC 
East 1986 I UC+IF 1 0 MEV 40mg 16 10.88 5,49 0.75 2.9 56 49 13 25 1 (304) 
Vega 1988 3 UC+IF 3 0 LOV 40mg 8w 10.37 5.69 0.59 2.31 39 37 30 40 (313) 
lIIingwolth 1990 12 UC+IF 10 2 LOV 40mg 12w 12.95 8.77 0.91 3.60 44 42 26 32 
~~ 
(316) 
Stuyt 1990 12 UC+IF SIM 80mg 6w 12.30 8.77 54 48 (314) 
Feussner 1992 19 UB+UC+IF 19 0 SIM 20mg 8w 13.24 13.47 0.72 3.54 39 42 18 36 2 -(31 
I 
FI 1992 13 UB+UC+IF 13 0 SIM 40mg 8w 9.70" 10.72' 0.72' 2.336 13 24 29 22 2 (318) 
6-
.~~~-
Tw i7(D) 9 " 19(1) 7j (3l8) Feussner 1992 6 UB+UC+!F 0 40/450 ~~9.l ~~ 9.64' 0.78' I 15~ 17' 2 
Zhao 1994 9 UC+IF 3 6 SIM 20mg lOw 9.08 4.09 0.99 2.94 44 37 5 44- 3 (323) 
Gylli 1994 5 UC+IF 5 0 LOV 401 12w 8.2 6.2 1.0 1.5 43 63 20 20 
~~::~~. 
Knopp 1996 20 UC+GE 20 0 PRA 40mg 6w 36 22 (325) 
Civeira 1999 10 UE+UC 1 9 SIM 20mg 4w 8.37 3,64 0.99 4.53 26 18 6 (D) 30 4 (238) 
.--~~~~.:.: ... ~ .. ~- r-:~:~~ 
40w~- 40 ~2 (Dj 38-
.. ~. i~~~:: 





















I Number of patients in study 
2 Indicates the criteria on which the diagnosis of dysbetalipoproteinaemia was based 
GE Genetic analysis of apoE 
IF Isoelectric focusing 
UB Ultracentrifugation and demonstration of fJ-migrating VLDL 






S+G Simvastatin +gemjibrozil 
SI M Simvastatin 
4 Total daily dosage 











Except if indicated the in TC and LDLC is a decrease while in HOLC refer to increases Increases (I))) 
(, Indicates the lipid levels on of simvastatin 
additional simvastatin dose to 40 mg 
g Indicates of simvastatin 
9 Indicates additional m 450 mg to simvastatin 40 mg 
1. This is the first use of a In with 
2. In this trial were started on 20 mg which was to 40 mg if the remained uncontrolled. 
was added to 40 mg if necessary. Patients with an initial response were maintained on simvastatin 20 
mg. 
3. statistics were calculated from the data in the paper. The includes a number of with autosomal 
dominant mutations. 











Table 4-11 Trials comparing statins and fib rates 
Note: This table only lists studies that compared statin and fibrate treatment prospectively in the same patient cohort. 
ApoE 
Author Year N1 
E2/E2 
lllingworth 1990 12 10 
Civeira 1999 10 1 








Statin 2 Fibrate 3 
TC 
LOV CLO 44 
40mg 2g 
SIM GEM 26 
20mg 1200mg 
%Change stalin % Change fibrale 
Comments 
TG HDLC LDLC' TC TG HDLC LDLC 
42 26 32 40 52 32 1 
I 

















4 LDLC was detennined 
1. LDLC was significantly lower with lovastatin treatment, but there was no 
other lipid measures. 
2. This included many with autosomal dominant mutations in 
in outcome treatment for any of the 
Patients did not as well to treatment as in many 
of the other studies 
seen in the vast 
hArn ..... .,.",..,ntp'-' and it is doubtful whether the is representative of the lipid response 
of dysbetallpoprotemaenuc The fibrate was more effective at VLDLC and 











4.2.1.3.4.3 Bayer versus historical data 
In previous studies (see statin treatment of dysbetalipoproteinaemic va"",,,,,,, 
was associated with decreases in TC from The 37% reduction 
nh"PrI]p/1 in TC 
using approximately 
cerivastatin 0.4 mg/d correlates well with the changes seen 
(as their LDLC potency in non-
dysbetalipoproteinaemic patients) dosages other statins. With 40 mg/d of lovastatin 
TC decreases by 39% (3 J 3) to 44 % (316). Simvastatin 20mg/d reduces TC by 26 
(238) to 44 % (323). The 26% decrease observed with simvastatin in the by 
Civeira et al is unusually low and likely not rpyu'p,o>"n,h,tHIP of the rn.,,,,,,,·,t,, of 
dysbetalipoproteinaemic patients. The study included only one homozygote. 
Studies fibrates TC reductions ranging from 11-57%. The response to 
fenofibrate, in dosages, is (320) to 39% (31 The 44% reduction 
TC observed in our study 200 mg of fenofibrate is well within the 
range of "AIJ""'ICU responses. 
results of statin and fibrate trials are not directly comparable because of 
variations in patient selection and characteristics, fib rates are in general associated 
with better reductions in TG than statins. This finding is confirmed in the two studies 
that directly compare fibrates and statins 16). In the Bayer cerivastatin 
lowered TG by 20%, which is less than the 37-63% observed in studies using 
lovastatin (31 17) or the 18-42% (238;31 observed using simvastatin 
The poor TG-Iowering of cerivastatin markedly contrasts with the 











in the study was similar to the 56% reduction observed by Fruchart (320), but 
better than the 39% reduction seen by Feussner (31 
As the HDLC assay used this study was not reliable (see changes In 
HOLC will be discussed in the section with lipoprotein analysis by 
Uf,U,"vu. Similarly VLOLC and LOLC will be discussed in the context of 
the detailed analysis of lipoproteins by ultracentrifugation. 
4.2.1.4 VLDL compositional analysis 
4.2.1.4.1 Ratio CV/TV 
Following discontinuation of lipid-lowering medication the mean CV/TV ratio was 
0.51 0.17 (median 0.51, range in the 28 patients that completed 
placebo washout phase. In the 20 V'H'''''''' that at least one treatment arm 
the mean ratio was 0.52 ± 0.17 (median 0.52, range 0.25-0.93). The CV/TV ratio at 
baseline in patients that continued in the study beyond the placebo washout did 
not differ 
due to 
unpaired t-test) from those that were discontinued 
termination. Patients with an identified 
that was more cholesterol-enriched than those with no known 
mutation had VLDL 
mutation (CV/TV 






















Unpaired t-test P=0.03 
Only p~",",H'" with a previously rpr'At"1rp/1 VLDL {"UTInt'" analysis considered 
diagnostic of dysbetaiipoproteinaemia (CVrrV :::: 0.42 andlor CV/TP :::: were 
enrolled in study. Amongst the 28 patients that rA,nnllpt"'11 the placebo washout 
phase the CV lTV ratio was:::: 0.42 in 18. Amongst the gellor;IOSI patients i 
a ratio while the ratio was positive in 217 patients 
Fisher's exact 
Lipid-lowering treatment not only decreased plasma lipids (see above), but also 











Table 4-12 Ratio CV/TV with lipid-lowering therapy 
Ratio CV/TV Tukey's multiple comparison test 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.52 0 .51 0.17 20 0.25- >0.05 >0.05 <0.01 
0.93 
I 
Cerivastatin 0.40 0.41 0.14 13 0.22-
~. >0.05 >0.05 
0.73 
F enofibrate 0.45 0.46 0.15 13 0.19- >0.05 
0.82 
I 
Combination 0.30 0.30 0.07 9 0.22-
0.46 .J.: 







~ -ns 0::: 0,25 
0.00 











Legend: * P<O.Ol for combination vs. baseline (Tukey's multiple comparison 
test) 
ANOVA P=0.005 
There were only four analyzable patients without identified apoE mutations. These 
patients had less cholesterol-enriched VLDL at baseline (see above), and the CV lTV 
ratio also decreased following institution of lipid-lowering therapy ; always remaining 
lower than the ratio observed in genopositive patients. 





CJ Genonegative patients 
~ 
~ > 0 0.50 8 ~ III 0:: 0 .25 ~ 
0.00 
I Baseline I I Cerivastatin I I F enofibrate I Icer+ FenD I 
4.2.1.4.2 Ratio CVITP 
At baseline the mean ratio of CV/TP was 0.35 ± 0.12 (median 0.35, range 0.14-0.55) 
in the 28 patients that completed the placebo washout phase. The ratio in the 20 
patients with analyzable results was 0.37 ± 0.11 (median 0.37, range 0.20-0.55) and 
did not differ significantly (P=0.18 by unpaired t-test) from that seen in patients that 











with an identified mutation had Tlf',.n"", higher ratios than in whom 
no apoE mutation had been identified 0.40::1: 0.12 for genopositive vs. 0.23 
0.04 patients; P=O.0002 unpaired 













Unpaired t-test P=0.0002 
The CV/TP ratio was in 17/28 VGlll"'ll"" at baseline. It was positive in 17/21 
genopositive patients and 117 genonegative patients (P=O.003, Fischer's exact test). 
Both the CV lTV and the CV ITP ratio were negative in 9 while both ratios 
were positive in 16 patients. Three patients had discordant ratios. 











Table 4-13 Ratio CV/TP with lipid-lowering therapy 
Ratio CYITP Tukey's multiple comparison test 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.37 0.37 0.11 20 0.20- >0.05 <0.01 <0.001 
0.55 , - - ... Cerivastatin 0.28 0.28 0.09 13 0.14- >0.05 >0.05 
0.44 
F enofibrate 0.26 0.28 0.09 13 0.07- !! >0.05 , 
0.39 




Figure 4-16 Ratio CV/TP during lipid-lowering therapy 
0.6 




9 0 -ctI 0.2 ~ 0.1 
0.0 











Legend: * P<O. 0 l/or / enofibrate vs. baseline (Tukey's multiple comparison test) 
/\ P<O.OOl for combination therapy vs. baseline (Tukey 's multiple 
comparison test) 
ANOVA P<O.OOOI 
Patients with no identified apoE mutation also responded to lipid-lowering therapy 
with a reduction in the cholesterol-enrichment of their VLDL, however, they had 
consistently lower CV ITP ratios than genopositive patients. 







ci l- T :> u 0.3 e y ¢ 0 :;; til 0.2 0: 
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0.0 
I Baseline I I Cerivastatin I I Fenofibrate I Icer+ Fenol 
4.2.1.4.3 Previously published data on changes in the VLDL compositional 
analysis with dysbetalipoproteinaemia treatment 
Table 4.14 lists studies that report changes in VLDL compositional analysis with 
lipid-lowering treatment. For ease of comparison where molar ratios have been 
repol1ed they have been converted to mass ratios. Many studies only report VLDL 
compositional analysis at baseline and do not provide sufficient raw data to calculate 











Table 4-14 Changes in VLDL compositional analysis with lipid-lowering therapy 
For more details on the studies listed below, please refer to the previous tables on the treatment of dysbetalipoproteinaemia. 
Baseline Values Treated Values % Change L 
Author Year Drug 1 Comments Ref 
CV/TV CV/TP CV/TV CV/TP CV/TV CV/TP 
East 1986 MEV 0.60 0.29 52 (304) 
1 
40mg 
Packard 1986 BEZ 0.97 0.77 21 (307) 
600mg 
Fruchart 1987 FEN 1 OOmg 0.40 0.30 25 (308;320) 
Dallongeville 1991 OM36g 0.36 0.33 8 (326) 
van Dam 2002 ATR40mg 0.50 0.34 32 (240) 

















OM3 Omega-3 fatty acid, 
2 Refers to change from baseline value 
3 Comments 











few report on changes in VLDL and if so 
only on the ratio of VLDLC to TG in plasma, lipid-lowering treatment is invariably 
associated with VLDL that is less cholesterol-enriched. A similar response is 
observed in the with both ratios used to assess VLDL 
with treatment. The decreases observed are of similar as 
"n'cpr'lIP" in the studies rpr,,'\rtp/'l above. 
Lipoprotein fractions: absolute masses 
Due to technical difficulties in the processmg and of data on 
comp>os:mcm were only available for 18 patients, Of the 18 17 
two treatment arms and one patient only completed a ann, Most 
(l5/ 18) had an identified apoE mutation: 11 were and 




was analyzed by 
with modifications. 
Two solutions are made that can be combined in 
solution of the desired density. 











I. Saline solution 1.006 g/ml. g NaCI and disodium EDT A 
is dissolved In distilled water, 2 ml of 1 mmoliL NaOH is added and the 
volume to 2 L. a further 6 ml of distilled water is 
2. Saline-NaBr solution of density 1.182 
L of saline of density 1.006 glml) 
(249.8 g ofNaBr is dissolved in 1 
Twoml is adjusted to a density of 1.118 glml addition of 0.341 g NaCI 
and careful mixing. 
Beckman Ultra-Clear ™ tubes for the SW40 rotor are coated with chloride 
to make them wettable and assist in gradient creation Briefly, 2 g of polyvinyl 
alcohol is in 50 ml of distilled water by gentle and heating. ml 
of isopropanol is added to the hot solution with continued gentle and heating. 
Once the solution is clear it is allowed to cool to room temperature. The Beckman 
tubes are with this solution for 15 minutes and the solution is then 
The tubes are allowed to dry and any residual fluid at the bottom of the tube is 
The tubes are filled with distilled water overnight and then finally rinsed 











The gradient is created by careful overlayering of solutions. Initially 0.50 ml of the 
I.IS2 glml solution is into the tubes. Further solutions are added with the use 
a solutions are added to the d= 1.IS2 solution 
the bottom to the 
I. 2.0 ml plasma to d=LlIS glml 
2. 1.0 ml of density solution 1.0988 g/ml 
3. 1.0 ml of density solution 1.0860 glml 
4. 1.0 ml of density solution 1.0790 g/ml 
5. 1.0 ml solution 1.0722 
6. 2.0 ml solution 1.0641 glm! 
7. 2.0 ml of density solution 1.05S8 glml 
U !tracen tri fu gati on 
Ultracentrifugation is np,-t",·rn~·t1 a Beckman LSO and SW 40 
rotor. The temperature the centrifuge is 23 0 Celsius. The is set to 
accelerate normally, but deceleration is set at 0 to avoid of the 
Table 4.15 the time and schedule used for the as well 











Table 4-15 Sequentialllitracentrifllgation schedule 
Time Volume 
ItJUprotem fraction Speed (rpm) 
Hours: Minutes removed (ml) 
i VLDLI 39000 1 :38 1.0 
VLDL2 18500 15:41 
1 0.5 
IDL 39000 2:35 I 0.5 
LDL 30000 21: 10 1.0 
The 1.0 ml supernatant removed following the first is rerllac:ed with 1.0 
ml of solution d= 1.0588 
replaced. 
Subsequently the removed np'.,,''''''nt~ are no longer 
4.2.1.5.1.2 Lipoprotein fraction analysis 
The FC, PL and TG were determined em~Ylllau.cal 
usmg available kits Wako) 
in the lipoprotein fractions 
to the manufacturer's 
instruction. Esterified cholesterol was calculated as the difference between TC and 
CE. The mass of CE was calculated as 1.67 x 
measured using a modification of the 
albumin as a standard. 
method 
Total lipoprotein mass was calculated as the sum of 
cholesterol. Protein was 
with bovine serum 
CE, TG, PL and protein. All 
data were entered in a 
all derived values. 











Figure 4-18 Example of lipoprotein fractional composition spreadsheet 
DATE. 19 SEPT. 2002 SUBJECT Mel VISIT 4 9 AUGUST 2001 
Data as for 2ml for plasma used in procedure DONE BY M.J.LEVEY REASON : TYPE 111 TRIAL 
PLASMA CONCENTRATIONS 
Fe CE TG TC FC CE PL 
mMIL mWL mMIL mM/l mMlL 
PLASMA Whole 3864 1358 2.638 4.985 1752 3.239 2.611 
Vl (1000u 2517 388 287 1.481 0.S01 0.371 0.130 0.352 
SEOUEN' V2 l500uL 391 1006 617 265 0.592 0.797 0.342 0.454 0.284 
IISOOuL) 404 373 521 213 514 0.219 0.673 0275 0.397 0.243 
L (1000uL 1173 300 1287 392 1495 718 0.176 1.663 OS06 1.155 0 .479 
Hs (1750l 1 1 1 0 1 0.001 0.001 0.001 0.000 0.001 
Hb 12130, 0 0.001 0.001 0.001 0.000 0.001 
He (2410u 1 0 0.001 0.001 0.001 0.000 0.001 
Hd 12290, 1 1 0 1 0.001 0.001 0.001 0.000 0.001 
He (2030L 1 1 1 1 0 1 O.QOl 0.001 0.001 0.000 0.001 
Vl10 Lp(a. 2308 4197 2814 1158 2766 2037 15280 LpB 2.469 3.636 1.496 2.137 1.358 
HOL s Prt- 3 4 4 0 4 15 LpNonB 0.002 0.004 0.004 0.000 0.002 
TOTAL in 2312 4201 2818 1162 2766 2041 15299.52 
Recovery LP/PLasrr: 0.012 0.936 0.014 0.856 0.661 0.521 0.072 
~ VI/Plasm., 0.002 0.561 0100 0.211 0040 0.135 
V2JPlasffil 0.002 0.224 1.000 0.195 0.140 0.109 
IJPlasma 0.002 0.083 0135 0.157 0.123 0.093 
UPlasma 0.006 0.067 0.333 0.289 0.357 0.163 
HaJPlaSm!: 0.000 0.000 0.000 0.001 0.000 0.000 
HblPlastnl, 0.000 0.000 0.000 0.001 0.000 0.000 
HclPlasm •. 0.000 0.000 0.000 0 .001 0.000 0.000 
HdlPlasm;. 0.000 0.000 0.000 0 .001 0.000 0.000 
HelPlasmi. 0.000 0.000 0.000 0 .001 0.000 0.000 
lP Comp (Ft, Mass) Protein TG TC FC CE PL Ferre FCiPL CEfTG TCIProl TG/Prol PllProt 
V1 0.080 0.595 0.092 0068 0.040 0.125 0.740 0.544 0.067 1. 145 7.425 1.558 
V2 0.119 0.306 0. 187 0080 0.179 0.129 0.429 0.622 0.584 1.578 2.573 1.090 
I 0.169 0.156 0.218 0.089 0215 0.152 0.409 0.585 1.379 1.290 0.923 0.901 
L 0.219 0.056 0240 0.073 0.279 0.134 0.305 0.546 4.982 1.097 0.256 0.612 
Ha 0.200 0.200 0200 0.200 0.000 0.200 1.000 1.000 0.000 1000 1.000 1.000 
Hb 0.200 0.200 0200 0.200 0.000 0.200 1.000 1.000 0.000 1.000 1.000 1.000 
He 0.200 0.200 0.200 0.200 0.000 0.200 1.000 1.000 0.000 1.000 1.000 1.000 
Hd 0.200 0.200 0.200 0.200 0.000 0.200 1.000 1.000 0.000 1.000 1.000 1.000 
He 0.200 0.200 0.200 0.200 0.000 0.200 1.000 1.000 0.000 1.000 1.000 1.000 
Plillisma, mg/L Protein TG TC FC CE PL Protein TG TC FC CE PL 
Vl 169.5 1258.5 194 143.5 84.335 264 ria 0.5 0.5 0.5 0.5 0 05 
v2 195.5 503 308.5 132.5 293.92 213 Hb 0.5 0.5 05 0.5 0 05 
202 186.5 260.5 106.5 257.18 182 He 0.5 0.5 0.5 0.5 0 0.5 
586.5 lSO 643.5 196 747.325 359 Hd 0.5 0.5 0.5 0.5 0 0.5 
He 0.5 0.5 0.5 0.5 0 0.5 
4.2.1.5.2 Plasma lipids 
Analysis of lipoprotein composition included determination of plasma lipids as well. 
Lipids were analyzed independently of the results obtained in the routine chemical 
pathology laboratory. Results for TC and TG were very similar to those reported 
above and will not be presented in detail here. 











Plasma FC concentration decreased significantly from baseline with all treatments 
(ANOY A P<O.OOO I) . Free cholesterol was the lowest with combination therapy, 
followed by fenofibrate and cerivastatin, but none of the differences between 
treatment arms was statistically significant. 
Table 4-16 Plasma free cholesterol concentration and lipid-lowering therapy 
ANaYA P<O.OOOI 
Plasma FC (mmoIlL) Tukey 's multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 4.43 3.36 2.97 18 2.03- P<O.OOI P<O.OOI P<O.OOI 
13.64 
Cerivastatin 2.28 1.92 1.26 13 1.24- P>0.05 P>0 .05 
6.01 
Fenofibrate 1.90 1.88 0.47 13 I.J 8- P>0.05 
3.09 
Combination 1.48 1.60 0 .35 9 0.84-
1.88 














4-19 Plasma free cholesterol concentration and lipid-lowering 
15 
10 
'* * '* 
5 
o~---------------------------------------
Baseline Cerivastatin Fenafibrate Cer + Fena 
* P<O.OOI vs. baseline 
There were no differences in free cholesterol and in the response to treatment between 
homozygotes and (R14SC) carriers (data not shown). 
4.2.1.5.2.2 Plasma cholesterol ester 
Plasma CE concentration decreased from baseline values in all treatment arms 
(ANOY A P<O.OOO1). Combination therapy was associated with the lowest levels of 
followed by fenofibrate and cerivastatin. Differences between the various 











Table 4-17 Plasma cholesterol ester concentration and lipid-lowering therapy 
Plasma CE (mmollL) Tukey's mUltiple comparison test 
Mean Median SD N Range P vs. P vs. 
Cerivastatin Fenofibrate 
Baseline 4.53 4.78 1.70 18 0.88- <0.05 <0.01 
7.45 
..•.. 
Ceri vastatin 3.17 3.03 0.96 13 1.78- >0.05 
4.78 
';!h 





:, I' " Combination 2.35 2.22 0.52 9 1.66- c, '" " 
3.41 ,', W 
'\<: 
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Plasma CE was significantly lower at baseline in the apoE (R 145C) mutation carriers 
than apoE2 homozygotes (2 .92 ± 0.95 mmo llL for apoE (R145C) vs. 4 .94 ± 0 .96 for 
apoE2/E2; P=0.03 by unpaired t-test) . Following resumption of lipid-lowering therapy 
the differences between the two genotypes were no longer significant (data not 
shown). 
4.2.1.5.2.3 Plasma phospholipid (PL) 
The mean PL concentration at baseline was 4 .61 ± 1.95 mmoliL. All treatments 
significantly decreased baseline PL (ANOY A P<O.OOO 1). 
Table 4-18 Plasma PL concentration and lipid-lowering therapy 
Plasma PL (mmollL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin F enofibrate Combination 
Baseline 4 .61 3.87 1.95 18 2.95- <0.01 <0.001 <0.001 
10.29 
Ceri vastatin 3.09 2.89 0.91 13 2.11- >0.05 >0.05 
5.73 


















I Data transformed for analysis 














Baseline Cerivastatin Fenofibrate Cer + Feno 
** P<O.Ol vs. 
*** P<O.OOl vs. baseline 
There were no in PL concentration to the nature of the 
mutation (data not shown). 
4.2.1.5.3 
4.2.1.5.3.1 VLDLl protein 
YLDLI protein decreased significantly from baseline following institution of lipid-
''''',JPrlnU therapy (ANOY A, P<O.OOOl). Fenofibrate and combination were 












Table 4-19 VLDLl protein and lipid-lowering therapy 
VLDLI protein (mg/L) 
Mean Median SD N Range 
Baseline 681 420 693 18 141-
2664 
Cerivastatin 345 301 199 13 181-
951 
F enofibrate 149 148 81 13 28-
293 
Combination 140 122 40 9 37-
446 
I Data log transformed for analysis 
















Baseline Cerivastatin Fenofibrate 
Tukey's multiple comparison test I 
P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 















Legend: *** P<O.OO I vs. baseline 
/V\ P<O.Ol vs. cerivastatin 
There were no significant differences In YLDLI protein between the two apoE 
genotypes studied, either at baseline or with lipid-lowering therapy (data not shown). 
4.2.1.5.3.2 VLDLI triglycerides 
YLDL I TG concentration decreased from baseline with lipid-lowering therapy 
(ANOY A P<O.OOOI), but the change seen with cerivastatin did not reach statistical 
significance on post-test. 
Table 4-20 VLDLI TG concentration and lipid-lowering therapy 
YLDLI TG (mmoI/L) Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 4.41 2.46 4.26 18 1.45- >0.05 <0.001 <0.001 
18 .31 
Cerivastatin 2.66 2. 17 1.64 13 1.05- <0.01 <0.01 
, 
7.48 
Fenofibrate 1.04 0.97 0.67 13 0.08- >0.05 
2.27 
Combination 1.11 0.95 1.11 9 0.07-
3.92 
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Baseline Cerivastatin Fenofibrate Cer + Feno 
Legend: *** P<O.OOI vs. baseline 
N\ P<O.Ol vs. cerivastatin 
There were no statistically significant differences in VLDLl TG levels between the 
two-apoE genotypes at any stage during the study (data not shown). 
4.2.1.5.3.3 VLDLl total cholesterol 
Total cholesterol concentration In VLDLJ decreased from baseline with all lipid-
lowering treatments (ANOV A, P<O.OOO 1), but the decrease seen with cerivastatin did 
not reach significance on post-test. There were no significant differences in VLDLl 











Table 4-21 VLDLl TC concentration and lipid-lowering therapy 
VLDLl TC (mmoIlL) Tukey ' s multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 2.90 2.17 2.32 18 0.58- >0.05 <0.001 <0.001 
7.51 
Cerivastatin l.33 0.98 l.24 13 0.56- <0.01 <0.01 
5.19 




Combination 0.39 0.29 0.39 9 0.04-
, 
l.38 
I Data log transformed prior to analysis 
Figure 4-24 VLDLl TC and lipid-lowering therapy 
8 
~ 7 
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Legend: *** P<O.OOI vs. baseline 
/V\ P<O.Ol vs. cerivastatin 
4.2.1.5.3.4 VLDLI free cholesterol 
The levels of FC in YLDLl responded similarly to TC to lipid-lowering therapy. FC 
concentration decreased with all therapies (ANOY A, P<O.OOO 1), but the change 
observed with cerivastatin did not reach statistical significance. There were no 
differences between the two apoE genotypes studied (data not shown). 
Table 4-22 VLDLl Fe response to lipid-lowering therapy 
YLDLI FC (mmoIlL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs . P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 1.86 1.16 1.82 18 0.38- >0.05 <0.001 <0.001 
6.85 
Cerivastatin 0.86 0.62 0.85 13 0.37- >0.05 <0.01 
3.57 
Fenofibrate 0.33 0.28 0.22 13 0.02- >0.05 
0.81 
.i.e:::. .' . 














I Data ".nlrTnF"" prior to analysis 












Baseline Cerivastatin Fenofibrate Cer + Feno 
*** P<O.OOl vs. baseline 
IV\ P<O.Ol vs. cerivastatin 
4.2.1.5.3.5 VLDLl cholesterol ester 
baseline in all treatment anns (ANOVA, 
P<O.OOOl). The decrease was for combination therapy followed by 
and V"",l.alj,,, treatment. There were no differences at any 











Table 4-23 VLDLI CE and lipid-lowering therapy 
VLDL 1 CE (rrunollL) Tukey's multiple comparison test 
Mean Median SD N Range p vs. p vs. p vs. 
Cerivastatin Fenofibrate Combination 
Baseline 1.03 0.8 I 0.77 18 0.20- <0.05 
2.98 
Cerivastatin 0.46 0.35 0.40 13 0.13-
1.63 
F enofibrate O. I 5 O. I 4 0.09 9 0.03-
0.32 
Combination O. I 2 0.09 0.13 9 0.02-
0.45 
I Data log transformed prior to analysis 
Figure 4-26 VLDLI CE and lipid-lowering therapy 
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Legend: * P<0.05 vs. baseline 
P<O.OI vs. cerivastalin 
4.2.1.5.3.6 VLDLI phospholipid 
*** P<0.001 vs. baseline 
P<O.OOI vs. cerivastatin 
The PL content of the YLDLl fraction decreased with all lipid-lowering treatments 
(ANOY A, P<O.OOO 1), but the decrease was not statistically significant with 
cerivastatin. There were no significant differences in VLDLl PL at any stage between 
the two apoE genotypes studied (data not shown). 
Table 4-24 VLDLl phospholipid concentration and lipid-lowering therapy 
VLDLl PL (mmoVL) Tukey's multiple comparison test I 
Mean Median SO N Range P vs. P vs. P vs. 
Ceri vastatin Fenofibrate Combination 
Baseline 1.56 0.89 1.55 18 0.38- >0.05 <0.001 <0.001 
5.83 
Cerivastatin 0.75 0.53 0.58 13 0.36- <0.05 <0.01 
2.51 
Fenofibrate 0 .30 0.25 0.17 13 0.03- >0.05 
0.65 
Combination 0.29 0.24 0.27 9 0.03-
0.96 
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Baseline Cerivastatin Fenofibrate Cer + Feno 
Legend: *** P<O.OOl vs. baseline 
P<O.05 vs. cerivastatin P<O.Ol vs. cerivastatin 
4.1.1.5.4 VLDL1 
4.2.1.5.4.1 VLDL2 protein 
VLDL2 protein co centration decreased from baseline with all (ANOVA, 
P<O,OOOl), but the ,",HUU",,", seen with was not significant on post-test 
analysis. There were no significant differences at any between the two 











Table 4-25 VLDL2 protein concentration and lipid-lowering therapy 
VLDL2 protein (mg/L) Tukey 's multiple comparison test I 
Mean Median SD N Range P vs. 
Cerivastatin 
Baseline 563 389 503 18 199- >0.05 
2410 
Cerivastatin 301 294 123 13 139-
620 
F enofibrate 216 205 79 13 40-
369 
Combination 137 148 63 9 6-215 
I Data log transformed prior to analysis 















Baseline Cerivastatin Fenoflbrate Cer + Feno 















Legend: ** P<O~ Ol vs. baseline *** P<O.OOl vs. baseline 
IV\ P<O.Ol vs. cerivaslatin 
4.2.1.5.4.2 VLDL2 triglycerides 
YLDL2 TG concentration decreased from baseline values in all three treatment arms 
(ANOYA, P<O.OOOI), but the change with cerivastatin did not reach statistical 
significance on post test. There were no statistically significant differences between 
the two apoE genotypes studied (data not shown). 
Table 4-26 VLDL2 TG concentration and lipid-lowering therapy 
YLOL2 TG (nunoIlL) Tukey's multiple comparison test J 
Mean Median SO N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 1.42 0.95 1.20 18 0.50- >0.05 <0.001 <0.001 
5.31 
I 
Cerivastatin 0.86 0.89 0.37 13 0.36- >0.05 <0.05 
1.83 
II ' 




Combination 0.39 0.38 0.20 9 0.11- '!. Ii!:!! ,! ~ (' 
:.:1 
111 iii" 
0.77 Ill! ' 
". .:.:. 'i .,. 

























Baseline Cerivastatin Fenofibrate Cer + Feno 
*** P<O.OOI vs. baseline 
1\ P<O.05 vs. cerivastatin 
4.2.1.5.4.3 VLDL2 total cholesterol 
VLDL2 TC concentration decreased from baseline with all lipid-lowering 
(ANOV A, P<O.OOO 1), but the seen with cerivastatin did not reach statistical 
At the VLDL2 TC was 1',,,.,,»,,,, lower in with the 
apoE than that seen in apoE2 homozygotes (2.59 ± 1.04 vs. 1.39 ± 0.22, 
P=O.Ol by t-test for vs. (R145C) mutation 
carries). With lipid-lowering no statistically significant differences were 











Table 4-27 VLDL2 TC concentration and lipid-lowering therapy 
VLDL2 TC (mmoIlL) Tukey 's multiple comparison test I 
Mean Median SO N Range P vs . P vs . P vs . 
Cerivastatin Fenofibrate Combination 
Baseline 2.10 1.72 1.03 18 0.78- >0.05 <0.001 <0.001 
4.73 
Cerivastatin 1.32 1.16 0.68 13 0.472 .90 >0.05 <0.01 
Fenofibrate 0.89 0.90 0.35 13 0.14- . >0.05 
1.55 
,,' i' ,~;;. .:: 
Combination 0.54 0.53 0.26 9 0.12-
.. " , ,. 
i 
0.92 I" 
I Data log transformed prior to analysis 

























Legend: *** P<O.OOI vs. baseline 
IV\ P<O. 01 vs. cerivastalin 
4.2.1.5.4.4 VLDL2 free cholesterol 
VLDL2 FC concentration decreased significantly from baseline in all treatment arms 
(ANOV A, P<O.OOO 1). The apoE genotype did not exert any significant influence on 
VLDL2 FC (data not shown). 
Table 4-28 VLDL2 Fe and lipid-lowering therapy 
VLDL2 FC (mmoUL) Tukey ' s multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs . 
Cerivastatin Fenofibrate Combination 
Baseline 1.00 0.75 0.65 18 0.33- <0.05 <0.001 <0.001 
3.23 
Cerivastatin 0.55 0.5\ 0.27 13 0.23- >0.05 <0.01 
1.23 
F enofibrate 0.37 0.40 0.13 13 0.07- >0.05 
0.53 
Combination 0.25 0.23 0.10 9 0.08-
0.40 













Figure 4-31 VLDL2 Fe and lipid-lowering therapy 
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Legend: * P<O.05 vs. baseline *** P<O.OOl vs. baseline 
P<O.Ol vs. cerivastatin 
4.2.1.5.4.5 VLDL2 cholesterol ester 
VLDL2 CE concentration decreased from baseline values in all three treatment arms 
(ANOV A, P<O.OOO 1), but the change with cerivastatin was not statistically significant 
on post test. There were no significant differences at any stage between the two apoE 











Table 4-29 VLDL2 CE concentration and lipid-lowering therapy 
VLDL2 CE (nunoIlL) Tukey's multiple comparison test I 
Mean Median SO N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 1.10 1.00 0.72 18 0.14- >0.05 <0.05 <0.001 
3.13 
Cerivastatin 0.77 0.66 0.43 13 0.24- >0.05 <0.01 
1.66 




Combination 0.29 0.26 0.17 9 0.04-
0.53 
, 
I Data log transformed prior to analysis 
Figure 4-32 VLDL2 CE and lipid-lowering therapy 
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Legend: * P<O.05 vs. baseline *** P<O.OOl vs. baseline 
fV\ P<O.Ol vs. cerivastatin 
4.2.1.5.4.6 VLDL2 phospholipid 
VLDL2 PL concentration decreased with lipid-lowering therapy (ANOV A, 
p<o.ooo I), but as with the other components of VLDL2 the change seen with 
cerivastatin did not reach statistical significance. There were also no differences at 
any stage between the two apoE genotypes studied in VLDL2 PL levels (data not 
shown). 
Table 4-30 VLDL2 PL concentration and lipid-lowering therapy 
VLDL2 PL (mmollL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.85 0.59 0.74 18 0.28- >0.05 <0.001 1<0.001 
3.35 
Cerivastatin 0.48 0.42 0.25 13 0.24- >0.05 <0.05 
1.17 
















I Data transfonned prior to analysis 





Baseline Cerivastatin Fenofibrate Cer + Feno 
Legend: *** P<O.OOJ vs. baseline 
1\ P<O.05 vs. cerivastatin 
4.2.1.5.5IDL 
4.2.1.5.5.1 IDL protein 
The content of the IDL fraction decreased from baseline in all treatment arms 
(ANOV A, P=O.0005), but the results seen in the fractions with 
lipoproteins (VLDLl + VLDL2) changes with cerivastatin reached statistical 











genotype did not exert a statistically significant influence on IDL protein levels at any 
stage (data not shown). 
Table 4-31 IDL protein and lipid-lowering therapy 
IDL protein (mg/L) Tukey ' s multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 270 226 139 18 95- <0.001 >0.05 <0.001 
556 
Cerivastatin 153 153 50 13 100- <0.05 >0.05 
243 
































Baseline Cerivaslalin Fenolibrale Cer + Feno 
Legend: *** P<O.OOI vs. baseline 
/\ P<O.05 vs. cerivastatin 
+ P<O.05 vs. combination therapy 
4.2.1.5.5.2 IDL triglycerides 
Lipid-lowering was associated with of IDL TO concentration in all 
three treatment arms P=O.0025), but the was only 
when cerivastatin formed part of the therapy. The two genotypes studied did not 











Table 4-32 IDL TG concentration and lipid-lowering therapy 
lDL TG (nunol/L) Tukey's mUltiple comparison test 
Mean Median SD N Range p vs. p vs. p vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.35 0.32 0.21 18 0.11- <0.01 >0.05 <0.05 
1.02 
Cerivastatin 0.19 0.18 0.09 13 O.J-
0.44 
F enofi brate 0.23 0.22 0.04 13 0.17-
0.33 
Combination 0.19 0.20 0.04 9 O.ll-
0.24 
Data log transformed prior to analysis 
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Baseline Cerivastatin Fenofibrate Cer + Feno 
Legend: * P<O.05 vs. baseline ** P<O.Ol vs. baseline 











4.2.1.5.5.3 IDL total cholesterol 
IDL TC concentration fell from baseline once lipid-lowering treatment was provided 
(ANOY A, P=O.OO 12), but this change was only statistically significant for cerivastatin 
monotherapy. At baseline IDL TC was significantly lower in patients with the apoE 
(RI45C) mutation when compared to apoE2 homozygotes (1.11 ± 0.54 mmollL vs. 
0.44 ± 0.19 mmollL for apoE2/E2 vs. apoE (RI45C) IDL TC, P=O.OI by unpaired t-
test). Once lipid-lowering treatment had been started the difference in IDL TC was no 
longer statistically significant (data not shown). 
Table 4-33 IDL TC concentration and lipid-lowering therapy 
IDL TC (mmollL) Tukey's multiple comparison test I 
Mean Median SO N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.97 0.79 0.56 18 0.20- <0.01 >0.05 >0.05 
2.27 I 
Cerivastatin 0.47 0.46 0.20 13 0.24- <0.05 >0.05 
0.89 
F enofibrate 0.79 0.79 0.16 13 0.53- >0.05 
1.01 
Combination 0.55 0.50 0.26 9 0.29-
1.10 I 











Figure 4-36 IDL TC and lipid-lowering therapy 
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Legend: ** P<O.Ol vs. baseline 
J\ P<O.05 VS. cerivastatin 
4.2.1.5.5.4 IDL free cholesterol 
IDL FC concentration responded similarly to TC to lipid-lowering therapy, with a 
decrease from baseline values In all treatment anus (ANOY A, but 
statistical only in the cerivastatin group. IDL FC was 
"~'_H"J lower (at baseline only) in the group to 
homozygotes (0.44 ± 0.22 mmol/L vs. 0.18 ± O.OS mmol/L for vs. apoE 











Table 4-34 IDL FC concentration and lipid-lowering therapy 
IDL FC CnunollL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.38 0.30 0.22 18 0.11- <0.01 >0.05 >0.05 
0.85 
Cerivastatin 0.20 0.16 0.08 13 0.10- <0.05 >0.05 
0.35 
F enofibrate 0.33 0.33 0.08 13 0.23- >0.05 
0.49 
Combination 0.24 0.18 O. II 9 0.12- 'u 
0.43 
I Data log transformed prior to analysis 
Figure 4-37 IDL FC and lipid-lowering therapy 
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Legend: ** P<O.OJ VS. UUSC:::IIIIC::: 
A P<O.05 VS. cerivastatin 
4.2.1.5.5.5 IDL cholesterol ester 
lDL CE concentration from baseline in all treatment arms (ANOV A, 
P=0.0036), but the change with fenofibrate monotherapy did not 
su:!;mtllcaIlce on post test. lDL TC in the apoE mutation 
carriers at baseline is due to both lower FC and CE values (0.66± 0.35 mmollL vs. 












Table 4-35 IDL CE concentration and lipid-lowering therapy 
IDLCE Tukey's mUltiple comparison test 
Mean Median SD N Range P vs . P vs . P vs . 
Cerivastatin Fenofibrate Combination 
Baseline 0.58 0.51 0.35 18 0.09- <0.01 >0.05 <0.05 
1.43 
Cerivastatin 0.27 0.23 0.12 13 0.14- >0.05 >0.05 
I 
0.54 
F enofibrate 0.46 0.47 0.15 13 0.04- >0.05 
0.61 
Combination 0.31 0.32 0.16 9 0.12-
0.66 













Baseline Cerivastatin F enofibrate Cer + Feno 











4.2.1.5.5.6 IDL phospholipid 
The PL concentration in IDL decreased when cerivastatin was prescribed, either as 
monotherapy or in combination with fenofibrate (ANOY A, P=0.0023). The final 
concentrations of PL were similar in both cerivastatin-containing arms, but on post 
test the change was not significant in the combination therapy arm, likely due to the 
smaller number of patients in this treatment arm. 
Table 4-36 IDL PL concentration and lipid-lowering therapy 
IDL PL (mmoIlL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs . 
Cerivastatin Fenofibrate Combination 
Baseline 0.97 0.79 0.56 18 0.20- <0.01 >0.05 >0.05 
2.27 
Cerivastatin 0.47 0.46 0.20 13 0.24- <0.05 >0.05 
0.89 
F enofibrate 0.79 0.79 0.16 13 0.53- >0.05 
1.01 
Combination 0.55 0.50 0.26 9 0.29-
1.10 
.-.. ,,~. ~ 











4-39 IDL PL and IiDid-l,ow.eriIII! therapy 
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Baseline Cerivastatin Fenofibrate Cer + Feno 
** P<O.OI vs. baseline 
P<O.05 vs. cerivastatin 
6 LDLfraction 
4.2.1.5.6.1 LDL protein 
Lipid-lowering therapy was associated with small changes In LOL protein 
concentration. LOL concentration decreased with 
but none of the ,",,,,">1,;;,,,, reached statistical (ANOY A, P=O.07). 
homozygotes showed a significant decrease in LDL with cerivastatin 
and combination Tnp,.",.,,, (ANaYA, P=O.0006). Although there was no 
difference between homozygotes and (R145C) carriers at baseline, LOL 
was significantly lower in homozygotes in each treatment arm 











Table 4-37 LDL protein concentration and lipid lowering therapy 
LDL protein (mg/L) Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs. 
Cerivastatin F enofibrate 
Baseline 482 437 239 18 180- >0.05 >0.05 
997 
Cerivastatin 326 277 174 13 120- ." >0.05 
664 
. .: . 
F enofi brate 425 339 190 13 238- . :: :: 
797 
Ii; :.1 ..... , 'j 
Combination 337 203 234 9 136- : 
! ."'. 
823 ! i 
I Data log transformed prior to analysis 

































Legend: ** P<O.Ol vs. baseline 
All significance levels refer to statistical analyses within the cohort of apoE2 
homozygotes. 
4.2.1.5.6.2 LD L triglycerides 
Lipid-lowering treatment reduced the TG concentration within LOL to a similar 
extent in all treatment arms CANOY A, P=0.0028). The apoE genotype did not 
influence LOL TG levels in a significant fashion (data not shown). 
Table 4-38 LDL TG concentration and lipid-lowering therapy 
LOL TG (nunoIlL) Tukey's multiple comparison test I 
Mean Median SO N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.27 0.23 0.14 18 0.10- <0.01 <0.05 <0.05 
0.6 1 
Cerivastatin 0.15 0.15 0.07 13 0.04- >0.05 >0.05 
0.29 
Fenofibrate 0 .16 0.16 0.04 13 0.10- >0.05 
0.27 , 












I Data log transformed prior to analysis 
Figure 4-4] LDL TG and lipid-lowering therapy 
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Legend: * P<O.05 vs. baseline ** P<O.OJ vs. baseline 
4.2.1.5.6.3 LDL total cholesterol 
LDL TC levels were generally low at baseline, as is to be expected in patients with 
dysbetalipoproteinaemia. Levels decrea<;ed with lipid-lowering therapy, but none of 











Table 4-39 LDL TC concentration and lipid-lowering therapy 
LDL TC (mmoIlL) Tukey 's mUltiple comparison test I 
Mean Median SD N Range Pvs. P vs . P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 1.25 0.98 0.9 1 18 0.14- >0.05 >0.05 >0.05 
3.33 
Cerivastatin 0.83 0.64 0.44 13 0.37- >0.05 >0.05 
1.71 
.. 
Fenofibrate 1.18 0.82 0.66 13 0.60- >0.05 
2.65 
Combination 0.96 0.78 0.67 9 0.31- 'II 
I 
2.21 
I Data log transformed prior to analysis 
Figure 4-42 LDL TC and lipid-lowering therapy 
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4.2.1.5.6.4 LDL free cholesterol 
LDL FC concentration did not change significantly with the initiation of lipid-
lowering treatment (ANOV A, P=O.27). There were no statistically significant 
differences in LDL FC between the two apoE genotypes studied (data not shown). 
Table 4-40 LDL Fe concentration and lipid-lowering treatment 
LDL FC (mmoI/L) Tukey's multiple comparison test 1 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.44 0.36 0.28 18 0.09- >0.05 >0.05 >0.05 
1.28 
Cerivastatin 0.28 0.25 0.13 13 0.14- >0.05 >0.05 
0.61 
F enofibrate 0.37 0.31 0.16 13 0.20- >0.05 
0.71 
Combination 0.33 0.34 0.20 9 0.10-
0.74 






















Baseline Cerivastatin Fenofibrate Cer + Feno 
4.2.1.5.6.5 LDL CE 
LDL CE concentration was lowest when vasral:!ll-I:.:onltalmnlg therapy was given, 
but none of the in LDL CE reached statistical (ANOVA, 
There were no statistically significant differences in LDL CE between the 











Table 4-41 LDL CE concentration and lipid-lowering therapy 
LDL CE (mmoVL) 
Mean Median SO N 
Baseline 0.81 0.58 0.66 18 
Ceri vastatin 0.54 0.40 0.32 13 
Fenofibrate 0.81 0.52 0.51 13 
Combination 0.63 0.40 0.49 9 
I Data log transformed prior to analysis 















Tukey's multiple comparison test I 
Range P vs . P vs. P vs. 
Cerivastatin Fenofibrate Combination 
0.05- >0.05 >0.05 >0.05 
2.49 





















4.2.1 .5.6.6 LDL phospholipid 
LDL PL concentration was lowest with cerivastatin therapy. None of the changes seen 
in LDL PL were statistically significant (A NOV A, P=0.16). There were no 
statistically significant differences in LDL PL between the two apoE genotypes 
studied (data not shown). 
Table 4-42 LDL PL concentration and lipid-lowering therapy 
LDL PL (nunoIlL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.45 0.40 0.24 18 0.19- >0.05 >0.05 >0.05 
0.97 
Cerivastatin 0.30 0.27 0.14 13 0.10- >0.05 >0.05 
0.53 
F enofibrate 0.40 0.35 0.16 J3 0.22- >0.05 
0.68 
Combination 0.39 0.24 0.32 9 0.1 3-
1.11 























Baseline Cerivastatin Fenofibrate Cer + Feno 
4.2.1.5.7 HDL fraction 
HDL was collected in five fractions sequential The data 
presented here rpn,rp<,pnt<: the sum of all the fractions collected. 
4.2.1.5.7.1 HDL 
Denser HDL fractions were contaminated by proteins, resulting in very 
levels of measured protein. The concentrations are several orders of 
magnitude higher than those measured in other fractions and therefore clearly do not 
reflect levels of HDL associated The protein data will therefore not be 
presented here. 











Although HDL is not a TGRL lipid-lowering therapy was associated with a definite 
decrease in HDL TG mass from baseline (ANOY A, P<O.OOO I). HDL TG mass 
decreased in all three treatment arms. 
Table 4-43 HDL TG and lipid-lowering therapy 
HDL TG (mrnoIlL) Tukey's mUltiple comparison test J 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.62 0.61 0.10 18 0.48- <0.001 <0.001 <0.001 
0.84 I 
Cerivastatin 0.44 0.47 0.09 13 0.30- >0.05 >0.05 
0.55 
i i; 






Combination 0.40 0.38 0.09 9 0.27-















Figure 4-46 HDL TG and lipid-lowering therapy 
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Baseline Cerivastatin Fenofibrate Cer + Feno 
Legend: *** P<O.OOl vs. baseline 
4.2.1.5.7.3 HDL total cholesterol 
The HDL TC concentration was low and increased when fibrates were prescribed. 












Table 4-44 HDL TC and lipid lowering therapy 
HDL TC (mmoIlL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs . P vs . P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.84 0 .84 0.21 18 0.44- >0.05 >0.05 >0.05 
1.17 
Cerivastatin 0.81 0 .79 0 .23 13 0.45- >0.05 >0.05 
1.22 I " 
-"-
F enofibrate 0.95 0 .85 0.36 13 0.37- ,:' >0.05 
1.75 .,' I: 
:r, ;; 
Combination 0 .89 0 .90 0.35 9 0.47-
:~ " , 
":. 
1.63 :". 






















Baseline Cerivastatin Fenofibrate Cer + Feno 
4.2.1.5.7.4 HDL free cholesterol 
HDL Fe concentration levels did not change significantly with lipid-lowering 











Table 4-45 HDL FC concentration and lipid-lowering therapy 
HDL FC (mmoVL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.24 0.21 0.08 18 0.13- >0.05 >0.05 >0.05 
0.43 
Cerivastatin 0.22 0.2 1 0.08 13 0.13- >0.05 >0.05 
0.43 
F enofibrate 0.28 0.25 0.14 13 0.09- >0.05 
0.66 
-
Combination 0.23 0.20 0.13 9 0.11- ':' 
. 
0.54 .. 
I Data Jog transformed prior to analysis 
Figure 4-48 HDL FC and lipid-lowering therapy 
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4.2.1.5.7.5 HDL cholesterol ester 
HDL CE concentration increased from baseline when fenofibrate-containing therapy 
was prescribed, but none of the changes seen were statistically significant (ANOY A, 
P=0.61). 
Table 4-46 HDL CE concentration and lipid-lowering therapy 
HDL CE (mmoVL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs . P vs. P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.61 0.58 0.18 18 0.30- >0.05 >0.05 >0.05 
0.90 
Cerivastatin 0.56 0.57 0.18 13 0 .33- >0.05 >0.05 
0.92 
Fenofibrate 0.67 0.63 0.24 13 0.29- >0.05 
1.10 
Combination 0.65 0.72 0.24 9 0.31-
1.10 
J' 

























Baseline Cerivastatin Fenofibrate Cer + Feno 
4.2.1.5.7.6 HD L phospholipid 
HDL PL concentration levels were lower in patients on aL<O""V.ULa'Ullll!', therapy, but 











Table 4-47 HDL PL concentration and lipid-lowering therapy 
HDL PL (mmoIlL) Tukey's multiple comparison test I 
Mean Median SD N Range P vs. P vs . P vs. 
Cerivastatin Fenofibrate Combination 
Baseline 0.44 0.38 0.27 18 0.15- >0.05 >0.05 >0.05 
1.13 
Cerivastatin 0.41 0.37 0 .26 13 0.16- >0.05 >0.05 
0.88 ~ 
Fenofibrate 0.38 0.31 0.29 13 0.11- >0.05 
1.01 
, ; 
Combination 0.35 0.30 0.17 9 0.17-
0.65 
I Data log transformed prior to analysis 






















4.2.1.6 Lipoproteins fractions: compositional changes 
Tbis section presents a brief overview of the relative compositional changes in the 
various lipoprotein fractions. Detailed data on compositional changes will only be 
presented where of relevance. 
4.2.1.6.1 VLDLI fractional composition 
Table 4-48 VLDLI fractional composition 
VLDLl Baseline Cerivastatin Fenofibrate Combination AN OVA 
I 
(Mean ± SO) 0.l0 ± 0.02 0.10 ± 0.01 0.11 ± 0.03 0.12 ± O.lO 
Prot/TM I 0.54 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.53 ± 0.06 0.60 ± 0.05 0.57 ± 0.07 0.60 ± 0.10 
TGITM 0.07 
P vs. base line >0.05 >0.05 >0.05 
(Mean ± SO) 0.1 6 ± 0.04 0.13 ± 0.03 0.13 ± 0.03 0.10 ± 0.02 1 
TC/TM 0.0002 
P vs. basel ine <0.05 <0.05 <0.001 
(Mean ± SO) 0.10 ± 0.02 0.08 ± 0.02 0.08 ± 0.02 0.07 ± 0.01 
FC/TM 0.03 
P vs. baseline >0.05 >0.05 <0.05 
(Mean ± SO) 0.11 ± 0.05 0.08 ± 0.03 0.08 ± 0.04 0.05 ± 0.02 I 
CE/TM 0.001 
P vs. baseline >0.05 <0.05 <0.01 
(Mean ± SO) 0.16 ± 0.03 0.14 ± 0.01 0.16±0.02 0.15±0.01 
PLlTM 0.09 











VLDLI Baseline Cerivastatin Fenofibrate Combination ANOYA 
(Mean ± SO) 0.60 ± 0.13 0.65 ± 0.10 ' 0.66 ± 0.12 0.70± 0.07 
FCITC 0.16 
P vs. baseline I, 
. >0.05 >0.05 >0.05 
:~ 
(Mean ± SO) 0.61±0.15 0.56 ± 0.11 0.53 ± 0.10 0.50 ± 0.09 
FC/PL 0.08 
P vs. bnseline I ' >0.05 >0.05 >0.05 
(Mean ± SO) 0.22 ± 0.10 0.13 ± 0.07 0.14 ± 0.08 0.09 ± 0.04 
CE/TG 0.001 
P vs. base li ne 
. <0.05 <0.05 <0.01 
. ~I' 
(Mean ± SO) 1.80 ± 0.57 1.38 ± 0.42 1.25 ± 0.42 1.15 ± 0.60 
TC/Prot I 0.006 
P vs. baseline >0.05 <0.05 <0.05 
,,-
(Menn ± SO) 5.91 ± l. 81 6.46 ± 0.76 5.58 ± 1.58 6.63 ± 2.57 
TG/Prot 0.44 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 1.74 ± 0.41 1.55 ± 0.25 l.51 ± 0.3\ 1.56 ± 0.56 
PLiProt 0.36 
P vs. baseline >0.05 >0.05 >0.05 











4.2.1.6.2 VLDL2fractionai composition 
Table 4-49 YLDL2 fractional composition 
VLDL2 Baseline Ceri vastatin Fenofibrate Combination ANOYA 
-
(Mean ± SO) 0.15±0.03 0.14 ± 0.01 0.16 ± 0.04 0.14 ±0.05 
Prot/TM I 0.42 
P vs. baseline >0.05 >0.05 >0.05 
(Mean± SO) 0.33 ± 0.10 0.35 ± 0.07 0.32 ± 0.08 0.36 ± 0.07 
TG/TM 0.64 
P "s. baseline ' >0.05 >0.05 >0.05 
(Mean ± SO) 0.25 ± 0.06 0.24 ± 0.05 0.24 ±0.04 0.23 ± 0.06 
TCITM 0.74 
P vs. baseline • >0.05 >0.05 >0.05 
; 
(Mean ± SO) 0.11±0.02 0.10 ± 0.02 0.10 ± 0.02 0.11 ± 0.02 
FCITM 0.21 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± S O) 0.23 ± 0.09 0.23 ± 0.06 0.24 ± 0.05 0.20 ± 0.08 
CE/TM 0.57 
P vs. baseline >0.05 >0.05 >0.05 
(Mea n ± SO) 0.17 ± 0.03 0.16 ± 0.02 0.18 ± 0.02 0.19 ± 0.03 
PLlTM 0.08 
P vs, baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.47±0.I4 0.43 ± 0.04 0.43 ± 0.05 0.50 ± 0.01 
FC/TC 0.22 
P vs, baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.67 ± 0. 16 0.60 ± 0.12 0.57 ± 0.08 0.61 ± 0.18 
FC/PL 0.27 
P vs , baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.81 ± 0.47 0.70 ± 0.28 0.81 ± 0.36 0.61±0.41 
CE/TG 0.53 











VLDL2 Baseline Cerivastatin Fenofibrate Combination ANOYA 
(Mean ± SO) 1.64 ± 0.36 1.66 ± 0.37 1.60 ± 0.30 2.32 ± 2.35 
TClProt 0.32 
P vs. baseline I' :1 >0.05 >0.05 >0.05 
I i 
(Mean ± SO) 2.22 ± 1.04 2.45 ± 0.41 2.18±0.75 3.96 ± 4.94 
TG/Prot 0.20 
P vs. baseline " >0.05 >0.05 >0.05 
" 
(Mean ± SO) 1.13 ± 0.23 1.17±0.20 1.20 ± 0.25 2.10 ± 2.63 
PLlProt 0.16 
P vs. baseline >0.05 >0.05 >0.05 
J TM=Total mass (sum ofTG, TC, PL and protein) 
4.2.1.6.3 IDLfractional composition 
Table 4-50 IDL fractional composition 
IDL Baseline Cerivastatin Fenofibrate Combination ANOYA 
(Mean ± SO) 0.20 ± 0.06 0.21 ± 0.02 0.22 ± 0.05 0.19 ± 0.04 
ProtITM I 0.59 
P vs. baseli ne 
" 
>0.05 >0.05 >0.05 
(Mean ± SO) 0.23 ± 0.09 0.23 ± 0.05 0.18 ± 0.04 0.22 ± 0.05 
TGITM 0.19 
P vs. baseline >0.05 >0.05 >0.05 
Ii 
(Mean ± SO) 0.27 ± 0.05 0.25 ± 0.04 0.28 ± 0.02 0.27 ± 0.07 
TCITM 0.22 
P vs. baseline .0.05 >0.05 >0.05 
::i,!' 











IDL Baseline Cerivastatin Fenofibrate Combination ANOVA 
I 
P vs. baseline 
I: >0.05 >0.05 >0.05 
I' 'Pi 
(Mean ± SO) 0.27 ± 0.07 0.24 ± 0.05 0.27 ± 0.07 0.26 ± 0.08 
CE/TM 0.49 
P vs. baseline I, >0.05 >0.05 >0.05 
" 
.; 
(Mean ± SO) 0.18 ± 0.02 0.21 ± 0.03 0.21 ± 0.02 0.21 ± 0.04 
PLITM 0.01 
P vs. baseline .il >0.05 <0.05 >0.05 
.. 
(Mean ± SO) 0.40 ± 0.07 0.43 ± 0.06 0.43 ± 0.15 0.44 ± 0. 10 
FCITC 0.80 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.61± 0.13 0.52 ± 0.11 0.59 ± 0.22 0.59 ± 0.22 
FC/PL 0.52 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 1.39 ± 0.64 1.13 ± 0.49 1.57 ± 0.55 1.31 ±0.70 
CE/TG 0.33 
". >0.05 >0.05 >0.05 P vs. baseline 
! , 
(Mean ± SO) 1.42±0.41 1.18 ± 0.24 1.33 ± 0.22 1.57 ± 0.84 
TC/Prot 0.22 
P vs. baseline >0.05 >0.05 >0.05 
(Mean± SO) 1.27 ± 0.72 1.09 ± 0.30 0.87 ± 0.25 1.20 ± 0.29 
TG/Prot 0.17 
P vs. baseline >0.05 >0.05 >0.05 
(Mea n ± SO) 0.94 ± 0.23 0.97±0.10 0.99 ± 0.21 1.13 ± 0.46 
PLiProt 0.32 
P vs. baseline >0.05 >0.05 >0.05 











4.2.1. 6.4 LDL fractional composition 
Table 4-51 LDL fractional composition 
LDL Baseline Cerivastatin Fenofibrate Combination ANOYA 
(Mean ± SO) 0.29 ± 0.06 0.28 ± 0.03 0.28 ± 0.05 0.27 ± 0.04 
ProtlTM I 0.60 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.14 ±0.06 0.11 ± 0 .03 0.09 ± 0.03 I 0.12 ± 0.05 
TGITM I 0.04 
P vs. baseline >0.05 <0.05 >0.05 
, I. 
(Mean ± SO) 0.26 ± 0.07 0.28 ± 0.04 0.29 ± 0.03 0.28 ± 0.07 
TClTM 0.42 
P vs. baseline 
I~ >0.05 >0.05 >0.05 
~ ':: 
(Mean ± SO) 0.10 ± 0.02 0.10 ± 0.03 0.10 ± 0.02 0.11 ± 0.03 
FCITM 0.65 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.27 ± 0.10 0.30 ± 0.05 0.32 ± 0.06 0.29 ± 0.09 
CE/TM 0.38 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.20 ± 0.03 0.20 ± 0.03 0.20 ± 0.03 0.22 ± 0.06 
PLlTM 0.46 
P vs. baseline 
,. Ji >0.05 >0.05 >0.05 
(Mean ± SO) 0.39 ± 0.10 0.36 ± 0.08 0.34 ± 0.08 0.39 ± 0.11 
FCITC 0.44 
P vs. base line 
- j -ii' 
>0.05 >0.05 >0.05 
;". 
(Mean ± SO) 0.50 ± 0.14 0.53 ± 0.15 0.48 ± 0.07 0.55 ± 0.27 
FCIPL 0.74 
P vs. baseline 
,W! ,:fJj:~!l;; >0.05 >0.05 >0.05 











LDL Baseline Cerivaslalin Fenofibrate Combination ANOYA 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.97 ± 0.45 1.01 ±0.19 1.07 ± 0.22 1.12 ± 0.42 
TC/Prot 0.70 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.50 ± 0.21 0.40 ± 0.12 0.35 ± 0. 11 0.43 ± 0.13 
TG/Prot 0.046 
P vs. baseline >0.05 <0.05 >0.05 
(Mean ± SO) 0.72 ± 0.27 0.70 ± 0.08 0.74 ± 0.13 0.83 ± 0.28 
PUProt 0.48 
PI'S. baseline >0.05 >0.05 >0.05 
I TM=Total mass (sum ofTG, TC, PL and protein) 
4.2.1. 6.5 HDL fractional composition 
As plasma proteins contaminated the HDL fractions, only data showing relationships 
between lipid constituents of HDL will be displayed here. 
Table 4-52 HDL fractional composition 
HDL Baseline Cerivastatin Fenofibrate Combination ANOYA 
(Mean ± SO) 0.28 ± 0.07 0.27 ± 0.08 0.29 ± 0.06 0.26 ± 0.07 
FCITC 0.79 
P vs. baseline >0.05 >0.05 >0.05 
(Mean ± SO) 0.76 ± 0.44 0.73 ± 0.41 1.03 ± 0.64 0.86 ± 0.60 
FC/PL 0.43 












HDL Baseline Cerivastatin Fenofibrate Combination ANOV A 
(Mean ± SD) 1.02 ± 0.36 1.39 ± 0.57 1.79 ± 0.68 1.67 ± 0.56 
CE/TG /--__ .....,.,.,= 0.001 
I' vs. baseline >0.05 <0.01 <0.05 
4.2.1.7 Lipoprotein fractions: Summary statistics 
4.2.1. 7.1 Trig/ycerides 
Approximately 80% of the total decrease in TG in aU three treatment arms was 
accounted for by decreased TG content of VLDL 1 and VLDL2, the lipoprotein 
subclasses which carry most of the plasma TG. Fenofibrate (either as monotherapy or 
as part of combination therapy) was more effective in reducing TG mass in the TGRL 
with an average reduction of 60-75% in VLDL 1 +VLDL2 TG compared to the 40% 
reduction with cerivastatin alone. Combination therapy was not significantly more 
effective in reducing TGRL TG content than fenofibrate monotherapy. IDL TG 
content was reduced by 34-45%; the reduction of 34% seen with fenofibrate was not 
statistically significant. LDL TG mass was reduced to a very similar degree (41-44%) 
by aU therapies. Although the reductions in triglyceride mass of IDL and LDL were 
mostly statistically significant (except the change in IDL triglyceride mass with 
fenofibrate) the contribution to overall triglyceride reduction was about 10% for 
cerivastatin and 5% for fenofibrate and combination therapy. More than 90% of 











In IJ'VC'-'''J,' with the and 
combination therapy being 94%, 
Table 4.53 and table 4.54 show the absolute and relative mean reduction 
in TG in and the apoB-containing lipoprotein fractions in the treatment arms 
of the study. 
Table 4-53 Absolute mean reduction in TG (in mmollL) from baseline 
I Fraction Cerivastatin F enofibrate Cer + Feno 
(mmoIlL) (mmoIlL) (mmoI/L) 
. Plasma 2.84 4.73 4.85 
VLDLl 1.74 3.36 3.30 
VLDL2 0.56 0.87 1.02 
IDL 0.] 5 0.12 0.16 
LDL 0,12 0.11 0.11 
Table 4-54 Mean percentage reduc ion in TG from baseline within lipoprotein fractions 
fntCllun Cerivastatin (%) Fenofibrate (%) Cer + Feno (%) 
[plasma 41.46 69.05 ~g.8 
IVLDLl 39.55 176.36 175 
IVLDL2 39.44 61.27 71.83 
lDL ~2.86 34.29 ~5.71 
ILDL ~4.44 ~0.74 ~0.74 
Table 4.55 illustrates the contribution of each lipoprotein fraction to triglyceride 











Table 4-55 Percentage of reduction in total TG accounted for by each lipoprotein fraction 
!Fraction Cerivastatin (%) IF'enofibrate (%) Cer + Feno (%) 
rvLDLl 61.27 71.04 68.04 
rvLDL2 19.72 18.39 21.03 
DL ~.28 ~.54 3.30 
tLDL 4.23 ~.33 2.27 
Sum of% reduction 90.49 94.29 94.64 
4.2.1.7.1.1 Changes in triglyceride according to apoE genotype 
Patients with the apoE (R145C) mutation had higher median TG at baseline than 
apoE2 homozygotes (7.85 vs. 4.06 mmol/L for apoE (R145C) vs. apoE2/E2), 
although the difference did not reach statistical significance (P=0.21 by unpaired t-test 
following logarithmic transformation). The small number of subjects in the apoE 
(RI45C) group limits the statistical power of any analysis. In these more 
hypertriglyceridaemic patients, reductions in VLDLl TG accounted for most of the 
observed TG reduction with less TG mass reduction attributable to denser lipoprotein 
fractions. 
Table 4-56 Absolute mean reduction in TG (in mmollL) from baseline by apoE genotype 
Fraction Cerivastatin Fenofibrate Cer+ Feno 
ApoE2/E2 ApoE2/E2 ApoE2/E2 
Plasma 2.55 4.29 8.20 4.25 8.31 
VLDLl 1.20 2.64 7.24 2.36 
VLDL2 0.75 1.07 0.65 1.22 
IDL 0.18 0.14 0.05 0.20 












Table 4-57 Mean percentage reduction in TG from baseline within lipoprotein fractions by apoE 
genotype 
Fraction Cerivastatin (%) Fenofibrate (%) Cer + Feno (%) 
ApoE2/E2 ApoE ApoE2/E2 ApoE ApoE2/E2 ApoE 
(R145C) (R145C) (R145C) 
Plasma 39.67 54.47 66.71 78.94 66.20 79.93 
VLDLl 32.03 59.77 70.79 88.11 63.28 88.16 
VLDL2 46.24 31.57 66.22 49.09 75.34 63.48 
lDL 46.89 16.04 38.16 18.78 51.91 20.00 
LDL 46.60 39.63 41.93 34.56 56.02 24.07 
Table 4-58 Percentage of reduction in total TG accounted for by each lipoprotein fraction by 
apoE genotype 
Fraction Cerivastatin (%) Fenofibrate (%) Cer + Feno (%) 
ApoE2/E2 ApoE ApoE2/E2 ApoE ApoE2/E2 ApoE 
(R145C) (R145C) (RI45C) 
VLDLl 46.86 86.75 ! 61.56 88.29 55.55 87.24 
VLDL2 29.43 7.42 25.05 7.93 28.77 10.11 
lDL 6.93 0.71 3.35 0.61 4.60 0.60 
LDL 4.19 1.94 2.24 1.10 3.02 0.84 
Sumof% 87.41 96.82 92.21 97.93 91.95 98.80 
4.2.1. 7.2 Total cholesterol 
Plasma TC decreased 39%-57% from baseline with treatment. The decrease was 
greatest with combination therapy, followed by fenofibrate and cerivastatin. Most of 
the reduction in plasma TC was accounted for by changes in the cholesterol content of 
VLDLl and VLDL2. Differences did, however, emerge between the treatment 
allocations. With fenofibrate monotherapy approximately 90% of the total reduction 
<, 
in plasma TC was explained by changes in VLDLl and VLDL2. With cerivasta'tin 











decrease of the cholesterol content of VLDLl and VLDL2. The most striking 
difference was observed in the VLDLl fraction where fenofibrate (as monotherapy or 
as combination therapy) decreased cholesterol 83-86%, compared to the 54% 
reduction observed with cerivastatin. Fenofibrate was less effective in reducing IDL 
and LDL cholesterol than therapies containing cerivastatin. IDL cholesterol decreased 
by 18% with fenofibrate while therapies containing cerivastatin resulted in a 42-50% 
decrease. For LDL cholesterol the reduction with fenofibrate was less than 5%, while 
cerivastatin containing therapies achieved a 22-33% reduction. Overall 93-95% of the 
reduction in plasma cholesterol was explained by changes in apoB containing 
lipoproteins. 
Table 4-59 Absolute mean reduction in TC (in mmollL) from baseline 
!Fraction Cerivastatin (mmoVL) IFenofibrate (mmoVL) Cer + Feno (mmollL) 
IPlasma 3.51 ~.06 5.11 
~LDLl 1.57 ~.42 ~.50 
~LDL2 0.77 1.20 1.56 
~DL 0.49 0.18 0.41 
ILDL 0.42 ~.06 0.28 
Table 4-60 Mean percentage reduction in TC from baseline within lipoprotein fractions 
!Fraction Cerivastatin (%) iFenofibrate (%) Cer + Feno (%) 
IPlasma 39.24 ~5.34 57.17 
~LDLl 54.33 83.74 86.51 
\TLDL2 36.84 57.42 74.64 
DL ~O.52 18.56 42.27 











Table 4-61 Percentage of reduction in total TC accounted for by each lipoprotein fraction 
[Fraction !Cerivastatin (%) iFenofibrate (%) Cer + Feno (%) 
~LDLl ~ 
59.66 ~8.89 
iVLDL2 /29.59 30.50 
mL 13.96 14.44 8.02 
fL'DL 11.97 1.48 5.48 
Sumof% 92.59 95.17 92.88 
4.2.1.7.2.1 Changes in total cholesterol according to apoE genotype 
In the genotype positive patients plasma cholesterol was reduced 38-64% with 
therapy. The greatest reduction in plasma cholesterol was achieved in the apoE2/E2 
patients with combination therapy (64%), while the lowest reduction was 38% in the 
apoE (RI45C) mutation carriers with fenofibrate monotherapy. Comparing the two 
genotypes the response to therapy of TC in the denser fractions IDL and LDL 
differed. In apoE2/E2 patients taking cerivastatin-containing regimes there was a 
reduction of 33-50% in TC within lDL and LDL TC, while fenofibrate reduced the 
values by28% and 12% respectively. In the apoE (R145C) mutation carriers with 
cerivastatin monotherapy there was a reduction of 9-12% in IDL and LDL TC, while 
combination therapy hardly changed IDL (reduced by 1%) and LDL TC increased by 
52%. Fenofibrate monotherapy in the apoE (RI45C) mutation carriers increased lDL 
and LDL TC 77% and 85% respectively. Correspondingly in the apoE (RI45C) group 
the reductions in VLDLl and VLDL2 total cholesterol were more than 100% of the 











Table 4-62 Absolute mean reduction in TC (in mmollL) from baseline by apoE genotype 
Fraction Cerivastatin (mmoVL) Fenofibrate (mmoVL) Cer + Feno (mmoI/L) 
ApoE2/E2 ApoE ApoE2/E2 ApoE ApoE2/E2 ApoE 
(R145C) (R145C) (R145C) 
Plasma 3.85 3.40 4.76 3.10 6.07 4.15 
VLDLl 1.57 2.55 2.43 3.65 2.46 3.80 
VLDL2 0.98 0.33 1.55 0.51 1.95 0.85 
IDL 0.56 0.04 0.31 -0.34 I 0.52 0.01 
LDL 0.30 0.12 0.12 -0.85 J 0.38 -0.52 J 
I Minus sign indicates that the absolute mass increased from baseline with treatment 
Table 4-63 Mean percentage reduction in TC from baseline within lipoprotein fractions by apoE 
genotype 
Fraction Cerivastatin (%) Fenofibrate (%) Cer + Feno (%) 
ApoE2/E2 ApoE ApoE2/E2 ApoE ApoE2/E2 ApoE 
(RI45C) (RI45C) (RI45C) 
Plasma 40.32 41.15 49.85 37.59 63.60 50.29 
VLDL1 52.52 62.10 81.68 89.13 82.44 92.77 
VLDL2 36.58 23.96 57.58 36.78 72.35 61.33 
IDL 50.89 9.70 28.23 -76.98 J 47.24 1.14 
LDL 33.25 12.13 12.64 -85.10 I 41.80 -52.00 J 












Table 4-64 Percentage of reduction in TC accounted for by each lipoprotein fraction by apoE 
genotype 
Fraction Cerivastatin (%) Fenofibrate (%) Cer + Feno(%) 
ApoE2/E2 ApoE ApoE2/E2 ApoE ApoE2/E2 ApoE 
(R145C) (RI45C) (R145C) 
VLDLI 40.65 74.88 51.14 117.88 40.47 91.65 
VLDL2 25.56 9.79 32.54 16.49 32.06 20.54 
IDL 14.67 1.26 6.58 -10.93 I 8.64 0.12 
LDL 7.86 3.57 2.42 -27.45 I 6.27 -i2.53 I 
Sumof% 88.74 89.50 92.68 96.00 87.44 99.78 
I Minus sign indicates that the TC increased from baseline 
4.2.1. 7.3 Free cholesterol and cholesterol ester 
Both FC and CE levels decreased from baseline with treatment. The percentage 
change of plasma FC was greater than that of CE for all therapies. The percentage 
reduction in plasma FC was greatest for combination therapy, followed by fenofibrate 
and cerivastatin. 
FC and CE were reduced by approximately equivalent percentages within VLDLl, 
although the reductions were much higher for fenofibrate and combination therapy. In 
VLDL2 FC was reduced more than CE, except for combination therapy where the 
reductions were very similar. In IDL CE was reduced more than free cholesterol. In 
LDL FC and CE were reduced by similar percentages with cerivastatin containing 


















Table 4-66 Mean percentage reduction in FC and CE from baseline within lipoprotein fractions 
Fraction Cerivastatin (%) Fenofibrate (%) Cer + Feno (%) 
FC CE FC CE FC CE 
Plasma ~8.53 30.02 57.11 33.77 66.37 ~8.12 
VLDLl 53.23 55.34 82.80 85.44 85.48 88.35 
VLDL2 45.45 30.00 63.64 52.73 74.75 73.64 
IDL 47.37 53.45 13.16 ~2.41 39.47 ~6.55 
L-DL 34.09 32.93 13.64 p.OO 22.73 21.95 
Table 4-67 Percentage of reduction in FC and CE accounted for by each lipoprotein fraction 
Fraction Cerivastatin (%) F enofibrate (%) Cer + Feno (%) 
FC CE FC CE FC CE 
VLDLl 28.21 16.24 37.93 ~1.67 31.12 17.81 
rvLDL2 12.82 9.40 15.52 14.29 14.48 15.85 
IIDL 5.13 8.83 1.23 3.20 2.94 5.28 
~DL 14.27 7.69 1.48 0.00 1.96 3.52 
Sum % 50.43 ~2.17 56.16 39.16 ~0.49 42.47 












In the apoE (R145C) mutation carriers FC rcduction in apoB-containing lipoproteins 
explained 74-96% of the total reduction observed in plasma cholesterol. In the 
apoE2/E2 group the corresponding figures for free cholesterol are 43-50%. In the 
apoE (R145C) mutation carriers increases in IDL and LDL CE were more important 
in accounting for the changed TC within these fractions than changes in FC. 
TabJe 4-68 AbsoJute mean reduction in FC and CE (in mmoJ/L) from baseline within lipoprotein 
fractions by apoE genotype 
Fraction 
J Minus sign indicates that the FC or CE increased from baseline 
TabJe 4-69 Mean percentage reduction in FC and CE from baseline within lipoprotein fractions 
by apoE genotype 
Fraction Cerivastatin (%) Fenofibrate (%) Cer + Feno (%) 
ApoE2/E2 ApoE (R145C) ApoE2/E2 ApoE (RI45C) ApoE21E2 ApoE (R145C) 
FC CE FC CE FC CE FC CE FC CE FC CE 
Plasma 45.84 35.12 60.21 6.34 58.81 41.44 61.68 -8.29 70.48 57.15 66.78 20.17 
VLDLl 47.08 60.11 68.63 38.26 78.56 86.01 90.57 83.86 79.23 86.93 92.83 92.61 
VLDL2 47.29 ~"" 
65.10 55.11 50.24 22.16 76.20 74.22 64.43 57.57 
IDL 47.32 5 7.60 28.75 26.88 -57.78 -97.48 44.09 48.82 -7.50 3.60 
LDL 30.59 3 23.53 6.87 20.65 7.93 -63.22 -95.29 36.06 45.33 -26.41 -63.82 












Table 4-70 Percentage of reduction in FC and CE accounted for by eacb lipoprotein fraction by 
apoE genotype 
Fraction Cer+ Feno % 
ApoE2!E2 ApoE 
R145C) 
FC CE FC CE 
28.55 22.59 94.07 23.81 19.64 
16.82 15.75 11.35 4.86 15.44 9.43 
3.20 0.22 
2.02 4.26 ·2.04 ·10.46 
43.24 44.10 80.53 18.83 
I Minus sign indicates that the FC or CE increased from baseline 
4.2.1.7.4 Phospholipid 
Plasma phospholipid concentration decreased significantly from baseline in all three 
treatment arms. The decrease was greatest with combination therapy, followed by 
fenofibrate and cerivastatin. There were no statistically significant differences 
between the decreases achieved with the various therapeutic regimens. The decrease 
in plasma phospholipid was mainly accounted for by the decreased phospholipid mass 
in TGRL. Reduced phospholipid in TGRL accounted for 77% of the decrease with 
cerivastatin, 87% with cerivastatinlfenofibrate and 100% with fenofibrate. The 
proportional reduction in phospholipid was greatest in VLDLl, and fenofibrate-
containing therapy was significantly more effective here, achieving a decrease of 
81 %, compared to the 52 % seen with cerivastatin. In IDL and LDL only cerivastatin 
significantly decreased phospholipid 











FractionlCerivastatin (mmol/L) Fenofibrate (mmol/L) Cer + Feno (mmoUL) 
Plasma 1.53 1.70 2.15 
VLDLl ~.81 1.26 1.27 
VLDL2 0.37 0.51 0.61 
DL 0.11 0.01 0.10 
L.DL 0.15 0.05 0.06 
Table 4-72 Mean percentage reduction in PL from baseline within lipoprotein fractions 
Fraction Cerivastatin (%) Fenofibrate (%) Cer + Feno (%) 
Plasma ~3.l9 36.88 46.64 
VLDLl 51.92 80.77 81.41 
IVLDL2 ~3.53 60.00 71.76 
DL ~5.48 3.23 32.26 
fLDL ~3.33 11.11 13.33 
Table 4-73 Percentage of reduction in PL accounted for by each lipoprotein fraction 
iFraction lCerivastatin (%) Fenofibrate (%) Cer+ Feno (%) 
IVLDLl ~2.94 74.12 59.07 
~ 
~4.18 30.00 28.37 
~.19 0.59 ~.65 
fLDL ~.80 ~.94 2.79 
Sumof% 94.12 107.65 94.88 
4.2.1.7.4.1 Changes in phospholipid according to apoE genotype 
In the genotype positive patients similar decreases in plasma PL concentration were 
seen compared to the total patient group. Comparing the two genotypes studied here, 
differences were noted in the phospholipid mass of the denser lipoproteins IDL and 











fenofibrate monotherapy and 37-50% with cerivastatin-containing therapy. These 
decreases accounted for approximately 6% (with fenofibrate) and 14-17% (with 
cerivastatin containing therapy) of total PL decreases. In the apoE (R145C) mutation 
carriers IDL and LDL phospholipid increased 34-86% with fenofibrate and 
combination therapy. Cerivastatin caused a minor increase (5%) in IDL phospholipid, 
but phospholipid in LDL fell by 13%. The changes in PL paralleled those observed 
for the behaviour of TC. 
Table 4-74 Absolute mean reduction in PL (in mmollL) from baseline by apoE genotype 
Fraction Cerivastatin (mmoVL) Fenofibrate (mmollL) Cer + Feno (mmoVL) 
ApoE2/E2 ApoE ApoE2/E2 ApoE ApoE2/E2 ApoE 
(R145C) (R145C) (R145C) 
Plasma 1.57 1.89 1.89 2.10 2.49 2.24 
VLDLl 0.73 1.63 1.16 2.24 1.14 2.26 
VLDL2 0.52 0.16 0.68 0.25 0.81 0.31 
IDL 0.13 -0.01 I 0.05 -0.11 I 0.17 -0.06 I 
LDL 0.14 0.06 0.06 -0.15 I 0.18 -0.38 I 
I Minus sign indicates that the PL mass increased from baseline 
Table 4-75 Mean percentage reduction in TC from baseline within lipoprotein fractions by apoE 
genotype 
Fraction Cerivastatin (%) Fenofibrate (%) Cer + Feno (%) 
ApoE2/E2 ApoE ApoE2/E2 ApoE ApoE2/E2 ApoE 
(R145C) (R145C) (R145C) 
Plasma 32.84 38.42 39.42 42.58 51.94 45.35 
VLDLl 48.97 64.04 78.13 87.97 76.46 88.67 
VLDL2 49.33 26.84 64.48 41.48 77.20 51.31 
IDL 37.26 -5.26 I 14.14 -60.05 I 48.29 -32.11 I 
LDL 39.69 13.64 15.89 -34.32 I 50.33 -86.48 I 











Table 4-76 Percentage of reduction in PL accounted for by each lipoprotein fraction by apoE 
genotype 
Fraction Cerivastatin (%) Fenofibrate (%) Cer + Feno (%) 
ApoE2/E2 ApoE ApoE2/E2 ApoE ApoE2/E2 ApoE 
(RI4SC) (RI45C) (R145C) 
VLDLl 46.47 86.40 61.60 106.82 45.75 100.94 
VLDL2 32.99 8.66 35.82 12.05 32.55 13.97 
lDL 8.31 -0.53 2.62 -S.43 1 6.79 -2.72 I 
LDL 9.10 3.17 3.03 -7.19 ] 7.28 -16.99 I 
Sumof% 96.87 97.71 103.06 106.25 92.37 95.20 
I Minus sign indicates that the PL increased from baseline 
4.2.1.8 Lipoprotein fractions: Graphical representation 
4.2.1.8.1 Lipoprotein fractions: absolute masses 
These graphs show the absolute mass of the lipid component of each lipoprotein 
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Figure 4-54 LDL lipids 
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4.2.1.8.2 LipoproteinJractions: relative masses 
These graphs show the relative contribution of protein and each lipid component to 
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Figure 4-60 All apoB containing lipoproteins- relative masses 
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4.2.1.9 Previously published data on changes in lipoprotein fractions 
with lipid-lowering therapy in dysbetalipoproteinaemic 
patients 
Most studies evaluating lipid-lowering therapy for patients with 
dysbetalipoproteinaemia report limited data on ultracentrifugal analysis of lipoprotein 
fractions. The most commonly reported data is uitracentrifugally derived VLDLC and 
LDLC, while only a few studies report detailed data on lipoprotein composition. 
Ultracentrifugal techniques also vary between studies. In many studies IDLC is 
included in the uitracentrifugally derived LDLC fraction. 
4.2.1.9.1 VLDL 
Most studies do not subdivide VLDL into VLDLl and VLDL2, but report on VLDL 
as a single fraction . Table 4 .77 illustrates changes in VLDL previously reported in 
response to lipid-lowering therapy. For more details on individual studies please refer 











Table 4-77 VLDL response to in studies 
Baseline 
% Reduction 5 
Author Year Drug VLDL isolation (mmoI/L) Comments 1 Ref 
TC TC TG 
19841 NA3g .006 4.25 3.60 54 147 
1984 I CLO 2g .006 4.25 3.60 49 45 
.006 3.03 2.94 +32 +53 
SS D<I.006 3.03 2.94 51 55 
SS D<1.006 3.03 
Stuyt 1985 SS D<1.006 4.76 












% Reduction 5 
Author Year Drug I VLDL isolation 2 (mmollL) Comments Ref 
TC j TG 4 TC TG 
Packard 1986 BEZ 600mg SUC 6.52 75 (307) 
East 1986 MEV 40mg NS 6.64 3.86 73 56 4 (304) 
Kuo 1988 GEM 1.2g SS D< 1.006 3.94 3.98 45 65 2 (309) 
Vega 1988 LOV 40mg SS D<1.006 7.52 45 (313) 
Lussier-Cacan 1989 FEN 300mg SS D< I .006 5.36 4.80 70 65 (308) 
Illingworth i990 LOV 40mg SS D< 1.006 7.79 53 (316) 
lllingworth 1990 CL02g SS D<I.006 7.79 61 (316) 
Dallongeville 1991 OM36g SUC 4.90 5.77 54 62 (326) 
Feussner 1992 SIM 20mg SS D<1.006 8.95 45 (318) 






















1994 GEM 1.2g 
1995 LOV 
1999 SIM 















TC TC TG 
16.29 79 
6.57 4.66 72 70 3 
3.7 3.8 54 50 
1.60 2.01 20 9 5 
2.02 2.05 50 53 5 
4.24 4.08 59 46 




















Sf M Simvastatin 
2 Refers to the method which VLDL was isolated 
SS 0<1.006 ultracentrifugation with isolation less dense than 1.006 
suc 
DG 











4 VLDL TG at U=I;HHI; 
5 from baseline values (+ indicates an increase 
I. The included a period the two arms, therefore the UQO."u.u"" 
2. study of two of 
3. VLDLC and VLDL TG calculated as the sum of 
4. method not stated in article. 
treatment mterruDtell bv a 
in VLDU and VLDL2 
S. The study specified a washout between each treatment arm. 











The reported reductions in VLDLC with lipid-lowering therapy differ widely, ranging 
from a low of 20% with simvastatin therapy in a group of patients with autosomal 
dominantly inherited dysbetalipoproteinaemia and low levels of VLDLC at baseline 
(322), to reductions of more than 70% with both fibrates (321) and statins (315). The 
observed reductions in VLDLC (taken as the sum of VLDLI and VLDL2) of 48%, 
73% and 80% for cerivastatin, fenofibrate and combination therapy respectively in the 
Bayer study fall well within the previously reported range. In the two studies directly 
comparing statin and fibrate treatment (238;316) fibrates consistently produce greater 
reductions in VLDLC than statins. In the Bayer study the same discrepancy in 
VLDLC response was observed when fenofibrate was given. 
Lipid-lowering therapy in dysbetalipoproteinaemia is generally associated with 
marked reductions in VLDL TO mass, except for colestipol which raised VLDL TO 
markedly (305). In head to head comparisons of statins and fibrates (238;316) fibrates 
reduce VLDL TO more effectively than statins. In this study a similar response was 
observed, with VLDL TO reductions of 40%, 73% and 74 % respectively for statin, 
fibrate and combination therapy. 
4.2.1.9.2 IDL 
The majority of published studies do not specifically report changes in lDL lipids, but 











Table 4-781DL response to in previous studies 
I Baseline values Reduction' 
Author I Year I Drug I I IDL isolation 2 I Comments Ref 
TC 3 TG 4 TC TG 
Lussier-Cacan I 1989 FEN ISUC I 1.42 033 40 44 (308) 




GEM 1 DG 2.47 0.70 34 51 
-
ng DG 0.9 0.2 33 50 
Civeira 1999 SIM SUC 0.67 0.19 41 15 
Civeira 1999 GEM 1.2g SUC 0.74 0.21 35 25 
van Dam 2002 ATR DG 1.80 0.59 51 46 

















OM3 Omega-3 fatty acids 
Sf M Simvastatin 
2 Refers to the method by which lDL was isolated 
SUC Sequential ultracentrifugation 
DG density gradient ultracentrifugation 
3 IDL TC at baseline 
4 lDL TG at baseline 
5 Reduction (in %) from baseline values 
Comments 











While fibrates were more effective than statins in VLDL lipids this finding 
does not hold true for denser fractions. Civeira (238) found that 
simvastatin reduced IDL TC more than gemfibrozil, while reduced the 
TG mass within IDL more than simvastatin. In the Bayer study cerivastatin was as 
effective as other statins in IDL TC and TG. Fenofibrate was less effective at 
reducing IDL TC than one would have expected reviewing the published 
literature. Tbe reduction in IDL TC was 51 18% and 43 % for 
fenofibrate and combination therapy respectively. IDL TG was reduced by 44%, 37% 
and 47 % respectively. 
4.2.1.9.3 LDL 
Most studies report changes in although the methods used to determine LDLC 
vary. None of the uses the Friedewald equation to calculate LDLC, 
which would clearly have been inappropriate. Most studies used the Lipid 
Clinics protocol to measure LDLC This protocol specifies removal of VLDL 
by ultracenttifugation (d<1.006 giml) and precipitation of containing 
lipoproteins. HDLC is measured in the supernatant and LDLC calculated by 
subtraction of VLDLC and HDLC from the plasma TC. As this technique only 
removes VLDL and not IDL before precipitation HDL the LDLC derived in this 
fashion does include IDLC. As can be seen from table 4.78 IDLC may be as high as 
1.0-2.0 mmoliL in patients with dysbetalipoproteinaemia. 
Table 4.79 shows LDLC responses to 
studies. 











Table 4-79 LDL response to d-Iowerim. in reviouslv published studies of 
~~- ~~~ ~~~ ~~ ~ 
LDLC Baselme values 
% .R pnllf'Jion 5 
Author Year I ..1~ (mmollL) Comments Ref UvlvlUl1 
f-
TC J TG 4 TC TG 
HOOg'wvlf 1984 NA3g LRC 3.86 11 (302) 
-~ 
~ ~ ~ ~~~ ~ ~ 
..c 1984 CL02g LRC 3.86 2 '"'' 
Hoo~l"d 1985 COL 20g LRC 3.78 32 (305) 
Hoog'wvlf 1985 CL02g LRC 3.78 +6 (305) 
-~ ~~-~ 
~I" 1985 C+C LRC 3.78 15 (305) ,W,,' , 
~~~- ~~~~~-















LDLC Baseline values 
% Reduction 
Year I detennination Comments Ref 
2 TC j TO" TC 
TO ......... 
Packard 1986 BEZ SUC 3.46 19 (307) 
...... - r--......... 
East 1986 MEV NS 2.9 25 (304) 
40mg 
.... - ------ --:-
1988 OEM 1.2g LRC 4.95 41 (309) 
Vega 1988 LOV40 LRC 2.31 40 (313) 
Lussier- 1989 FEN SUC 1.66 +25 (308) 
Cacan 300mg 
------ f---
Illingworth 1990 LOV40 LRC 3.6 32 (316) 











LDLC Baseline values 
% Reduction 5 
Author Year Drug I determination (mmoIlL) Comments Ref 
2 TC j TG 4 TC TG 
Dallongeville 1991 OM36g LRC(M) 1.92 +20 (326) 
Feussner 1992 SIM 20mg LRC 3.54 36 (318) 
Larsen 1994 GEM 1.2g LRC 3.57 22 (321) 
Larsen 1994 CL02g LRC 3.57 12 (321) 
Zhao 1994 GEM 1.2g DG 1.87 0.41 0 49 (306) 
Gylling 1995 LOY DG 1.5 0.2 20 0 (317) 
40mg 
Civeira 1999 SIM 20mg SUC 4.53 30 I (238) 
Civeira 1999 GEM l.2g SUC 4.48 2 I (238) 











LDLC Baseline values 
% 5 
Year I determination (mmol/L) Comments Ref 
2 TC- TG 4 TC TG 






















NA Nicotinic acid 
OM3 Omega-3 fatly acids 
SIM Simvastatin 
2 Refers to the method by which LDLC was measured 
LRC Lipid research clinic protocol (IDL included with LDL fraction) 
LRC (M) A modified protocol including ultracentrifugation at d= 1.0 1991mL to remove IDL 
SUC Sequential ultracentrifugation 
DG density gradient ultracentrifugation 
3 LDLC at baseline 
4 LDL TG at baseline 
5 Reduction (in %) from baseline values 
Comments 











On review of the LDLC levels it is obvious that studies 
LDLC the LRC methodology generally higher LDLC levels than those 
that exclude IDLe. In the former LDLC levels 
approximate 3.5 mmolfL, while the latter LDLC of less than 2.0 mmollL in 
most instances. The notable is the paper by Civeira and 
that reoorts a baseline LDLC of almost 4.5 mmollL. As previously discussed the 
in this study are atypical in many ¥O"""" 
As seen from the table above LDLC may fall or remain unchanged with 
therapy. LD LC 
which was also 
decreases more with statins than fibrates 
(238;3] in the study. In this study 
fenofibrate and combination therapy lowered LDLC by 34%, 6% and 23% 
The effect of fibrate therapy on LDLC may be very dependant on the 
baseline characteristics of the entered into the study, as patients with high 
baseline TG levels are more to to therapy with LDLC 
increases. 
few report on changes in LDL TG mass, but all studies except Gylling et 
af (31 find decreased LDL TG with lipid-lowering The decreases of 
41 % and 44% observed with and combination therapy in the 












There have been significant changes in the methodology used to measure HDLC over 
the last few decades (257). The CDC recommended reference method involves 
removal of TGRL by ultracentrifugation followed by precipitation of apoB-containing 
lipoproteins and measurement of cholesterol in the supernatant (330). Early 
precipitation based assays on whole plasma are subject to significant interference 
from elevated TG, which often preclude complete precipitation of aggregated apoB-
containing lipoproteins and lead to falsely elevated HOLC levels. Newer generation 
homogenous HOLC assays are said to be free of interference by TG (331), except if 
present in extremely high concentrations. This, however, does not apply to patients 
with dysbetalipoproteinaemia where newer methods may give either falsely low (332) 
or falsely high results (333). Measurement of HOLC in dysbetalipoproteinaemic 
patients is therefore problematic and this is especially so if they are severely 
hypertriglyceridaemic. 
The HOLC responses to lipid-lowering therapy repOited in tables 4.8-4.11 are highly 
variable, ranging from modest decreases to increases as high as 54% (309). The 
majority of studies do, however, report more modest changes in HOLe. In the Bayer 
study the ultracentrifugally derived HOLC decreased 4 % with cerivastatin while 
increasing 13% with fenofibrate and 6% with combination therapy. These responses 
are within the lower range of what has been previously reported in the literature. 
Only Ishigami el 01 (315) report on changes in HOL TG in a study of apoE2 
homozygotes treated with atorvastatin 20mg. HOL TG mass decreased by 26% and 
36% in HOL2 and HOL3 respectively. This is comparable to the 29% reduction in 











4.2.1.9.5 Studies that report changes in compositional analysis of lipoprotein 
fractions 
few of the trials listed in tables 4.8-4.11 report detailed information on changes 
In compositional of treatment of 
dysbetalipoproteinaemia. lshigami et al (315) lipid masses within each 
lipoprotein fraction, but do not protein levels within fractions 
making it impossible to calculate composition. Lussier-Cacan ef af 
data for nine dvsbetaliDoDroteinaemic patients treated 
with fenofibrate. Zhao et al compositional data in two studies. The first study 
(306) reports eight patients homozygous for apoE2 treated with while the 
second study (323) the of simvastatin treatment in nine patients with a 
variety mutations. 
4.2.1.9.5.1 VLDL composition 
Two studies report on VLDL compositional changes in patients taking fibrates. Zhao 
et af (306) that significantly decreased PL relative mass in VLDL I 
(Baseline: 14.2 ±1.4; Therapy: 11.9 ± and CE relative mass in VLDL 2 (Baseline: 
32.3±41, 27.0 ± 4.0). The relative content ofVLDL2 increased 
significantly (Baseline: 9.5 ± 1.0; 12.4 ± I No other changes 
were observed in the composition of either VLDI 1 or VLDL2. In contradistinction 
Lussier-Cacan el al (308) analyzed VLDL as a fraction and found 











Table 4-80 VLDL composition as found by Lussier-Cacan et at 
Parameter Baseline I 
FCITM j 8.2 ± 1.2 
CE/TM 32.7 ± 9.4 
TGITM 35.1 ± 9.6 
PLITM 17.5± 1.2 
PR 4/TM 6.5 ± 1.9 
CE/TG 1.09 ±0.66 
CE/PR 5.83 ± 3.34 
I Mean ± SD 
2 P by unpaired t-test 
3 Total mass 
4 Protein 
Fenofibrate I pL 
6.8 ± 1.0 <0.02 
19.4 ± 2.5 <0.005 
47.5 ± 2.2 <0.01 
16.1 ± 0.8 <0.025 
10.2 ± 1.5 <0.001 
0.41 ± 0.06 <0.02 
1.95 ± 0.45 <0.01 
Evaluating simvastatin treatment Zhao et al found that the relative TG mass in 
VLDL2 increased significantly in apoE2 homozygotes (Baseline : 29.6 ± 2.3; Therapy: 
39.6 ± 4.3). No other significant changes were found in VLDLI or VLDL2. The 
statistical power of this study is, however, limited as the authors analyzed patients 












In the therapy was associated with In 
the composition of VLDLl, while VLDL2 composition remained virtually 
unchanged. The in VLDL 1 composition were for the most HllV~VU:> to 
those observed by Zhao and Lussier-Cacan. In particular we also observed significant 
reductions in FC and CE relative mass in VLDLl as well as a reduction in the CE/TG 
ratio. Although many other of the changes in compositional indices in our study did 
not reach statistical we observed simi lar to those 
by namely an increase in the relative TG mass and a 
reduction in PL content 
4.2.1.9.5.2 IDL 
Zhao (306) found no significant 
while Lussier-Cacan (308) found 
in lDL composition with gemfibrozil therapy 
decreased CE 
44.1 ± Therapy: 33.0 ± and increased TG relative mass (Baseline: 14.8 ± 5A; 
Therapy: 4.8). Simvastatin did not 
genotypes studied by Zhao et al in 
IDL composition were not discernible either with fibrate or statin treatment. 
4.2.1.9.5.3 LDL 
Zhao (306) reports decreased relative TG mass in LDL with gemfibrozil therapy 
(Baseline 11.1 2.1; Therapy 8.0 ± I while Lussier-Cacan found PL 
content with fenofibrate 17.1 ± 1.3: Therapy: 20.0 ± 1.8). Simvastatin was 











In the Bayer study there was a significant decrease in relative TG mass but no change 
in the relative PL mass. 
4.2.1.9.5.4 HDL 
There are no reports in the published literature of HDL compositional changes with 
lipid-lowering therapy in dysbetalipoproteinaemic subjects and comparisons with 
previously published data are therefore not possible. 
4.2.1.10 Agarose gel electrophoresis 
All patients had agarose gel electrophoresis at baseline and at completion of each 
treatment arm. Plasma and aliquots of the lipoprotein fractions obtained by sequential 
ultracentrifugation was electrophoresed. Agarose gel electrophoresis was done within 
72 hours of venesection. All plasma and ultracentrifugal samples were kept 
refrigerated until electrophoresis was performed. Gels were reported on in the 
conventional fashion and then also scanned for densitometric analysis. Optical density 











Figure 4-61 Agarose gel (plasma) 
D Chyl omicrons :W.\31l 
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Pre-j3 band Broad (l-band 
Illustrated below are two representative agarose gels of plasma and lipoprotein 











Figure 4-62 Agarose gel of plasma and lipoprotein fractions (patient JJV) 
LDL IDL VLDL2 VLDL 1 Plasma 
Gel31 
Figure 4-63 Densitometric scans of plasma and lipoprotein fractions (Pat JJV) 
The 00 scans are those of figure 4.62 . The patient is a male apoE2 homozygote. The 
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Figure 4-66 VLDL migration relative to LDL (Pat JJV) 
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Figure 4-67 Agarose electrophoresis of plasma and lipoprotein fractions (Pat FCC) 











Figure 4-68 Densitometric scans of plasma and lipoprotein fractions (Pat 
The OD scans are those 4.69. patient is male and has no ui".nt"h".,-I 
mutation. The was taken in the untreated state following 
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From the above graphs it is clear that the VLDLl fractions of patients show 











VLDLI in the two examples listed above. The graph has been normalized with the 
LDL peak of each patient set at a migration distance of 1 cm. 










Migration relative to LDL 
Pat FCC VLDL 1 
Pat JJV VLDL 1 
VLDLI migration did not onl  differ by migration distance, but four patterns of 
VLDLI migration defined by the number, location and morphology of peaks seen on 
optical density scanning were identified. 
VLDLI migration patterns: 
I. Two distinct peaks with beta and prebeta mobility (Beta peak dominant) 
2. Two distinct peaks with beta and prebeta mobility (Prebeta dominant) 
3. Prebeta peak only 
4 . Single, broad peak originating in the beta area and extending to the prebeta 




















I LDL peakl 
Migration distance 
- Beta and prebeta (Beta dominant) 
- Beta and prebeta (Prebeta dominant) 
- Prebeta migration 
- "Broad-beta" migration 
VLDL2 band morphology was much more uniform than VLDLl band morphology. 




























Migration relative to LDL 
- Pat FCC VLDL2 
- Pat JJV VLDL2 
IDL migration was highly uniform as a single, narrow band that migrated with beta 
mobility (not illustrated). 
4.2.1.10.1 Agarose gel electrophoresis of plasma 
In the untreated state 40% (8 of 20) patients had a Fredrickson Type 1lI pattern . This 
pattern was only found in patients with identified apoE mutations. The next most 
common pattern was Fredrickson Type UB. The introduction of lipid-lowering 
therapy was associated with significant changes in electrophoretic patterns. In patients 
with a Type III pattern at baseline this pattern persisted in 3/5 patients treated with 
cerivastatin, l /8 patients treated with fenofibrate and 1/4 of patients taking 
combination therapy. Two patients had a Type III pattern only when taking 
cerivastatin, these patients respectively had Type V and [lB patterns at baseline. 
Fenofibrate and combination therapy were associated with significantly lower TG 











patterns were seen most commonly with cerivastatin treatment followed by 
fenofibrate and combination therapy (P=O.0042 by Chi-square test). 
Table 4-81 Agarose gel electrophoresis of plasma 
Patient group Baseline Cerivastatin Fenofibrate Combination 
IIA 0 I 7 8 
llB 1 1 8 6 1 
CIl -s:: 
(l) 
III 8 4 I 1 .;:: 
~ 
0.. 
<t:: IV 0 0 0 0 
V 1 0 0 0 
E 
(l) IIA 0 I 6 5 t:l 
~ 
0.. 
CIl lIB 7 6 5 I .(jj (l) 
(l) > .... .;:: 
0 








V 1 0 0 0 0 .... 
~ 
OJ:J 
<t:: IIA 0 0 I 3 
(l) lIB 4 2 1 0 
> .;:: 
~ 




IV 0 0 0 0 (l) 
0 
V 0 0 0 0 
4.2.1.10.2 Agarose gel electrophoresis of lipoprotein fractions 
VLDLI patterns changed significantly from baseline with lipid-lowering treatment 











included a component, even if this was not dominant. Following 
institution of lipid-lowering therapy a prebeta band was clearly the dominant 
pattem in patients fenofibrate either alone or in combination with 
cerivastatin. In both the cerivastatin and fenofibrate arms there were two instances 
each of a "broad-beta" VLDLI Different patients were affected in each 
case, but these came the TG quartile of their 
treatment arm (detailed data not shown). As previously shown TG levels were 
in the cerivastatin group and this group also had more patients with u,-"a-1.lll 
VLDLI 
Table 4-82 VLDLI patterns on agarose electrophoresis 
I Baseline Cerivastatin Fenofibrate I Combination 
Two peaks 5 0 0 0 
Beta dominant 
Two peaks 1 4 0 I 
I Prebeta dominant 
n. only 14 7 12 9 
" Broad-beta" 9 2 2 0 
Although there were only four patients with no identified apoE mutations In this 
analysis cohort all had nr~'hpt" VLDLl and behaviour did 
not change with lipid-lowering thpr<>r\\! All I-',U1'-'11'" with identified mutations 











Table 4-83 VLDLt patterns according to apoE mutation status 
Baseline Cerivastatin Fenofibrate Combination 
Geno+ Geno - Geno+ Geno - Geno+ Geno - Geno+ Geno -
Two peaks 5 0 0 0 0 0 0 0 
Beta dominant 
Two peaks I 0 4 0 0 0 1 0 
Prebeta dominant 
Prebeta only 0 4 5 2 10 2 6 3 
"Broad-beta" 9 0 2 0 2 0 0 0 
VLDL2 morphology did not change from baseline with lipid lowering treatment and 
VLDL2 uniformly migrated as a single peak. The VLDL2 peak was generally found 
in the beta area of the gel, although it did on average migrate a fraction further than 
LDL. VLDL2 migration was assessed relative to LDL migration for each sample by 
determining the distance between the two peaks. The mean ± SD difference was 0.14 
± 0.15 cm at baseline, 0.16 ± 0.15 cm with cerivastatin, 0.14 ± 0.10 cm with 
fenofibrate and 0.16 ± 0.12 with combination therapy (ANOVA, P=0.93). 
The changes in VLDL migration relative to LDL migration with lipid-lowering 
therapy were assessed individually for each patient. Lipid-lowering therapy was 












Figure 4-75 Changes in individual VLDL2 migration from baseline relative to LDL migration 
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(1) Cerivastatin Fenofibrate Combination 
lDL migration was very uniform throughout the study as a single narrow band with 
beta mobility. The mean ± SD distance between IDL and LDL peaks at baseline was 
0.03 ± 0.04 em, 0.03 ± 0.03 em with eerivastatin, 0.02 ± 0.03 em with fenofibrate and 
0.0 I ± 0.04 cm with combination therapy (ANOV A, P=0.34). 











Samples for PGGE were frozen at -800 Celsius and stored until the study had been 
completed. Electrophoresis was then performed on batched samples. Previous 
experience in the lipid laboratory (unpublished) had indicated that electrophoretic 
patterns are not altered by storage at -800 Celsius. 
AI1 samples were assigned a classification according to the scheme il1ustrated in 
figure 3.20. OD tracings were also obtained to measure the Rf, and therefore the size, 
of LDL if particles of this size were seen on the gel. 
At baseline the majority of patients (15/21) had the A pattern which IS highly 
characteristic of dysbetalipoproteinaemia. 
Table 4-84 PGGE patterns at baseline and with lipid-lowering therapy 
Pattern Baseline Cerivastatin F enofi brate Combination 
A 15 9 8 3 
B I 2 3 3 
C 4 2 I I 
D 1 0 2 3 
PGGE responded variably to lipid-lowering therapy . In many patients there was no 
change in PGGE pattern despite significant lowering of serum lipids . When changes 
in PGGE patterns were observed they commonly were: staining of LDL-sized particle 
where there previously had been none, increased size of LDL peak or reduction in 











The following figures illustrate a few representative responses to lipid-lowering 
therapy. 
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Fifty-three % (8/15) patients with an A pattern at baseline retained this pattern 
throughout the study. In the other 7 subjects LDL-sized particles became visible in 73 
% (8/11) of gels studied. The staining of LDL-sized particles was interpreted as low 
intensity in all but one of these patients. None of the patients that had visible LDL-
sized particles on the gel at baseline reverted to an A pattern with lipid-lowering 
therapy. 
In those patients with LDL-sized particles visible in the untreated state the most 
frequent change was a reduction in TGRL (2/5) or no change (2/5). In one patient a 
marked reduction in the intensity of staining of LDL-sized particles was observed. 
4.2.1.11.1 PGGE and apoE genotype 
There were marked differences in the distribution of PGGE between patients with 
identified apoE mutations and those without. At baseline almost all patients with an 
identified apoE genotype had no visible LDL staining, while all genonegative patients 
had visible LDL-sized particles (P=O.OOI by Chi-square test for presence of LDL-











Table 4-85 PGGE patterns and apoE genotype 
Baseline Cerivastatin Fenofibrate Combination 
Geno+ Geno- Geno+ Geno- Geno+ Geno- Geno+ Geno-
A IS 0 9 0 8 0 3 0 
B 0 0 2 0 3 0 3 0 
C 1 3 0 2 1 0 1 0 
D 0 I 0 0 0 2 0 3 
4.2.1.11.2 LDL-size and lipid-lowering treatment 
In patients with visible LDL-sized particles LDL particle-size was analyzed by 
comparing retardation factors measured at peak OD_ Peak LDL-size was larger in the 
two treatment arms containing fenofibrate than at baseline or with cerivastatin 
(P=O.009 by ANOV A; Tukey 's multiple comparison test with P<O.05 for baseline and 
cerivastatin vs. fenofibrate). This is consistent with the described effects offibrates on 
LDL-species size. 













4.2.1.11.3 TGRL size and lipid lowering treatment 
The size of TGRL was examined on and off treatment in the 8 patients that 
maintained an A pattern throughout the entire study period. The Rf was measured at 
the peak optical density ofTGRL staining. 















The size ofTGRL decreased from baseline with lipid-lowering therapy, but the 











Figure 4-8] Change in Rf of TGRL with lipid-lowering therapy in patients maintaining an A 
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4.2.1.12 Safety Results 
This section includes data from all patients who received at least one dose of study 
medication. Patients with compliance less than 80% compliance were included in the 
safety assessment. 
4.2.1.12.1 Serious adverse events (SAEs) 
Two SAEs occurred during the course of the study. Both of the SAEs were assessed 
as probably not related to study medication. A brief description and commentary on 











.. A 5 J -year old male with pre-existing IHD (2 previous myocardial infarctions) 
and frequent but stable angina pectoris had a fatal anterolateral myocardial 
infarction 8 after the placebo washout and 
therapy with The patient died approximately 36 hours after the 
onset of chest pain shock by acute renal failure and 
pulmonary oedema. The had undergone coronary angiography 17 years 
before being enrolled into the study at which stage severe diffuse distal 
coronary disease not amenable to or ",,,,,,",ve.,, intervention 
had been demonstrated. 
occurrence of a MI in this 
severe IHD was present at baseline and the 
is not entirely Ul"~AL}\ .. """,U Yet there is 
concern that withdrawal lipid-lowering therapy may have increased the risk 
of an acute cardiac event. In 2002 Heeschen et al reported an 
approximately 3-fold increase in death and MI in patients admitted 
with an acute coronary syndrome when statins were withdrawn at admission. 
Much of this effect was found to have been due to an error in 
statistical analysis Although not studying dysbetalipoproteinaemia the 
"Treat to New " (TNT) trial the most definite evidence on the 
effect of statin withdrawal in patients with stable coronary disease. In 
this 9395 patients with IHD who had been a statin entered a six 
week washout followed an week open label of 
atorvastatin 10 mg/d. Cardiac event rates did not differ between the two 
U5i='~~""'5 that short-term withdrawal of statins is not associated with 











• A 56-year-old male patient underwent laparoscopic cholecystectomy for acute 
cholecystitis 22 days after starting fenofibrate , following washout of previous 
lipid-lowering medications. Unfortunately, an adequate description of the 
gallstones was not provided and they were not preserved for chemical 
analysis. The patient had previously been exposed to various fibrates and 
statins over a period of more than 10 years. Fibrates increase the relative 
concentration of phospholipids and cholesterol in bile, whereas the 
concentration of bile acids is reduced (337). Increased cholesterol 
concentration or saturation of bile may promote formation of cholesterol 
stones (338). Fibrates influence biliary composition mainly by decreasing the 
activity of cholesterol-7-a-hydroxylase (CYP7Al), the first enzyme in the 
major pathway of bile acid synthesis (339). The effect of fibrates on CYP7 Al 
activity is PPARa mediated reduced mRNA transcription. Additionally 
PPARa stimulation increases mRNA levels for ABCG5 , MDR3 and SREBP2 
slightly (340). In this particular patient long-tenn fibrate therapy may have 
increased the risk of cholesterol gallstones forming (although there is no proof 
that the patient did in fact have cholesterol stones), but there is no evidence to 
suggest that fenofibrate precipitates cholecystitis in patients with gallstones. 
4.2.1.12.2 Adverse events leading to discontinuation of study medication 
Three patients discontinued study medication before the sponsor terminated the study. 











events. Two patients 
adverse events. 
study medications due to medication related 
• A 
while 
female backache and headache 
cerivastatin during her second treatment The myalgia 
was not associated with elevation of serum CK. She had taken 
fenofibrate without problems. The myalgia following statin 
withdrawal and subsequently recurred during routine follow-up following 
trial discontinuation when a statin was added to bezafibrate 
in an attcmpt to improve lipid control. This patient's myalgia clearly 
relates to statin exposure. is a well known side effect of 
although the exact mechanism remains to be determined ). 
• A 42-year-old male withdrew from the study while 
4.2.1.12.3 
cerivastatin in the second treatment period. He had been randomized to 
cerivastatin and fenofibrate in the first treatment period. The patient 
described symptoms highly su~~.geS(l\/e of panic attacks from the U'"',::,11lUHI'5 
of the study, including the placebo but felt that these 
had been by medication. He was initially 
to continue with study medication, but later decided to withdraw 
from the The has had symptoms while 
taking other lipid-lowering medications. These symptoms are much more 
to relate to an anxiety than side 











Other clinical adverse events included upper respiratory tract infections, dental 
infections, headache, gastrointestinal disturbances and musculoskeletal (excluding 
myalgia) problems. None of these adverse events occurred at a higher frequency than 
would be expected in routine clinical practice. These other clinical adverse events 
were evenly distributed amongst all trial phases, including the placebo period. None 
of the other adverse events was judged clinically to be related to study drug. Detailed 
data on other clinical adverse events is not presented here. 
4.2.1.12.4 Laboratory monitoring 
4.2.1.12.4.1 Creatine kinase 
During the study one patient developed myalgia, without elevation of CK, while 
taking cerivastatin (see above) and withdrew from the study. 
The laboratory ULN for CK for this study was 170 UlL. In this small study 
rhabdomyolysis did not occur. A single patient had an elevation in CK of more than 5 
x ULN. This male patient had a CK of 6.4 x ULN while taking cerivastatin. He 
reported having an influenza-like syndrome around the time of his study visit with 
fever, muscle aches and respiratory symptoms. He was not discontinued from the 
study and when next assessed, while taking combination therapy, his CK was only 











4-82 CK (x t:LN) during the study 
7 
z 








Baseline Cerivaslatin Fenofibrate Cer + Feno 
Legend: The graph shows the CK values in relationship to the ULN. 
There was no In mean CK from baseline during any of the 
treatment arms (ANOV A; 
4.2.1.12.4.2 Liver function tests 
4.2. J .12.4.2.1 Transaminases 
The local laboratory reference ranges for transaminases in this study were 1-38 U/L 
for aminotransferase CAST) and 1-4 I for alanine aminotransferase 
withdrawal of lipid lowering medication the mean ALT was 25.6 13.0 












The mean ALT increased from baseline in each treatment arm. The mean AL T with 
cerivastatin, fenofibrate and combination therapy was 33.8 ± 10.8 U/L, 40.4 ± 44.0 
U/L and 38.3 ± 21.4 U/L respectively (ANOY A of log transformed data, P=0.05). 
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Baseline Cerivastatin Fenofibrate Cer + Feno 
Legend: The thin dashed line indicates the ULN and the thick dashed line 2 x ULN 
ANOYA P=0.05 
Tukey's multiple comparison tests- all comparisons P>0.05 
The mean AST with cerivastatin, fenofibrate and combination therapy was 26.0 ± 8.1 

















Baseline Cerivastatin Fenofibrate Cer + Feno 
Legend: The thin dashed line indicates the ULN and the thick dashed line 2 x ULN 
ANOYA P=O.004 
Tukey's comparison test: Baseline VS. Fenofibrate P<O.05 
Baseline vs. Combination therapy P<O.Ol 
An increase of more than 2 x ULN in the ALT andJor AST was observed in two 
patients: 
.. A female patient had an ALT ] 88 U/L and an AST of ] 39 U/L while 
fenofibrate. This patient had taken combination therapy during the previous 











AL Twas 14 u/L with an AST of 17 u/L. The study was terminated two days 
after the patient had completed the fenofibrate arm and bezafibrate has 
subsequently been prescribed with the transaminases remaining within the 
normal range. There was no other identifiable reason for this patient's 
transaminitis and the elevation in transaminases therefore is ascribed to study 
medication. 
• A male patient was noted to have an AL T of 95 u/L and an AST U/L of 71 
while taking combination therapy. Previously, while taking cerivastatin 
monotherapy, his ALT and AST were 36 u/L and 29 u/L respectively . At 
baseline the ALT was 25 u/L with an AST of 27 U/L. The patient currently 
takes bezafibrate and his transaminases are normal. No other causes of 
transaminitis were identified and the trallsaminitis was ascribed to study 
medication. 
If the two patients with increases of more than 2 x ULN in transaminases are excluded 
from the analysis as outliers the change in ALT with therapy is no longer significant 
(ANOY A of log transformed data, P=0.07) but the change in AST remains highly 
significant (ANOY A of log transformed data, P=0.0006). 
Many patients treated with statins show transient increases in transaminase values, but 
elevations in AL T of > 3 x ULN on at least two occasions, in clinical trials of various 
statins, occurred in only 70 patients per 100000 patient-years of statin exposure (342). 
Clinical liver disease or acute liver failure is extremely rare with statins and the rate of 
acute liver failure in patients taking statins is similar to the background rate of 











trials of fenofibrate to date (FIELD study) ALT reached 3 x ULN or more on at least 
one occasion in a similar number of on fenofibrate and placebo (11/4895 and 
the 944 were 
statins at the end of the trial as well with no reported increase in hepatic side-effects 
(344). Fenofibrate is there generally 




from a hepatic point view and 
not associated with excess hepatic 
Fibrates are known to reduce semm ALP levels (345;346). This effect is with 
bezafibrate and smallest with with fenofibrate having intermediate 
(347). of ALP has been suggested as an indirect method of 
monitoring compliance in patients taking fibrates (348). ALP 
measurement was not included in the panel of biochemical tests when the was 
conceived and therefore no data on ALP are available. 
4.2.1.12.4.2.3 Other measures of function 
Albumin, total protein and bilirubin were all within normal limits at baseline and none 












None of the patients on the study developed pancreatitis and the amylase remained 
within normal limits at all visits. Lipid-lowering treatment had no influence on the 
amylase values (data not shown). 
4.2.1.12.4.4 Renal function tests 
Increased levels of plasma w-ea and creatinine have been reported in patients taking 
fenofibrate. The reported increases in serum creatinine range from 8-18 % (349) , and 
are generally reversible on discontinuation of fenofibrate . In the FIELD study 
creatinine was 10-12 I-lmoliL higher in the fenofibrate arm, but when a subset of 661 
patients was retested 8 weeks after completion of the study there were no differences 
in creatinine between the two arms (344). Increased serum creatinine secondary to 
fenofibrate is not associated with reductions in glomerular filtration rate measured by 
sensitive techniques (350), but seems to be due to enhanced endogenous creatinine 
production (351). Many trials do not report changes in serum urea, but when they are 
reported, they are generally of similar magnitude as the changes in creatinine. 
Although fenofibrate therapy elevates serum creatinine, it is associated with reduced 
progression to microalbuminuria (352) in diabetes and with a reduced need for retinal 
laser therapy for diabetic retinopathy (344). The mechanism of these beneficial effects 
on the microvasculatw-e is not clear and it is also not known to what extent they are 
secondary to the lipid effects offenofibrate. 
4.2.1.12.4.4.1 Urea 
The mean urea at baseline was 5.2 ± 1.2 mmollL (median 5.1 , range 2.7-7 .0 mmoIlL). 
When taking cerivastatin, fenofibrate and combination therapy the urea levels 











(A NaY A, P=0.09). urea levels were increased in patients taking 
fenofibrate, the were not statistically significant in this small cohort. 
4.2.1.12.4.4.2 Creatinine 
The mean baseline creatinine was 90.6 ± 17.7 flmol/L (median 94, range 64-117 
flmoI/L). On cerivastatin the creatinine was 93.6 ± 19.0 flmollL, it was 101 ± 
23.0 flmollL on fenofibrate and 113 19.8 flmol/L on combination therapy (ANaYA, 
The mean increase in creatinine from baseline with fenofibrate mono- or 
combination therapy) was 15.6 flillol/L. discontinuation of fenofibrate the 
creatinine returned to the patient's baseline level. 












Baseline Cerivastatin Fenofibrate 
P=0.03 












Sodium, potassium, calcium and inorganic phosphate were all within normal limits 
and showed no significant changes with therapy (data not shown). 
4.2.1.12.4.5 Urate 
Fenofibrate is unique amongst the fibric acid derivatives in its ability to reduce serum 
urate concentrations. This effect is seen in healthy normolipidaemic volunteers (353) 
and in hyperlipidaemic patients (354). In a study of hyperuricaemic men with gout 
fenofibrate reduced urate by a mean of 19%. This effect was due to a 36% increase in 
urate clearance (355). Fenofibrate has been suggested as alternative or add-on therapy 
for patients poorly responsive or intolerant of allopurinol (355-357). 
The mean baseline urate was high in the study cohort at 0.42 ± 0.08 mrnollL (median 
0.44, range 0.27-0.57 mrnoI/L). This is not surprising considering the high prevalence 
of hypertension (39%) and the frequent use of thiazide diuretics (35%) in the study 
population . There is also a well-reported association of hyperuricaemia with features 
of the metabolic syndrome such as hypertriglyceridaemia, hypertension and impaired 












With cerivastatin monotherapy the urate was Ull\AIUUJ;<;\.U at 0.40 0.08 mmollL but 
decreased to 0.28 ± 0.06 mmollL with fenofibrate and to 0.27 ± 0.07 mmollL with 
combination (ANOY A, P<O.OOO 1). The mean decrease in urate when 
fenofibrate was taken was 0.14 mmol/L (34%). 
4-86 Urate during lipid-lowering therapy 
0.6 








Baseline Cerivastatin Fenofibrate Cer + Feno 
ANOYA P<O.OOOl 
Tukey's comparison tests 
All comparisons P<O.OOOI except for: 
Baseline vs. cerivastatin P>O.05 
Cerivastatin + fenofibrate vs. fenofibrate P>O.05 
None of the trial had a clinical of gout and no acute attacks of 











with allopurinol may occasionally precipitate acute gouty arthritis, but adding 
fenofibrate to allopurinol as additional hypouricaemic therapy in patients with poorly 
controlled gout did not precipitate acute gout, despite substantial lowering of serum 
urate (355). 
4.2.1.12.4.6 Glucose 
Of the 20 patients that had analyzable results 7 (35%) were diabetic. The mean fasting 
glucose at baseline in the non-diabetic patients was 5.45 mmol/L (median 5.4, range 
4.3-6.8 mmoIlL). Of the non-diabetic patients five met the American Diabetes 
Association (ADA) criteria for the diagnosis of impaired fasting glucose (lFG) or pre-
diabetes of a fasting glucose of 5.6-6.9 mmollL (361). The mean glucose in patients 
with IFG was 6.08 mmollL (median 6.05, range 5.6-6.8 mmoI/L). In patients with 
diabetes the mean fasting baseline glucose was 8.02 mmollL (median 7.5 mmollL, 
range 3.5-13.8 mmoIlL). 
Lipid-lowering therapy did not change fasting glucose significantly in any treatment 
arm (data not shown). None of the patients with IFG developed overt diabetes during 
the course of the study. 











white cell count (Wee) and were 
generally within normal limits and did not appreciably with lipid-lowering 
therapy (data not No had abnormalities on that 











5 Chapter Five: Breath test to study chylomicron 
remnant metabolism 
A subset of patients participating In the Bayer study was enrolled in a study of 
chylomicron remnant metabolism using a stable isotope breath test. This test was first 
developed at the University of Western Australia, Perth. Following initial experience 
in animal models (362-364) this technique has been applied to human subjects with 
hereditary and other forms of dyslipidaemia (365;366). It has subsequently been used 
to examine chylomicron remnant metabolism in a wide variety of clinical and 
experimental settings (367-374). Dysbetalipoproteinaemic subjects have previously 
been shown to have a markedly reduced fractional catabolic rate (FeR) when studied 
with this test (365). 
5.1 Material and methods 
5.1.1 Introduction 
Standard methods for assessing the kinetics of chylomicron remnant metabolism 
involve measurement of plasma triglycerides, retinyl esters or apoB48 following an 
oral fat load (375;376). Measuring fasting apoB48 levels may also predict the kinetic 
response of apoB48 and retinyl esters to an oral fat load (377). Unfortunately, none of 
these tests clearly distinguishes between defective lipolysis and defective hepatic 
remnant binding. Nascent chylomicrons must undergo partial lipolysis before they can 











to inhibit activity (380). may also exchange into TGRL of 
(381), limiting their usefulness for the study of chylomicron remnant 
metabolism. Kinetic studies also require multiple patient 
The breath test described here circumvents many of the problems associated with 
previous measurements of chylomicron remnant metabolism. The test uses artificial 
chylomicron remnant These lipid emulsions 
remant-Iike associate with apoE in the circulation following intravenous 
without any 




apoE-mediated binding to hepatic 
lipoprotein rp{,pnt(w<: 13C is a stable ( nonradioactive) carbon and serves as the 
tracer in this 
hydrolysis of 
The label is in the fatty acid moiety of the cholesteryl ester. 
of chylomicron renU1ant-like particles and lysosomal 
acids, mitochondrial oxidation liberates 1 which is ultimately 
excreted in the breath as 13C02. the enrichment of in end-tidal 













Figure 5-1 Breath test of chylomicron remnant metabolism 
Picture: Professor T.Redgrave (University of Western Australia, Perth,) 
Following intravenous injection the chylomicron remnant-like particle associates with 
apoE in the circulation and is endocytosed by the liver. Hydrolysis of the fatty acid 
moiety of cholesteryl ester and subsequent oxidation liberates 13C which appears in 
breath as 13 CO2 
CR: Chylomicron remnant-like particle 
5.1.2 Preparation of emulsions 
All emulsions were prepared at the University of Westem Australia, frozen and then 











The relative ('('rnn"", by mass of the emulsions was as follows: 
55.9 ± 1.6 
.. Phosphaditylchoiine 28.2 1.8 % 
.. Cholesteryl oleate 8.2 ± 0.7 % 
.. Cholesterol 7.7 0.7 % 
The lipid had a mean diameter of 55 3 nm as measured by negative-stain 
electron microscopy. 
oleic acid was synthesized from uniformly labelled [J3C] oleic acid 
Australia) and cholesterol. amounts of [13C] oleic 
acid and cholesterol were reacted for 17 hours at room temperature in dry carbon 
with 107 mol% of dicyclohexylcarboiimide in the presence of 16 mol% 
N,N-dimethylaminopyridine. A 1% volume of water was added and the mixture was 
stirred for 4 hours. the mixture was extracted with spirits and 
then 2% dietbyl ether in petroleum. After filtration through a small silica thin 
was Fractions with ester were 
combined, reduced in volume and by flash chromatography on silica gel. The 
was dried under high vacuum to constant mass. The cholesteryl 
[13C] oleate thus obtained was a colourless oil and its structure was confirmed by 
proton nuclear magnetic resonance. 
Cholesteryl [,3C] oleic acid (70mg), cholesterol (24mg), triolein (135 mg) and 
phosphaditylcholine were emulsified by sonication for 1 hour in 8.5 ml of 











for 10 min to remove titanium fragments and then filtered through a 0.22 flm filter 
into sterile vessels. All emulsions were tested for sterility and pyrogen contamination 
before being frozen at -200 C. 
5.1.3 Clinical protocol 
Chylomicron remant metabolism was studied on the same day as the patient' s 
scheduled routine trial visit. Following collection of routine blood samples the 
chylomicron remnant-like emulsion was injected into an antecubital vein utilizing an 
appropriately sized butterlly needle. 
Figure 5-2 Chylomicron remnant-like emulsion prior to injection 
End-expiratory breath samples were collected in sterile tubes with the aid of a short 
drinking straw. Patients were instructed to exhale slowly but fully through the 
drinking straw placed in the tube. At the end of expiration patients quickly removed 











asked to practice the collection of alveolar air under supervision several times before 
the actual study commenced. 
Figure 5-3 Equipment used to collect end-tidal breath samples 
Patients collected breath samples at time zero (before the injection of the lipid 
emulsion) and at the following intervals: 
• Every ten minutes for the first hour 
• Every twenty minutes for the next hour 
• Every 30 min for the next five hours 
• Hourly for the next seven hours 
• Once at 24 hours 
Patients remained at the clinical trial facility for the first seven hours of the 
investigation. During their stay at the trial facility patients were asked to remaIn 
seated in their chairs except for visits to the toilet. They remained fasting. After seven 











After consuming their lunch patients were allowed to go home with instructions to 
continue collecting breath samples. They were asked to refrain from any vigorous 
physical activity and to avoid consuming carbonated beverages. Additional 
sandwiches were provided for supper, although this meal was not consumed under 
supervision. 
5.1.4 Breath sample analysis 
All breath samples were shipped to the University of Western Australia and analyzed 
there. The CO2 in the breath samples was analyzed by isotope mass ratio spectroscopy 
using a Finnigan BreathmatPlus machine (Thermoquest Systems Pty. Ltd, Sydney; 
Australia). The ratio of 13col2c02 was referenced to Peedeebelimnite standard 
values and the delta unit value was calculated using the Breathmat software. The delta 
unit values reference a sample of limestone, a standard in the 13C isotope field, and 
basal (non-enriched) values correspond approximately 1% 13c. There may be small 
variations amongst patients in the basal I3C values, depending on the diet consumed. 
Endogenous I3C enrichment varies between different food groups (382) and patients 
on very low fat diets have previously been shown to have starting enrichment values 
about 2 units higher than normolipidaemic control subjects (365). 
5.1.5 Kinetic analysis of 13C-enrichment of CO2 
Kinetic data were analyzed using a previously developed and published 











model. The model assumes that the fractional rate constants are first order and time 
invariant. 
5-4 Compartmental model used to fit breath test enrichment data 
\------- K(2, 1) ------+{ 
k(O,2) .., 
(3,1) d(2, 
Compartment I IS the into which the labelled 
chylomicron rerrmant-like emulsion is (ex I). Compartment 2 ("Breath") 
represents labelled CO2 in breath and is sampled (s I) during the course of the 
The third eompartment is the primary pathway through which 
the rerrmant emulsion is cleared. It all the and 
processes that take place before the label is released and found in the breath. 
Compartment 3 therefore accounts for of the rerrmant-like 
emulsion to hepatic lipoprotein endocytosis, hydrolysis and finally 
oxidation of the oleate. The metabolic processes associated with movement of label 
from compartment I to 3 and then to 2 are of course not instantaneous and 











K(2, 1) represents the fractional transfer rate of tracer from compartment 1 to 
compartment 2, while k(3 ,1) describes the fractional transfer rate of tracer from 
compartment 1 to compartment 3. The main movement of tracer is represented by 
k(3, 1). The fractional catabolic rate (FCR) is calculated as the sum of k(2, I) and 
k(3,1). 
The observed 13C02 data was fit ted in Cape Town to the above model using the 
SAAM II program (SAAM Institute, Seattle; USA). Model rate constants and FCR 
were estimated after the observed values had been fitted to the model. 
The following figures illustrate the fitting of experimental values to the 
compartmental model. 















The circled data points were excluded from the data set as outliers. 


















Figure 5-7 Kinetic variables obtained after fitting data to compartmental model 
:-. SAAM II Compartmental - [Statistics] 
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5.1.6 Illustrative Results 
The following figures illustrate a few characteristic curves previously obtained in 
nonnolipidaemic and hyperlipidaemic populations. The data are all means with 
standard error of the mean bars and the line represents that fitted by the 
comp31tmental model to the averaged data. 
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Figure 5-10 Breath enrichment with ueoz in subjects with dysbetalipoproteinaemia 
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Figures 5.8-5.10 are taken from reference (365). The with 
hyperlipidaemia and dysbetalipoproteinaemia were studied in Cape Town. 
5.1.7 limitations of breath 
the breath test was designed primarily to evaluate chylomicron remnant 
.v", .• ",,,,,,,,,, the appearance the 13C02 label in breath does not reflect the 
at which emulsion particles enter the liver for catabolism. Variations in respiratory 
acid and oxidation may also influence the results the breath 
test. 
In the circulation ester transfer protein activity may potentially 
confound the interpretation of the breath test. CETP may transfer the labelled 
cholesteryl oleate from the emulsion to other before the oleate 
can be catabolized. Expansion of the acceptor lipoprotein pool may also be relevant as 
transfer of esters may be enhanced despite CETP 
However, in a previous study breath test results In patients with Type I 
and a very large TGRL pool, were no different from those obtained 
in control subjects (365). In a study the effect of atorvastatin in 
obese men baseline CETP activity was not correlated with FCR and atorvastatin did 
not CETP significantly 
Once the remnant-like emulsion has been injected it 











LRP/HSPG) and mediates the uptake of emulsion particles . Functional alterations in 
these receptors may alter the observed FCR. In humans the breath test FCR does not 
differ between normolipidaemic individuals, patients with heterozygous FH and 
patients with homozygous FH (366). Additionally there were no differences in FCR 
between homozygous patients with LDL-receptor mutations that differed substantially 
in their binding affinities for LDL apoB. In humans the LDL-receptor is therefore is 
not critical for clearance of the chylomicron remnant-like emulsion. However, 
alterations in expression and function of hepatic lipoprotein receptors may still affect 
chylomicron remnant clearance. In viscerally obese men atorvastatin increased the 
breath test FCR and there was a significant inverse relationship between changes in 
FCR and plasma LDLC, suggesting that decreased competition between LDLC and 
remnants of TGRL for the LDL-receptor may be a mechanism by which atorvastatin 
increased the breath test FCR (373). This finding does suggest that LDL-receptors do 
have a role to play in chylomicron remnant metabolism. Little is known about the 
differential effect statin therapy may have on the expression and functionality of 
various hepatic lipoprotein receptors. 
In subjects consuming a very low-fat, high carbohydrate diet endogenous production 
of CO2 will be higher leading to dilution of the label. Similarly physical activity is 
associated with excess oxidation of unlabelled substrates and dilution of the label. 
Consumption of carbonated beverages could potentially lead to additional CO2 
contamination of the alveolar air sample. The influence of the last two factors can be 











Alterations of fatty acid pool size and flux may also conceivably affect the breath test. 
Hepatocytes may either oxidize or re-esterify fatty acids . The degree to which fatty 
acids will be oxidized depends on hepatic glycogen stores and the relative 
concentrations of insulin and glucagon. Low hepatic glycogen stores with high levels 
of glucagon and low levels of insulin would, for instance, be associated with increased 
fatty acid oxidation. All patients were studied in the fasting state and fed a 
standardized meal. Additionally no significant differences were found when 
normolipidaemic volunteers were studies in the fasted and fed state (365) . 
5.2 Results 
The Bayer study protocol stipulated that 12 of the 36 planned patients would be 
enrolled in the breath test substudy. Due to the early termination of the study fewer 
patients were enrolled in the substudy and none had breath tests during all treatment 
arms. Six patients that were recruited for the breath test substudy entered the trial 
substantially later than the main cohort of patients and could therefore only be studied 
at baseline. 
Table 5-\ Number of patients studied with breath test during Bayer study 
Treatment N 
Baseline 14 
Ceri vastatin 5 












5.2.1 13C02 profiles at baseline (prior to fitting data to 
compartmental model) 
In the untreated state the I3C profile was similar to that previously reported in 
dysbetalipoproteinaemic subjects (365), with a delayed and smaller rise in tracer 
excretion when compared to normolipidaemic controls. 
















o 100 200 300 400 500 600 700 800 9001000110012001300140015001600 
Minutes 
The symbols indicate the mean values and the error bars the SEM. The line connects 
the means and does not represent the fitted data. 
Patients with identified apoE mutations had a smaller and slower rise in tracer 
excretion than those patients in whom no apoE mutation had been identified. 











patients (see Fig 5.12) and the difference is therefore best illustrated by showing the 
absolute change in 13C02 enrichment (Fig 5.13). 
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Figure 5-13 IJCO l at baseline in genopositive and genonegative patients (absolute changes) 














Figure 5.14 shows the J3C02 response at baseline in those 8 patients that had at least 
one breath test done while taking lipid-lowering therapy. 



























5.2.2 13C02 profiles with lipid-lowering therapy (data not fitted to 
compartmental model) 
In patients on lipid-lowering therapy IJC02 was excreted earlier and more rapidly 
with larger absolute changes than in the untreated state. The 13C02 profiles changed 
most, by simple visual inspection, in patients taking fenofibrate either as monotherapy 











Figure 5-15 DCOZ in patients taking cerivastatin (absolute change) 
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Figure 5-17 13COz in patients taking cerivastatin and fenofibrate (absolute change) 
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~ Ceriv + Feno 
5.2.3 Breath test data fitted to compartmental model 













The following figures illustrate the modelling of data for an individual patient and the 
changes observed in the profile. In this patient lipid-lowering therapy resulted In 
higher peak enrichment of the breath with 13COz and earlier attainment of this peak. 
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Figure 5-20 Patient MHH: Compartmental modeling on cerivastatin 
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Figure 5-21 Patient MHH: Compartmental modeling on fenofibrate 
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5.2.3.2 Study cohort 
The following figures illustrate the lines derived by fitting the compartmental model 
to the averaged data for each treatment period. The 13COZ enrichment follows a 
similar contour during all treatment periods except for the combination therapy group. 
In the latter group the peak enrichment is substantially delayed compared to the other 
groups. Lipid-lowering therapy is consistently associated with higher maximum 
enrichment. 
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Figure 5-24 Compartmental modeling of averaged data at baseline (patients that completed more 
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Figure 5-26 Compartmental modeling of averaged data on fenofibrate 
5 . ., 
C) 
c 
4. '" .r:; 
" ., 

















4 6 10 12 
Hours 
14 16 
- Line fitted to data by compartmental model 
• Fenofibrale (Mean. SEM) 
18 20 22 
Figure 5-27 Compartmental modeling of averaged data on cerivastatin and fenofibrate 
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5.2.4 Kinetic variables 





Cerivastatin + Fenofibrale 
20 22 24 
Table 5.2 shows the model rate constants and FCR for the labelled chylomicron 
remnant-like infusion at basel ne and with lipid-lowering therapy. Relative to baseline 
there was a significant increase in FCR and k(3, I) with fenofibrate monotherapy. The 
breath test results are congruent with the changes in lipids and lipoprotein 
composition as fenofibrate was associated with the largest reduction in VLDLl lipids. 
Chylomicron remnants are found mainly found in this fraction and a reduction in 
VLDLl lipids does therefore imply an increase in FCR. Interpretation is, however, 
complicated by the fact that the VLDLl fraction does not contain chylomicron 
remnants exclusively. 











Baseline Cerivastatin Fenofibrate Combination 
k(2, I), pools/h 0.0246 ± 0.027 0.0164 ± 0.008 0.0398 ± 0.0176 0.0307 ± 0.0183 
k(3, 1), pools/h 0.0169 ± 0.0187 0.0456 ± 0.0277 0.0721 ± 0.0404 0.0391 ± 0.0212 
k(2,3), pools/h 5.492 ± 2.830 7.841 ± 4.591 6.471 ± 4.563 3.215 ± 0.464 
k(0,2), pools/h 1.211±0.6147 1.619 ± 0.4554 1.590 ± 0.6060 1.245 ± 0.5455 
FCR, pools/h 0.0416 ± 0.0381 0.062] ±0.0332 0.1] 19 ± 0.0533 0.06989 ± 0.0] 71 
Table 5-3 Model rate constants and FCR: ANOV A 
Tukey's multiple comparison test ANOYA 
Baseline Cerivastatin Fenofibrate 
p vs. P vs. P vs. 
Cer [ Feno 2 Com 3 Feno Com Com 
k(2, 1), pools/h NS 4 NS NS NS NS NS 0.29 
k(3, 1), pools/h NS <0.05 NS NS NS NS 0.02 
I 
k(2,3), pools/h NS NS NS NS NS NS 0.31 
I 
k(0,2), pools/h NS NS NS NS NS NS 0.50 
FCR, pools/h NS <0.05 NS NS NS NS 0.04 
I Cer=Cerivastatin 
2 Feno= Fenofibrate 
3 Com= Combination therapy 
4 NS= Not significant (P>0.05) 













Baseline: Cerivastatin Fenofibrate Combination 
P<O.05 vs. baseline 
5.3 Discussion 
5.3.1 Kinetic studies in dysbetalipoproteinaemia 
Only a limited number of kinetic have been III 
dysbetalipoproteinaemic .'>LUJI<O'"C". Many of these studies used experimental U"'''bHv, 
schedules and mathematical models that are currently as 
suboptimal Table 5.4 lists a selection of kinetic studies III 











Table 5-4 Kinetic studies in dysbetalipoproteinaemia 
Author Year N Labelling - Administration Tracer Tracee Sampling Drug Model 6 Comment Ref 
1 3 4 5 
Turner 1984 II Exogenous Bolus Ij I 1- VLDL+ apoB In 90h Y Exponential I (384) 
IDL and 1251_ lipoprotein 
LDL fractions 
Packard 1986 6 Exogenous Bolus u'I-VLDL2+ apoB In 336h Y Multicompartmental 2 (307) 
12sl_VLDLl lipoprotein 
fractions 

















Gylling 1 Bolus VitA 
Tracee 
4 
Retiny I-esters 1211 
In 
1I1 I 33611 




1 Modell) Comment 1 Ref 
N 4 (386) 
Y 5 (313;387) 
N Residence time 











Author Year N Labelling - Administration Tracer Tracee Sampling Drug Model 6 Comment Ref 
I 3 4 5 
Mann 1995 1 Exogenous Bolus IJ I I- apoE3+ Plasma activity l48h N Area under curve 8 (200) 
125I_apoE 
(LysI46~Glu) 
Tremblay 2006 2 Endogenous PCI I D3-leucine apolipoproteins 12h Y Multicompartmental 9 (388) 
Legend 
Refers to the number of subjects with dysbetalipoproteinaemia included in the study 
2 Describes whether labelling was endogenous or exogenous 
3 Describes whether label was administered as a bolus or as an infusion 
4 Duration of sampling 
5 Refers to whether patients were studied on and off lipid-lowering therapy(Y=\ipid-lowering therapy, N= no lipid-lowering therapy) see 
comments for details 
6 Briefly describes the type of data analysis 












A and detailed study of lipoprotein kinetics In 
dysbetalipoproteinaemia. Two patients were studied on and off 
with gemfibrozil. 
A very detailed study metabolism a 
multicompartmental model. Patients were studied prior to and after 
treatment with bezafibrate. 





This was a study of 
palmitate labelling. 
In this small study 
with lovastatin. 
remnant metabolism with retinyl 
were studied prior to and after therapy 
This was a study of chylomicron metabolism iodinated 
autologous chylomicrons. 
7 This study examined vitamin A and squalene clearance and 
8 
cholesterol in response to lovastatin. 
This study examined the 
patient. 
kinetics ma 
9 The two dysbetaiipoproteinaemic patients in this study were also 
heterozygous for LDL-receptor mutations. were studied 











5.3.2 Lipoprotein kinetics in dysbetalipoproteinaemia 
5.3.2.1 Chylomicron metabolism 
Despite varymg methodologies all studies of chylomicron metabolism In 
dysbetalipoproteinaemia report delayed catabolism of chylomicrons or their remnants . 
Iodinated postprandial chylomicrons had a circulatory residence time of] 7.4 ± 3.5 h 
in dysbetalipoproteinaemic subjects compared to 4.8 ± 2. ] h in patients with Type IV 
hyperlipidaemia and 5.9 ± 1.6 h in normolipidaemic subj ects (387). The delayed 
clearance of chylomicrons in this study was not attributable to the expanded TG pool. 
In a study of chylomicron remnant metabolism following Vitamin A labelling the 
half-time of retinyl palmitate clearance from the chylomicron remnant fraction (which 
also contained hepatic VLDL and small nascent chylomicrons) was 6] 1.9 ± 419 .9 
minutes in dysbetalipoproteinaemic subjects compared to ]4.] ± 9.7 minutes in 
normolipidaemic controls and 50.7 ± 20.8 minutes in Type IV hyperlipidaemia (386). 
Another study confirmed delayed clearance of vitamin A from plasma following an 
oral load in dysbetalipoproteinaemic subjects. Lovastatin did not increase postprandial 
vitamin A clearance significantly (317). Sta]enhoef used apoB48 as a chylomicron 
marker and the half-life of injected labelled apoB48 was prolonged by a factor of 23-
138 (385) 10 dysbetalipoproteinaemic patients, including a patient with 
"normolipidaemic dysbetalipoproteinaemia". As discussed previously none of these 
studies can accurately distinguish between the effects of defective lipolysis and 
impaired hepatic binding. However, the study by Redgrave (365) utilizing an artificial 
chylomicron remnant-like emulsion that does not require lipolytic conversion, does 
suggest that defective hepatic remnant binding accounts largely for delayed 











VLDL, IDL and metabolism 
Dysbetalipoproteinaemic patients have an approximately threefold VLDL pool 
size (PS), with lower production rates (PR) and lower FCR (approximately 
30% of control) than controls (384). In another study of FH 
heterozygotes (FH HTZ), FH HTZ with apoE2/E2 and normolipidaemic 
controls VLDL PS was in the group and this was mainly 
attributable to a marked reduction % compared to FH 1HZ) in FCR (388). 
IDL PS is increased in dysbetalipoproteinaemia 4.8 fold) and FCR is reduced (41 % 
of control). PR was not significantly different between dysbetalipoproteinaemia and 
controls FHdysf3 have larger IDL PS than both FH HTZ and controls. The 
PS is due to reduced FCR and increased PR (388). In dysbetalipoproteinaemia the 
mean conversion time of IDL to LDL was 18.7 h compared to 3.8 h in controls and 
the mean conversion rate was also significantly lower (384). 
LDL PS and PR were significantly lower (57% and 66% of control) In 
Although mean LDL FCR was higher in 
dysbetalipoproteinaemia the difference from controls was not statistically significant 
(384). In FHdysf3 
was mainly due to a 
the LDL PS was smaller (56%) than in FH HTZ and this 
LDLFCR (388). 











5.3.2.3.1 Fibrate therapy 
Packard and colleagues treated six dysbetalipoproteinaemic patients with bezafibrate. 
VLDLC was reduced and plasma HDLC increased, while LDLC was unchanged. The 
reduction in plasma VLDL was mainly ascribed to inhibition of synthesis of both 
large and small subfractions of VLDL. Catabolism of large VLDL also increased. 
Although plasma LDLC levels were unchanged the LDLC FCR fell by about 50% but 
this was compensated for by decreased synthesis of LDL from small VLDL and IDL 
(307). Turner reports changes in kinetic parameters in two patients treated with 
gemfibrozil. In both patients the PR of VLDL and IDL decreased with no changes in 
FCR (384). The kinetic changes observed by Tremblay in response to fenofibrate in 
the FHdysJ3 subjects are somewhat different. Chylomicron (apoB48), VLDL and IDL 
PS decreased significantly from baseline with treatment and this decrease was largely 
due to increases in FCR with only modest reductions in PR (388). In contrast to the 
study by Packard LDL PR increased significantly, while LDL FCR increased in one 
patient and decreased in another patient. The authors speculate that LDL FCR may 
have decreased in the one patient due to a larger increase in LDL PS and subsequent 
saturation of LDL-receptor pathways. Unfortunately the study by Tremblay did not 
include any subjects with dysbetalipoproteinaemia only and it is therefore not possible 
to compare changes in kinetic parameters directly with other studies. 
5.3.2.3.2 Statin therapy 
The only report on changes in lipoprotein kinetics in dysbetalipoproteinaemic subjects 
treated with statins refers to three patients treated with lovastatin (313) . VLDLC and 











not allow the authors to rH,.·rpr,>nt> whether the changes were due to inhibition of 
synthesis of apoB-containing or increased activity of -reCerHOJrS and 
removal of synthesized The latter mechanism would 
decrease the rates into later and the observed decrease in LDL 
FCR could be explained by saturation of LDL-receptors by the more rapidly removed 
lipoproteins. Conceivably both mechanisms may also simultaneously (313). 
5.3.2.3.3 Comparison of breath test results with previously published 
literature 
There are no published of the effects of lipid-lowering treatment on breath test 
results in In FH '''''''''111'' 40 mg of simvastatin did not alter 
the FCR the breath test (372), similarly there was no change in FCR when 
postmenopausal women with Type II DM were treated with 40 mg of pravastatin 
(368). In viscerally obese men atorvastatin 40 mg improved the FCR of the 
remnant-like emulsion, after a had documented impaired 
remnant catabolism in obese men to non-obese men 
(374). The FCR was ascribed to decreased cholesterol and 
subsequent upregulation of _rpf'pr,tArc and decreased secretion of hepatic 
lipoproteins. Increased availability and decreased of 
chylomicron remnants with 100 lipoproteins results in catabolism of the 
former (373). 
Chylomicron catabolism is markedly delayed 111 dysbetalipoproteinaemia many 
reasons. levels of inhibit LPL defective binds poorly to 











remnants compete for hepatic lipoprotein receptors . Defective apoE is of course not 
altered by lipid-lowering therapy and an alternative explanation is therefore necessary 
for improved chylomicron remnant catabolism. As the breath test is not reliant on 
LPL activity (365) upregulation of the LPL gene by fibrates does not provide a direct 
answer. However, upregulation of lipolysis by fibrates reduces circulating remnant 
lipoprotein and therefore apoE concentrations. As high apoE levels increase VLDL 
production (73 ; 178), reductions in circulating apoE further reduce VLDL secretion. 
Decreased competition for hepatic lipoprotein receptors, such as LRP and HSPG to 
which apoE2 can still bind may result in improved chylomicron remnant clearance. 
Lovastatin did not Improve postprandial vitamin A clearance In 
dysbetalipoproteinaemia (317), but in another study atorvastatin did reduce plasma 
levels of apoB48 (315). Upregulation of LDL-receptor activity can not explain 
improved chylomicron remnant clearance directly as apoB48/apoE2 lipoparticles do 
not bind well to hepatic LDL-receptors . In dysbetalipoproteinaemia the effect of 
statins on chylomicron remnant clearance must therefore again be indirect and due to 
decreased competition at other hepatic lipoprotein receptors. However, improvements 
in chylomicron remnant clearance, as assessed by the breath test, have only been 
demonstrated when relatively high dose (atorvastatin 40 mg/day) statins have been 
used (373). More potent statins upregulate LDL-receptor activity and decrease 
lipoprotein production more profoundly than less potent statins. An alternative 
explanation for the reduction seen in circulating apoB48 in dysbetalipoproteinaemic 
subjects treated with atorvastatin is that apoB48 production may be reduced by statins. 
In cultured transformed enterocytes atorvastatin accelerates the degradation of 











not affect chylomicron production, reduced VLDL production has been attributed to 
statin therapy and this would reduce competition at lipoprotein rt3 (,pntArc 
In the present an increased remnant FCR was seen with fenofibrate 
but not with cerivastatin. The statin dose (cerivastatin 0.4 had less potency than 
atorvastatin 40 which is the only statin dose at which an increase in breath 
test FCR has been observed thus far. It must be that the number of 
subjects studied was smaller than and that none of the all 
three treatment arms as planned. In some patients it was not possible to obtain an ideal 
fit of the model to the observed due to outlying data As discussed above 
inadequate collection, 
failure to close the sampling tube 
significantly. 
Clearly, the available 
consumption of carbonated 
can influence tracer 
or 
In lipoprotein flux 
brought about by statins and fibrates in dysbetalipoproteinaemic subjects is "''''''1v'''''1"" 
In There are significant differences in the of the studied as well 
as the kinetic study 
dysbetalipoproteinaemic 
labelling of 
computer based modelling 
A lipoprotein turnover 
treated with various lipid-lowering with 
utilizing stable IS01:OD!~S and state of the art 











6 Chapter Six: Diagnostic issues in 
dysbetalipoproteinaemia 
6.1 VLDL-compositional analysis 
As described in section 1.6.2 there is no universally accepted diagnostic test for 
dysbetalipoproteinaemia. Analysis of VLDL-composition has, however, replaced 
detection of /3-VLDL as the phenotypic test of choice in almost all studies published 
on dysbetalipoproteinaemia in the last twenty years . 
The GSH lipid clinic experIence of partial VLDL-compositional analysis was 
evaluated. The laboratory has performed a large number of VLDL-compositional 
analyses over the years. These have all been performed by a single technician 
according to the same protocol and with the same equipment (see methods section for 
details). 
6.1.1 VLDL-compositional analysis cohort 




















VLDL-compositional analysis was performed on with a very wide range of 
lipid concentrations. At the time of VLDL-compositional only IC and IG 
was determined routinely. 
Table 6-2 Lipid concentrations at time of VLDL-compositional analysis 
Mean Median SD Range 
IG (mmoIlL) 4.19 3.30 3.78 0.10-62.00 
IC (mmoI/L) 6.79 6.30 2.75 1.90-40.60 
6.1.1.1 ApoE genotyping 
For the 779 individuals in whom had been "P,"TO,,..,,,· .... 











retrospectively (as part of this thesis), as the standard practice in the early years of the 
clinic had been to only genotype patients with cholesterol-enriched VLDL. In some 
cases VLDL-compositional analysis and genotyping had been perfonned on request 
of clinicians at other hospitals. These patients were included in the analysis of the 
diagnostic utility of VLDL-compositional analysis, but could obviously not be 
included in the clinical database. In a few instances no DNA was available for testing. 
Table 6-3 ApoE isoforms in patients who underwent VLDL-compositional analysis 
ApoE E2/E2 E2/E3 E2/E4 E3/E3 E3/E4 E4/E4 
Genotype 
n 71 102 30 348 190 20 
% 9 13 4 46 25 3 
As there is a high local prevalence of the apoE (RI45C) mutation all patients that 
were not apoE2 homozygotes were screened for this mutation where possible. 
Table 6-4 ApoE (R14SC) mutational screening 
Patients "at risk" 690 
Patients tested 684 
Mutation detected 41 











Of the 779 1.'''''1'-'11''' that had 
41 apoE mutation carriers + 5 
11 7 (71 
(K146Q) mutation 
were found to have a associated with dysbetalipoproteinaemia. 
the remaining patients, 646 did not have an identified mutation linked to the 
For the purposes of analyzing the 
these were as 
in distinction to the group of !Zerl0[IOslltl U""Cl'-'lll"" This 
obviously has its as there may be other undetected mutations in in 
the genonegative group. As there is no absolute diagnostic gold standard for 
it is not unreasonable to compare the diagnostic "'>r+"Y""''' 
of a phenotypic test that of even a limited test. The Hixson 
fragment, which includes the ,·p(,pn"r.r binding domain of apoE where most described 
mutations are localized, was also sequenced in all n'>tipntc with cholesterol-enriched 
VLDL and no known mutation, Sequencing did not identify any additional 
mutations. 
6.1.2 VLDL-cholesterol enrichment 
6.1.2.1 Ratio 
The ratio of VLDLC to VLDL-TO from 0.06-1.76 with a mean ratio 
of 0.29 and a median of 0.26, Results were not distributed 
seen in figure 6. I. 











Figure 6-1 Frequency distribution histogram of ratio cvrrv 
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Ratio CVITV 
Ratios ojCVITV> 1.0 are not shown on this graph 
The ratio did not correlate significantly with either TG, as reported by Albers (229) , 
or TC (data not shown). 
6.1.2.2 Ratio CV ITP 
The ratio of VLDLC to TG (CV/TP) ranged from 0.03 to 9.4 . The mean was 0.22 
with a median of 0.18. Only 7 ratios were higher than 0.7 and in 3 cases the ratio 
CV/TV was very much lower than would be expected considering the CV/TP ratio . In 
many cases the plasma TG levels were also very low and it is likely that the ratios 
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Ratios >0.8 are not shown on this graph 
The ratio did not correlate significantly with either TG or TC (data not shown). 
6.1.2.3 Relationship between ratios of VLDL cholesterol-enrichment 
Both the ratios discussed above aIm to describe the degree to which VLDL is 
cholesterol-enriched. VLDLC is common to both ratios and it is therefore not 
surprising that both ratios correlate well (r2 =0.70 by linear regression) with each 
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CV/TV 
Ratios ojCVITP >0.75 were this analysis 
1 Diagnostic performance of VLDLpcompositional analysis 
Ratio CV/TV 
The ratio CV/TV was clearly higher in !?:erlODOSI patients (0.45 ± 0.19 vs. 0.26 
0.09 for vs, genonegative, P<O,OOOI Mann Whitney test), but there 



















-- Genonegative patients 


















The graph does not show ratios > I. O. One of the proposed diagnostic thresholds of 
0.42 is also indicated on the graph. 
To eliminate the possibility that the degree of hyperlipidaemia may have influenced 
the observed ratio, the ratios obtained in specimens matched for lipid values were 
compared. There were 160 specimens from genopositive patients that could be tightly 
matched with specimens from genonegative patients. The ratio remained significantly 
higher in the genopositive patients (0.46 ± 0.18 vs. 0.25 ± 0.07 for genopositive vs . 
genonegative, P<O.OOO I by Mann Whitney test). 
The ratios found in apoE2 homozygotes and apoE (R145C) carriers also overlapped 
broadly, but on average apoE2 homozygotes had higher ratios (0.47 ± 0.18 vs. 0.42 ± 
0.21 for apoE2 vs . apoE (R145C), P=O.O I by Mann Whitney test) when all tests were 











were compared, there was no longer a statistically significant difference (0.42 ± 0.12 
vs. 0.41 ± 0.11 for apoE2 vs. apoE (RI45C), P=0.98 by Mann Whitney test) 
6.1.3.2 Ratio CV/TP 
The ratio CV/TP was higher in genopositive than genonegative patients (0.32 ± 0.26 
vs . 0.19 ± 0.36 for genopositive vs. genonegative, P<O.OOO I by Mann Whitney test). 
Once again there was significant overlap between the groups. 




















- Genopositive patients 
- Genonegative patients 
Ratio CV/TP 
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The graph does not show ratios > 0.75. One of the proposed diagnostic thresholds of 
0.30 is also indicated on the graph. 
Comparing only ratios obtained for speCImens matched for plasma lipids the 
difference between genopositive and genonegative patients remained highly 
statistically significant (0.33 ± 0.27 vs. 0.17 ± 0.05 for genopositive vs . genonegative, 











When all analyses were considered the CY ITP ratio was higher in apoE2 
homozygotes than apoE (R l45C) carriers (0.34 ± 0.30 vs. 0.27 ± 0.12 for apoE2 vs. 
apoE (RI45C), P=0.003 by Mann Whitney test), but when analyses were matched for 
lipids the difference was no longer obvious (0.27 ± 0.10 vs . 0.27 ± 0.09 for apoE2 vs. 
apoE (RI45C), P=0.96 by Mann Whitney test). 
6.1.3.3 Concordance of ratios 
As the two ratios discussed above strongly correlate with each other, it is important to 
know in what proportion of cases YLDL-compositional analysis would be classified 
as positive or negative by both ratios. This question was examined using "high" 
(CY/TY>0.42 and CY/TP>0.30) and "low" (CY/TY >0.35 and CY/TP> 0.25) 
diagnostic thresholds . 
Figure 6-6 Concordance of ratio CV/TV and CV/TP when using "high" threshold 
cvrrv ;:: 0.42 + 
cvrrp ;:: 0.30 + 
Patient Groups 
_ Ratios concordant + 
_ Ratios concordant -











Figure 6-7 Concordance of ratio CV/TV and CV ITP when using "low" threshold 
All patients Genopositive patients Genonegative patients 
CVrTV ~ 0.35 + 
CVrTP ~ 0.25 + 
Patient Groups 
_ Ratios concordant + 
_ Ratios concordant -
_ Ratios discordant 
Using the "high" diagnostic threshold fewer spms are discordant, considering all 
patients, than when "low" criteria are used. Genopositive patients have a higher 
incidence of discordant spins than genonegative patients, as they have higher ratios 
and therefore a higher likelihood of ratios that lie close to the diagnostic limits. The 
higher concordance of "high" diagnostic thresholds in the total patient group has to be 
traded off against reduced diagnostic sensitivity and increased rates of discordance in 
the genopositive cohort. 












Many patients had VLDL-compositional analysis performed on more than one 
occasion as diagnostic often remained high an initial test 
In other patients VLDL-compositional was repeated to investigate the effect 
of lipid-lowering medication or other interventions. 
Patients that had at least two VLDL-compositional were included in this 
analysis. The clinical practice at the lipid laboratory is to VLDL-
cOlnposluonal analysis as positive if either the ratio CV lTV or the ratio CV ITP meets 
the "high" diagnostic criteria. This criterion was applied to all analyses and In 
who all were either classified as positive or were labelled concordant 
Table 6-5 Concordance of VLDL-compositional analysis in individual patients 
" Spi concordant Spins discordant , 
I All patients 172 47 
. Genopositive patients 26 21 
26 
~ 
patients were more likely to have discordant spins than genonegative 
(P<O.OOO I by Fisher's exact In most instances VLDL-cholesterol 
enrichment decreased below the diagnostic level with the institution of 
medication. In genonegative patients the commonest scenario was for 











Receiver-operator characteristic curve (ROC) analysis 
ROC analysis is useful in examining the between sensitivity and "1J'_"AJlI"'LY 
when setting cutoff values for diagnostic tests. The area under the ROC curve 
quantifies the of the test to truly between affected and non-affected 
If the area is 0.5 minimum the test has no value at 
all, while an area of 1.0 indicates a perfect test. An area of 0.8 for instance indicates 
that a randomly selected patient, with the disease being tested will have a higher 
test value than 80% of randomly selected controls. ROC analysis relies on the true 
having been established by a gold-standard diagnostic test. As previously 
discussed there is no such test for but in this analysis 
genotyping is used as the gold-standard rr..nn<lr"tr.r The ROC therefore 
describes the utility of VLDL-compositional analysis in identifying apoE2 
or (R 145C) mutation 
6.1.3.5.1 Ratio 
The AUC for the ratio CV/TV was 0.87 (95% CI 0.84-0.90) if all analyses performed 
were included in the data set. 
specificity at selected cutoff values. 

















o 10 20 30 40 50 60 70 80 90 100 110 
100% - Specificity% 
Area I 0.8681 
Std. Error 0.01678 
95% confidence interval 0.8352 to 0.9010 
95%CI Specificity% 95%CI 
67.53% 94.45 92.77% to 95.84% 
95%CI Specificit % 95%CI 
61.44% 95.54 
95%CI Specificily% 95%CI 






As is to be decreases and increases as the ~".,.., .. ~., 
threshold is raised. At a threshold 0.355 sensitivity is 71 % while is 91%. 
Raising the diagnostic threshold to 0.415 increases to 96%, but this occurs 
at the cost of marked reduction in to 54%. 
The effects on sensitivity and specificity of the to with 











Table 6-6 ROC analysis of ratio CV/TV with plasma lipid criteria 
Lipid criteria Diagnostic threshold AUC 
(mrnoIlL) 0.315 0.355 0.385 0.415 0.425 
Sens Spec Sens Spec Sens Spec Sens Spec Sens Spec 
TG>I.5 83 82 74 91 64 94 56 96 53 96 0.88 
TG>2.0 85 82 75 91 68 93 58 96 54 96 0.89 
TG>2.5 84 81 74 91 65 94 59 95 55 96 0.88 
TG>5.0 80 85 69 94 64 95 56 96 51 97 0.86 
TG>7.5 61 90 50 94 44 95 33 95 28 96 0.73 
TC>5.2 87 80 80 89 74 93 68 95 65 95 0.89 
TC>7.5 88 69 83 82 80 88 77 90 75 91 0.87 
TC>IO.O 80 53 71 71 67 80 63 80 63 82 0.74 
I 
TG>2.5 + TC>5.2 87 80 79 90 73 93 66 95 62 96 0.89 
TG>2.5 + TC>7.5 94 66 88 80 86 86 84 88 82 90 0.96 
TG = 2.5-10 + TC>7.5 100 64 98 80 95 86 93 88 90 90 0.96 
Figure 6.9 illustrates the ROC curve obtained when only specimens with a TC>7.5 











6-9 ROC curve for ratio CV/TV (TC >7.5 and TG range 2.5-10.0) 
o 10 20 30 40 50 60 70 80 90 100 
100% - Specificity% 
6.1.3.5.2 Ratio CVffP 
The AVC the ratio CV ffP was 0.83 (95% CI 0.79-0.86) when all analyses were 
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0 25 50 75 100 125 
100% - Specificity% 
Area under the ROC curve 
Area 0.8260 
Std. Error 0.01963 
95% confidence interval 0.7875 to 0.8645 
P value < 0.0001 
Cutoff Sensitivity% 95%CI Specificity% 95%CI Likelihood ratio 
> 0.2450 61.05 53.73% to 68.03% 90.34 88.23% to 92.18% 6.32 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
> 0.2550 57.37 50.00% to 64.50% 92 .43 90.51% to 94.06% 7.57 
Cutoff Sensitivity% 95%CI Specificity% 95%CI Likelihood ratio 
> 0.2850 49.47 42.16% to 56.81% 96.60 95.20% to 97.68% 14.54 
Cutoff Sensitivity% 95% CI Specificity% 95%CI Likelihood ratio 
> 0.3050 41.58 34.49% to 48.94% 97.59 96.37% to 98.48% 17.22 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
> 0.3250 35.26 28.49% to 42.51 % 98.24 97.16% to 98.99% 20.08 
The effects on sensitivity and specificity of restricting the analysis to samples with 




















TO>2.S + TC>5.2 
TO>2.5 + TC>7.S 
TO = 2.5-10 
of ratio CV/TP with plasma criteria 
Diagnostic threshold AUC 
0.245 0.255 
70 89 
64 90 64 9 
50 90 50 
73 
80 







44 96 0.76 
96 0.90 
78 94 76 97 
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100% - Specificity% 
6.1.3.5.3 Defining a diagnostic threshold 
Choosing a diagnostic cutoff level requires establishing a balance between sensitivity 
and specificity. High sensitivity, achieved by choosing a low numerical cutoff, must 
be traded for a reduction in specificity. The magnitude of this tradeoff varies 
according to the baseline plasma lipid levels at the time of VLDL-compositional 
analysis . 
The sensitivity of the CV lTV ratio decreases by about 20% in specimens with TG 
values >7.5 mmollL, irrespective of whether a low (0.355) or high (0.415) threshold is 
set. Specificity remains relatively unchanged at all TG values. For the CV/TP ratio the 
sensitivity decreases most with increasing TG values at a low threshold (0.255), while 
the decrease is smaller at the higher threshold of 0.305 . Specificity is again relatively 











Both ratios are the most sensitive, using either high or low cutoffs, when the TC is 
>7.5 mmol/L. If only 
reduction in both 
"1J~'v"U"'''' with TC > I 0 mmoliL are considered there is a 
and 
The ratio CV lTV n",,'fArm best overall if only 
raised TG (2.5-10 mmollL) and 
with a raised TC 
are considered. In 
meeting these lipid criteria a ratio of 0.355 is highly sensitive (98%) with a reasonable 
of 80%. At a ratio of 0.415 93% of cases will still be detected and the 
specificity is high at 88%. 
The CV/TP ratio also has the best overall I'\p,.fnrt'Yl·"n['p in specimens with a TC>7.5 
mmol/L and TG range from 2.5-10.0 mmoliL. The cutoff of 0.255 is with a 
93% and a of 86%. the threshold to 0.305 reduces 
sensitivity to 86% while specificity rises to 94%. 
In summary hypertriglyceridaemia reduces the diagnostic of 
VLDL-compositional analysis, but if a 
false are very low. The test is most 
specimens with moderate hypertriglyceridaemia 
2.5-7.5 mmollL is very similar and is not 
result is obtained the chances of a 
to be 
10.0 mmol/L -data 
useful in 
the range 
and a TC > 7.5 mmol/L. Patients 
that have within this range and an mutation (apoE2 or apoE 
(RI45C) for the purposes of this analysis) will almost certainly be detected using the 
low thresholds. If the thresholds are met the of 











The results of YLDL-compositional analysis should always be interpreted in the 
context of the patient's lipid levels. Dysbetalipoproteinaemia may be difficult to prove 
by ultracentrifugation when the dyslipidaemia is not (yet) severe. 
6.1.3.6 Other ratios 
Other ratios that could be potentially diagnostically useful were examined. The ratio 
of YLDLC to TC (CY/TC) was clearly higher in genopositive patients than 
genonegative patients (0.37 ± 0.21 vs. 0.26 ± 0.32 for genopositive vs. genonegative 
patients, P<O.OOO 1 by Mann-Whitney test). The overlap between the two groups was, 
however, so large that it was not possible to suggest a cutpoint that would separate the 
two groups. 















- Genopositive patients 
- Genonegative patients 



























The ratio of VLDL-TG to plasma TG wa<; slightly, but statistically significantly, 
in genopositive than subjects (0.78 0.84 \IS. 0.76 ± 0.73 for 
vs. P=0.03 by Mann Whitney The between 
both ratios was, however, almost complete and this ratio therefore is of no 
use (data not 
6.1.3.7 VLDL-compositional analysis in the context of previously 
published experience 
Almost all literature on VLDL-compositional was in the period 
from 1970-1976 (207;229-232;390). Tables 6.8 and 6.9 list details 
these studies. 
Table 6-8 Proposed diagnostic cutoffs for VLDL-compositional analysis 
Author CV/TV CV/TP CV/TC Comments Reference 
" 
~ 
0.25-0.50 1 (390) 
H NA (230) 
Frear 0.25 (s) I (207) 
0.30 2 
• Mishkel I 0.35 0.25 2 (231 ) 
Vessby NA NA 3 (232) 













3 TG dependant cutoff (> 0.38 x 0.00885 
Comments 
1. Suggested range 
in mmol/LD 
2. Ratios apply II mmolJL and TC>5.2 mmol/l 
3. The author proposes a ,",VJJIJIJV':" index of VLDL and LDL composition, but 
the text no definite diagnostic cutoffs 











Table 6-9 Details of orevious studies on 
Author Year Subjects Controls Analyses Diagnosis ,CVITV Ratio CVITP CO!TIment Reference 
Subjects Controls Subject Control Subject Control 
W:tbenga 1972 NS NS 55 152 f3-VLDL NA NA NA NA I (390) 
Hazzard 1972 9 34 9 34 f3-VLDL 0.60 ± 0.11 0.31 ±0.08 NA NA 2 (230) 
Fredrickson 1975 59 123 3164 in total f3-VLDL NA NA Not 3 (207) 
Mishkel 1975 19 119 191 119 I3-VLDL 0.50 0.13 0.29 0.09 0.35 0.10 0.20 ± 0.05 4 (231) 
Vessby 1975 12 198 f3-VLDL Not gi' Not given 5 (232) 
Albers 1976 43 191 198 191 I3-VLDL Not Not given 6 ~29) 
-~~~ 
I. The author proposes that a ratio of VLDLC to TC be calculated. The ratio for is said to range from 0.25-0.50 
and 0.52-0.80 in Tvoe IV 











3. The authors compare a large number of VLDL- compositional analyses in a relatively small group of patients. Some patients had> I 00 
analyses. They calculate a mean CVffP ratio and plot the distribution of this ratio. 
4. The study included a large proportion of patients with mixed hyperlipidaemia. 
5. The author proposes that a "III index" be calculated as follows: VLDLCIVLDL-TG 
LDLC/LDL-TO 
XlO 
6. The authors define a diagnostic ratio by creating a linear regression based cutline below which lie 95% of all f3-VLDL negative 











All previous studies defined dysbetalipoproteinaemia the presence of 13-VLDL. As 
the UCT lipid laboratory did not electrophorese the ultracentrifugal supernatant 
routinely, no data on the sensitivity and specificity of 13-VLDL in relationship to 
dysbetalipoproteinaemia identified by testing are available for this study. 
Fredrickson found discordant for 13-VLDL in 12% of all subjects (207). In 
the study agarose of VLDLl revealed a 
component in all genopositive patients at This was no longer the case when 
lipid-lowering therapy was 13-VLDL is rnprPT,(WP also not an ideal 
standard for dysbetalipoproteinaemia as discordant results may be found and 
lowering may result in the disappearance of I3-VLDL. Despite the limitations 
of this and previous analyses the cutoffs are remarkably similar. 
ApoB as a diagnostic test
ApoB is and reliably by automated methods and the test is 
available (39 I). Clinicians are measuring levels more frequently and there are 
that apolipoprotein measurements should lipid measurements 
when cardiovascular risk and the response to therapy (70;392;393). 
measurements have incorporated in a few national lipid guideline statements 
(69). 
Each lipoprotein contains one apoB molecule and apoB levels the total 
number of contain 
proportionally less and more lipid than smaller lipoproteins. Remnant 











dysbetalipoproteinaemic patients should have lower apoB levels relative to plasma 
cholesterol than patients in whom the predominant abnormality is increased 
circulating LDL. Additionally one may speculate that apoB levels should be even 
higher in patients with mixed hyperlipidaemia due to the presence of numerous small 
dense LDL particles. 
ApoB levels and ratios derived from apoB and plasma lipids between patients with 
dysbetalipoproteinaemia and other forms of mixed hyperlipidaemia were thus 
compared . 
6.2.1 Definition of patient groups studied 
For this analysis the following definitions were used: 
Dysbetalipoproteinaemia: 
• apoE2 homozygosity 
• CV/TV >0.42 and/or CV/TP>0.30 
Mixed hyperlipidaemia 
• apoE genotype: neither apoE2/E2 nor apoE (R145C) 
• CV/TV<0.35 and CV/TP<0.25 
Indeterminate VLDL-composition 











... CV/TV in range 0.35-0.42 or CV/TP in range 0.25-0.30 
"Low" eutoffs were chosen to exclude to minimize 
the chance of falsely including dysbetalipoproteinaemic subjects in the mixed 
cohort. Patients with indeterminate 
separately. Only in this 
were studied 
as this is the 
commonest genetic cause of dysbetalipoproteinaemia worldwide. This approach 
ensures maximum at other centres. 
Results 
6.2.2.1 Lipids 
There were 254 patients with mixed hyperlipidaemia, 57 with 
dysbetalipoproteinaemia and 22 with indeterminate VLDL 
Dysbetalipoproteinaemic patients had higher levels of TC and TG than patients with 
mixed hyperlipidaemia or indeterminate VLDL 
indeterminate VLDL-compositional analysis 
cholesterol enrichment from the mixed 
levels of TC found in dysbetalipoproteinaemic subjects 
this group. 
Patients with 
in their VLDL 
the 











Table 6-10 Clinical characteristics and lipid values in patients with dysbetalipoproteinaemia and 
mixed hyperlipidaemia 
Dys/llipoproteinaemia Mixed hyperUpidaemia Indeterminate VLDL 
composition 
Number of patients 57 254 22 
ApoE criterion £2 homozygosity £3 or £4 allele present, Not £2/ £2 or E 
not E (R 145C) (RI45C) 
VLDL composition CV/TV >0.42 CVITV < 0.35 CV/TV 0.35-0.41 
criteria or and or 
CV/TP >0.30 CV/TP <0.25 CV/TP 0.25-0.29 
Age at presentation, 50.1 ± 9.3 52.9 ± 11.8 54.43 ± 16.32 
years 
Male/Female, 29/28 1011153 7/15 
Diabetes, % 17.5% 38.8% 36.4% 
Total cholesterol, mmoliL 11.75 ± 4.4 7.94 ± 1.7 8.61 ± 1.7 
Triglycerides, mmol/L 5.86 (4.89-7.00) 4.32 (4.11-4.45) 4.19 (3 .59-4.88) 
HDLC, mmollL 1.20 ± 0.4 1.14 ± 0.3 1.05 ± 0.4 
ApolipoproteinB 1 00, giL 1.15 ± 0.48 1.61 ±0.37 1.68 ± 0.52 
Ratio TCITG 2.1 ± 0.9 1.9 ± 0.6 2.2 ± 0.9 
VLDL-CNLDL-TG 0.50 ± 0.14 0.23 ± 0.05 0.38 ± 0.02 
VLDL-C/Plasma-TG 0.35 ± 0.09 0.16 ± 0.04 0.24± 0.01 
Ratio apoB/TC, glrnmol 0.10 ± 0.04 0.20 ± 0.03 0.19±0.04 






















P<O.05 vs. in whom dysbetaiipoproteinaemia has been excluded 
3 P<O.05 vs. patients with indeterminate VLDL composition 
4 Geometric mean 95% confidence intervals 
5 P<O.05 VS. with indeterminate VLDL cornp()s 
Figure 6.13 illustrates that apoB levels are lower in II V.""C;!.dl 
but that there is a wide overlap with the other groups. 












6.14 illustrates the differences in the apoBJTC ratio between the three 
groups. 
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Dysbetalipoprotelnaernla Mixed hyperllpldaemla Indeterminate VLOL compo 
Legend: The solid lines indicate median values: the broken line indicates the 











Comparing patients with dysbetalipoproteinaemia to those in whom the diagnosis has 
been definitely excluded (mixed hyperlipidaemia cohort) an apoB/TC cutoff value of 
O. J 5 identifies dysbetalipoproteinaemia with a sensitivity of 89% (CI 78-96) 
and a specificity of 97% (CI 94-99). The positive value is 88% (CI 
and the value 98% 
patients with a ratio of >0.20 
95-99). No dysbetalipoproteinaemic 
were found. Including patients with 
indeterminate VLDL-composition in the mixed hyperlipidaemia cohort leaves the 
but the specificity decreases to 96% 93-98) with a positive 
predictive value of 81 % (CI 69-90) and a negative predictive value of 98% 93-
99). If with indeterminate 
dysbetalipoproteinaemia with unrecognized 
decreases to 71 % 60-81) with a 
positive predictive value is 89% (Cr 
87-95). 
are considered to have 
mutations, the sensitivity of the test 
97% (CI 94-99). In this case the 
with a value of 91% 
The ratio well as a diagnostic test when evaluated by ROC 
The ROC AUC is 0.98 (CI 0.96-0.99) when 












Figure 6-15 ROC curve for apo8/TC ratio for dysbetalipoproteinaemia and mixed 
hyperlipidaemia 
~ w ~ w ~ ~ ro ro 00 00 100 
100% - Speclflclty% 
If patients with indeterminate VLDL-compositional analysis are included in the mixed 
hyperlipidaemia group the ROC AUC is 0.97 (CI 0.95-0.99). Classifying patients with 
indeterminate VLDL-composition as dysbetalipoproteinaemic reduces the ROC AUC 
to 0.87 (CI 0.81-0.93). 
6.2.2.3 Ratio apoB/TG 
The diagnostic utility of the apoB/TG ratio was also evaluated. It was significantly 
lower (P<O.OOOI by ANOVA) in dysbetalipoproteinaemic patients (0.24 ± 0.16) than 
mixed hyperlipidaemia (0.39 ± 0.19) subjects and subjects with indeterminate VLDL 
composition (0.43 ± 0.20). The values, however, overlapped widely and this ratio was 
































Dysbetalipoproteinaemia Mixed hwerlipidaemia Indeterminate VLDL cOIl1J. 
The lines indicates median values 
6.2.3 Discussion of utility of apoB as a diagnostic 
There are few screening tests for dysbetalipoproteinaemia suitable for use. 
of plasma 
is both sensitive and specific (227). is 
and not technically demanding, it is not available in routine clinical 
The ratio has been previously evaluated in 40 
dysbetalipoproteinaemic and 48 controls matched for lipid values (235). 
sensitivity was 95% with a of88%. The ratio is 












dysbetalipoproteinaemia, but apoE measurements are generally not available from 
routine chemical pathology laboratories in South Africa. 
A precipitation-based screening method for dysbetalipoproteinaemia has also been 
described (236). Dextran suifate/MgCl2 used in first generation direct LDL assays 
precipitates both LDL and remnants . The combination of high precipitate cholesterol 
and triglycerides identifies dysbetalipoproteinaemia with high sensitivity but has poor 
specificity (30%). Third generation direct LDLC assays have largely replaced first 
generation assays and may overestimate LDLC in patients with 
dysbetalipoproteinaemia (394;395). Some of the dysbetalipoproteinaemic subjects 
included in this series were initially evaluated in laboratories that perform direct 
LDLC measurements (various methods) and unpublished observations indicate that 
their measured LDLC is often much lower than the LDLC calculated by the 
Friedewald formula. 
It has been suggested that measuring TC adds little to cardiovascular risk assessment 
when HDLC and LDLC are measured directly (396). This approach is valid for most 
patients but will underestimate atherosclerotic risk in conditions where abnormal non-
measured lipoproteins such as remnants accumulate. ApoB levels are an important 
component of cardiovascular risk assessment (69;70). Elevated levels of apoB are 
associated with higher numbers of circulating atherogenic lipoproteins and higher 
cardiovascular risk. In dysbetalipoproteinaemia the situation is somewhat reversed 
and apoB levels lower than the 75th North American population percentile (397) are 











and TG indicate risk, once highlighting that and lipid measurements 
are not identical but complementary parameters for risk assessment 
The ratio of can be calculated rapidly when faced with a patient with mixed 
hyperlipidaemia. It best identifies patients that are unlikely to be 
dysbetalipoproteinaemic. this the number of undergoing 
further testing for dysbetalipoproteinaemia can be reduced. The ratio should not be 
calculated or used in the setting of other lipoprotein phenotypes. 
determination may in the future be routinely included in the assessment of 
dyslipidaemia and it is important to understand the additional diagnostic information 
by this measurement, but also the limitation of 
6.3 Suggested diagnostic strategy for 
dysbetalipoproteinaemia 
Based on the data nrpcpn,tpn above 
should be adapted to the clinical 
on apoB. 
for 
If large numbers of need to be screened for the dysbetalipoproteinaemic 
phenotype, e.g. an epidemiological study, PGGE is the method of choice. This 
method allows of numbers of "0.":1111\0" at a low cost. The 
sample volume is small and samples may be frozen. Lipid measurement is required to 
ascertain whether the characteristic electrophoretic seen is with 
hyperlipidaemia or not. This means that a substantial proportion of the individuals 











Confinnation of the diagnosis in SUSpICIOUS samples will then require apoE 
genotyping with or without VLDL-compositional analysis. 
Dysbetalipoproteinaemia should be considered in all patients referred to the clinic 
with mixed hyperlipidaemia. A TC: TG ratio of 2: I is suggestive, but the ratio is so 
variable that its absence should not be used to exclude the diagnosis. The presence of 
PVD should increase diagnostic suspicion further. Clinically palmar crease 
xanthomata are the most useful physical sign. 
If an apoB measurement is available, the ratio apoBITC should be calculated. A ratio 
of <0.15 g/mmol is highly suggestive of dysbetalipoproteinaemia and further 
investigations should be pursued. If the ratio is >0.2 dysbetalipoproteinaemia is very 
unlikely. PGGE may be used similarly in this setting. 
All patients with mixed hyperlipidaemia that do not have clearly negative screening 
tests should be investigated further. The likelihood of detecting 
dysbetalipoproteinaemia is maximized jf apoE genotype (common isofonns) and 
VLDL-compositional analysis are both perfonned. If other apoE mutations are known 
to be locally prevalent or the patient has suggestive ancestry, these mutations should 
be included in the work-up. Phenotypic testing helps identifY patients with unusual 


















Clinical aspects of dysbetalipoproteinaemi~ 
The prevalence of dysbetalipoproteinaemia was 3.15% in patien'ts attending a tertiary 
lipid service and therefore selected for severe hyperlipidaemiii. The diagnosis was 
I 
made in patients from all ethnic groups, but was particularly Icommon in Africans, 
i 
likely due to an increased likelihood of referral in the p~esence of cutaneous 
I 
xanthomata. Homozygosity for apoE2 was the commonest molecular cause of 
i 
dysbetalipoproteinaemia, but the apoE (R145C) mutation acbounted for about one 
quarter of patients with known apoE mutations. In about ~7% of the cohort no 
I 
mutations were identified in apoE by limited sequencIng (Hixson fragment 
I 
sequenced). 
The mean age at presentation in females was 6.25 years higher than in males; a 
finding that is consistent with the known protective effects of~he premenopausal state. 
I 
i 
Occasionally patients present during childhood or early ad<,>lescence, usually in the 
I 
face of severe precipitating metabolic stressors. Cutaneous: xanthomata (eruptive or 
: 
tuboeruptive) lead to earlier diagnosis and referral, while parmar crease and tendinous 
xanthomata usually go unrecognized. 
I 
YeHow palmar crease xanthomata are characteristic of dysbetalipoproteinaemia. LpX 
I 
is the only other lipid disorder in which lipid infiltration of the palmar creases was 











xanthomata are found in about 25% of patients. ApoE2 homozygosity, high levels of 
TC and highly cholesterol-enriched VLDL are risk factors for palmar crease 
xanthomata. Other cutaneous xanthomata (excluding xanthelasmata) are found in 23% 
of patients. Their presence is strongly associated with increasing severity of 
hyperlipidaemia, especially hypertriglyceridaemia. Tendinous xanthomata are 
uncommon and only occur in 17% of patients. Their presence is not predicted by lipid 
values. The prevalence j of tendon xanthomata is much lower In 
dysbetalipoproteinaemia than in FH, where they are found in 80% of patients 
attending the lipid clinic at GSH (253). Xanthelasmata occur more commonly in 
females than In males,' but bear no relationship to lipid values m 
dysbetalipoproteinaemia. The'prevalence of arcus comealis increases with age. 
The physical signs of dyslipidaemia tend to cluster in patients and there were 11 
patients in whom tendinous, ~palmar crease and tuboeruptive xanthomata occurred 
concurrently. 
Cardiovascular complications are frequent in dysbetalipoproteinaemia. At least 44% 
of the cohort had manifest IHD at their last visit to the clinic. As follow-up was 
incomplete this figure likely underestimates the true prevalence of IHD. For unknown 
reasons remnant lipoprotein accumulation is strongly associated with the development 
of atherosclerosis in the peripheral vasculature. This is borne out by the striking 
difference in prevalence rates for PVD between subjects with FH (4%) and 
dysbetalipoproteinaemia (28%) attending the same clinic. This finding is more 
remarkable when taking into consideration that prevalence rates for IHD were nearly 











alcohol abuse are risk factors for severe hypertriglyceridaemia. 
Hypercholesterolaemia tends to be severe with mean untreated values of more than 
I 
11.5 mmollL. HDLC decrease with increasing hypertriglyceridaemia and is also lower 
in apoE (RI4SC) mutation carriers. 
ApoB levels are raised in dysbetalipoproteinaemia, but not to the extent expected 
I 
I 
considering the markedly elevated levels of TC. Patients without identified apoE 
I 
mutations have higher mean apoB levels and higher ratios of ap:oB/TC. 
Cholesterol-enriched VLDL is characteristic of dysbetalipopr teinaemia and was one 
I 
of the criteria used to select patients for inclusion in this review. Patients without an 
identified apoE mutation therefore had to have at least one ratio (CV/TV or CV/TP) 
exceeding previously published diagnostic thresholds. We fm;lnd that the ratio CV/TV 
at a threshold of 0.42 was more frequently diagnostic of dysbetalipoproteinaemia in 
genonegative patients than the ratio CV/TP (threshold 0.30). In genopositive patients 
the situation was the reverse. 
I 
7.2.2 Electrophoresis in dysbetalipoproteinaer;nia 
I 
Dysbetalipoproteinaemia gets its alternative name of Type III hyperlipidaemia from 
the characteristic paper (and subsequently agarose) electrpphoretograms seen in this 
condition. Agarose gel electrophoresis is, however, a poor diagnostic test for 
dysbetalipoproteinaemia. Characteristic electrophoretogr~ms were only seen in 32% 











also occasionally seen in patients in whom the diagnosis of dysbetalipoproteinaemia 
can not be established either by genotyping or repeated VLDL compositional analysis. 
In the Bayer study electrophoresis of ultracentrifugally derived lipoprotein fractions 
was perfonned on agarose gels. Although the method and density cutpoints used in 
the Bayer study differ from the original method described by Fredrickson (14), all 
patients with identified apoE mutations had a beta-migrating component in their 
VLDLl fraction at baseline. Only 4 patients without identified apoE mutations were 
studied, but none oftheir VLDLl had a beta-migrating component. 
Agarose gel electrophoresis is therefore only diagnostically useful in 
dysbetalipoproteinaemia if combined with ultracentrifugation to isolate VLDL. This 
additional step adds extra work, cost and complexity. Frozen samples are also 
unsuitable for agarose gel electrophoresis, which is inconvenient for an infrequently 
requested investigation. 
PGGE perfonns better than agarose gel electrophoresis in the diagnosis of 
dysbetalipoproteinaemia. We found electrophoretic patterns very suggestive of 
dysbetalipoproteinaemia in 70% of all patients and 80% of all patients with identified 
apoE mutations. Subjects with the apoE (R14SC) mutation were more likely to have 
visible LDL-sized particles than apoE2 homozygotes, especially if they had TG 
values in the lower two quartiles. 
PGGE is also not entirely specific for dysbetalipoproteinaemia and we were unable to 











Some of these patients were extensively investigated with genotyping and repeated 
VLDL compositional analyses. In many patients with A patterns little clinical 
information was available, but the specimens were known to originate from clinical 
settings that may be associated with the phenotypic expresSlOn of 
dysbetalipoproteinaemia. 
7.3 Treatment of dysbetalipoproteinaemia 
The treatment of dysbetalipoproteinaemia was analyzed in two different settings. 
Treatment responses were studied in the "real-world situation" of a busy lipid clinic 
and during the controlled conditions of a clinical trial. 
At the lipid clinic fibrates were the preferred agent for patients with 
dysbetalipoproteinaemia and 82% of patients received a fibrate. In about half of these 
patients a statin was given concurrently. Increasing length ,of follow-up at the clinic 
was associated with increasing rates of combination therapy. Many patients that were 
initially well-controlled on a single agent (usually a fibrate) later required an 
additional agent as they aged, gained more weight, became diabetic or lost their initial 
enthusiasm for dietary modification. 
Most patients responded very well to lipid-lowering therapy, which was often 
prescribed in submaximal dosages due to fiscal constraints. Poor compliance was the 
commonest reason for the failure to achieve adequate control of lipid levels. The best 
median lipid values achieved were a TG of 2.0 mmol/L and a TC of 5.05 mmol/L. 











whom no mutations had been identified. Diabetes and abdominal obesity, as defined 
by the WHR, were associated with less favourable therapeutic responses. 
The clinical trial to prospectively evaluate the efficacy of three treatment strategies in 
dysbetalipoproteinaemia could unfortunately not be completed as planned due to the 
worldwide withdrawal of cerivastatin from the market. Nevertheless, some insights 
were gained. 
Statins and fibrates are useful drugs classes in dysbetalipoproteinaemia. Cerivastatin 
and fenofibrate were equally effective in lowering the TC, but fenofibrate was much 
better at lowering TG than cerivastatin. The combination of both drugs achieved the 
lowest lipid levels, but in most instances the difference between the combination and 
fenofibrate alone was not statistically significant. Lipid-lowering therapy did not 
change HDLC significantly in this study. 
Based on clinical experience and the results of the Bayer study fibrates are preferred 
as the initial drug class in dysbetalipoproteinaemia as they achieve better TG 
reductions than statim and are therefore more likely to be successful as monotherapy. 
Fibrates also act primarily on the less dense lipoprotein fractions in which remnant 
lipoproteins are found. Fenofibrate did not reduce LDLC significantly in our study. In 
fact, LDLC increased in some patients, but in dysbetalipoproteinaemia LDLC values 
are low and remnant lipoproteins are the main concern. Statins can in most instances 











7.4 Diagnosis of dysbetalipoproteinaemia 
Awareness and knowledge of dysbetalipoproteinaemia are essential prerequisites for 
its diagnosis. Because dysbetalipoproteinaemia is an unusual disorder of lipoprotein 
metabolism few physicians are aware of it. The diagnosis is therefore usually not 
suspected and further investigations are not undertaken. The lipid clinic at aSH has 
been able to collect a large cohort of dysbetalipoproteinaemic patients due to the high 
awareness of the disorder in its staff and a low threshold for performing specialized 
investigations. A drug policy tbat required all lipid-lowering medications dispensed in 
the public sector to be initiated at a lipid clinic meant that most patients were initially 
evaluated in the untreated state. 
From a clinical point of view, palmar crease xanthomata are useful diagnostic pointers 
as a mutation in apoE will be found in almost all patients with this physical sign. This 
physical sign should thus be included in medical curricula. The absence of palmar 
crease xanthomata can, however, not be used to exclude the diagnosis. Further 
investigations are therefore necessary whenever dysbetalipoproteinaemia is a 
diagnostic possibility. 
The apoB/TC ratio and paGE are useful initial screening tests. Both tests are 
inexpensive and can be used to rule out dysbetalipoproteinaemia. The demonstration 
of a mutation known to be predictive of dysbetalipoproteinaemia in a patient with 
mixed hyperlipidaemia can be considered diagnostic. Definite exclusion of apoE 
mutations, however, requires sequencing of the entire apoE gene. VLDL 
compositional analysis is useful to characterize the lipid phenotype and determine the 











analysis varies according to the degree of hyperlipidaemia present at the time of 
analysis. Patients on lipid-lowering therapy have less cholesterol-enriched VLDL. 
Assays of apoE could not be evaluated in this study. While high levels of apoE are 
characteristic of dysbetalipoproteinaernia severe hypertriglyceridaemia of other causes 
may also be associated with high concentrations of apoE. 
7.5 Changes in lipoprotein fractions associated with lipid-
lowering medication 
Lipid-lowering therapy reduces plasma lipids significantly. The bulk of the changes 
seen in plasma lipids are accounted for by reduced lipid masses within the VLDLl 
and VLDL2 fractions. Lipid-lowering therapy does reduce lipid concentrations within 
other lipoprotein fractions as well, but these fractions contribute relatively little to the 
total lipoprotein mass in dysbetalipoproteinaemia. 
VLDLl TG reduction accounts for between 61-71% of plasma TG reduction, 
depending on the lipid lowering agent chosen. VLDL2 accounts for a further 18-20% 
ofTG reduction. For TC the figures are 44-60% in VLDLl and 22-31 % in VLDL2. 
Lipid-lowering therapy is associated with significant compositional changes within 
VLDLI. The cholesterol content of VLDLl is reduced with particular reduction of 
CEo Relatively more TG and less CE is found in the lipoprotein core. The ratio of FC 
to PL in the lipoprotein shell also decreases, but the changes were not statistically 
significant. The composition of the other lipoprotein fractions remains unchanged 











7.6 Patients without identified apoE mutations. 
For the purposes of this study both phenotypic and genotypic diagnostic criteria were 
used. Dysbetalipoproteinaemia was diagnosed if either of the. criteria was fulfilled. 
We chose to include "genonegative" patients in this series because the standard 
genotyping performed at the laboratory only screens for the common apoE isoforms 
and two autosomal dominant mutations. 
Thirty-seven patients with no known apoE mutation were included in this series. 
Sequencing the binding region of the apoE gene failed to reveal a mutation in any of 
these patients. The genonegative patients share many similarities with the 
genonegative patients but there are also important differences. 
7.6.1 Similarities between genonegative and gEmopositive patients 
Genopositive and genonegative patients presented at equivalent ages with a severe 
mixed hyperlipidaemia of similar magnitude. Overweight and obesity were very 
common, irrespective of whether an apoE mutation had been identified or not. 
Genopositive and genonegative patients had similar rates of atherosclerotic 
complications, including similar rates of PVD. 
VLDL cholesterol-enrichment was comparable between genopositive and 
genonegative patients as assessed by the ratio CV /TV but the ratio CV ITP was 











7.6.2 Differences between genonegative and genopositive patients 
Genonegative patients had higher levels of apoB, higher ratios of apoB!TC and less 
cholesterol-enriched VLDL when assessed by the ratio CV!TP. Broad-beta bands on 
agarose gel electrophoresis were unusual in genonegative patients and PGGE patterns 
also differed significantly from those seen in patients with identified apoE mutations. 
LDL-sized particles were seen much more frequently in genonegative patients. 
Palmar crease xanthomata, cutaneous xanthomata and tendinous xanthomata were 
found infrequently (or very infrequently for palmar crease xanthomata) in 
genonegative patients. About half (46%) of genonegative patients were diabetic, a 
much higher rate than found amongst the genopositive patients. Genonegative patients 
were observed to respond less favourably to therapy with smaller deceases in TC than 
those observed in patients with identified mutations in apoE. 
7.6.3 Conclusions 
Some of the main clinical differences between genopositive and genonegative patients 
are the high prevalence of diabetes and low prevalence of physical signs such as 
cutaneous and tendinous xanthomata in genonegative patients. The lipid phenotype of 
genonegative patients is characterized by higher levels of apoB and the frequent 
presence of small LDL-sized particles on PGGE. These patients therefore have small 
dense LDL in the presence of excess circulating TGRL, while 
dysbetalipoproteinaemia is characterized by low levels of LDL due to decreased LDL 











However, the group of genonegative patients is heterogeneous. On review of all the 
medical and laboratory records of the genonegative patients it i~ possible to separate 
and group patients by several criteria. 
The presence of a tendinous xanthoma is generally taken to be indicative of a genetic 
disorder oflipoprotein or sterol metabolism. Four genonegative patients had tendinous 
xanthoma. For two of these patients little follow-up data are available and VLDL-
compositional analysis was not repeated. One patient has had repeated VLDL 
compositional analyses with one positive and three "borderline" results. (Note added 
in proof A mutation in the LDL-receptor (Q357X) has subsequently been found in 
this patient). The other patient with tendinous xanthomata underwent two VLDL 
compositional analyses with a positive and negative result. 
One genonegative patient was found to have palmar crease xanthomata. This patient 
has undergone 4 VLDL compositional analyses with consistently positive results. The 
response to fibrate monotherapy has been excellent, with recurrent severe mixed 
hyperlipidaemia during periods of non-compliance. This patient clearly requires 
further investigation, including an analysis of apoE in lipoproteins and sequencing of 
the entire apoE gene. 
There are further patients in whom no palmar crease xanthomata were found, but 
VLDL compositional analysis has been positive on multiple occasions. In these 












There were four genonegative patients with renal disease characterized by heavy 
proteinuria. Positive VLDL compositional analysis in this setting may be a "false 
positive" or occur if overproduced lipoproteins are not cleared rapidly enougb. 
There is another large group of patients characterized by diabetes and mixed 
hyperlipidaemia. In many of these patients VLDL compositional analysis was only 
performed on a single occasion and the result may well be "false positive". Where 
repeat VLDL compositional analysis was available or could be requested it tended to 
be negative, though not universally so. It is likely that many of these patients have a 
lipoprotein disorder such as FCH with a prominent increase in TGRL secondary to 
poorly controlled diabetes. 
The group of genonegative patients therefore likely includes subjects with true 
dysbetalipoproteinaemia but as yet undiscovered mutations in apoE, patients with FH 
and moderately severe hypertriglyceridaemia, patients with FCH and 
hypertriglyceridaemia as well as secondary hyperlipidaemia with remnant 
accumulation. Some of the genonegative subjects may have had HL deficiency, but no 
specific investigations were done to confirm or refute this diagnosis. In particular 
HDL size was not assessed routinely to screen for large HDL particles that are often 
seen in HL deficiency. 
7.7 Limitations of this study 











The GSH lipid clinic sees patients referred with severe hyperlipidaemia or physical 
stigmata of dyslipidaemia. There is therefore a referral bias towards more severe 
clinical problems. This may have biased the cohort studied to include the most 
extreme phenotypic manifestations of dysbetalipoproteinaemia. Establishing the true 
phenotypic spectrum of dysbetalipoproteinaemia would require a population-based 
study. 
The analysis of the GSH lipid clinic experience is based on data collected 
retrospectively. The analysis is therefore limited by the problems known to be 
associated with retrospective data collection: 
• Data is not complete in all subjects 
• Diagnoses were not made according to predefined criteria 
, 
• Length of follow-up varies widely and some patients have no follow-up 
information available 
• The treating clinicians were free in their choice of initial treatment and 
subsequent further modifications of therapy. 
The impact of many of these potential problems was limited by the fact that almost all 
patients were evaluated using a standardized clerking sheet and patients were seen by 
a small number of highly experienced clinicians with little staff turnover. 
Dysbetalipoproteinaemic patients have markedly elevated levels of apoE (5). None of 
the patients reported here underwent determination of apoE levels. Therefore no data 











there is any correlation between apoE levels, the degree of hyperlipidaemia, treatment 
response or apoE mutation. Analysis of apoE levels in genonegative patients may also 
have been instructive. Low apoE levels in the setting of cholesterol-enriched VLDL 
may also have indicated the possibility of apoE deficiency. 
The analysis also included patients with no identified apoE mutations. As outlined 
above these patients differ in several important aspects from patients with known 
apoE mutations. Inclusion of these patients may therefore have skewed some results. 
This issue has been addressed by presenting results for the whole cohort and by 
mutational status. 
7.7.2 Clinical trial 
The Bayer study was a well designed clinical trial to evaluate three treatment 
strategies in dysbetalipoproteinaemia. The major limitation of the trial was its 
premature termination. As a result of this fewer patients than planned were enrolled 
and none of the patients completed the entire triaL This obviously limits the statistical 
power of the trial and the planned analysis using ANOVA with repeated measures 
could not be performed. All ancillary investigations including analysis of changes in 
lipoprotein composition, chylomicron remnant metabolism (breath test) and 
electrophoresis were affected likewise. 
The Bayer study protocol also included measurement of apolipoproteins (apoB, apoE, 
apoCIIl) and lipoparticles as secondary outcome variables. These analyses were to be 
performed on batched samples following completion of the study. Unfortunately the 











subset of patients that had at least completed two treatment armS'. The apolipoprotein 
and lipoparticle data could have yielded useful insights into re~ant metabolism and 
the distribution of apoE amongst various lipoprotein classes. 
Patients could be included in the Bayer study based on a single positive VLDL 
compositional analysis. As a result of this 4 patients, of the patients with sufficient 
data for analysis, had no identified apoE mutations. Some ()f these genonegative 
patients may have had false positive results on VLDL compositional analysis and 
therefore may have diluted the treatment effect seen m "true" 
dysbetalipoproteinaemia. 
7.8 The role of a lipid clinic in the diagnosis'and management 
of dysbetalipoproteinaemia ' 
Lipid clinics are tertiary referral centers for patients with severe or unusual 
dyslipidaemia. They offer specialized diagnostic services and management advice to 
patients. Lipid clinics also engage in basic, clinical and therapeutic research. Another 
function is the training of medical professionals, both at an undergraduate and 
postgraduate level. 
There is little knowledge about dysbetalipoproteinaemia amongst physicians, 
including internists and many endocrinologists. The disord,er is therefore generally not 
recognized and investigated appropriately. Referral of patients with severe mixed 
hyperlipidaemia to a lipid clinic may therefore benefit the patient in multiple ways. 
ldentif')ting the lipid phenotype is helpful in choosing lipid-modifying therapy. 











possible precipitating disorders. Once the diagnosis of dysbetalipoproteinaemia has 
been confirmed and the apoE mutation identified it is also possible to provide genetic 
advice regarding the risk of siblings and children developing dysbetalipoproteinaemia. 
Genetic advice can then be complemented by screening at risk individuals for apoE 
mutations. Collection and collation of information relevant to the local context is also 
much easier ifpatients are seen at a central referral facility at least once. 
Dysbetalipoproteinaemia generally responds well to therapy and patients stabilized on 
treatment can therefore be followed-up by their general practitioner or primary health 
care clinic as long as a reliable supply of lipid-lowering medication and intermittent 
monitoring of treatment response can be assured. Unfortunately both the public and 
the private health care system in South Africa fail to provide these basic essentials 
unacceptably often. 
7.9 Future work on dysbe alipoproteinaemia in Cape Town 
The atherogenic nature of dysbetalipoproteinaemia can be studied by carotid IMT 
using a standardized ultrasound protocol recently introduced in Cape Town. Currently 
all traceable dysbetalipoproteinaemic patients are undergoing ultrasound evaluation. 
Ultrasound screening in families known to carry the apoE (RI45C) mutation is of 
particular interest to assess whether there are early changes in IMT in adolescence 
before overt hyperlipidaemia sets in. 
Diagnostic criteria for VLDL composition need to be established for the local 











both VLDL-compositional analysis and IMT screening. The former will provide a 
i 
better range of expected results, while the latter will assist in b~ilding experience of 
IMT and comparing age-matched values with previously published studies. This 
benchmarking exercise is important if IMT measurements are to be included in future 
risk assessments of patients with intermediate risk. 
The effect of ART on South African individuals genetically predisposed towards 
developing dysbetalipoproteinaemia is of interest. A collaboration with researchers 
from the Division of Endocrinology at UCT, who are conducting research on the 
metabolic effects associated with ART, is underway. A large c}oss-sectional survey of 
patients on ART has been initiated to study the metabolic effects of ART. The lipid 
laboratory will be evaluating lipid data, performing GGE and apoE genotyping. This 
study will therefore provide further data on the population prevalence of the apoE 
(R145C) mutation, the risk ofhyperlipidaeroia developing w~en exposed to metabolic 
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